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ABSTRACT 
Staphylococcus aureus is recognized as one of the main human pathogens, which 
has developed resistance to many classes of antibiotics. Information on antibiotic 
susceptibility pattern is of great importance for clinicians in the selection of empiric 
antimicrobial therapy. Moreover, data on phenotypic and genetic characterization of S. 
aureus isolates (especially MRSA) are crucial in monitoring and limiting the intra- and 
interhospital spread in the control of staphylococcal infections. 
In this study, antibiotic susceptibility of S. aureus isolates obtained from clinical 
microbiology laboratones in Southwestern Nigeria (200 isolates) and KwaZulu-Natal 
(KZN) province, South Africa (227 isolates) was investigated. All the isolates from both 
countries were susceptible to teicoplanin, vancomycin and fusidic acid, while the 
prevalence of MRS A was 1.5% and 27% in Southwestern Nigeria and KZN province, 
South Africa, respectively. Resistance of methicillin-sensitive S. aureus (MSSA) to 
sulfonamides, tetracycline, and the number of multi-drug resistant MSSA was 
significantly higher in Nigeria compared with South Africa. Most of the MRSA isolates 
(87%) from KZN were resistant to at least four classes of antibiotics. Apart from 
vancomycin, teicoplanin and fusidic acid, quinipristinldalfopristin, linezolid and 
fosfomycin are recommended for the treatment of MRS A infections in the two countries. 
Characterization of MRSA from South Africa indicated the widespread 
dissemination of strains in pulsotypes a and b, suggesting that there appears to be a major 
clone circulating in health institutions in KZN, South Africa. Clonal relatedness between 
one MRSA from Ibadan, Nigeria and EMRSA-15 was identified indicating clonal 
dissemination of the pandemic clone. The characterization of low-level mupirocin 
v 
resistant S. aureus from South Africa revealed that a dominant clone exists in health 
institutions located in Durban. A 41.1 kb plasmid mediating resistance to mupirocin was 
identified from a methicillinimupirocin resistant S. aureus strain from South Africa. Base 
substitution at nucleotide position 671 A to T of the i/eS-2 gene in the mupirocin-resistant 
strain from Nigeria indicated a change in the amino acid sequence from leucine to 
phenylalanine. These findings clearly indicate that urgent measures including strict 
antibiotic and infection control policies are needed in curtailing the spread and 
establishment of mupirocin and methicillin-resistant strains in both countries. 
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INTRODUCTION AND LITERATURE REVIEW 
1.1 Introduction 
Staphylococcus aureus remains one of the important pathogenic microorganisms 
in many countries causing infection in hospitals and the community. One of the reasons 
for its persistence might be its great variability, occurring at different periods and places 
with diverse clonal types and antibiotic resistance patterns. Epidemiological 
investigations of S. aureus at the moment have observed four major trends. In many 
countries, infections caused by multiresistant strains (especially methicillin-resistant S. 
aureus - MRS A) are of great concern, whereas in other countries, the frequency of 
MRS A is low. The third trend is the emergence of MRS A in the community and finally 
the recent reports of vancomycin-intermediate and resistant S. aureus in hospitals. 
Studies on the epidemiology of antibiotic-resistant S. aureus are important and 
necessary for many reasons. In order to have adequate information for treatment of 
staphylococcal infections, it is crucial to understand the trends in the antibiotic-resistance 
patterns of S. aureus. In addition, the occurrence and changes in types of S. aureus, clonal 
identities, and their geographic spread is essential for the establishment of adequate infection 
control programs in hospitals and in the community. The long term or epidemiologic 
question is whether the strain causing disease in one geographic area is related to those 
causing disease in other regions. There is presently a growing interest in tracking, 
identifying and understanding the diversity of major multi-drug resistant S. aureus clones, 
especially due to the increasing number of infections caused by methicillin-resistant 
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Staphylococcus aureus (MRSA). The tendency for specific strains of S. aureus to spread 
within a hospital and across geographic boundaries has also led to the evaluation and 
establishment of a number of techniques aimed at the strain-specific typing of clinical 
isolates. 
The main objective of the study was to provide baseline data on the epidemiology of 
clinical isolates of S. aureus isolates in SouthWestern Nigeria and the KwaZulu-Natal 
province in South Africa. Data based on phenotypic and genetic characterization of isolates 
would be important in understanding and monitoring the geographic expansion of S. 
aureus clones in the global surveillance network, in different population. Although 
studies have been carried out in many countries on S. aureus (especially MRSA), there is 
paucity of data on the epidemiology of S. aureus (MSSA and MRS A) in Nigeria and South 
Africa using phenotypic and molecular techniques. In addition, there is no information on 
clonal identities and diversity of S. aureus in both countries. Furthermore, data does not 
exist on the emergence and dissemination of pandemic MRSA clones in the two 
countries. 
This study is expected to provide baseline information for health personnel and 
policy makers, in the development of health intervention strategies. Furthermore, data from 
this study would be useful in the establishment of adequate infection control programmes, 
regulate national drug policies in the treatment of staphylococcal infections, and bring a 
better understanding on the epidemiology of S. aureus in both countries. 
2 
1.2 Literature review 
1.2.1 Staphylococcus aureus infections 
"Micrococcus, which when limited in its extent and activity, causes acute 
suppurative inflammation, produces, when more extensive and intense in its action on the 
human system, the most virulent forms of septicaemia and pyaemia" Ogston (1882). 
Staphylococcus aureus has been known as a causative agent of infection since 1882, 
when Alexander Ogston identified its role in sepsis and abscess formation (Ogston, 1982). It 
has continued to be one of the commonest human pathogen in community and hospital 
acquired infections. S. aureus is an opportunistic bacterium, which is frequently part of 
the human micro flora, causing disease when the immune system becomes compromised. 
Although S. aureus can be found in different parts of the body, the anterior nares are the 
primary ecological niche in humans. From here, staphylococci may spread to the skin 
(especially eczematous lesions), surgical wounds, foreign bodies (e.g. tracheostoma, 
external fixation devices), bums and the upper respiratory tract. Nasal carriage differs 
between individuals and it is one ofthe major risk factors for S. aureus infection 
(Kluytmans et al., 1997). In the healthy populations, approximately 20% of the 
individuals carry S. aureus persistently, about 60% intermittently and about 20% do not 
carry this bacterium (Kluytmans et al., 1997). Another important mode of transmission is 
via transiently colonised hands of health care workers who acquire the organism after close 
contact with colonised patients or contaminated equipment (peacock et al., 1980; Lamm1er 
et al., 2001). 
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S. aureus can cause a wide range of infections (Figure 1.1). They include (i) 
superficial lesions such as wound infections (ii) systemic and life-threatening conditions 
such as endocarditis, osteomyelitis, pneumonia, brain abscesses, meningitis, and 
bacteremia; and (iii) toxinoses such as food poisoning, scalded skin syndrome and toxic 
shock syndrome (Tenover and Gaynes, 2000). 
boils , carb'uneles----41'\ 
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Figure 1.1: Sites of infection and diseases caused by Staphylococcus aureus 
Reference: http://textbookofbacteriology.netlstaph.html 
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1.2.2 Emergence of antibiotic resistance - a silent revolution 
Major discoveries in antibiotics were made in succession from the 1950s through 
the 1970s, an era that has come to be known as the "Golden Age of Antibiotics". These 
accomplishments created a sense of euphoria in the medical community, as it perceived 
that bacterial infections were curable. Victory over bacteria was declared and financial 
resources were redirected toward more pressing scientific questions. By the late 1980s to 
the early 1990s, a decline in research for discovery and development of new types of 
antibiotics in many pharmaceutical companies was observed, a trend that was shadowed 
by federal agencies such as the National Institutes of Health, which showed more 
inclination to support studies of non-microbial systems during that period (Golemi-Kotra 
et ai., 2003). 
Antimicrobial agents are a critical element of the therapeutic armamentarium of 
modem medicine. Antimicrobial drug consumption costs more than seven billion dollars 
annually in the United States, of which four billion dollars are used for treatment of 
hospital-acquired infections due to antibiotic resistant bacteria (Guven and Uzun, 2003). 
Meanwhile, liberal use of antibiotics in the clinics, in agriculture, in aquaculture, and in 
animal husbandry was facilitating a quiet revolution in microbial populations. These 
events resulted in antibiotic-resistant organisms that were perfectly treatable a decade or 
two earlier. These organisms were included among those defined as re-emerging 
infectious agents (lOM, 1992; Heymann and Rodier, 2001). While this trend was 
progressing steadily over the past decades, previously unknown infectious agents were 
also being discovered (WHO, 1996; Desselberger, 2000). A decline in the effectiveness 
of existing antimicrobial agents began to emerge, and thus infections became more 
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difficult and expensive to treat and epidemics became harder to control (Moellering, 
1998a; Mah and Memish, 2000). These events contributed to high morbidity and 
mortality of previously treatable infectious diseases such as tuberculosis, malaria, acute 
respiratory diseases and diarrhoea (Cohen, 1994; Sack et ai., 1997; Espinal, 2000; WHO, 
2000a; 2000b). 
The emergence of antimicrobial resistance is a complex problem driven by 
numerous interconnected factors, many of which are linked to the use of antimicrobials in 
animals, plants and man (DuPont & Steele, 1987; Schwarz et ai., 2001; Tan et ai., 2002; 
Vidaver, 2002). Antimicrobial use has been credited as the single most important factor 
responsible for increased antimicrobial resistance (Mitema et ai., 2001; Rubin and 
Samore, 2002; McGarock, 2002). Antimicrobial use is influenced by a number of factors 
including knowledge, expectations, and interactions of prescribers and patients, economic 
incentives, characteristics of the health systems, the regulatory environment and 
availability of resources. There are factors that are inherent within the organisms 
themselves, which are enhanced by other environmental features (Allen et ai., 1999; 
Tumbarello et ai., 2002; Harris et at. , 2002; Zaidi et ai., 2003). 
Hospitals are critical in the development of resistance. In addition to the heavy 
burden of infections acquired in the community setting, lack or underutilization of 
diagnostic tests, non-compliance with basic infection control measures, as well as a false 
feeling of security once the patient is placed on antibiotics, are the common reasons for 
irrational use in hospitals. Travel and migration also increase the potential for spread of 
plasmid-mediated, multi-resistant bacteria throughout the world (Guven and Uzun, 2003). 
Overall, these trends could have a substantial impact on health care costs. Each year 
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about two million patients acquire nosocomial infections in the United States, and about 
60% of these infections involve antibiotic resistant bacteria (Lowy, 1998). In a study 
conducted in a university-based tertiary-care medical center, the average hospital bill 
increases by about $9,000 if a hospital patient becomes infected with a methicillin-
susceptible S. aureus in primary blood stream infections (Abramson and Sexton, 1999). 
Moreover, if the strain is methicillin-resistant as well, the cost triples to $27,000, which 
add up to substantially increased expenditures in local hospitals. A study by Rubin et al. 
(1999) in New York City indicated that the cost for treating resistant S. aureus exceeded 
$400 million in 1999. Palumbi (2000) also reported that the hundreds of thousands of 
penicillin-resistant and methicillin-resistant infections in the United States add to the 
national health care bill by an estimated $30 billion. 
1.2.2.1 History of penicillin and epidemiology of penicillin resistance in S. aureus 
The rapid progression from a uniformly antibiotic-sensitive bacterium to a 
uniformly antibiotic-resistant species is well demonstrated in the case of S. aureus. 
Before the antibiotic era, S. aureus diseases had high mortality rates. In 1941 , the 
mortality rate of S. aureus at the Boston City hospital was reported to be 82%, and over 
70% developed metastatic infections (Skinner and Keefer, 1941). In 1940, a policeman 
was admitted to the John Radcliffe Infirmary at Oxford with an aggressive cellulitis 
spreading from a lesion on the comer of his mouth (Jevons, 1961). S. aureus was isolated 
together with Streptococcus pyogenes. Because the S. aureus strain was already 
suphonamide resistant, the first experimental preparation of penicillin was used as 
treatment. The patient began to respond, but penicillin could not be produced rapidly 
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enough and he died. This experience nevertheless revealed the potential of penicillin, and 
provided the impetus for further development. In the early 1940s, when penicillin was 
introduced into therapy, all strains of staphylococci were highly sensitive to this 
antibiotic. The first successes of penicillin therapy were related to the cure of formerly 
untreatable staphylococcal diseases (Abraham et al. , 1941). When Kirby' s description of 
penicillinase-producing strains of S. aureus was published in 1944 (Kirby, 1944), 
resistance was infrequently encountered, with only a handful of strains available for 
study. 
Penicillinase-producing strains were first isolated from hospitalized patients and 
by 1946; about 6% of S. aureus produced penicillinase (~-lactamase), and were resistant 
to penicillin (Barber and Rozwadowska-Dowzenko, 1948). Studies in London then 
showed an increase in the proportion of penicillinase-producing isolates during the late 
1940s (Barber and Rozwadowska-Dowzenko, 1948). The reasons why so many isolates 
had penicillinase as early as 1946 are unclear, but reasons for the subsequent rise were 
linked to heavy and inappropriate antibiotic use. Penicillin powder was dusted on 
infected wounds and penicillin-containing snuff was available to treat respiratory 
infections (Livermore, 2000). Colonization of hospital staff by penicillin-resistant strains 
and their role in transmission were also notable features of these early reports. By 1948, 
over 50% of hospital S. aureus were penicillin-resistant (Barber and Rozwadowska-
Dowzenko, 1948). During the mid 1950s, the number of S. aureus clinical isolates 
showing high-level resistance to penicillin increased rapidly, to such an extent that 
penicillin ceased to be a useful therapeutic agent against staphylococcal infections. This 
proportion has subsequently grown to 80-90% (Chen et al. , 1993; Henwood et al. , 2000). 
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Although penicillinase-producing strains were universally present in hospitals in 
the early 1950s, community isolates of S. aureus were considered to be largely penicillin 
susceptible. Penicillin continued to be recommended as an effective anti-staphylococcal 
agent as late as the early 1970s (Weinstein, 1975). Spread to household contacts of 
patients with hospital-acquired penicillin-resistant strains was recognized as one notable 
exception, but the capacity for community transmission was largely ignored (Gerberding 
and Chambers, 2001). Furthermore, there was no systematic surveillance for antibiotic 
resistance among S. aureus isolates circulating within communities. S. aureus acquired 
the penicillinase-based resistance mechanism from an unknown "extra species" source 
and penicillin resistance spread across the entire species with the "plasmid epidemic" 
(Tomasz, 2003). The effects of this "plasmid epidemic" which were first seen on hospital 
isolates of S. aureus afterwards found its way into community isolates (Jessen et al. , 
1969). 
A comprehensive description and accurate assessment on the epidemiology of 
drug-resistant S. aureus strains was described by Jessen et al. (1969). Examination of 
more than 2,000 blood culture isolates of S. aureus received at the Statens Seruminstitut 
in Copenhagen from 1957 to 1966 for which detailed information on the origin of 
infection (hospital or community) was available confirmed a high prevalence of penicillin 
resistance (85% to 90%) for hospital isolates of S. aureus. Somewhat unexpected was 
that penicillinase-producing strains were almost as common in the community, with 65% 
to 70% of isolates resistant to penicillin. The community-acquired isolates were resistant 
only to penicillin, whereas nosocomial strains typically were resistant to multiple 
antibiotics. By the 1970s, it was apparent that the high prevalence of penicillin resistance 
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among community isolates was not limited to Denmark. A prevalence of 70-80% of 
penicillinase-producing strains was observed regardless of location in inner cities, 
surburbs and rural areas within and outside the United States (Ross et al. , 1974; Hughes 
et a!. , 1976; Hahn and Baker, 1980). Furthermore, a population-based study conducted in 
1972 revealed that 47% of healthy school-aged children under 10 years of age were 
carriers of S. aureus and that 68% of colonizing strains were penicillin-resistant (Ross et 
a!. , 1974). An evaluation of resistance pattern of 551 ,563 S. aureus community and 
hospital isolates from 1961 to 1990 by Faber and Rosdahl (1993) also confirmed this 
trend. 
The final stage of this remarkable and sweeping genetic change, is documented in 
a study conducted in Portugal (Sa-Leao et al. , 2001). Screening the S. aureus nasal flora 
recovered from 1,000 young and healthy volunteers who had never received antibiotics 
showed that 97% of the S. aureus colonizing these individuals produced penicillinase and 
was resistant to penicillin (Sa-Leao et al. , 2001). It became clear that the extra-species 
drug-resistance gene penicillinase had become a domesticated genetic component of S. 
aureus without causing any survival deficit to the cells. 
In summary, penicillin-resistant S. aureus was reported shortly after penicillin 
was introduced; within less than a decade, more than 25% of hospital strains were 
resistant, and within two decades, more than 75% were resistant (Gould and Cruikshank 
1957; Harris and Wise, 1969). This rapid increase in the prevalence in hospitals was 
followed a decade or so later by a similar rate of increase in the community. By the early 
1980s, roughly four decades after penicillin was widely available for civilian use, the 
prevalence of penicillin resistance in health care and community settings was virtually 
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identical and exceeded 85%, a situation which persists today (Gerberding and Chambers, 
2001; Tomasz, 2003). 
Some natural antibiotics were developed soon after the introduction of penicillin 
(Figure 1.2). These included chloramphenicol, erythromycin, streptomycin and 
tetracycline. However, the immense genetic repertoire of this bacterium for adapting to 
rapidly changing and uniformly hostile environments was repeatedly shown by the 
emergence of S. aureus strains that acquired resistance mechanisms to antimicrobial 
agents shortly after the introduction of these drugs into clinical practice (Oliveira et at., 
2002). Records of the Danish Health Board registered the years of introduction of various 
antimicrobials into clinical practice, beginning with penicillin in 1944-1946, 
streptomycin in 1948, tetracycline in 1950, and erythromycin in 1953 (Jessen et al. , 
1969). The same records indicate that S. aureus bloodstream isolates resistant to 
penicillin, streptomycin, tetracycline and erythromycin were recovered as early as 1957, 
and resistance to these antibiotics was often mediated by plasmids and transposons 
(Lacey, 1984). As the 1950s ended, resistant S. aureus posed major problems in many 
hospitals. International concerns centred upon the phage type 80/81 strain (resistant to 
penicillin), which caused rapid and devastating skin and wound infections while less 
devastating strains were multi-resistant to penicillin, tetracycline and streptomycin 
(Rountree and Freeman, 1955; Williams, 1959). 
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Figure 1.2: 








Clinical use of antibiotics. The beginning of each arrow indicates the time when the given 
antibiotic was introduced for clinical use and the tip of the arrow indicates when 
resistance emerged. The arrow is in reverse for penicillin G, since the first case of 
resistance to penicillin was reported two years prior to the first large-scale clinical use of 
penicillin in 1942. (Abraham and Chain, 1940). Reference: Wong and Pompliano (1998); 
Golemi-Kotra et al. (2003). 
1.2.2.2 Mechanisms of penicillin resistance 
The report by Kirby (1944) demonstrated that penicillin was inactivated by 
penicillin-resistant strains of S. aureus. Bondi and Dietz (1945) subsequently identified 
the specific role of penicillinase. The mechanism of penicillin resistance involved the 
acquisition of a plasmid-borne penicillinase capable of degrading the antibiotic before it 
reaches its cellular targets. The gene for ~-lactamase is part of a transposable element 
located on a large plasmid, often with additional antimicrobial resistance genes (e.g. 
gentamycin and erythromycin). 
Staphylococcal resistance to penicillin is mediated by blaZ, the gene that encoded 
~-lactamase production (Figure 1.3). This predominantly extracellular enzyme, 
synthesized when staphylococci are exposed to ~-Iactam antibiotics, hydrolyses the ~-
lactam ring, rendering the ~-Iactam inactive. BlaZ is under the control of two adjacent 
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regulatory genes, the antirepressor blaRl and the repressor blaI (Kernodle, 2000). Studies 
have also demonstrated that the signaling pathway responsible for ~-lactamase synthesis 
requires sequential cleavage of the regulatory proteins BlaRI and BlaI. Following 
exposure to ~-lactams, BlaRI, a transmembrane sensor-transducer, cleaves itself (Gregory 
et al., 1997~ Zhang et al., 2001). Zhang and his co-workers hypothesize that the cleaved 
protein functions as a protease that cleaves repressor BlaI, directly or indirectly (an 
additional protein, BlaR2, may be involved in this pathway) and allows blaZ to 
synthesize the extracellular enzyme. 
Figure 1.3: 
a 
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Mechanisms for penicillin and methicillin resistance. (a) Induction of staphylococcal 6-
lactamase synthesis in the presence of the 6-lactam antibiotic penicillin. I. The DNA-
binding protein Blal binds to the operator region, thus repressing RNA transcription from 
both blaZ and blaRl-blaJ. In the absence of penicillin, 6-lactamase is expressed at low 
levels. II. Binding of penicillin to the transmembrane sensor-transducer BlaRl stimulates 
BlaRl autocatalytic activation. ill- IV. Active BlaRl either directly or indirectly (via a 
second protein, BlaR2) cleaves Blal into inactive fragments, allowing transcription of 
both blaZ and blaRl-blaJ to commence. V-VIT. 6-Lactamase, the extracellular enzyme 
encoded by blaZ (V), hydrolyzes the 6-lactam ring of penicillin (VI), thereby rendering it 
inactive (Vll). (b) Mechanism of S. aureus resistance to methicillin. Synthesis of PBP2a 
proceeds in a fashion similar to that described for 6-lactamase. Exposure of MecRl to a 
6-lactam antibiotic induces MecRl synthesis. MecRl inactivates MecI, allowing 
synthesis of PBP2a. MecI and Blal have coregulatory effects on the expression of PBP2a 
and 6-lactamase. Reference: Lowy (2003). 
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1.2.3 History and epidemiology of methicillin-resistant Staphylococcus aureus 
(MRSA) 
Methicillin, introduced in 1961 was the first of the semisynthetic penicillin 
resistant to destruction by staphylococcal p-Iactamase. The discovery of methicillin was 
an important development as many hospital strains of S. aureus had become penicillin 
resistant in the 1950s through the production of p-Iactamase (Reacher et ai., 2000). 
However, its introduction was rapidly followed by reports of methicillin-resistant isolates 
(Jevons, 1961). First reported in a British hospital, MRSA clones rapidly spread across 
international borders. Waves of clonal dissemination with different phage types (e.g. 83 
complex) were reported in the 1960s and were responsible for a large proportion of 
staphylococcal infections (Jessen et ai., 1969; Parker and Hewitt, 1970). In the United 
States, the first nosocomial outbreak of MRSA was reported at Boston City Hospital, in 
1968 (Barrett et ai., 1968). Gentamicin-resistant MRSA (GR-MRSA) was first reported 
as causing an outbreak in 1976 (Shanson et ai., 1976), and subsequently, there was 
another outbreak of GR-MSRA involving three hospitals (Speller et ai., 1976). Data from 
the National Nosocomial Infections Surveillance System (NNIS) of the United States 
Centers for Disease Control and Prevention (CDC), which represents a large 'cross-
section of US hospitals, indicated that in the early to mid 1980s, MRSA was detected in 
tertiary referral hospitals, and in these hospitals, 5-10% of S. aureus isolates were MRSA, 
compared with rates well below 5% at smaller non-referral hospitals (Chamber, 2001). 
By the 1990s, the proportion of S. aureus isolates that were MRS A was 40% at tertiary 
referral centers and 20% at hospitals with less than 200 beds. 
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Epidemic MRSA (EMRSA) strains emerged in British hospitals in the late 1980s. 
Seventeen EMRSA strains are currently recognized and are given the nomenclature 
EMRSA-l to 17 (Anonymous, 1994; Aucken et at. , 2002). EMRSA-l has been shown to 
be similar to Australian eastern seaboard multiresistant MRSA (Townsend et ai. , 1984). 
It became prominent in Britain in the mid- to late 1980s (Cookson and Phillips, 1988) and 
was subsequently replaced by EMRSA-3, EMRSA-15 and EMRSA-16, which became 
the dominant strains a decade later. EMRSA-15 emerged in 1991 in Southeast England 
and spread to the Midlands area by early 1992 (Richardson and Reith, 1993). EMRSA-16 
emerged in East Northamptoshire, UK, in 1991 (Cox et at. , 1995). In 2000, most British 
MRSA bacteremias were due to EMRSA-15 or EMRSA-16 (Johnson et at., 2001). 
EMRSA-15 has been reported in New Zealand (Anonymous, 2001), Australia (Pearman 
et ai., 2001), the Czech Republic (Melter et at. , 2003) and Spain (Perez-Roth et ai. , 
2004). EMRSA-16 has also been identified in Greece (Aires de Sousa et ai. , 2003a), 
Mexico (Aires de Sousa et ai., 2001), Canada (Simor et ai. , 2002) and Spain (Perez-Roth 
et al. , 2003 , 2004). 
In Australia, the MRSA epidemic occurred in four waves involving distinctly 
different strains. The first was documented in Sydney between 1965 and 1972 (Vickery et 
at. , 1986). The second, a major epidemic of multi-resistant nosocomial MRS A 
(mMRSA), involved hospitals in Eastern and Southern Australia beginning in the late 
1970s (Pavillard et ai. , 1982; Turnidge et at., 1989). The third was due to non-
multiresistant MRS A (nmMRSA) strains, which were initially detected causing 
community-acquired infections in remote communities in Western Australia WA (Udo et 
al., 1993) and which subsequently spread to the capital, Perth (Riley et al. , 1995; O'Brien 
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et al., 1999). The fourth occurred as part of a wider epidemic of community-acquired 
nrnMRSA involving island communities in the South-Western Pacific (SWP), Auckland, 
New Zealand and major cities in eastern Australia (SWP-MRSA) (Mitchell et al., 1996; 
Collignon et al. , 1998; Riley et al., 1998; Nimmo et al. , 2000). 
New epidemic MRSA strains susceptible to several or virtually all, non-~-lactam 
antibiotics have emerged in several European countries. In 1992, a new phenotype arose 
in French hospitals, characterized by the unexpected reappearance of heterogeneous 
expression of methicillin resistance and susceptibility to various antibiotics including 
gentamicin, tetracycline, minocycline, lincomycin, pristinamycin, co-trimoxazole, 
rifampicin and fusidic acid (Aubry-Damon et aI., 1997; Lelievre et al., 1999). The 
incidence of isolation of strains of this phenotype has increased steadily throughout 
France, often replacing the classical multidrug-resistant MRSA (Lelievre et al. , 1999). A 
similar clone was recently reported to have replaced the usual multi-resistant MRSA 
clones and to predominate in a Greek and Spanish hospital with a high incidence of 
MRS A (Polyzou et al., 2001; Perez-Roth et al., 2004). A marked decrease in the use of 
gentamicin was suspected to be a factor contributing to the emergence of gentamicin-
susceptible MRSA from predominantly gentamicin-resistant MRSA populations in 
France (Aubry-Damon et al., 1997). However, changes in aminoglycosides consumption 
alone may not explain the increase in susceptibility to other antibiotics and the 
reappearance of heterogeneous resistance to methicillin observed with the new MRSA 
phenotypes. Fitness benefit, namely growth advantage, has been attributed to be an 
important factor for the spread of these susceptible clones (Laurent et al. , 2001). 
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1.2.3.1 Clinical importance of MRSA 
The major reservoir of MRS A in institutions are colonized and infected inpatients, 
while transient hand carriage of the organism on the hands of health care workers account 
for the major mechanism for patient-to-patient transmission (Thompson et ai., 1982). 
Patients with MRS A infections have been noted with worse clinical and economic 
outcomes compared with patients with MSSA infections. MRSA infections are 
particularly difficult to treat if they are located at anatomical sites, where antibiotic 
penetration is reduced (Duckworth, 2003). A study by Chang et ai. (2001) indicated that 
bacterial meningitis caused by MRSA was associated with a mortality rate of 56%, 
compared to a mortality rate of 13% in a patient group with meningitis caused by 
methicillin-susceptible S. aureus (MSSA). In addition, cohort studies of patients with 
MRSA bacteremia have reported higher mortality rates, increased morbidity, longer 
hospital length of stay, and higher costs compared with patients with MSSA bacteremia 
(Blot et ai., 2002; Melzer et ai., 2003; Kopp et ai. , 2004). In a meta-analysis study, the 
death rate for patients with MRS A bacteremia was estimated to be about two times higher 
than the death rate due to bacteremia caused by MSSA (Cosgrove et ai., 2003). 
Moreover, in comparison to patients with MSSA surgical site infections (SSI), patients 
with MRSA SSI had five additional days of hospitalization, a 1.9-fold increase in hospital 
charges and a 3.4-fold increase in mortality during the 90-day post-operative period 
(Engemann et ai., 2003). 
The higher cost of treating MRSA infections is due to a variety of factors. Firstly, 
high rates of MRSA infection result in the need for vancomycin, which is more expensive 
than the drugs normally used to treat S. aureus infections. Secondly, it is often necessary 
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to isolate the patients to keep them from infecting other patients. Finally, patients with 
MRS A infection stay longer in the hospital (Salyers and Whitt, 2002). A systematic audit 
of studies describing economic aspects of nosocomial infections revealed that a mean of 
$35,367 was attributed to MRSA infections (Stone et ai. , 2002). Studies performed in 
hospitals in the United States in 1999 showed that the direct medical cost for MRS A 
infections is $27,083-$34,000 per patient (Abramson and Sexton, 1999; Rubin et ai., 
1999). Consequently, annual United States health care costs associated with MRS A 
infections are estimated to be approximately $6 billion. A large fraction of additional 
costs that are attributed to the development of nosocomial pneumonia caused by S. 
aureus results from prolonged hospital stay, rather than the use of antibiotics to treat 
these infections (Dietrich et ai. , 2002). Verhoef et ai. (1999) also estimated that the costs 
to bringing an outbreak of MRS A (in which three to five patients are infected) under 
control in the Utrecht University Hospital, the Netherlands, could amount to $250,000. 
1.2.3.2 The mecA gene - Mechanism of resistance 
The spread of antibiotic resistance among S. aureus strains is of great concern in 
the treatment of staphylococcal infections, since S. aureus has quickly acquired resistance 
to most antibiotics introduced for clinical use. MRSA was 'born' at the moment it 
acquired the methicillin-resistance gene mecA, a 2.1kb exogenous DNA fragment, by 
horizontal transfer. MRSA was first described in 1961 in England (Jevons, 1961) and, 
since then, has gradually disseminated, reaching epidemic proportions in some European 
countries in the 1960s and in the United States in the 1970s (Haley et ai. , 1982). By the 
mid-1980s, they emerged as the most important nosocomial pathogens worldwide. 
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The central genetic component of the resistant mechanism in these bacteria is 
mecA, which - embedded in a larger block of ' foreign ' DNA - is not native to S. aureus 
but was imported from an unidentified extraspecies source (Beck et al. , 1986; Kuhl et al. , 
1978). The chromosomally located mecA gene encodes a 78-kDa penicillin-binding 
protein (PBP) 2A, which has unusually low affinity for all p-Iactam family of 
antimicrobial agents (Hartman and Tomasz, 1981; Hartman and Tomasz, 1984; Reynolds 
and Brown, 1985; Utsui and Yokota, 1985). PBPs are membrane-bound enzymes that 
catalyse the transpeptidation reaction that is necessary for cross-linkage of peptidoglycan 
chains (Ghuysen, 1994) (Figure 1.4). Their activity is similar to that of serine proteases, 
from which they appear to have evolved. PBP2A is a transpeptidase that, assisted by the 
transglycosidase domain of the native PBP2 of S. aureus, takes over the function of the 
cell wall biosynthesis in the presence of p-Iactam antibiotics (Pinho et al. , 2001). Thus, 
resistance to methicillin confers resistance to all p-Iactam agents, including 
cephalosporins. Recent studies determined the crystal structure of a soluble derivative of 
PBP2a. PBP2a differs from other PBPs in that its active site blocks binding of all P-
lactams but allows the transpeptidation reaction to proceed (Lim and Strynadka, 2002). 
Phenotypic expression of methicillin resistance is variable, and each MRSA strain has a 
characteristic profile of the proportion of bacterial cells that grow at specific 
concentrations of methicillin (Tomasz et al. , 1991). Expression of resistance in some 
MRS A strains is regulated by homologues of the regulatory genes for blaZ. The mecJ and 
mecRl genes regulate the mecA response to p-Iactam antibiotics in a fashion similar to 
that of the regulation of blaZ by the genes blaRl and blaI upon exposure to penicillin. 
Deletions or mutations in mecJ or the promoter region of mecA result in constitutive 
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expression rather than variable expression of mec (Niemeyer et al. , 1996). Moreover, 
Rosato et al. (2003) recently found that either mecI or bla! must be functional in all 
MRSA, and suggested that this may be protective mechanism preventing overproduction 
of a toxic protein. 
Since no homologue of mecA exists in methicillin-susceptible staphylococci, it 
has been assumed that mecA was acquired from one of the several coagulase-negative 
staphylococcal species (Archer and Niemeyer, 1994a). Couto et al. , (1996) identified a 
mecA gene in a methicillin-sensitive S. sciuri with 88% homology on the amino acid 
level to MRSA. Transduction of the S. sciuri mecA into an MSSA resulted in increased 
resistance to methicillin coupled with the detection ofPBP2a (Couto et al. , 2003). This 
study suggests one possible source of the mecA element in S. aureus. Hiramatsu et al. 
(2002a) and Okuma et al. (2002) have also speculated that the simultaneous detection of 
the SCCmec type IV in different geographical regions of the world potentially reflects its 








Model for the cooperative functioning of the transglycosylase (TGase) domain of PBP2 
and the transpeptidase (TPase) activity ofPBP2A in methicillin-resistant S. aureus. 
Upper section: In the absence of antibiotic, it is assumed that both the TPase and TGase 
domains of PBP2 participate in the biosynthesis of staphylococcal peptidoglycan. Lower 
section: When antibiotic is added to the mediwn, the TPase domain of PBP is acylated 
and is no longer capable of performing its peptide crosslinking activity. However, the 
penicillin-insensitive TGase domain ofPBP2 remains functional and cooperates with the 
TPase activity of the acquired PBP2A for cell-wall synthesis and bacterial growth in the 
presence of ~-lactam antibiotics in the surrounding medium. Reference: Pinho et al. 
(2001). 
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1.2.3.3 Other factors governing staphylococcal methicillin resistance 
The mecA gene is the primary determinant of intrinsic methicillin resistance but 
additional genes are required for a high-level resistance phenotype, besides other 
environmental factors (Hartman and Tomasz, 1984; Chambers, 1997; Berger-Bachi, 
1999; Berger-Bachi and Rohrer, 2002; Katayama et at. , 2003a). These genes are native 
constituents of the S. aureus genome and participate mostly but not exclusively in cell-
wall biosynthesis and turnover. The murF,JmtA-C, sigB, hmrA and hmrB, dtt, and ctaA 
genes, as well as the auxiliary genes (aux) essential for methicillin resistance (genes or 
mutants of JemA-F,JemR, andJemX) have been described (Chambers, 1997; Berger-
Bachi, 1999). Staphylococcal murein hydrolases, like the lytH gene product, also playa 
pivotal role as lytic enzymes in peptidoglycan growth and turnover. Some factors only 
have a minute effect on methicillin resistance, like those encoded by the global regulators 
sar and agr, which control production of virulence factors. However, functions for 
several genes and gene products like lim and aux16-encoded protein remain elusive (de 
Lencastre et at. , 1999; Berger-Bachi and Rohrer, 2002; Ray et al. , 2003). 
1.2.4 Current trends in global prevalence and characterization of MRS A 
The prevalence of MRS A in hospitals continues to increase worldwide. Data from 
the SENTRY surveillance study reported a nosocomial prevalence of26.3% in Europe 
and 34.9% in Latin America from 1997-1999 (Diekema et at. , 2001), 40.4% in South 
Africa (Johannersburg), 66.8% in Japan and 22.4% in Australia between 1998-1999 (Bell 
and Turnidge, 2002). In Central Europe (Austria, Germany and Switzerland), the 
prevalence of MRS A increased from 1.7% in 1990 to 8.7% in 1995 (Witte et al. , 1997). 
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In the United States, the National Nosocomial Infections Surveillance (NNIS) system 
reported a 51.3% methicillin rate among S. aureus strains from 18,397 intensive care unit 
patients between January 1998 and June 2002 (NNIS, 2002), which corresponds to an 
increase of25% relative to the rates reported for 1995-1999 (NNIS, 2001). Recent reports 
indicate that MRSA is currently the most commonly identified antibiotic-resistant 
pathogen in hospitals in the United States with a mean prevalence of 60% among patients 
in intensive care units (NNIS, 2003; Diekema et ai., 2001 ; Diekema et ai., 2004). 
An international study of antimicrobial resistance of hospital S. aureus 
comprising 21 worldwide hospital laboratories in 19 countries and states was conducted 
(Zinn et ai., 2004). Resistance patterns varied by region and MRSA occurred in low 
levels in countries within Northern Europe - Sweden (1 %), Finland (2%), increasing 
levels in Central Europe - Germany (6%) France (12%), United States - Colorado (9%), 
New Zealand (10%) and Australia (10%) and very high levels in Southern European 
countries - Belgium (30%), Greece (63%) as well as parts of the United States-
California (22%), Asia - Malaysia (49%) and South Africa - Johannersburg (39%) (Zinn 
et ai. , 2004). The prevalence of MRS A based on multicentre studies conducted in 
different regions of the world is presented in Table 1.1. The analysis of the nationwide 
survey in relation to regions are as follows; Asia-Pacific - Japan (67%), Europe - Greece 
(44.4%), North America - United States (34.2%), Latin America - Colombia (52%) and 
Africa - South Africa (34%) (Christiansen et ai. , 2004). 
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Table 1.1: Prevalence of MRSA in various regions based on multicentre studies 
Region/ No of Samples Total MRSA Year of References 
Country institutions number (%) Study 
of isolates 
Asia-Pacific 
Japan 3 Clinical 570 67 1999-2001 Christiansen et at. (2004) 
Korea 8 Clinical 682 64 1999-2001 Kim et al. (2004) 
Taiwan 3 Clinical 207 60 1999-2001 Christiansen et at. (2004) 
Australia 21 Clinical 19000 20 1989-1999 Nimmo et al. (2003) 
Africa 
South Africa 1 Clinical 163 34 1999-2001 Christiansen et at. (2004) 
(Johannersburg) 
Nigeria (Lagos) 1 Clinical 142 29.6 1996-1997 Kesah et al. (2003) 
Kenya 1 Clinical 137 27.7 1996-1997 Kesah et al. (2003) 
Cote D'Ivoire 1 Clinical 155 16.8 1996-1997 Kesah et at. (2003) 
Algeria 1 Clinical 208 4.8 1996-1997 Kesah et al. (2003) 
Latin America 
Colombia 15 Clinical 296 52 2001-2002 Arias et at. (2003) 
Chile 2 Clinical 428 45.3 1997-1998 Diekema et al. (2001) 
Argentina 2 Clinical 424 42.7 1997-1998 Diekema et al. (2001) 
Brazil 12 Clinical 852 34 1997-1999 Sader et at. (200 I) 
North America 
United States 30 Clinical 7169 34.2 1997-1998 Diekema et al. (2001) 
Canada 8 Clinical 1410 5.7 1997-1998 Diekema et al. (2001) 
Europe 
Greece 19 Blood 1126 44.4 1999-2002 Tiemersma et at. (2004) 
United Kingdom 27 Blood 5343 41.5 1999-2002 Tiemersma et al. (2004) 
Israel 5 Blood 849 38.4 2001-2002 Tiemersma et al. (2004) 
Croatia 6 Blood 341 36.7 2001-2002 Tiemersma et al. (2004) 
France 24 Blood 3376 33 .1 2001-2002 Tiemersma et al. (2004) 
Slovenia 8 Blood 657 18.4 2000-2002 Tiemersma et al. (2004) 
Germany 25 Blood 3757 13.8 1999-2002 Tiemersma et at. (2004) 
Czech Republic 35 Blood 2426 5.9 2000-2002 Tiemersma et al. (2004) 
Sweden 54 Blood 6071 0.8 1999-2002 Tiemersma et al. (2004) 
Netherlands 45 Blood 5359 0.6 1999-2002 Tiemersma et al. (2004) 
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1.2.4.1 Characterization of MRSA based on phenotypic and genetic methods 
Monitoring and limiting the intra- and interhospital spread of MRSA strains 
requires the use of efficient and accurate epidemiologic typing systems that allow the 
discrimination between unrelated isolates and the recognition of isolates descending from 
a common ancestor (i.e. belonging to the same clone). During the past four decades, 
multiple phenotypic and genotypic methods have been developed to type MRSA. The 
choice of a typing method depends upon the needs, the skills level, resources of the 
laboratory and the type of question to be answered. An optimal typing method should 
show high typeability, adequate stability, high technical reproducibility and high 
discriminatory power. In addition, ease of use, ease of interpretation, rapidity, 
accessibility and low costs may be considered convenient criteria (Struelens, 1996). 
Phenotypic typing methods such as phage typing, antimicrobial susceptibility testing and 
multi-locus enzyme electrophoresis are often limited in reproducibility, as the expression 
of different genes is often influenced by environmental factors. Moreover, some of these 
methods lack typeabililty or discriminatory power and, consequently, are not the most 
adequate approaches for bacterial comparison. 
The shortcomings of phenotype-based typing methods have led to the 
development of typing methods based on the microbial genotype or DNA sequence. The 
main genotypic techniques used for MRSA typing include (i) plasmid analysis; (ii) 
Southern hybridization analysis of digested chromosomal DNA, such as ribotyping, ClaI-
mecA::Tn554 polymorphisms, and binary typing; (iii) polymerase chain reaction (PCR)-
based techniques such as random amplified polymorphic DNA (RAPD), repetitive 
element sequence based-PCR (rep-PCR), amplified fragment length polymorphism, and 
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SCCmec typing; (iv) pulsed-field gel electrophoresis (PFGE) and (v) sequence typing 
techniques such as spa typing and multi locus sequence typing (MLST). These genotyping 
techniques minimize problems with typeability and reproducibility and, in some cases, 
enable the establishment of large databases of characterized organisms (Aires de Sousa 
and de Lencastre, 2004). 
1.2.4.2 International surveillance of MRSA and identification of pandemic clones 
Based on a combination of different typing methods such as DNA hybridization 
with the mecA and Tn554 probes, PFGE, RAPD, SCCmec typing, spaA typing and 
MLST, seven clonal types have been identified (the Iberian, Brazilian, Hungarian, New 
York/Japan, Pediatric and the EMRSA-15 and 16 clones) to spread in different regions of 
the world (Figure 1.5). 
The Iberian clone was first identified as the strain responsible for the 1989 
outbreak of MRS A disease in a hospital in Barcelona, Spain (Dominguez et al. , 1994), 
but seemed to have been already present in Belgium and France at least since 1984 
(Deplano et al. , 2000). Subsequently, it was detected in several Portuguese hospitals 
(Sanches et al. , 1995a; Sanches et al. , 1995b; Sanches et al. , 1996; de Sousa et al. , 1998; 
Oliveira et al. , 1998; Sa-Leao et al. , 1999) and in many other European countries such as 
the Czech Republic (Melter et al. , 1999), Poland (Krzyszton-Russjan et aI. , 2002), 
Sweden (Murchan et al., 2003), Italy and Scotland (Mato et al., 1998). This clone was 
also associated with epidemics in Germany and the Netherlands (Deplano et al. , 2000) 
and found in some community-acquired MRSA (CA-MRSA) in Finland among persons 
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who had contact with hospitals (Salmenlinna et at. , 2002). Moreover, the Iberian clone 
was detected in one hospital in New York (Roberts, 1998b). 
The Brazilian clone was shown to be widely disseminated in Brazilian hospitals 
(Teixeira et at. , 1995) and to have spread to neighboring countries in South America: 
Argentina (Corso et at., 1998; Aires de Sousa et at., 2001), Uruguay and Chile (Aires de 
Sousa et at. , 2001), and to Europe: Portugal, the Czech Republic (Sanches et at. , 1996; de 
Sousa et at. , 1998; Oliveira et al., 1998; Melter et al., 1999) and one hospital in Greece 
(Aires de Sousa et al., 2003a), where it displaced the local major clone. It has been 
detected in other European countries such as Finland, Germany, Ireland, The 
Netherlands, Poland, Sweden and the United Kingdom (Enright et at., 2002). 
The Hungarian clone has been widely spread in Hungarian hospitals since 1993 
(de Lencastre et at. , 1997; Oliveira et at. , 2001a) and was recently described as the major 
clone in two hospitals in Taiwan and China (Aires de Sousa et al. , 2003b). 
The New York/Japan clone was identified as the major clone in different states in 
the United States, namely in New York, Connecticut, New Jersey and Pennsylvania (de 
Lencastre et at. , 1996a; de Lencastre et at. , 1996b; Roberts et at. , 1998a; Roberts et ai., 
1998b), in several hospitals across Canada (Simor et ai., 2002) and in a hospital in Tokyo 
(Aires de Sousa et at. , 2000). Besides, it has also been detected in Europe: in Finland, 
Ireland and the United Kingdom (Enright et at., 2002). 
Epidemic MRSA (EMRSA-15) is one of the most prevalent MRSA clones in 
hospitals in the United Kingdom and detected in northern Berlin, Germany, the Czech 
Republic and Spain (O'Neill et at., 2001 ; Witte et at. , 2001; Moore and Lindsay, 2002; 
Melter et at. , 2003; Perez-Roth et ai., 2004). EMRSA-16 is one of the dominant types of 
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MRSA found in hospitals in the United Kingdom. This clone was widely disseminated in 
Greece (Aires de Sousa et aI., 2003a), Mexico (Aires de Sousa et al., 2001), Canada 
(Simor et aI., 2002) and Spain (perez-Roth et al., 2003). EMRSA-16 was responsible for 
the largest single-strain outbreak in Scandinavia that occurred in Sweden during the 
period 1997-2000 (Seeberg et al., 2002) and in community-acquired MRSA in Finland 
among persons who had contacts in hospitals (Salmenlinna et aI., 2002). This clone was 
also identified in other European countries such as Denmark, Switzerland and Belgium 
(Murchan et al., 2003). 
The Paediatric clone was first reported in 1991, in a pediatric hospital in Portugal 
(Sa-Leao et al., 1999) and since then has been identified in Poland (Leski et al., 1998), 
France and the United Kingdom (Enright et al., 2002), Colombia, Argentina, and the 
United States (de Lencastre et al., 1996a; Corso et al., 1998; Gomes et al., 2001; Aires de 
Sousa et al., 2001). 
Figure 1.5: Distribution of six pandemic clones in different regions of the world. Reference: Aires de 
Sousa and de Lencastre (2004). 
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1.2.4.3 Staphylococcal chromosome cassette mec (SCCmec) 
The genetic element of mec has long been known to be localized on the 
chromosome of S. aureus (Sjostrom et al., 1975). It was mapped to a locus between the 
genes encoding protein A (spa) and a protein involved in the biosynthesis of purines 
(purA) (Kuhl et al., 1978). The mecA gene, which encodes PBP 2A, and its regulatory 
genes, mecI and mecRI , were cloned and sequenced in the 1980s (Matsuhashi et al. , 
1986; Song et al. , 1987). Direct chromosome analysis of MRS A strains revealed that a 
substantial length of the chromosome DNA segment (greater than 30kb) carrying mec 
had no allelic equivalence in methicillin-susceptible S. aureus strains. Therefore, the 
segment was called additional DNA or mecDNA (Beck et aI. , 1986; Skinner et al. , 1988; 
Dublin et al. , 1992). The mecDNA and its regulatory genes are widely distributed among 
many staphylococcal species (Sjostrom et al. , 1975; Kuhl et al., 1978; Hiramatsu et al. , 
1992; Hurlimann-Dalel et al. , 1992; Suzuki et al. , 1992; Suzuki et al. , 1993; Archer et 
ai. , 1994b; Luong et aI. , 2002). The chromosome region surrounding mecA gene of the 
pre-MRSA strain N315 was sequenced and compared to the corresponding region of the 
methicillin-susceptible S. aureus strain NCTC 8325. This procedure demarcated this 
genomic island (GI) as a specific structure for the genetic trait of methicillin resistance 
(Ito et al., 1999) and was therefore included into the family of staphylococcal GIs. 
Subsequent experiments showed that the entire island was precisely excised from the 
N315 chromosome by the function of two site-specific cassette chromosome 
recombinases A (cerA) and B (cerB) encoded by the island; thus it was named the 
staphylococcal cassette chromosome mec (SCCmec) (Katayama et al. , 2000). Therefore, 
MRSA is produced when methicillin-s'fisceptible S. aureus (MSSA) acquires a genetic 
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element called staphylococcal cassette chromosome mec (SCCmec). Expression of both 
ccr proteins also promoted site-specific integration at a unique attBscc site located at the 
3' end of an open reading frame (ORF) of unknown function called orjX (Ito et al., 2001). 
It is located near the replication origin of S. aureus, which is 10kb downstream of pur A 
and 66-89kb upstream of spa gene depending on the size of the integrated copy of 
SCCmec (Kuroda et al. , 2001 ; Baba et ai. , 2002). This location may provide advantage 
for the instant utilization of imported antibiotic resistance genes (Ito et al., 2003). 
Since the discovery of the first SCCmecelement from pre-MRS A strain N315 in 
1999, several types ofSCCmec elements have been identified by determining their entire 
nucleotide sequences (Ito et ai. , 1999; Ito et al. , 2001 ; Ma et al. , 2002; Aires de Sousa 
and de Lencastre, 2003c). Pre-MRS A is a mecA gene-carrying MSSA strain in which 
mecA gene expression is strongly repressed by the presence of an intact mecI gene. The 
SCCmec element contains the mec gene complex composed oflS431mec, mecA, and 
intact or truncated sets of regulatory genes, mecR1 and mecI, and the ccr gene complex, 
which encodes site-specific recombinases responsible for the mobility of SCCmec 
(Katayama et al., 2000) . 
The mec gene complexes are classified into four classes according to their 
structure (Katayama et al., 2001), i.e. Class A, IS431-mecA-mecR1-mecI; Class B, IS431-
mecA-l1mecR1-mecI; Class C, IS431-mecA-l1mecR1- IS431 ; and Class D, IS431-mecA-
I1mecR1. The ccr gene complex contains two site-specific recombinase genes, cerA and 
ccrB, which are responsible for the mobility of SCCmec (Katayama et al. , 2000; Ito et al. , 
2001) There are four allotypes in each of the cerA and ccrB genes: ccrA1 , ccrA2, ccrA3, 
and ccrA4 for cerA and ccrB1 , ccrB2, ccrB3, and ccrB4 for ccrB. SCCmec is classified 
30 
into allotypes according to the combination of the mec gene complex class and the ccr 
gene complex type that it possesses (Ito et ai. , 2001 ; Ma et ai., 2002), as follows : type I 
SCCmec, (class B mec gene complex and type 1 ccr gene complex); type II SCCmec, 
(class A mec gene complex and type 2 ccr gene complex); type III SCCmec, (class A mec 
gene complex and type 3 ccr gene complex); and type IV SCCmec, (class B mec gene 
complex and type 2 ccr gene complex) (Figure 1.6). The region other than the mec and 
ccr gene complexes is designated the J (junkyard) region. Each SCCmec type is further 
classified into subtypes on the basis of the J-region sequence (Hiramatsu et ai., 2002b). 
The J regions contain various genes or pseudo genes whose presence does not appear 
essential or useful for the bacterial cell; the notable exceptions are resistance genes for 
non-p-lactam antibiotics or heavy metals, some of which are derived from plasmids or 
transposons. However, the J regions differ greatly among types and sUbtypes of SCCmec 
leading to variations in their sizes. Type-I SCCmec does not contain any antibiotic 
resistance genes other than mecA, and the J-region contains pis gene, encoding plasmin-
sensitive surface protein (Hilden et ai., 1996). Type-II SCCmec ofN315 and Mu50 
contain integrated copy of plasmid pUB110 and transposon Tn554 in the J region (Ito et 
aI. , 1999; Kuroda et ai. , 2001). Type-III SCCmec contains integrated copy of plasmid 
pT181 , transposon Tn554, and pseudo Tn554 that encodes resistance to tetracycline, 
erythromycin, and cadmium, respectively in its J-region (Ito et aI. , 2001). Types-IVa and 
-IVb SCCmec do not habour any resistance genes except for mecA. 
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Structures of four types of SCCmec. SCCmec is composed of two essential gene 
complexes, the ccr gene complex (orange) and the mec gene complex (gray). ccr gene 
complex is composed of cerA, ccrB genes which are responsible for the mobility of the 
SCCmec and some orfs surrounding them. The J-region (light gray) of the SCCmec is 
divided into three regions, H-13. Reference: Ito et al. (2003). 
Ito et al. (2004) recently identified a novel type V (Figure 1.7). It was found on 
the chromosome of a community-acquired methicillin-resistant Staphylococcus aureus 
strain (strain WlS - WBG8318) isolated in Australia. The element shared the same 
chromosomal integration site with the four extant types of SCCmec and the characteristic 
nucleotide sequences at the chromosome-SCCmec junction regions. The novel SCCmec 
carried mecA bracketed by IS431 (IS431-mecA-llmecR1-IS431), which is designated the 
class C2 mec gene complex; and instead of ccrA and ccrB genes, it carried a single copy 
ofa cassette chromosome recombinase C (ccrC). Type V SCCmec is a small SCCmec 
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element (28 kb) and does not carry any antibiotic resistance genes besides mecA. Unlike 
the extant SCCmec types, it carries a set of foreign genes encoding a restriction-
modification system that might playa role in the stabilization of the element on the 





Structure of the novel SCCmec type V. a: Essential structure of type V SCCmec. The 
locations of the essential genes are illustrated. b: ORF's in and around type V SCCmec. 
Yellow arrows indicate ORF's unique to type V SCCmec, orange arrows, orjX; gray 
arrows, ORF's conserved in the five types of SCCmec elements with identities of 48.1 to 
93.4%; blue arrows, ORF's commonly found in both the type SCCmec and the J region 
of type ill SCCmec. Reference: Ito et al. (2004) . 
1.2.4.4 see without antibiotic resistance determinants 
SCC elements that contain the essential features of SCCmec, but lack the mecA 
gene have been recognized in some coagulase-negative staphylococci as well as in S. 
aureus (Luong et ai., 2002~ Ito et aI. , 2003 ~ Katayama et ai., 2003b). SCCcapl, which 
carries type 1 capsular polysaccharide, was identified in S. aureus strain M, a methicillin-
susceptible strain (Luong et ai., 2002). SCC12263 was recently identified in S. hominis 
ATCC 27844. Because it carries a functional pair of ccr genes and other sequences with 
variable homology to those found in SCCmec elements, it was proposed that SCC12263 
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might be an ancestral form of SCCmec elements (Katayama et ai. , 2003b). SCC476 was 
found in MSSA strain 476, which showed great similarity with the previously described 
S. homonis non-mec SCC element. It carries a novel gene with homology to the fusidic 
acid resistance gene/arl (O'Brien et ai. , 2002). SCCpbp4 (contains pbp4 and tagF genes) 
was recently discovered in S. epidermidis strain ATCC 12228, and has been proposed to 
represent the primordial genetic element contributing DNA sequences to the SCCmec 
elements found in S. aureus (Mongkolrattanothai et al. , 2004). 
1.2.4.5 Models for MRSA evolution 
The key genetic component of methicillin resistance, the mecA gene determinant, 
is not native to Staphylococcus aureus. Thus, the evolution of methicillin-resistant S. 
aureus (MRSA) must have begun with the acquisition of the mecA determinant from an 
unknown heterologous source some time before the first reported appearance of MRS A 
isolates in clinical specimens in the United Kingdom and Denmark (Crisostomo et al. , 
2001). The first MRSA isolated in England in 1961 were only resistant to p-Iactam 
antibiotics, with resistance conferred by type I SCCmec. The relationship between this 
isolate and modem MRSA has been the subject of some investigations (Enright, 2003). 
Two models of MRSA evolution were initially proposed in the early 1990s, based on 
studies using different typing techniques. The first model, described by Kreiswirth et al. 
(1993), was based on analysis of restriction fragment length polymorphisms generated by 
CiaI digestion of chromosomal DNA, followed by hybridization with Tn554 and mecA 
probes. The limited number of patterns observed in a geographical and temporally 
diverse sample of MRS A isolates were taken as evidence that S. aureus had acquired the 
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methicillin resistance gene (mecA) on only one occasion, and the authors therefore 
hypothesized that all extant MRSA clones were recent descendants of this prototypical 
isolate. 
Several months before the publication of this study, Musser and Kapur (1992) 
described MRSA as being polyclonal in a multilocus enzyme electrophoresis analysis of 
254 MRS A isolates. The association of mecA with divergent genetic backgrounds was 
taken as strong evidence that the gene is transferred horizontally between S. aureus 
isolates. The explanation from these results was that MRSA isolates had diversified so 
rapidly between 1961 and 1992 that they had lost any genetic similarity. The existence of 
modem MRSA lineages that are unrelated to the first MRSA strain by molecular typing 
methodologies also supported the theory of Musser and Kapur, and was further 
strengthened by evidence from micro-array analysis (Fitzgerald et ai., 2001a) and 
multilocus sequence typing (MLST) (Enright et ai. , 2002). These studies indicated larger 
genetic differences between MRS A lineages than would be expected if they were 
descended from a strain that emerged after the introduction of methicillin in 1959. It is 
therefore generally accepted that modem MRSA represent independent acquisitions of 
SCCmec by different genetic lineages of S. aureus. 
1.2.4.6 Investigation on the epidemiology and evolution of MRSA - Use of 
epidemiological tools 
The recovery of isolates with identical bacteriophage types from different 
hospitals within and between countries was described in the 1950s by Rountree and 
Freeman (1955) and Rountree and Beard (1958), in which increased epidemicity was 
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demonstrated. However, bacteriophage typing has fallen out of favour as a means of 
characterizing S. aureus, because of difficulties in typeability and reproducibility, as well 
as the cryptic genetic basis upon which characterization relies (Bannerman et al., 1995 ; 
Weller, 2000). Molecular typing techniques are commonly used to study the 
epidemiology of S. aureus. The international spread of epidemic clones, such as the 
Iberian (Sanches et al. , 1995a), UK epidemic (Marples and Cooke, 1985; Kerr et al. , 
1990), New York-Japanese (Ito et al. , 1999; Oliveira et al. , 2001), German MRSA 
(Witte, 1999a; Witte et al. , 2001) and Viennese (Witte et al., 1999b) have been 
investigated with a variety of techniques, the most popular of which has been pulsed-field 
gel electrophoresis (PFGE) (Tenover et al., 1995; Chung et al. , 2000). 
1.2.4.6.1 Multilocus sequence typing (MLST) 
MLST (Maiden et al. , 1998) involves sequencing DNA fragments 
(approximately 500bp) of seven housekeeping genes and comparing these sequences to 
known alleles at each locus site via the MLST website (http://www.mlst.net). An allelic 
profile consisting of seven integers that defines a sequence type (ST) is thus obtained. 
MLST was first applied to S. aureus in a study published in 2000 (Enright et al. , 2000), 
in which 155 invasive S. aureus isolates were typed. In addition to validating the method 
against PFGE, the study showed how epidemic clones of MRSA and MSSA could be 
unambiguously defined by their sequence types (STs). The MLST website currently 
contains allelic profile of more than 1000 isolates from disease and carriage from about 
25 countries. 
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1.2.4.6.2 SCCmec typing 
The methicillin resistance structural gene mecA is a part (2007bp) of a much 
larger genetic element, which is inserted precisely into the S. aureus chromosome. This 
staphylococcal chromosomal cassette mec (SCCmec) varies in size from 20 to 68 kb, but 
always contains mecA and at least part of a regulatory gene mecRI and chromosomal 
cassette recombinase genes (ccr) . Five main types ofSCCmec have been described (Ito et 
at., 2001; Ma et at., 2002; Ito et at., 2004), and although the same types are often 
associated with divergent lineages, particular MRSA clones are associated with single 
SCCmec elements. 
1.2.4.6.3 Origin of the first MRSA 
The evolutionary history of the first MRSA clone was clarified by two 
research groups, using MLST and SCCmec typing (Crisostomo et at. , 2001; Enright et 
at., 2002). In the first investigation, a high level of genetic similarity was found between 
the most prevalent MRS A (ST36) and the methicillin-sensitive S. aureus (MSSA; ST30) 
genotypes (Enright et at., 2000). An evolutionary scenario was therefore proposed 
describing the emergence of ST36 from ST30 upon acquisition of SCCmec. ST36 
represents UK epidemic clone 16, one of the major MRSA currently circulating in the 
country (Anonymous, 1997). In a thorough genetic analysis using several typing 
technologies, Crisostomo et at. (2001) compared the genetic backgrounds and phenotypes 
of a group of methicillin-susceptible S. aureus (MSSA) recovered in the early 1960s, 
MRSA isolates obtained during the same period, and contemporary epidemic clones of 
MRS A. The MSSA strains may have been the original recipients of the mec element at 
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the time when the first European isolates of MRSA were identified in Denmark and in the 
United Kingdom. All the early MRSA isolates resembled a large group of the early 
MSSA blood isolates in phenotypic and genetic properties, including phage group, 
antibiotype (resistance to penicillin, streptomycin, and tetracycline), pulsed field gel 
electrophoresis pattern, and spaA type. The early MSSA strains shared a common MLST 
allelic profile (3-3-1-1-4-4-16; ST 250) with the first MRSA isolates from England, 
suggesting that the early MSSA examined represented the progeny of a strain that served 
as the one of the first S. aureus recipients of methicillin-resistance determinant in Europe. 
It was therefore proposed that the first MRSA evolved from this MSSA clone upon 
acquisition of SCCmec I. The close genetic similarity between the first MRSA isolates 
and the Iberian MRSA clones was also described; and it was suggested that the Iberian 
clone (ST247-MRSA-I) is a single locus variant (SLV) ofST250. This genotype was 
proposed as the ancestor of the first member of the Iberian clone, a modem pandemic 
MRSA that shares the high epidemicity of the 'archaic' clone, a genotype that spread 
extremel y rapidly after its first emergence in 1961 and was identified in 1993. This report 
highlighted the success of a particular genotype sequentially acquiring resistance 
determinants. 
In 2002, an MLST study was published that provided evolutionary scenarios for 
all major MRSA clones and a rational nomenclature for S. aureus genotypes derived from 
resistance type (MSSA, MRSA), vancomycin-intermediate and resistant S. aureus (VISA 
or VRSA), ST and SCCmec type (Enright et ai., 2002). The advantage that this study had 
over previous investigations was the representative selection of strains chosen (912 
isolates from 20 different countries), the use of SCCmec typing and MLST to define 
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clones, and more importantly, the use of BURST (Based Upon Related Sequence Types) 
algorithm to examine genetic relationships. BURST was developed by Ed Feil 
(University of Bath, UK) to analyse recent evolutionary events using multi locus datasets 
such as those produced by MLST. Briefly the algorithm places STs that share five out of 
the seven MLST alleles into a common clonal complex (CC). 
The evolution of the earliest MRS A (ST2S0) was demonstrated to be more 
complicated than the scenario outlined by Crisostomo et ai. (2001). ST-2S0-MRSA-I was 
shown to be derived from ST-2S0-MSSA, which arose from STS-MSSA, a common 
cause of epidemic MSSA disease (Figure 1.S). The assignment of STS-MSSA as the 
ancestor of ST2S0-MSSA was supported by the finding that STS and ST2S0 differed at a 
single locus whose alleles are identical except for a point mutation in yqil, unique to 
ST2S0 and its descendants (Enright et ai., 2002). Further support for this hypothesis was 
the finding that all isolates of ST2S0 and its descendants were MRSA with the SCCmec 
class 1. STS-MSSA was therefore proposed to be the ancestral genotype of the first 
MRSA (Enright et ai., 2002). Application of BURST showed that all epidemic hospital 
MRSA isolates that have been found in more than one country belong to five CCs. (Table 
1.2). These CCs were named according to the ST of their proposed ancestor, and included 
CCS (archaic MRSA), CCS, (which contains most of the VISA isolates studied to date), 
and three clonal complexes (CC4S, CC30 and CC22) that contain recently emerged 
international MRSA clones such as UK EMRSA-16 (CC30) (Anonymous, 1997), Berlin 
epidemic MRSA (CC4S) (Witte et ai., 1999b) and UK EMRSA-1S or Bamim epidemic 
MRSA (Witte et ai., 2001). 
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To improve the resolution ofMLST and SCCmec typing, eight genetic targets 
were sequenced in a study of five nosocomial MRSA CCs (Robinson and Enright, 2003). 
In addition to seven MLST genes, those of the seven S. aureus surface (sas)- associated 
proteins (Mazmanian et ai., 2001) and the IgG binding protein A gene (spa) (Shopsin et 
ai., 1999) were sequenced. Phylogenies of concatenated sequences from seven MLST 
and seven sas genes were constructed for 147 genotypically diverse isolates of MRS A 
and MSSA, in order to examine the patterns of SCCmec acquisition within the five major 
MRS A-containing lineages. This study provided the first estimate of the number of times 
methicillin resistance had been acquired in this species (at least 20 times). It also 
indicated that SCCmec type IV is the most frequently acquired element within the five 
major lineages responsible for most hospital-acquired infections (10 acquisitions of 
SCCmec type IV and 10 acquisitions of the other SCCmec types). Nearly half (9 of 20) of 
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Proposed evolutionary models for the emergence of international MRSA in 
CCS. The large circle represents STS-MSSA- the presumed ancestral genotype 
of this cc. Smaller circles represent descendant clones. Arrows indicate the 
direction and relative amount of change between clones. Names and countries of 
isolation are given for all clones. Historically early MSSA and MRSA isolates 
. are indicated with asteriks next to their country of isolation. Previously named 
clones are indicated in black boxes. Reference: Robinson and Enright (2003); 
Feil and Enright (2004). 
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Table 1.2: Details of pandemic MRSA clones and their clonal complexes 













ST5-MRSA-I 1-4-1-4-12-1-10 UKEMRSA-3 
ST5-MRSA-II 1-4-1-4-12-1-10 New York/Japanese 
ST-228-MRSA-I 1-4-1-4-12-24-29 Southern German 
ST8-MRSA-II 3-3-1-1-4-4-3 Irish-l 
ST8-MRSA-IV 3-3-1-1-4-4-3 UK EMRSA-2,-6 
ST239-MRSA-II 2-3-1-1-4-4-3 UK EMRSA-I, -4, -II, Portuguese, Brazilian, 
Viennese 
ST247-MRSA-I 3-3-1-12-4-4-16 UK EMRSA-5, -17, Iberian 
ST250-MRSA-I 3-3-1-4-4-16 First MRSA 
ST22-MRSA-IV 7-6-1-5-8-8-6 UK EMRSA-15, Barnim 
ST36-MRSA-II 2-2-2-2-3-3-2 UK EMRSA-16 
ST45-MRSA-IV 10-14-8-6-10-3-2 Berlin 
Reference: EnrIght (2003). 
1.2.5 Community-acquired methicillin resistant Staphylococcus aureus (CA-
MRSA) 
For many years, methicillin-resistant S. aureus was considered a multi-drug 
resistant pathogen that has been historically associated with hospitals and health care 
facilities (Livermore, 2000). However, MRSA besides having established itself as a 
major hospital pathogen has now been documented in the healthy community and 
affecting persons without established risk factors for MRSA acquisition (Vandenesch et 
ai. , 2003). Until 1980, cases of community-onset MRSA infection were attributed to a 
history of recent hospitalization, close contact with a person who had been hospitalized, 
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or similar exposures (Payne et aI. , 1965; Layton et al. , 1995; Gross-Schulman et al., 
1998; L'Heriteau et al. , 1999). In addition, some cases of community-onset infection 
were actually due to acquisition of MRSA in long-term settings, an environment that also 
promotes emergence and spread of resistant staphylococci. However, cases of 
community-onset MRSA infections occurring in 1980 and 1981 that were reported from 
Detriot provided the first suggestive evidence that MRSA could spread in communities 
independent of direct health care exposure. Most of the affected patients were injection 
drug users, sharing needles was the most likely mode of spread, and previous 
antimicrobial (especially cephalosporin) use was an important risk factor for infection 
with the outbreak strain (Saravolatz et al. , 1982). 
The deaths of four children from rural Minnesota and North Dakota caused by 
community-onset MRS A infection in 1999 focused attention on this emerging problem 
(Centers for Disease Control and Prevention, 1999). These children lacked established 
risks for MRSA infection. In addition, their infections were caused by isolates susceptible 
to most non-beta-Iactam antimicriobials and had identical genotypes distinct from those 
of MRSA isolates from local hospitals. These reports of infection and colonization by 
strains of MRSA in children provided compelling evidence that MRSA strains, like 
penicillinase-producing strains almost 30 years ago, have gained foothold in the 
community and have emerged as important outpatient pathogens. 
Although many authors reported the emergence of community-acquired 
methicillin resistant S. aureus (CA-MRSA) isolates, a standard definition did not exist 
and at least eight different classifications were observed by Salgado et al. (2003) to have 
been used to classify MRSA infection as community-acquired. The commonly used term 
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CA-MRSA implies that it is known that the organism was acquired in the community. 
However, this term is often used to refer to the detection of colonization or infection in 
the community, rather than to actual acquisition of MRS A in the community. MRSA 
colonization may persist for months to years, and the acquisition of MRS A frequently 
goes unrecognized unless clinical infection develops, making it difficult to know with 
certainty the true site of acquisition (Salgado et at. , 2003). Salgado et at. (2003) therefore 
proposed that the presence of risk factors known to be associated with acquisition of 
MRSA, i.e. recent hospitalization, recent surgery, recent outpatient visit, recent nursing 
home admission, recent antibiotic exposure, chronic illness, injection drug use and close 
contact with a person with risk factor(s) , should be evaluated before classifying an 
MRSA isolate as CA-MRSA. 
A global analysis that examined the results of 57 studies on the prevalence of CA-
MRSA among hospital patients or among community members reported that most 
persons with CA-MRSA had more than one health care-associated risk, suggesting that 
the prevalence of MRSA among persons without risk factors still remains very low 
«0.24%) (Salgado et at. , 2003). However, the high MRSA colonization rates reported 
among members of "closed populations", such as Australian aboriginal (Udo et at. , 1993) 
and Native American (Groom et at., 2001) communities, may be associated with risk 
factors for spread in the community, such as overcrowding, high rates of skin infections 
and frequent use of broad-spectrum antibiotics (Maguire et at., 1998). Salgado et at. 
(2003) observed that the increase in CA-MRSA among non-hospitalized patients seems 
to be mainly due to the introduction of health-care associated strains into the community. 
Aires de Sousa and de Lencastre (2003c) found similarities between CA-MRSA and 
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sporadic nosocomial MRSA isolates, raising the possibility that at least some of the 
MRSA strains described as community-acquired may actually originate in hospitals. 
However, other authors reported that clones found in CA-MRSA were different from any 
of the major hospital-acquired MRSA clones (Dufour et ai., 2002; Okuma et ai. , 2002), 
suggesting CA-MRSA could have appeared de novo through horizontal acquisition of the 
mecA gene (Salmenlinna et ai., 2002). Moreover, an Australian study reported the 
introduction of a strain (originating in the community) into the hospital setting (O'Brien 
et ai., 1999; Saiman et ai., 2003). 
Three main hypotheses were initially proposed to account for the appearance of 
CA-MRSA. First, they may actually be health-care acquired pathogens, but the direct link 
to health care was not detected in the relevant investigations. This hypothesis was 
consistent with some early investigations of community-onset infections, but recent 
studies of community MRS A failed to detect health care risks despite detailed 
investigations. Another hypothesis to account for the emergence of MRSA was that these 
isolates are direct descendants of health-care acquired strains that are now circulating in 
the community. The density of health care-acquired MRSA in the community has 
increased over the past decade, as the prevalence of colonized patients discharged to 
home or other community settings increased. Hence there are more opportunities for 
spread to household contacts or others in close proximity to patients in health care 
settings. However, this hypothesis was inconsistent with the phenotypic (e.g. 
antimicrobial susceptibility) and genotypic (e.g. genotypic pattern) differences between 
community-acquired and health care-acquired isolates. 
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The last hypothesis to explain the appearance of MRS A in communities is that the 
mecA gene, the genetic determinant necessary for the expression of methicillin resistance, 
has been transferred to one or more penicillin-resistant, methicillin-susceptible strains of 
S. aureus that occupy traditional community niches. This possibility accounts for the 
distinct phenotypic and genotypic characteristics of CA-MRSA. Horizontal transmission 
of the plasmid-borne penicillinase gene responsible for penicillin resistance likely played 
the dominant role in the emergence of community-acquired penicillin-resistant S. aureus. 
S. aureus plasmid genes can be transferred by transduction or conjugation, a fact which 
may explain the enormous genetic diversity among penicillin-resistant methicillin-
susceptible S. aureus (Gerberding and Chambers, 2001). 
1.2.5.1 Prevalence of CA-MRSA 
One of the earliest investigations on CA-MRSA was described in Western 
Australia (Udo et at. , 1993). Most CA-MRSA infections have been reported for other 
patient populations across many regions of the United States (Moreno et at. , 1995; 
Adcock et at. , 1998; Herold et at. , 1998; Centers for Disease Control and Prevention, 
1999; Gorak et at. , 1999; Frank et at. , 1999; Suggs et at. , 1999; Groom et at. , 2001 ; 
Naimi et at. , 2001; Charlebois et at. , 2002; Fey et at. , 2003; Baggett et at. , 2004; 
Buckingham et at. , 2004; Ellis et at. , 2004; Shukla et at. , 2004) and Australia (Udo et at. , 
1993; Gosbell et at. , 2001 ; Nimmo et aI. , 2001 ; Munckhof et at. , 2002; Munckhof et at., 
2003 ; Coombs et at. , 2004; Murray et at. , 2004). Other countries include Latvia 
(Miklasevics et at., 2004), Hong Kong (Ho et ai., 2004); Taiwan (Fang et ai. , 2004; 
Wang et at. , 2004), Switzerland (Liassine et ai., 2004), Germany (Witte et ai. , 2004a; 
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Witte et ai. , 2005), United Kingdom (Klein et ai. , 2003), New Zealand (Adhikari et ai. , 
2002), Saudi Arabia (Bukharie et al. , 2001), France (Dufour et ai. , 2002), Finland 
(Salmelinna et ai. , 2002) and recently, in Singapore (Hsu et ai., 2005) and in South 
America (Ribeiro et ai., 2005). 
Certain ethnic groups are reported to have a propensity for the acquisition of CA-
MRSA. These include Native American populations in the Mid-West United States 
(Groom et ai., 2001; Fey et ai., 2003) and aboriginals in Canada (Taylor et ai. , 1990; 
Embil et ai. , 1994) and Australia (Maguire et al. , 1996; Tumidge et ai. , 2000). There is 
accumulating evidence that the virulence of CA-MRSA differs quite considerably, with 
some isolates having more potential to cause skin infections and others with potential to 
cause systemic, life-threatening infections. Most infections are mild and limited to skin 
and soft tissues, but serious infections like pneumonia (Gillet et ai. , 2002; Boussaud et 
ai. , 2003; Klein et ai. , 2003; Peleg and Munckhof, 2004), endocarditis (Villar et al. , 
1999; Lin et ai., 2000), liver abscess associated with renal disease (Chi et al., 2004a), 
bacteremia (Chi et ai., 2004b), ear infections (Hwang et ai. , 2002), foodbome illness 
(Jones et ai., 2002a), arthritis (Kallarackal et al., 2000) and brain abscess (Khan et al. , 
2000) have also been reported. 
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1.2.5.2 Pathogenesis and Virulence Factors of CA-MRSA 
Several genetic factors that may enhance the ability of community-associated 
MRSA strains to cause disease have been identified. 
1.2.5.2.1 Enterotoxins 
The sentinel report detailing the cases of four children who died of fulminant 
MRSA infections in the Northern Plains states acutely raised the awareness ofthe 
presence and seriousness of MRS A in the community (Centers for Disease Control and 
Prevention, 1999). These isolates produced staphylococcal enterotoxins B (SEB) or C 
(SEC), which are members of the superantigen family implicated in approximately 50% 
of toxic shock syndrome cases, and were later, reported to produce Panton-Valentine 
leukocidin (PVL) (Gillet et ai., 2002). A larger study of MRS A isolates from American 
Indians in Nebraska compared community isolates with hospital isolates obtained at an 
institution, and with a reference collection of isolates causing nonmenstrual toxic shock 
syndrome (NMTSS) (Fey et ai., 2003). It was observed that most of the community 
MRS A isolates were closely related genotypically to one another (and to MW2) but 
unrelated to the Nebraska hospital strains or to most of the other reference strains. High 
levels of SEB or SEC were produced in the CA-MRSA isolates along with 76% of the 
NMTSS-causing isolates (although none ofthe hospital MRS A isolates did). The genes 
for PVL and SEH were found in at least two of the community MRS A isolates. The 
community isolates were closely related to other community MRS A isolates obtained in 
the upper MidWest (Groom et ai. , 2001; Naimi et ai., 2001;) and from other sites around 
United States (Said-Salim, 2003) suggesting that these strains are circulating widely. 
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They also appeared to be descendants of a methicillin-susceptible NMTSS-causing strain 
isolated in Alabama in 1986 because their genomes differed only by the apparent 
insertion of SCCmec into the chromosome (Fey et al., 2003). 
1.2.5.2.2 Panton-Valentine leukocidin 
Panton-Valentine leukocidin is an exotoxin that induces pore formation in 
neutrophils and monocytes, leading to their activation, degranulation and release of 
inflammatory mediators (Dinges et al. , 2000). Found in both MRSA and MSSA, it has 
been associated with skin abscesses and furuncles (Cribier et al., 1992), and severe 
necrotizing pneumonias in children (Gillet et al., 2002). Although it was only identified 
in 2% to 3% of S. aureus strains (Dinges et al. , 2000), a study of clinical isolates 
submitted to a French national reference laboratory found PVL producing strains to be 
strongly associated with furuncles and community-acquired severe necrotizing 
pneumonia (Lina et al. , 1999). A recent study from the same national laboratory 
specifically examined PVL-producing MRSA isolates that caused infection in health 
patients without known MRSA risk factors (Dufour et al., 2002). All isolates carried the 
genes encoding PVL (lukS-PV-IukF-PV) and also genes for another leukocidin (encoded 
by lukE-IukD) that had been found in isolates causing impetigo (Gravet et al., 2001) and 
other infections (Dufour et al. , 2002), but lacked genes encoding for other toxins. A 
limited number of CA-MRSA clones carrying the PVL genes are currently spreading 
across several continents (Vandenesch et al., 2003). In Europe, closely related PFGE 
patterns have been reported for PVL-positive CA-MRSA isolated in Switzerland, France 
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and the Netherlands, pointing to clonal spread 
(http://www.eurosurveillance.org/ew/2003/030306.asp). 
1.2.5.2.3 Exfoliative toxins 
A recent survey of S. aureus isolates obtained from Japanese patients with 
bullos impetigo revealed an unexpected clonal group of MRSA strains producing types A 
or B exfoliative toxins (ET; exfoliatin, epidermolytic toxin) (Yamaguchi et al., 2002). 
These toxins, known to cause large blisters at the site of infection, had not been 
previously detected in MRS A strains. The investigators presented several lines of 
evidence suggesting that the exfoliative toxin-producing MRSA strains have arisen 
recently, perhaps by incorporation of a phage carrying the eta gene into a new 
background MRSA, or by acquisition of mecA by ET -B producing MSSA strains. Clonal 
relatedness of exfoliative toxin-positive CA-MRSA strains in Switzerland and Japan has 
also been reported suggesting clonal spread (Liassine et al., 2004). 
1.2.5.2.4 Haemolysins 
A study of West Samoan phage pattern (WSSP) -1 and -2 isolates from 
Australia, New Zealand, and Western Samoa found that they consistently produced 
higher levels of a and ~ hemolytic toxins than hospital-endemic MRS A strains (Adhikari 
et al., 2002). The former lyses red blood cells by pore formation in the cell membranes 
(and also is known to be dermonecrotic and neurotoxic), whereas the latter is a 
sphingomyelinase (Dinges et al., 2000). These community strains were also found to be 
more salt-tolerant and adhered better than nosocomial strains to human epithelial cells. 
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In summary, there appears to be four different clonal groups of CA-MRSA 
circulating in geographically defined areas: the exfoliative-producing isolates from Japan, 
the French PVL-positive isolates, the halotolerant a-toxin-producing isolates from 
Australia and the enterotoxin-producing isolates from the USA (Eady and Cove, 2003). 
1.2.5.3 Genetic characterization of CA-MRSA 
Several factors seem to distinguish the community-onset MRSA infections not 
attributable to health care exposure from those that are health care associated. 
Community-acquired MRS A tends to cause infections that occur in clusters or small 
outbreaks that affect unique populations such as young children, Australian Aborigines, 
Native Americans, Alaskan Natives, prisoners and college athletes. Most CA-MRSA 
isolates harbor the SCCmec type IV that appears to be resistant only to beta-Iactam 
antibiotics and have a heterogenous methicillin resistance phenotype that is consistent 
with the lack of any antibiotic genes other than mecA (Oliveira et al., 2001 b; Okuma et 
al. , 2002). This does not, however, preclude chromosomally encoded resistance or the 
presence of resistance plasmids. Some CA-MRSA strains isolated in Australia contained 
a 41.4kb plasmid encoding resistance to tetracycline and trimethoprim, as well as 
resistance to mupirocin and cadmium (Pearman and Grubb, 1993; Udo et al. , 1994). 
Resistance to erythromycin has also been reported in some regions (Embil et al. , 1994; 
Layton et al., 1995; Groom et al., 2001; Fergie and Purcell, 2001; Sattler et al. , 2002) and 
a minority of isolates is multiply resistant (and thus may represent mis-classified hospital 
MRSA). 
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CA-MRSA carries a class B mec complex (Oliviera et ai. , 2001b; Damn et ai. , 
2002; Hiramatsu et ai. , 2002b; Oliviera et ai. , 2002; Ma et al. , 2002;). The SCCmec type 
IV element is found not only in CA-MRSA but also in some hospital MRSA (H-MRSA), 
notably in EMRSA-15 (Enright et al., 2002), one of the most common hospital MRSA in 
the United Kingdom that is now spreading globally, and in the paediatric clone that is 
prevalent in hospitals worldwide, especially among infants and children (Sa-Leao et ai. , 
1999). Type IV SCCmec is also responsible for methicillin resistance in gentamicin 
susceptible MRSA from France (Laurent et ai., 2001; Hiramatsu et ai. , 2002b). Besides 
the relatively simple antibiotic resistance profile, CA-MRSA strains displaying SCCmec 
type IV were also reported to show several additional differences from most hospital-
acquired MRSA strains. CA-MRSA seemed to grow faster in vitro (Okmna et ai. , 2002) 
and to carry additional virulence genes (Oliveira et al. , 2002). A recent study by Ito et ai. 
(2004) reported an SCCmec type V, which was recently identified from the chromosome 
of a community-acquired methicillin-resistant Staphylococcus aureus strain (strain WIS 
WBG8318) isolated in Australia. 
Often a large proportion of CA-MRSA strains within one specific region show a 
high degree of genetic relatedness (usually identified by pulsed field gel electrophoresis 
typing) and many belong to one or a small number of distinct clonal groups or pulsotypes 
(Nimmo et ai. , 2000; Groom et al. , 2001; Naimi et ai. , 2001 ; Adhikari et ai., 2002; 
Dufour et ai. , 2002; Salmelinna et ai. , 2002; Yamaguchi et al. , 2002). In Minnesota, more 
than 80% of CA-MRSA was clonally related (variants of a single pulsotype), yet over 
250 PFGE subtypes had been found in the region since 1995 (Naimi et ai. , 2001). In 
other regions, this appears not to be the case and isolates demonstrate much more 
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phenotypic heterogeneity and PFGE profiles (Embil et al. , 1994; Layton et al. , 1995; 
Moreno et al. , 1995; Hussain et aI. , 2000). A recent study on the characterization of 117 
CA-MRSA isolates from three continents indicated four major findings (Vandenesch et 
al. , 2003). Firstly, two genes are unique to CA-MRSA isolates and shared by isolates 
from all three continents: a type IV SCCmec cassette (further designated IVa by Okuma 
et al. (2002) and the Panton Valentine Leukocidin (PVL) locus. These findings suggested 
that PVL and SCCmec IV might confer a selective advantage for community-based 
MRSA pathogens. Secondly, CA-MRSA were generally susceptible to most of the 
antibiotics tested apart from ~-lactams, although European isolates appeared more 
resistant (i.e. to kanamycin, tetracycline and fusidic acid) than the United States and 
Oceanian isolates. Thirdly, the genetic background of CA-MRSA organisms was 
different in each of the three continents, although it was predominantly restricted to the 
agr 3 background, which corresponds to one of the three major phylogenetic lineages of 
pathogenic MSSA previously described (Baba et al., 2002). Finally, MLST and PFGE 
analysis showed that within a continent, the genetic background of CA-MRSA strains did 
not correspond to that of the HA -MRSA in the same continent, suggesting that CA-
MRSA did not emerge from local HA-MRSA. However, analysis by MLST indicated 
that CA-MRSA of each continent shared a common genetic background with HA-MRSA 
or MSSA of other continents, suggesting that intercontinental exchange of MRSA or 
MSSA had occurred, possibly followed by the introduction of the SCCmec in MSSA and 
the PVL locus in MSSA or MRS A. The association of SCCmec IV (SCCmec IVa 
according to Baba et al. , 2002) with PVL in the CA-MRSA strains most likely did not 
result from co-acquisition of the two determinants on a single mobile genetic element 
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because the two loci are widely separated on the S. aureus chromosome (Baba et al. , 
2002). 
Using MLST and the SCCmec typing as the methods of choice, it has been 
possible to unravel how CA-MRSA emerged and their relationship to H-MRSA and 
MSSA. Three key findings have been reported. Firstly, CA-MRSA does not belong to 
either a distinct or a single clonal lineage. The majority of CA-MRSA isolates for which 
MLST profiles are known fall into the same clonal complexes as nosocomial MRSA 
(Tables 1.2 and 1.3), suggesting their derivation from common MSSA ancestors with 
identical allelic profiles or sequence types (STs) (Enright et al. , 2002). Enright and co-
workers also defined five of such clonal complexes (based on ST 5, 8, 22, 30 and 45). 
Fey et al. (2003) proposed another sequence type (STl), regarding isolates from the great 
plains of North America. In addition, Okuma et al. (2002) identified two CA-MRSA 
isolates with type IV SCCmec belonging to clonal complex 298, indicating a likely 
seventh group (Table 1.3). Secondly, some CA-MRSA was indistinguishable from 
widely dispersed H-MRSA clones. The best example is EMRSA-15, a globally 
disseminated clone that was first identified in the UK (O'Neil et al. , 2001). Thus some 
hospital clones may have moved into the community or conversely may have risen 
undetected in the community and imported into hospitals. Thirdly, some CA-MRSA 
clones have already become widely disseminated with identical clones (within ST8) 
being associated with community-acquired infection in America and Australia (Okuma et 
al., 2002). Other outbreak strains have been reported (Stemper et al. , 2004), and the CA-
MRSA strain MW2, which was responsible for the death of a Native American child in 
North Dakota in 1998, (Centers for Disease Control and Prevention, 1999; Baba et al. , 
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2002) has been linked to several other reports (Groom et ai. , 2001; Naimi et ai., 2001 ; 
Fey et ai. , 2003). 
Table 1.3: Multilocus sequence types (SIs) of definitive community-acquired MRSA 
isolates and candidate community-acquired clones 
Allelic profile (ST) Clonal SCCmec Definitive CA-MRSA (number of Candidate CA-
complex isolates) MRSA (c1ones)a 
1-1-1-1-1-1-1 I Type IV Minnesota (5), North Dakota (2), Nebraska 
Perth (l), NORSA, Adelaide (2), 
NORSA, Perth (2), NORSA, 
Brisbane (2) 
1-63-1-1-1-1-1 I Type IV Adelaide ( I) 
1-4-1-4-12-1-10 5 Type IV None yet found Paediatric c10ne
b 
1-4-27-4-12-1-10 5 Type IV NORSA, Adelaide (I) 
3-3-1-1-4-4-3 8 Type IV Minnesota (2), NORSA, Perth (1) Clone V, EMRSA-2, 
EMRSA-6 
3-3-1-1-4-4-3 8 New NORSA, Adelaide ( I) 
3-32-1-1-4-4-3 8 Type IV None yet found 
7-6-1-5-8-8-6 22 Type IV Oxford, UK (I) EMRSA-15c 
7-6-1-5-8-8-6 22 New NORSA, Adelaide (1) 
2-2-2-2-6-3-2 30 Type IV W ooloongabba (8) 
10-14-8-6-10-3-2 45 Type IV Tennessee (I) Berlin 
10-14-8-6-10-3-2 45 New Perth (1) 
22-1-14-23-12-53-31 298 Type IV Perth (2) 
Type V Australia (I) 
ST, sequence typing; MRSA, methicillin resistant S. aureus; SCC, staphylococcal cassette chromosome; 
CA-MRSA, community-acquired methicillin-resistant S. aureus; NORSA, non-multiresistant oxacillin-
resistant S. aureus; H-MRSA, hospital associated methicillin resistant S. aureus. 
aH-MRSA clones that contain type IV SCCmec that may have arisen in the community but are now 
associated with nosocomial infections. Alternatively, the clones may initiate infection in the community but 
the infecting strains were acquired in hospitals. The existence of such clones blurs clonal complex into 
which they fit has not been published. Taken mainly from Enright et af. (2002) . 
bIsolates belonging to the paediatric clone are typically non-multiresistant and thus are phenotypically 
indistinguishable from CA-MRSA. Until now this clone was considered to be a minor pandemic H-MRSA. 
cEMRSA-15 is another non-multiresistant clone with evidence of global spread. Reference: Eady and Cove 
(2003); Ito et al. (2004). 
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1.2.5.4 Treatment of CA-MRSA 
The majority of community-acquired skin and soft tissue infections are treated 
either in the community, or in one of the two hospital settings - accident and emergency 
departments or dermatological outpatient clinics. Local prescribing guidelines are 
important in assisting clinicians in their choice of antibiotic treatment. In most cases, 
such guidelines will specify one or more ~-lactamase stable penicillins or second-
generation cephalosporin as the treatment of choice where systemic antibiotic therapy is 
indicated (Eady and Cove, 2003). However, the key issue is to identify patients for whom 
~-lactams are contra-indicated. The dilemma of clinicians and policymakers is to identify 
effective alternative treatment options. This is difficult because other possible antibiotics 
have issues of resistance associated with CA-MRSA (Eady and Cove, 2003). 
In contrast to health care-associated MRSA, CA-MRSA is often susceptible to 
trimethoprim sulfamethoxazole, clindamycin, doxycycline or minocycline, and 
fluroquinolones although susceptibility to these agents may vary by geographic area 
(Naimi et al., 2003; Charlebois et al. , 2004). For superficial and localized infections, 
short courses of topical treatment with mupirocin or fusidic acid have been advocated 
(Eady and Cove, 2003). Linezolid has also been suggested as an alternative to the new 
fluoroquinolones for the treatment of CA-MRSA infections (Shopsin et al., 2004). 
Surgical intervention, however, remains an important adjunct to antimicrobial therapy. 
Perhaps the best policy is to recommend that non ~-lactams could be used only in high-
risk patients and not to rely on a single alternative agent. Clinicians need to be 
particularly prudent about using non ~-lactams whose selection is not merited by the 
severity of infection and be aware that increasing use of these agents in emergency and 
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outpatient departments may encourage an expanding spectrum of resistances among 
isolates ofCA-MRSA. Local monitoring of the prevalence ofCA-MRSA is therefore 
important. Improved hygiene also offers a very reasonable approach to prevent the spread 
ofCA-MRSA (Eady and Cove, 2003). 
1.2.6 Antimicrobial Agents effective against MRSA 
1.2.6.1 Historical background of vancomycin and teicoplanin 
Vancomycin, the first glycopeptide antibiotic, was isolated in the mid-1950s from 
a strain of Amycolatopsis orientalis during the course of a large-scale screening 
programme promoted by Eli Lilly. This programme was conducted to isolate 
anti staphylococcal drugs effective against a spate of serious infections caused by 
penicillinase-producing S. aureus strains (Griffith, 1984). The new antibiotic, introduced 
into clinical practice in 1958, proved to be highly effective in the treatment of 
staphylococcal infections. However, it soon fell from favour due to its toxicity (especially 
oto- and nephrotoxicity) and adverse reactions during administration (Woodley and Hall, 
1961) and was quickly overshadowed by the novel agents methicillin and cephalothin. 
Shortly afterwards, ristocetin, another glycopeptide antibiotic, was isolated from 
Norcadia lurida and marketed by Abbott Laboratories but soon had to be withdrawn due 
to bone marrow toxicity and for causing platelet aggregation during administration 
(Perkins, 1982). Conversely, vancomycin, though virtually unused for many years, was 
still kept on the market. 
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A resurgence of clinical interest in vancomycin began in the late 1970s (Esposito 
and Gleckman, 1977; Cook and Farrar, 1978; Newsom, 1982; Perkins, 1982; Farber, 
1984; Kucers, 1984; Anonymous, 1985; Ingerman, 1989) due to a variety of reasons 
including: (i) the gradual increase in Gram-positive bacterial infections; (ii) the 
emergence of highly and often multiply resistant, but vancomycin-susceptible, Gram 
positive pathogens (e.g. methicillin-resistant staphylococci, enterococci and JK 
corynebacteria), in hospital-associated infections of compromised patients; (iii) the 
introduction of novel uses of vancomycin, such as oral administration as a topical agent 
in the treatment of pseudomembranous colitis or utilization in prophylactic regimens; and 
(iv) the improved control of vancomycin toxicity resulting from the greater purity of 
modem drug formulations and the clinical monitoring of serum levels. 
The same factors leading to the revival of vancomycin prompted the 
pharmaceutical industry to seek and develop new glycopeptide antibiotics. Teicoplanin, 
obtained in the late 1970s in the Lepetit research laboratories by the fermentation of 
Actinopianes teicomyceticus became commercially available in Europe in the late 1980s 
(Parenti et ai. , 1978; Somma et ai. , 1984). However, glycopeptide antibiotics suffered a 
major setback during this period, due to the unexpected emergence of the first acquired 
resistances, in staphylocci and enterococci. Besides their utilization in human 
chemotherapy, glycopeptides have also been employed as growth promoters in animal 
husbandry. In particular, avoparcin, a glycopeptide antibiotic isolated in the late 1960s by 
the fermentation of Stretomyces candidus (Kunstmann et ai., 1968) became available in 
the late 1970s as a feed additive in many European countries. A voparcin feeding of farm 
animals was suggested to have a selective influence on the emergence of glycopeptide-
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resistant enterococci responsible for human infections (Witte and Klare, 1995; Wegener 
et ai. , 1999), and, although the matter gave rise to much controversy, in 1997, this 
practice was banned in the European Community. However, the use of vancomycin and 
teicoplanin has increased dramatically in the last 20 years, in large because of the 
increasing prevalence of methicillin resistance in both coagulase-negative staphylococci 
and S. aureus. 
1.2.6.2 Mechanism of action 
Biochemical studies indicate that glycopeptides inhibit the late stages of 
peptidoglycan synthesis (Bambeke et ai., 2004). The biosynthetic pathway of this 
polymer involves three steps: (i) the synthesis of cytostolic precursors made of 
pentapeptides fixed on a disaccharide; (ii) the coupling of these precursors with a lipid 
carrier and the transfer of the resulting amphiphilic molecule to the outer surface of the 
membrane; and (iii) the reticulation between individual precursors by transpeptidation 
and transglycosylation reactions, accompanied by the release ofthe lipid carrier and its 
recycling to the inner face of the membrane. Bacteria incubated with vancomycin 
accumulate cytosolic precursors, suggesting that glycopeptides interfere with the 
assembly of peptidoglycan and in particular, with transglycosylation reactions (Reynolds, 
1989). At the molecular level, the primary target of vancomycin was shown to be the D-
Ala-D-Ala terminus of the precursors. Molecular modelling and experimental studies 
indicate that vancomycin forms a stoechiometric complex with the D-Ala-D-Ala 
dipeptide via the formation of five hydrogen bonds with the peptidic backbone of the 
glycopeptide. The formation of this complex prevents the transpeptidation reactions by 
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steric hindrance (Williams and Waltho, 1988; Reynolds, 1989; Arthur et al. , 1996; Loll 
and Axelsen, 2000). 
Vancomycin resistance among staphylococci was developed in laboratories even 
before the drug was in use clinically (Geraci, 1956; Ziegler, 1956). However, this 
resistance was so difficult to induce that many felt it would be unlikely to occur in a 
clinical setting (Moellering, 1998b). Resistance to vancomycin among the organisms 
encompassed in its spectrum of activity was not observed in the first 30 years of the 
drug' s clinical utilization (Newsom, 1982; Kucers, 1984; Cooper and Given, 1986) and in 
the mid 1980s, a similarly uniform susceptibility was also believed to be the rule with 
teicoplanin (Williams and Gruneberg, 1984; Willams and Gruneberg, 1988). 
Glycopeptide resistance emerged in the second half of the 1980s in coagulase negative 
staphylococci (CNS) and enterococci. As for enterococci, after initial reports of 
resistance in clinical isolates (Leclercq et al. , 1988; Uttley et al. , 1988), a number of 
phenotypically and genotypically distinct types of acquired glycopeptide resistance were 
identified. They include vanA (inducible resistance to high levels of both vancomycin and 
teicoplanin), vanB (inducible resistance to various levels of vancomycin only), vanC and 
vanD (constitutive resistance to vancomycin and teicoplanin) (Dukta-Malen et al. , 1992; 
Evers et al. , 1993; Grissom-Arnold et al. , 1997; Leclercq and Courvalin, 1997), and vanE 
(biochemically and phenotypically related to vanC) (Fines et al. , 1999). The vanG gene 
was reported by McKessar et al. (2000) but vancomycin-resistant Enterococcus faecium 
(VRE) with those complexes are not as widespread as VRE with the vanA , vanB and 
vanC gene complexes (Clark et al. , 1993; Moulin et al. , 1996; Schouten et al. , 2000; Lu 
et al. , 2001; Petrich et al. , 2001; Kolar et al. , 2002). In the vanA and vanB types, the 
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resistance genes are usually located on mobile elements, and resistance is transferred to 
susceptible recipients either by self-transferability of the relevant plasmids or by 
transposition of the resistance determinants between different replicons, ostensibly in the 
absence of plasmid DNA (Leclercq et ai. , 1989; Uttley et al. , 1989; Dukta-Malen et al. , 
1990). The potential of the natural spread of van A or vanB resistance to other Gram-
positive organisms is illustrated by the detection of vanA determinant in previously non-
involved Enterococcus species (Dukta-Malen et al., 1994) and in Corynebacterium, 
Arcanobacterium, Oerskovia, Lactococcus (French et al., 1992), Bacillis species 
(Fontana et al. , 1997), and of a vanB-related gene in a faecal isolate of Streptococcus 
bovis (Poyart et al. , 1997). 
True teicoplanin-resistant CNS was first reported in 1986 in the United States 
(Del Bene et al. , 1986) and the United Kingdom (Wilson et al. , 1986), followed by the 
report of Schwalbe et al. , (1987). In these instances, strains of S. haemolyticus were 
implicated. The first Enterococcus faecium isolate with transmissible vancomycin 
resistance was reported in France (Leclercq et al. , 1988) and this raised concerns by 
public health officials and infection control specialists that the vanA determinant, which 
mediated high-level vancomycin resistance in the enterococcal isolate, would be 
transferred to S. aureus (Hospital Infection Control Practices Advisory Committee, 1995; 
Centers for Disease Control and Prevention, 1997; Wenzel and Edmond, 1998). In-vitro 
conjugative transfer of the vanA determinant from an E. faecalis donor to an S. aureus 
recipient by Noble et al. (1992), further heightened concerns about the possible spread of 
vanA to S. aureus. 
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1.2.6.3 Definition of vancomycin resistance 
Various countries use different breakpoints where vancomycin-resistant 
staphylococci have been reported. In the United States, the National Committee for 
Clinical Laboratory Standards (NCCLS) defines S. aureus isolates with vancomycin 
MICs between 8 and 16uglml as intermediately sensitive, and isolates with a MIC of 
32ug/ml as resistant (NCCLS, 2000) whereas in Japan, the breakpoint for resistance is 
8~g/ml (Cosgrove et al., 2004). Similarly, British and Swedish definitions do not include 
a category for intermediate susceptibility to vancomycin or teicoplanin (Walsh and 
Howe, 2002). In addition to VISA and vancomycin-resistant S. aureus, Hiramatsu et ai. 
(1997) described another type of vancomycin resistance called hetero-VISA (h VISA). 
This strain is susceptible to vancomycin but contains a subpopulation, at a frequency of 
10-6 or higher with a MIC of vancomycin or more than 4uglml. The potential importance 
ofhVISA is that it may be associated with treatment failures (Hiramatsu et al. , 1997; 
Wong et aI. , 1999; Wong et al. , 2000) and a precursor of VISA (Sieradski et ai. , 1999b; 
Hussain et al. , 2002). 
1.2.6.4 Mechanisms of resistance in glycopeptide-resistant S. aureus 
1.2.6.4.1 Vancomycin-intermediate S. aureus (VISA) 
The pathogenesis of resistance of S. aureus to glycopeptides is not fully 
understood. Except for rare cases, reduced susceptibility to glycopeptides is not found in 
methicillin-susceptible S. aureus (MSSA) (Bobin-Dubreux et al. , 2001 ; Reverdy et al. , 
2001). The genetic events resulting in phenotypic expression of resistance appear to be 
62 
different in strains with high-level vancomycin resistance compared with strains 
exhibiting intermediate levels of resistance. S. aureus with reduced susceptibility to 
vancomycin has a thick cell wall in comparison to susceptible S. aureus (Cui et al. , 
2003), whereas vancomycin-resistant S. aureus (VRSA) is as a result of the acquisition of 
the vanA gene from vancomycin-resistant enterococcus, which is integrated into the S. 
aureus conjugative plasmid. As reviewed by Hiramatsu et al. (2001a), the first clinical S. 
aureus strains with reduced susceptibility (Mu50) had 30-40 layers of peptidoglycan 
compared to approximately 20 layers in fully susceptible strains. The increased number 
oflayers of vancomycin intermediate S. aureus (VISA) contains many D-alanyl-D-
alanine targets to which glycopeptides molecules can bind (affinity trapping), thus 
resulting in reduced access of glycopeptides to their site of action, namely the D-alanyl-
D-alanine residues of murein monomers, which are located in the cytoplasmic 
membranes (Figure 1.9). Penetration of glycopeptides to their site of action in the 
cytoplasmic membrane is further inhibited by the destruction of the mesh structure of the 
outer layers of peptidoglycan by the trapped glycopeptide molecules themselves. This 
event is described as "clogging phenomenon" (Cui et al. , 2000). 
The overproduction of murein causes detrimental effects on the rapid growth of 
the cell leading to a prolonged doubling time for cell replication (Cui et al. , 2003). This 
could explain why VRSA strains do not quickly prevail in health care facilities and their 
detection is mostly confined to patients with MRSA infection undergoing long-term 
vancomycin therapy (Tenover, 1999; Chesneau et al., 2000; Fridkin, 2001 ; Tenover et 
al. , 2001). Hiramatsu and his co-workers proposed that the emergence ofVRSA would 
be the result of vancomycin selection exerted upon a hetero-VRSA strain in the hospital, 
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which returns to hetero-VRSA when vancomycin is not used for a while and the selective 
pressure lifted. On the other hand, some hetero-VRSA strains are extremely stable and 
can be disseminated across wards and even across hospitals (Cui et ai., 2003). 
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Mechanisms of S. aureus resistance to vancomycin: VISA strains. VISA strains appear to 
be selected from isolates that are heterogeneously resistant to vancomycin. These VISA 
strains synthesize additional quantities of peptidoglycan with an increased number of D-
Ala-D-Ala residues that bind vancomycin, preventing the molecule from getting to its 
bacterial target Reference: Sieradski et al. (1999a) and Lowy (2003). 
1.2.6.4.2 Vancomycin-resistant S. aureus (VRSA) 
The vanA gene is carried by a transposon, Tn1546, which is integrated in the 
conjugative plasmid harboured by vancomycin-resistant enterococcus (Hiramatsu et ai, 
2004). Showsh et ai. (2001) reported that the enterococcal plasmid containing vanA also 
encodes a sex pheromone that is synthesized by S. aureus, suggesting a potential 
facilitator of conjugal transfer. VRSA isolates demonstrate complete vancomycin 
resistance, with MICs of 128J.lg/ml. Analysis of the first VRSA isolated in Michigan, 
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USA, revealed that Tn1546 is integrated in as. aureus conjugative plasmid designated 
pLWI043 (Weigel et ai., 2003). 
pL WI 043 is a multi-resistant plasmid with resistance genes against gentamicin, 
trimethoprim, penicillins, quaternary ammonium compounds, and vancomycin (Weigel et 
ai., 2003). Tn1546 also carries a set of regulator genes, vanSR, that control transcription 
of vanA in a way that allows the expression of vancomycin only when the cell is exposed 
to vancomycin (Arthur et ai., 1992). The vanA dependent mechanism activates a cell wall 
biosynthetic pathway that avoids the vancomycin-sensitive step by producing an 
abnormal cell wall precursor in which the carboxyl-terminal dipeptide D-Alanyl-D-
Alanine is replaced by the vancomycin-insensitive depsipeptide composed of D-Alanyl-
D-Lactate (Arthur et ai., 1998; Bugg et ai., 1991; Arthur and Quintiliani, 2001) (Figure 
1.10). This inducible nature of vanA genotype is part of the explanation for the successful 
maintenance of the vanA plasmid in methicillin resistant S. aureus (MRS A) without 
selective pressure from vancomycin. Therefore, vancomycin-resistant S. aureus could be 
taken to be an MRSA with a pL WI 043-vanA plasmid newly added to the useful genetic 
repertoire for S. aureus. The S. aureus cell that accidentally takes up genetic material 
from this repertoire might flourish if the product turned out to be useful in the 
environment it inhabits (Hiramatsu et ai., 2004). 
In the second VRSA case reported by Whitener et ai. (2004), vancomycin was not 
administered but the patient received courses of topical and oral antimicrobial agents for 
a right-heel ulcer during the three years before the isolation ofVRSA. It therefore 
appears that the multiple resistance nature of the vanA plasmid probably provided the 
mechanism for the stable maintenance of the plasmid by the MRSA (Hiramatsu et ai., 
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2004). A recent analysis (pCR and DNA sequence analysis) of the Tn1546 elements from 
the two clinical isolates ofVRSA indicated that while the Michigan VRSA element was 
identical to the prototype Tn1546, the Pennsylvania VRSA showed three distinct 
modification. This observation and differences in the Tn1546-like elements indicate that 
the first two VRSA isolates were the result of independent genetic events (Clark et al., 
2005). 
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Mechanisms of S. aureus resistance to vancomycin: VRSA strains. VRSA strains are 
resistant to vancomycin because of the acquisition of the vanA operon from an 
enterococcus that allows synthesis of a cell wall precursor that ends in D-Ala-D-Lac 
dipeptide rather than D-Ala-D-Ala. The new dipeptide has dramatically reduced affinity 
for vancomycin. In the presence of vancomycin, the novel cell wall precursor is 
synthesized, allowing continued peptidoglycan assembly. Reference: Murray (2000); 
Lowy (2003). 
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VRSA strains carry both the chromosomally located mecA gene and a plasmid-
borne vanA gene complex (Weigel et ai. , 2003). These resistance mechanisms are 
targeted on the bacterial cell wall by distinct mechanisms. While these two mechanisms 
coexist in the same VRSA strain and are capable of providing high-level resistance 
against each class of antibiotics, the mechanisms of expression of the resistant 
phenotypes are independent and even mutually antagonistic (Severin et ai. , 2004a). It has 
been shown that expression of high-level vancomycin resistance does not depend on an 
intact mecA, because selective inactivation of the gene did not reduce the vancomycin 
MIC of the bacteria (Severin et ai. , 2004a). Furthermore, vancomycin resistance was 
suppressed by adding oxacillin to the growth medium under conditions where bacterial 
growth and cell wall synthesis depends on the transpeptidase activity ofPBP2A (de 
Jonge et ai. , 1992). A recent study by Severin et ai. , (2004b) also indicated that while 
mecA is essential for oxacillin resistance, penicillin binding protein 2A, the protein gene 
product of mecA, appeared to be unable to utilize the depsipeptide cell wall precusor 
produced in the vancomycin-resistant cells for transpeptidation. Severin and his co-
workers therefore concluded that penicillin-binding protein 2 (PBP2) could be important 
for vancomycin resistance and for the synthesis of abnormally structured walls 
characteristic of vancomycin-resistant S. aureus. 
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1.2.6.5 Epidemiology of Glycopeptide Resistance in Staphylococcus aureus 
Infections caused by S. aureus with high-level resistance to vancomycin are rare. 
Only three cases have been reported (Centers for Disease Control and Prevention, 2002a; 
2002b; 2004; Tenover et al. , 2004; Whitener et al. , 2004). All three patients had 
underlying disease, had received antibiotics and were reported from the USA. 
Coinfection with MRS A and VRE was present. Intermediate resistance of S. aureus to 
vancomycin is clearly more common than high-level resistance and at least 20 cases of 
VISA infections have been reported from various continents (Walsh and Howe, 2002). 
Pretreatment with vancomycin was a common feature in many of these patients (Ploy et 
al., 1998; Rotun et al., 1999). The prevalence of S. aureus with heteroresistance to 
glycopeptides appears to be higher than the corresponding prevalence of VISA. In many 
areas, the prevalence of vancomycin resistance appears to be low. A recent prevalence 
survey of more than 1,000 MRSA isolates in Belgium found only one homogeneous 
vancomycin-resistant S. aureus (VISA) and five heterogenous VISA (h VISA) based on 
population analysis profiling (Pierard et al. , 2004). In a Brazilian study of 140 MRSA 
isolates, five S. aureus with reduced susceptibility to vancomycin (8 ,....g/ml) were 
detected (Oliveira et al. , 2001c). None were positive for vanA and all had thickened cell 
walls. The Netherlands has a very low prevalence of MRS A. As heteroresistance to 
vancomycin appears to be associated with vancomycin use to treat MRSA infections, 
heteroresistance would not be expected to be prevalent in countries with low prevalence 
ofMRSA. However, van Griethuysen et al. (2003) reported a rate of 6% of 
heteroresistance to vancomycin in MRSA strains. Epidemiological information on the 
origin of the affected patients revealed that none of the isolates originated from the 
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Netherlands. The patients were from Turkey, Greece, Italy, France, Germany, and Cote 
d'Ivoire. 
1.2.7 Approved antimicrobial agents with activity against staphylococci including 
MRSA 
The newest licensed antimicrobials on the United States market as well as many 
in the pipeline target serious infections caused by Gram-positive bacteria. The most 
important impetus for developing these agents in the early 1990s, included the 
intolerance of patients to both beta-lactams and glycopeptide antimicrobial agents, and 
the emergence and rapid spread of vancomycin-resistant Enterococcus faecium (VRE) 
(Eliopoulos, 2004; Ray and Rice, 2004). While the treatment ofVRE infections remains 
an important therapeutic goal, difficulty enrolling VRE-infected patients in clinical trials 
and the sharp rise in methicillin-resistant S. aureus (MRS A) worldwide caused some 
pharmaceutical companies developing new agents to eschew United States Food and 
Drug Administration (FDA) approval for VRE indications in favor of targeting MRSA. 
The approval of two new antimicrobial agents, in 1999 and 2000, provided additional 
options for therapy of Gram-positive infections. 
1.2.7.1 Quinupristin-dalfopristin 
Representatives of the streptogramin A and streptogramin B families of 
antibiotics occur naturally in combinations that synergistically achieve levels of activity 
superior to those provided by either antibiotic alone. Quinupristin-dalfopristin are 
derivatives of pristinamycin, an agent widely used in animal feed as a growth promoter. 
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Dalfopristin is a streptogramin A and quinupristin is a streptogramin B in a 70:30 ratio, 
yielding a water-soluble drug suitable for intravenous administration (Batts et ai., 2001). 
Both compounds bind the 23rRNA of the 50S ribosomal subunit and inhibit protein 
synthesis (Vannuffel et ai., 1994; Canu et ai., 2001). Alone, each factor displays a 
moderate bacteriostatic activity while the combination of both factors is often bactericidal 
(Canu et ai., 2001). Quinupristinldalfopristin was the first antimicrobial on the United 
States market with clinically important activity against VRE (the vast majority of which 
are resistant to ampicillin and vancomycin). Approved in September 1999, the 
components of this combination inhibit protein synthesis by binding to different 
ribosomal sites, thereby achieving synergy (Barriere et ai., 1998; Canu et ai., 2001; Ray 
and Rice, 2004). In the United States, the overwhelming majority (>99%) of S. aureus, 
including both MRS A and oxacillin-susceptible strains, were susceptible to this agent in-
vitro (Ballow et ai. , 2002). The combination is potentially bactericidal against isolates 
susceptible to both components. Against isolates with constitutive resistance to the 
macrolide-lincosamide-streptogramin B (MLSB) class of antibiotics, which is seen 
frequently in MRS A and less commonly among methicillin-susceptible S aureus (Fluit et 
ai., 2001), the combination loses bactericidal activity in vitro (Fuchs et ai., 2000). This is 
because such isolates are resistant to quinupristin, which is a streptogramin B antibiotic. 
As long as strains remain susceptible to dalfopristin, however, the combination retains 
inhibitory activity. 
In the United States, the only Food and Drug Administration-approved use 
(Aventis Pharmaceutical, 2000) of quinupristin-dalfopristin as an anti-staphylococcal 
agent is for treatment of adults with complicated skin and skin structure infections when 
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the pathogen is a methicillin-susceptible S aureus. Otherwise, the drug is approved for 
complicated skin and skin structure infections caused by Streptococcus pyogenes and for 
serious vancomycin-resistant Enterococcus faecium infections associated with bacteremia 
(the drug is not active against Enterococcus faecalis) (Eliopoulos, 2004). While its 
approval was met with enthusiasm, quinupristin-dalfopristin' s clinical utility, has been 
limited by its intravenous-only formulation. Because this antibiotic is very irritating when 
given by peripheral vein, a deep catheter is usually required. A syndrome of arthralgias 
and myalgias, which may become very severe, develops in many patients treated with 
this combination (Olsen et al. , 2001). This syndrome is, however, made reversible with 
the discontinuation of treatment. Administration of quinupristin-dalfopristin can interfere 
with clearance of drugs that are eliminated through the cytochrome P450 system, so care 
is required to avoid potentially serious drug-drug interactions (A ventis Pharmaceutical, 
2000). 
1.2.7.2 Linezolid 
In April 2000, linezolid became the first antimicrobial with a novel mechanism of 
action to obtain FDA approval in 35 years. The first and only approved oxazolidinone, 
linezolid inhibits bacterial protein synthesis by interfering with ribosomal initiation of 
translation (Shinabarger et al. , 1997). It has a narrow spectrum of activity against Gram-
positive organisms, including staphylococci, streptococci, and enterococci. Essentially all 
strains of S. aureus, including MRSA, from clinical surveys are inhibited by this agent at 
or lower than the susceptibility breakpoint of 4 Jlg/ml (Ballow et al. , 2002). To date, there 
are three published reports of clinical isolates of S. aureus resistant to linezolid on the 
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basis of mutations in the 23S ribosomal RNA, in an area central to peptide bond 
formation (Tsiodras et al., 2001; Wilson et al., 2003; Meka et aI., 2004). Single point 
mutations in the 23 rRNA genes can reduce linezolid binding and the presence of this 
mutation in two or more of the cellular 23S genes can confer clinically significant levels 
of resistance (Marshall et al. , 2002; Meka et al. , 2004). The first point mutation appears 
to be the important one, thereafter, the bacteria are capable of amplifying the resistance 
through homologous recombination (Lobritz et al., 2003). Similar mutations, leading to 
linezolid resistance, have also been encountered among enterococcal strains (Gonzales et 
al. , 2001). 
The action of linezolid against S. aureus is best described as bacteriostatic, 
although some bactericidal activities can occur slowly with time (Fuchs et al. , 2002). A 
major advantage of this agent is that it is available both for intravenous and oral use, 
however, overuse in the community is a concern, as resistance may limit the drug' s 
usefulness (Ray and Rice, 2004). The Food and Drug Administration-approved 
indications for linezolid use are relatively broad (Pharmacia and UpJohn Corporation, 
2001). They include (but are not limited to) complicated skin and skin structure infections 
caused by MRS A or methicillin-susceptible S. aureus or group A or B streptococci, S. 
aureus nosocomial pneumonia, and infections caused by vancomycin-resistant 
enterococci. With compassionate use protocols, linezolid has been used successfully in 
many patients who do not respond to treatment with vancomycin (Moise et al. , 2002). 
However, patients with MRS A endocarditis who experience failure in attempts at 
treatment with linezolid have also been reported, (Ruiz et al., 2002) and the 
oxazolidinone is not approved for this indication. 
72 
Linezolid has the potential to cause myelosuppression (Pharmacia and UpJohn 
Corporation, 2001). Although all cell lines may be affected (Halpern, 2002), the greatest 
attention has focused on thrombocytopenia. In comparative clinical trials, there was a 
small, but not statistically significant increase in occurrence of substantially low platelet 
counts in patients treated with linezolid (2.4% vs 1.5%), which generally became 
apparent after approximately 2 weeks of therapy (Gerson et ai., 2002). However, in some 
case series, low platelet counts were observed in 2:20% of patients receiving the drug 
(Attassi et ai., 2002; Orrick et ai. , 2002). Recommendations for monitoring blood counts 
are included in the package insert for this agent (Pharmacia and UpJohn Corporation, 
2001). Linezolid is a weak monoamine oxidase inhibitor (Batts et ai., 2001) and serotonin 
syndrome has been reported rarely in patients who had also received a selective serotonin 
reuptake inhibitor (Wigen and Goetz, 2002). 
1.2.7.2.1 Drugs being clinically investigated 
1.2.7.2.1.1 Daptomycin 
Several agents with in-vitro antimicrobial activity against staphylococci have 
been studied in clinical trials. In September 2003, daptomycin became the first cyclic 
lipopeptide approved by the United States Food and Drug Administration. Derived from 
the fermentation of Streptomyces roseosporus, it has been known as an antibacterial 
agent for nearly 20 years (Stratton et ai. , 1987). Initial clinical studies with this agent 
commenced in the 1980s, but development was halted. At a time of increasing concern 
about the rates of resistance to other antimicrobial agents, deVelopment of daptomycin 
resumed in the late 1990s. Daptomycin' s bactericidal activity results from disrupting the 
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cytoplasmic membrane integrity in a reaction that requires sub-physiologic 
concentrations of calcium and causes depolarization and cell death (Silverman et ai., 
2003). 
The drug exhibits this mechanism against staphylococci, including MRSA, 
vancomycin-intermediate S aureus, coagulase-negative staphylococcal species, and many 
other Gram-positive bacteria (Barry et aI. , 2001; Petersen et aI. , 2002). The drug's 
activity is typically bactericidal against staphylococci (Fuchs et aI. , 2002). Though no 
mechanism of resistance has yet been identified, resistance reported by the sponsor -
Cubist Pharmaceuticals, MA, USA - during the Phase II and Phase III clinical trials is 
very low «0.2%). The first report of the development of daptomycin resistance in a 
clinical isolate of MRSA has recently been described (Mangili et ai. , 2005). Clinical trials 
using a higher dose (6mg/kg) for treatment of staphylococcal bacteremia is ongoing (Ray 
and Rice, 2004). The drug has the potential to cause a reversible myopathy which is 
evident when high doses were given twice daily, however, it appears to be an infrequent 
event with new dosing regimens (Tally and DeBruin, 2000). 
1.2.7.2.1.2 Oritavancin 
This agent is a glycopeptide antibiotic derived semi-synthetically from a 
precursor drug closely related to vancomycin. It has activity in vitro against 
staphylococci, including MRSA, which is generally comparable with that of vancomycin 
(Schwalbe et ai. , 1996; Zeckel et ai. , 2000). Oritavancin is currently in Phase III clinical 
trials for skin and soft tissue infection and Phase II for bacteraemia (Ray and Rice, 2004). 
A striking difference in in-vitro activity between this agent and vancomycin is that 
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oritavancin can inhibit vancomycin-resistant enterococci, including strains with 
vancomycin minimum inhibitory concentrations> 1 OOOIlg/ml, at concentrations of 
approximately 1.0Ilg/ml (Zeckel et ai. , 2000). Oritavancin is bactericidal against S. 
aureus, including MRSA (Zeckel et ai., 2000). Another major difference between the 
new glycopeptide and vancomycin is that the elimination half-life of oritavancin is much 
longer, in the range of 5 to 15 days compared to vancomycin (Barrett, 2001). 
1.2.7.2.1.3 Dalbavancin 
Dalbavancin is another semi-synthetic glycopeptide antibiotic that is being 
clinically investigated. This agent is as much as 16-fold more active than vancomycin 
against staphylococci tested in vitro (Candiani et aI. , 1999). Like oritavancin, 
dalbavancin is eliminated slowly from the serum, with a half-life of several days, even in 
individuals with normal renal function. The developmental program for this agent has 
exploited this pharmacokinetic feature, with once-weekly dosing strategies having been 
used in phase II studies of complicated skin and skin structure infections (Selzer et ai. , 
2003). 
1.2.7.2.1.4 Other antibacterial agents 
Telithromycin is the first ketolide antibiotic. Ketolides are a subclass of 
macrolides modified to improve ribosomal binding and thereby retain activity against 
resistant organisms (Ray and Rice, 2004). 
Garenoxacin is a novel des-fluoro (6) quinolone designed to have improved 
activity against resistant respiratory pathogens. Its structure modification is the absence 
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of fluorine at C-6; however, its mechanism of action is the same as other in its class 
(Fung-Tomc et al. , 2000). DW286, a naphthyridone, is among several fluoroquinolones 
in development that has in-vitro activity against MRS A (Kim et al. , 2003). Active against 
MRS A strains that are resistant to other fluoroquinolones, it selects fluoroquinolone-
resistant mutants at a lower frequency than older agents (Yun et al. , 2002; Firsov et al. , 
2004). 
Glycylcyclines are a subclass of tetracyclines designed to avoid the problems of 
microbial resistance faced by the traditional tetracyclines. The prototype is tigecycline, a 
derivative of minocycline. Currently in Phase II studies of intra-abdominal and 
complicated skin and soft-tissue infections, tigecycline has demonstrated in-vitro activity 
and early in-vivo efficacy against a wide variety of pathogens, including MRSA. Most of 
the tetracycline-resistance mechanisms prevalent in clinical bacteria are inactive against 
tigecycline (Ray and Rice, 2004; Fritsche and Jones, 2004). 
Novel ~-lactamase-stable cephalosporins with high affinity for PBP2a are in 
clinical development (Glinka, 2002). The PBP2a affinity ofBMS-247243 is 100-fold 
greater than that of methicillin or cefotaxime, and the drug is bactericidal against MRSA 
at twice the rate of vancomycin (Fung-Tomc et al. , 2002). Other drugs in this class in 
development include the zwitterionic cephem RWJ-54428 (Malouin et al., 2003), CB-
181963 (Huang et al., 2004), BAL5788 (Azoulay-Dupuis et al. , 2004), a prodrug of 
BAL9141 (Enteza et al. , 2002; Jones et ai. , 2002b), and S-3578 (Fujimura et ai. , 2003). 
SM-197436, SM-232721 , and SM-232724 are novel methy1carbapenems that are also 
active in-vitro against MRSA (Ueda and Sungawa, 2003). 
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The lantibiotics nisin, alone and combined with peptidoglycan-modulating 
antibiotics, shows activity against MRS A and vancomycin-resistant enterococci 
(Wiedermann et al., 2001 ; Brumfitt et al. , 2002). The lantibiotic gallidermin is as active 
as nisin and is currently produced and developed for clinical studies (Gotz and Jung, 
2001 ). Other novel antimicrobial agents include ramoplanin (Cudic et al., 2002), 
muraymycins (Lin et al. , 2002), mannopeptimycins (Ruzin et al., 2004), arylalkylidene 
rhodanines and arylalkylidene iminothiazolidin-4-ones (Zervosen et al., 2004). 
Several agents targeting virulence factors have also being investigated. They 
include RNAIII-inhibiting peptide, which acts against S. aureus pathogenesis by 
disrupting quorum-sensing mechanisms (Dell ' Acqua et al. , 2004), and a truncated 
thiolactone peptide found to be a potent inhibitor for all the four agr-specificity groups of 
S. aureus (Lyon et al. , 2000). S. aureus immune globulin intravenous (human) 
(Altastaph; NAB I Biopharmaceuticals) is a hyperimmune, polyclonal, intravenous 
immunoglobulin product derived from the plasma of human donors who have previously 
been vaccinated with S. aureus polysaccharide conjugate vaccine (Staph V AX: NABI 
Biopharmaceuticals). This vaccine is a bivalent conjugate capsular polysaccharide 
covalently bound to recombinant exoprotein A, which has been demonstrated to provide 
temporary protection against the occurrence of S. aureus bactereamia in patients 
receiving haemodialysis (Shinefield et al. , 2002; Robbins et al. , 2004). Others include 
Tefibazumab (Aurexis; Inhibitex), a humanized monoclonal antibody directed at the 
microbial surface components recognizing adhesive matrix molecule (MSCRAMM) 
clumping factor A (Hall et al., 2003), INH-A21 (Veronate; Inhibitex), BYSX-A110 
(Weisman, 2004), and Aurograb (Neu Tec Pharma) (Burnie et al. , 2000; Patti, 2004). 
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1.2.8 Genome sequencing of Staphylococcus aureus 
The impact of human health of S aureus infections in the community and hospital 
settings have led to intensive investigation of this organism over recent years. More 
complete genomes are now available for S. aureus than for any other bacterial species, 
thus providing detailed insight into the evolutionary processes leading to strains of 
differing virulence and drug-resistance potential (Holden et aI. , 2004). To date, seven 
complete genome sequencing of S. aureus have been conducted; six have been published, 
namely an hospital-acquired MRSA (N315) and vancomycin intermediately susceptible 
S. aureus (Mu50) (Kuroda et al., 2001), a community-acquired MRSA (MW2) (Baba et 
aI., 2002), an EMRSA-16 clone (MRSA252), a representative of an invasive community-
acquired S. aureus clone (MSSA476) (Holden et al. , 2004) and recently the S. aureus 
COL strain (Gill et al. , 2005). The remaining unpublished but sequenced strains is NCTC 
8325 (www.genome.ou.edulstaph.html; ST8) (Table 1.4). 
Table 1.4: Details of the seven sequenced Staphylococcus aureus strains 
Strain Source Year Comments References 
N315 Pharynx, Japan 1982 Hospital-acquired MRSA Kuroda et al. (2001) 
Mu50 Wound, Japan 1997 Hospital-acquired VISA, Kuroda et at. (2001) 
related to N315 
MW2 Fatal paediatric 1998 Typical USA community- Baba et al. (2002) 
bacteremia, North acquired MRSA, PV-
Dakota, USA toxin positive 
MRSA252 Fatal bacteremia, 1997 Typical UK hospital- Holden et al. (2004) 
Oxford, UK acquired epidemic MRS A 
(EMRSA-16) 
MSSA476 Osteomyelitis, 1998 Community-acquired Holden et al. (2004) 
Oxford, UK MSSA 
COL Colindale, UK 1961 Early MRS A htto://www.ti!!r.om; Gill et al. (2005) 
NCTC8325 Colindale, UK < 1949 Laboratory strain, parent htlg://www.genome.ou.edulstagh 
of non-lysogenic 8325-4 
Adapted from Lmdsay and Holden (2004); GIll et al. (2005). 
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1.2.8.1 Phylogenetic relatedness to other organisms 
Phylogenetic classification places S. aureus in the Bacillus/Staphylococcus group. 
Accordingly, up to 52% of predicted proteins encoded by the N315 genome are similar to 
those in Bacillus substilis and B. halodurans (Kuroda et al. , 2001). They typically contain 
housekeeping genes involved in essential functions of the vegetative life of the bacteria 
such as DNA replication, protein synthesis and carbohydrate metabolism. This finding 
indicates that about half of the S. aureus genome has been vertically transmitted from a 
common ancestor ofthe Bacillus/Staphylococcus group of bacteria, comprising the 
backbone of S. aureus genome. The rest of the genome encodes proteins similar to those 
produced by bacterial species ranging from species belonging to Streptococcus to far 
distant eukaroytes including Homo sapiens (Kuroda et al. , 2001). 
The genome of a bacterial species has been proposed to comprise core, auxiliary 
and lost or foreign genes. Core genes are suggested as those present in more than 95% of 
species isolates, with auxiliary genes present in 1-95% of isolates, and foreign genes 
found in less than I % of isolates (Lan and Reeves, 2000). The differentiation of S. aureus 
core genes and auxiliary genes is facilitated by the identification of regions of the 
chromosome that are hotspots of variation, have discrete ends, and carry genes predicted 
to be involved in horizontal gene transfer (Lindsay and Holden, 2004). Preliminary 
investigation of the genetic diversity of S. aureus strains by DNA micro-array analysis 
suggests that approximately 22% of S. aureus genomes are composed of variable regions 
(Fitzgerald et al. , 2001a) and much of the diversity was associated with large scale 
variations. 
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The five S. aureus sequenced genomes (N315 , Mu50, MW2, MSSA476 and 
MRSA252) range in size from 2.820Mb to 2.903Mb and are predicted to contain 2592 
and 2748 protein coding sequences (Holden et al. , 2004). Gene order is conserved and 
the similarity of individual genes between the isolates is typically 98%-100% at the 
amino acid level. As expected, the majority of genes comprising the core genome are 
those associated with central metabolism and other housekeeping functions. 
Supplementing these are genes that are associated with common species functions but are 
not essential for growth and survival, including virulence genes not carried by other 
staphylococcal species, surface binding proteins, toxins, exoenzymes and the capsule 
biosynthetic cluster (Lindsay and Holden, 2004). A summary of the major variable 
genetic elements in sequenced S. aureus strains is presented in Table 1.5. 
Subtle variation between orthologous genes (groups of similar genes in different 
organisms that have the same function and have evolved from a common ancestor) and 
multilocus sequence typing (MLST) has been used to estimate how closely or distantly 
related the five sequenced strains are to one another (Lindsay and Holden, 2004). 
Comparison of the percentage similarities ofthe DNA of the core genomes showed that 
N315, Mu50 and MW2, MSSA476 are closely related. Furthermore, the hospital strains 
N315 and Mu50 and the community-acquired MW2 and MSSA belong to identical but 
separate sequence types (STs) - (ST5 and STI respectively) while COL and NCTC8325 
belong to closely related STs (ST250 and ST8). Notably, the level of relatedness inferred 
by MLST correlates well with the overall genomic divergence over all orthologous gene 
pairs in the core genome (Lindsay and Holden, 2004). MRS A 252 is the most divergent 
of the sequenced strains (ST36) and it is a representative of the EMRSA-16 epidemic 
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clonal group responsible for 50% ofthe MRSA infections within the UK, and one of the 
major MRSA clones found in the United States (Johnson et al. , 2001 ; McDougal et al. , 
2003). About 6% of the MRSA 252 genome was previously undescribed when compared 
with other published genome, including the hospital-acquired strains. These additional 
genes fall into the accessory category. The genetic diversity observed was attributed to 
numerous mechanisms involving the horizontal acquisition of mobile DNA, both on the 
large and small scale (Holden et al., 2004). 
1.2.8.2 Accessory genome 
The accessory genome consists of mobile (or once mobile) genetic elements that 
transfer horizontally between strains. These elements include bacteriophages, 
pathogenicity islands, chromosomal cassettes, genomic islands and transposons. Many of 
these genetic elements carry genes with virulence of resistance functions. Therefore, the 
distribution and horizontal transfer of these elements could have important clinical 
implications. The identification and characterization of these elements has provided some 
insights into how S. aureus cause disease, and how they are evolving. In particular, 
several studies have suggested that certain toxin genes are associated with particular 
lineages ofMLST clonal complexes (Moore and Lindsay, 2001 ; Peacock et al., 2002), 
including toxic shock syndrome toxin-l (tst) , leukocidin DE (lukDE) , serine protease-like 
B (splB) , and superantigens A, G and I (sea, seg and sei). The association is not due to 
vertical transmission alone, but there is evidence of frequent acquisition and loss of 
particular elements that is restricted to particular clonal complexes (CCs). Although the 
mechanisms are still unclear, this is a possible explanation for the dominance of certain 
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CCs in carriage and disease. These observations also suggest the importance of 
mechanisms that control the distribution of such elements in S. aureus populations 
(Lindsay and Holden, 2004). 
1.2.8.2.1 Bacteriophages 
S. aureus temperate bacteriophages are common, with most strains carrying at 
least one phage. The five sequenced strains have nine prophages genomes in their 
chromosomes and are classified into five families on the basis of intergrase gene 
homology, which dictates insertion site. None of the sequenced strains appeared to have 
more than one phage of each family type, presumable owing to phage immunity or 
competition for insertion sites (Lindsay and Holden, 2004). All the sequenced S. aureus 
strains have prophage ~Sa3 and in each case are integrated into the hib (~-haemolysin) 
gene (Holden et ai., 2004). The prophage contains staphylokinase (sak) and enterotoxin 
type A (sea) genes except in N315 which carries a different enterotoxin gene, designated 
sep, that encodes a protein with only 77% amino acid similarity to enterotoxin A (Kuroda 
et ai., 2001). Two additional enterotoxin gene alleles, seg2 and sek2, which encode 
putative enterotoxin G and K homologues are reported in MW2 and MSSA476 (Table 
1.5) (Baba et ai., 2002; Holden et ai., 2004). 
A unique feature on the MW2 chromosome is the ~Sa2mw, which carries the 
iukF-PVand iukS-PV genes that encode the Panton-Valentine (PV) leuckocidin 
components. It has a potent toxic effect on human white-blood cells and is strongly 
associated with severe forms of pneumonia (necrotic pneumonia) caused by community-
acquired S. aureus strains (Gillet et ai., 2002). In addition, PV toxin strains have been 
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associated with an increase in severe boils and skin infections among inmates in prisons, 
and the homosexual community (Anonymous, 2003). The IPSa2 attachment site is present 
in all the sequenced strains but they exist in different allelic forms, and only IPSa2mw has 
the Panton-Valentine leukocidin genes (Table 1.5) (Baba et ai. , 2002). 
1.2.8.2.2 Transposons 
Transposons and insertions sequences can integrate themselves into any 
chromosome loci by illegitimate recombination (Murphy, 1989). Thus they tend to 
shuffle genome structure and are thought to contribute much to adaptability of S. aureus 
to the adverse environment (Baba et ai. , 2002). Tn554 is a site-specific transposon that 
encodes resistance to spectinomycin and macrolide-lincosamide-streptogramin B 
antibiotics. Two copies of Tn554 were found in N315, Mu50 and MRSA252 genomes. 
Three additional copies were found in the N315 genome. Another transposon Tn5801 
was uniquely found in Mu50, which carries a gene (tetM) encoding tetracycline and 
minocycline resistance (Kuroda et ai. , 2001). The MRSA252 chromosome also contained 
a Tn552 transposon that encodes the Bia!, BiaR and BiaZ components of the inducible S. 
aureus ~-lactamase. There is also an element integrated into the chromosome that 
contains similarity to the Tn916 transposon, however, it does not appear to carry any 
obvious resistance determinants (Holden et ai. , 2004). Transposons are scarcely recorded 
in the MW2 and MSSA476 genome (Table 1.5) (Baba et ai. , 2002; Holden et ai. , 2004). 
It would be reasonable to assume that hospitals are a severe environment for 
microorganisms to survive in, because they are constantly exposed to various antiseptics 
and new antibiotics. Multiple insertions of transposons and insertions sequences in 
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hospital-acquired MRSA genomes might be testament to the evolutionary ordeal they 
have gone through (Baba et ai., 2002). 
1.2.8.2.3 S. aureus pathogenicity islands (SaPIs) 
SaPIs often carry superantigen genes, such as toxic shock syndrome (tst) and 
enterotoxins Band C, implicated in toxic shock and food poisoning. Seven SaPIs in 
human isolates (SaPInl) (Kuroda et ai. , 2001), SaPIml (Kuroda et ai. , 2001), SaGIm 
(Kuroda et ai. , 2001), vSa3 (MW2) (Baba et ai. , 2002), SaPIl (Lindsay et ai. , 1998), 
SaPI3 (Yarwood et ai. , 2002) and SaPI4 (Holden et ai. , 2004) and two in bovine isolates -
SaPIbov (Fitzgerald et ai., 2001b) and SaPIbov2 (Ubeda et ai. , 2003) have been 
sequenced. Human SaPIs are classified into four groups on the basis of integrase 
homology and insertion site, and none of the sequenced strains carried more than one 
copy of each type. The MSSA476 does not have a pathogenicity island in its genome 
while the MRSA252 carries a SaPI-like element - SaPI4, that contains homologues of 
pathogenicity island proteins and displays synteny (conserved gene order) with the 
previously characterized SaPIl, SaPIbov and SaPI3 (Lindsay et ai. , 1998; Fitzgerald et 
ai., 2001b; Yarwood et ai., 2002). 
SaPI4 has an integrase gene and insertion site downstream of the ribosomal 
protein gene rpsR but contains several hypothetical proteins with no similarity to 
characterized virulence genes (Holden et ai. , 2004). N315 and Mu50 possess the 
superantigen genes sel , se3 and tst. A feature of the toxic shock syndrome toxin (TSST) 
island family is its close linkage to prophages ~N315/~Mu50A and ~Mu50B, 
respectively, which are integrated in close proximity to these islands. These phages may 
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be involved in the horizontal transfer of the islands. (Kuroda et ai. , 2001) A unique 
feature ofMu50 is the carriage of SaG 1m (jhuD) gene that possibly encodes a 
ferrichrome-binding ABC transporter. This iron transporter might confer a selective 
advantage to Mu50 in human tissue. MW2 also carries two allelic forms of enterotoxin 
sei2 and se14 (Table 1.5) (Baba et ai., 2002; Lindsay and Holden, 2004). 
1.2.8.2.4 Genomic Islands 
Two types of genomic islands are found in S. aureus: vSaa and vSa~ (Kuroda 
et ai. , 2001 ; Baba et ai. , 2002). Both islands appeared to be extremely stable as they are 
found in all sequenced isolates in the same location with some genes highly conserved. 
However, they vary remarkably between strains, each carrying their own number and 
variants of superantigens, lipoproteins and proteases. Some also carry leukocidins, 
hyaluronate lyase and lantibiotic genes (Lindsay and Holden, 2004). The genomic island 
VSaa is distinctive because it carries many putative staphylococcal exotoxin (set) genes 
in all the sequenced strains (Suzek et ai. , 2001 ; Williams et ai. , 2000). They are capable 
of inducing proinflarnmatory cytokine production by human peripheral blood 
mononuclear cells (Williams et ai. , 2000). The Mu50 and N315 genome have 9 and 10 
set genes respectively, and the set clusters are nearly identical except for one paralogue 
(set9) , which is missing in Mu50. The structure of vSa~ differs from strain to strain with 
the presence or absence of some genes. The superantigen gene cluster (composed of six 
enterotoxin genes) carried by islands ofN315 and Mu50 (type I) are missing from vSa~ 
of MW2 (type II). Instead, vSa~mw has a novel gene cluster, designated bsa (bacteriocin 
of S. aureus), which encodes a putative bacteriocin (toxin or antibiotic to other bacteria) 
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(Baba et al. , 2002). However, the spl (staphylococcal serine proteases) and exotoxins 
were present in N315 , Mu50 and MRSA252. The lukDE gene (leuckocidin DE) was 
absent in MRSA252 (carried a hysA - hyaluronate lyase gene) and the genomic islands 
found in MSSA476 matched that ofMW2 (Table 1.5) (Kuroda et al., 2001; Baba et al., 
2002; Lindsay and Holden, 2004). 
1.2.8.2.5 Plasmids 
S. aureus isolates, and particularly those from hospitals, often carry one or 
more free or integrated plasmids. S. aureus plasmids can be classified into three types on 
the basis of size and the genes they carry (Paulsen et al., 1997). All types of S. aureus 
plasmids frequently carry antibiotic resistance genes, or resistance to heavy metals or 
antiseptics. Some virulence genes are also reported to be carried on plasmid, such as 
exfoliative toxin B and some superantigens (Zhang et al. , 1998;Yamaguchi et al. , 2001). 
Notably, all the sequenced strains carried plasmids. The MW2 strain contained no 
antibiotic resistance genes apart from blaZ (encoding penicillinase) and a cadD 
(cadmium resistance gene) on plasmid pMW2 (20654bp) (Baba et al., 2002; Lindsay and 
Holden, 2004). The N315 plasmid pN315 (24653bp) contained a cadmium resistance 
determinant cadDX and an arsenate resistance determinant arsRBC. On the Mu50 
plasmid pMu50 (25107bp), there is a copy of Tn4001 that carries aac-aphD (encoding 
amino glycoside resistance). Others include the qacA genes that encode resistance to 
quaternary ammonium compounds (such as diamidines, chlorhexidine, and intercalating 
dyes) and traA, which encodes a probable nicking enzyme for bacterial conjugation. The 
blaZ and cadD genes are the only apparent resistance genes within the MSSA476 
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genome located on a pSAS 1 plasmid (Holden et ai. , 2004). Strain MRSA252 carries an 
integrated plasmid that confers resistance to heavy metals arsenic (arsBC) and cadmium 
(cadAC). Strains N315 and Mu50 also carries a pUB110 plasmid with bleomycin- and 
kanamycin-resistance genes while MRSA252 carries an integrated pUB 110 plasmid 
(Table 1.5) (Kuroda et ai. , 2001 ; Holden et ai. , 2004). 
1.2.8.2.6 Stapbylococcal cassettee cbromosome (SCC) 
SCC elements are mobile genetic elements that integrate at the same site on the 
S aureus chromosome (Ito et ai. , 2001). These elements carry the mec region encoding 
methicillin resistance, but alternatively they can also carry other sets of genes such as the 
capsule gene (Hiramatsu et ai. , 2001 b; Luong et ai. , 2002). At least, four different 
versions of SCCmec are found in S. aureus: SCCmec types I to IV (Ito et ai. , 2001 ; Ma et 
ai., 2002). Recently, the type IV was divided into subtypes IVa, IVb and recently a third 
subtype IVc was reported in France and Japan (Hiramatsu et ai. , 2002; Ma et ai. , 2002; 
Ito et ai., 2003) and a novel type V has been described recently (Ito et ai., 2004). The 
three hospital-acquired MRSA strains (N315, Mu50, MRSA252) possess the type II 
SCCmec elements (Table 1.5). The SCCmec encodes resistance to beta lactams, 
bleomycin, macrolide-lincosamide-streptogramin B, aminoglycosides (tobramycin, 
amikacin), and spectinomycin (Kuroda et ai., 2001). The community-acquired MRS A 
strain (MW2) has a type IVa element and its structure is smaller in size from that of 
hospital-acquired MRSA strains. Type IVa SCCmec of MW2 comprises two allelic 
elements - class B mec-gene complex (mecA and its regulatory genes) and type-2 ccr A 
and B genes (Hiramatsu et ai., 2001a). Notably, the methicillin-susceptible MSSA476 
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contained a novel SCC-like element (SCC476), which showed the greatest similarity to a 
previously described S. hominis non-mec SCC element (SCC12263) (Katayama, 2003b). 
SCC476 shares the same left and right boundaries (attL and attR, respectively) and similar 
inverted repeat sequences with the SCCmec elements, but does not carry the mecA gene. 
However, it carries a novel gene with homology to the fusidic acid resistance gene far 1 
(Table 1.5) (O'Brien et al. , 2002). 
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Table 1.5: 
SCC mec type II 


























Summary of the major variable genetic elements in sequenced 
Staphylococcus aureus strains 
N315 Mu50 MW2 MSSA476 
mecA mecA - -
- - mecA -
- - - fari 
homologue 
- NI - -
- - /ukSF-PV -
sak, sep sea, sak sea, sak, seg2, se~ sa~ seg2, sek2 
sek2 
- - - NI 
- - - -
set [10]" set [9]" set [11]" set [ll]C 
sp/ [5]" sp/ [5]" , sp/ [4]", sp/ [4]", /ukDE, bsa 
lukDE, lukDE, /ukDE, bsa 
exotoxin [6]C exotoxin [6]" 
- - - -
seJ, sec3, tst seJ, sec3, tst - -
- thuD ear, sel2, sec4 -
- - - -
ble, kan ble, kan -
(pUBIlO)b (pUBllO)b 
cadDX, arsBC - blaZ, cadD blaZ, cadD 
(pN315B)b (pMW2)b (pSAS)b 
- aacA-aphD, - -
qacA 
(pVRSA)b 
ermA, spc [51' ermA, Sf)C [2]C - -
- - - -
- tetM - -
- - - -


























"Abbreviations: NI - virulence or drug resistance genes not identified at present; aacA-aphD, 
aminoglycoside resistance; arsBC, arsenic resistance genes; blaZ, penicillin resistance; bsa, bacteriocin 
biosynthetic genes; cadACDX, cadmium resistance genes; ear, putative p-Iactamase type protein; ermA, 
erythromycin resistance;far 1, fusidic acid resistance;jhuD, siderophore transporter; qacA, quartenary 
ammonium compound (antiseptic) resistance; hysA, hyaluronate lyase; /ukDE, two components of the 
leukocidin DE toxins; lukSF-PV, two components of the Panton-Valentine leukocidin toxin; mecA, 
penicillin-binding protein 2a conferring resistance to methicillin; sak, staphylokinase; SCC, Staphylococcal 
cassette chromosome; sea, enterotoxin A; sec3, enterotoxin C3 ; sec4, enterotoxin C4; seg2, enterotoxin G2; 
sek2, enterotoxin K2; sel, enterotoxin L; sel2, enterotoxin L2; sep, enterotoxin P; set, staphylococcal 
enterotoxins; spc, spectinomycin resistance; spl, staphylococcal serin proteases; tst, toxin shock syndrome 
toxin-I; tetM, tetracycline resistance. . 
bThe number of homologues, including pseudogenes, located in that region. 
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1.3 Objectives 
Numerous studies have been carried out in most parts of the world on MRSA, 
which has identified the appearance of multi-drug resistant MRSA clones replacing other 
MRSA lineages. However, epidemiological information and comparison of S. aureus 
strains in Africa are lacking. The extent of the epidemiological characteristics of antibiotic 
resistant S. aureus in most communities in Africa is largely unknown in spite of the 
established fact that infections attributed to multidrug-resistant S. aureus, in particular 
MRSA are an important health problem worldwide. At present, there is scarcity of data on 
antibiotic susceptibility patterns, clonal identities and diversity of S. aureus in Africa 
using traditional and molecular epidemiological techniques. 
The main goal of the study was to provide baseline data on the epidemiology of 
clinical isolates of S. aureus strains in Nigeria and South Africa in the development of health 
intervention strategies. Data from this study would be useful in the establishment of 
adequate infection control programmes, adjust treatment and national drug policies in the 
treatment of staphylococcal infections and bring a better understanding on the epidemiology 
of S. aureus. 
The specific objectives of the study are: (1) to determine the antimicrobial 
susceptibility pattern of S. aureus from clinical samples in Nigeria and South Africa; (2) 
determine the prevalence of methicillin resistant S. aureus (MRS A) in both countries; 
(3) understand epidemiologic relationship among MRSA clones and (4) investigate clonal 
identities and geographic spread of MRSA clones using various genotyping methods. 
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A STUDY ON THE ANTIBIOTIC SUSCEPTffiILITY OF CLINICAL ISOLATES 
OF Staphylococcus aureus OBTAINED FROM SOUTHWESTERN NIGERIA 
AND KW AZULU-NATAL PROVINCE OF SOUTH AFRICA 
2.1 INTRODUCTION 
Infectious diseases remain the leading cause of death worldwide in which seventeen 
million (32%) of the 52 million who die each year succumb to infectious disease or 
complications arising from infection (ASM, 1997). One of the most important pathogenic 
microorganisms causing infection in the hospitals and the community all over the world is 
Staphylococcus aureus. It is associated with a variety of clinical infections including 
septicemia, pneumonia, wound sepsis, septic arthritis, osteomyelitis, and post-surgical toxic 
shock syndrome (Boyce, 1997; Shopsin and Kreiswirth, 2001). One ofthe reasons for the 
success of this human pathogen is its great variability, occurring at different periods and 
places with different clonal types and antibiotic resistance pattern within regions and 
countries. In most cases, the strains responsible for these infections are hospital-acquired, 
where susceptible strains have been largely eliminated and antibiotic resistant strains 
predominate. This is as a result of selective pressure exerted by the widespread use of 
antibiotics (Thomas, 1988). Antibiotic resistance is a serious problem in health 
institutions: treatment failures extend the length of hospital stay, or demand repeated 
physician visits; hospital beds are blocked to new patients and productive time is lost 
(Livermore, 2003). The resistance of S. aureus to antimicrobials is a worldwide problem 
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causing substantial rates of morbidity and mortality (Cosgrove et al. , 2003 ; Engemann et 
al. , 2003). Although the infections caused by antibiotic-resistant S. aureus cause serious 
problems in the general population, such infections can be particularly devastating for the 
very young, the elderly and the immunocompromised (ASM, 1997). 
Methicillin-resistant Staphylococcus aureus (MRSA) is a well-known etiologic 
agent of a wide variety of infections, and has assumed increasing importance internationally 
as a cause of both nosocomial and community-acquired infections. MRSA infections are 
additional to the burden of methicillin susceptible S. aureus and are particularly difficult 
to treat especially if they are located at anatomical sites, where antibiotic penetration is 
reduced (Duckworth, 2003). Cohort studies of patients with MRSA bacteremia have 
reported higher mortality rates, increased morbidity, longer hospital length of stay, and 
higher costs compared with patients with methicillin-susceptible S. aureus (MSSA) 
bacteremia (Blot et al. , 2002; Cosgrove et al., 2003; Engemann et al., 2003 ; Melzer et al., 
2003; Kopp et al. , 2004; Cosgrove et al. , 2005). Studies have also indicated that the 
direct medical cost for MRSA infections in hospitals in the United States is $27,083-
$34,000 per patient (Abramson and Sexton, 1999; Rubin and Samore, 2002). 
Consequently, annual United States health care costs associated with MRSA infections 
are estimated to be approximately $6 billion. 
Major waves of infectious agents are encountered on the African continent. One of 
these agents is S. aureus, which is implicated as the major etiological agent of wound 
infections (Kotisso and Aseffa, 1998; Andhoga et al. , 2002; Eriksen et al. , 2003; Wariso and 
Nwachukwu, 2003) and life-threatening infections, especially neonatal sepsis, with high 
mortality rates (Dawodu and Alausa, 1985; Adejuyigbe et al. , 2001 ; Bode-Thomas, 2004). 
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Studies have also indicated that S. aureus is implicated in about 40% of all clinically evident 
cases of persistent middle ear effusion in otitis media in African children (Cisse et ai. , 1995; 
Ndip et ai. , 1995; Nwawolo et ai. , 2001). One of the earliest reports of MRS A in Africa was 
that of Scragg et ai. (1978) in a Durban hospital in South Africa, while varying reports on 
the prevalence of MRSA from health institutions in different regions in Africa have been 
described. MRSA prevalence of 4.8% have been reported in Algeria (Kesah et ai. , 2003), 
17.4% in Tunisia (Ben Jemaa et ai. , 2004), 27% in Nigeria (Okesola et ai., 1999), 39.8% 
in Kenya (Omari et ai. , 1997), 39% in South Africa (Zinn et ai., 2004), and 66% in 
Senegal (Sow et ai. , 1998). MRSA intermediately resistant to vancomycin and teicoplanin 
in a South African hospital have also been reported (Ferraz et ai. , 2000). 
For practicing physicians, clinical microbiologists and public health officials, 
knowledge oflocal antimicrobial resistance patterns of bacterial pathogens is essential to 
guide empirical and pathogen specific therapy. This information is also critical for optimal 
decisions regarding hospital formulary and infection control policies. In the African 
continent, there are relatively few studies on antimicrobial susceptibility of S. aureus 
compared with surveys in other regions of the world. This is in spite of the established 
fact that multidrug-resistant S. aureus, especially MRSA is an important health problem 
worldwide. Furthermore, there is paucity of data on the resistance profile of S. aureus 
isolates from various regions in the continent. Extensive studies on the prevalence of 
MSSA and MRSA in Southwestern Nigeria and KwaZulu-Natal province in South Africa 
are lacking. The importance of monitoring antimicrobial susceptibility pattern of S. 
aureus is important as a first step in understanding its epidemiology and information on 
drug-resistance pattern could assist clinicians in the selection of empiric antimicrobial 
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therapy. It is also essential for the rational formulation of public health care policies, and 
provide useful information on the global surveillance of this pathogen regarding 
antimicrobial resistance. This study therefore investigated antibiotic susceptibility of S. 
aureus isolates, obtained from clinical samples in Nigeria and South Africa, with various 
antibiotics used in clinical therapy. 
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2.2 MATERIALS AND METHODS 
2.2.1 Study Areas 
Six health institutions in Southwestern Nigeria were included in this study. They 
comprised of three hospitals located in Ile-Ife, and one health facility in Ilesa, Ipetumodu 
and Ibadan. The duration of the collection of isolates was from June 2002 to August 
2004. A total of 14 hospitals in the KwaZulu-Natal (KZN) province, South Africa, 
participated in this study from June 2002 to August 2004. The health institutions included 
four hospitals in the city of Durban, two from Pietermaritzburg, and one health institution 
from Newcastle, Greytown, Kokstad, Eshowe, Port Shepstone, Scottburgh, Empangeni 
and Ubombo. 
2.2.2 Microbiological analysis and Identification 
The S. aureus isolates were obtained from the clinical microbiology laboratories of 
the various health institutions, in both countries. Identification was based on growth and 
fermentation on mannitol salt agar, colonial morphology on nutrient agar, Gram stain, and 
positive results for catalase, coagulase and DNase tests. Atypical isolates were identified 
using API STAPH according to the manufacturer' s instructions. The isolates were preserved 
in MicroBank (Diagnostic Pro-Lab) and stored at -20oe for further characterization. 
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2.2.3 Antibiotic susceptibility testing 
The susceptibility testing of isolates to twenty antibiotics was carried out by the disk 
diffusion method according to the National Committee for Clinical Laboratory Standards 
guidelines (NCCLS, 2000, 2003) using antibiotic disks. The antibiotics (Mast Diagnostics, 
UK) included penicillin (10units), ampicillin (10j.lg), oxacillin (lj.lg), gentamicin (10j.lg), 
kanamycin (30j.lg), streptomycin (30j.lg), neomycin (30j.lg), erythromycin (15j.lg), 
clindamycin (2j.lg), tetracycline (30j.lg), minocycline (30j.lg), trimethoprim (2.5j.lg), 
trimethoprimlsulfamethoxazole (25j.lg), chloramphenicol (30j.lg), ciprofloxacin (5j.lg), 
fusidic acid (10j.lg), rifampicin (30j.lg), teicoplanin (30j.lg), vancomycin (30j.lg) and 
mupirocin (5 and 200j.lg). S. aureus ATCC 25923 was the control strain in every test run. 
Interpretative zone diameters for resistance to fusidic acid, neomycin and streptomycin 
which are not stated in the NCCLS guidelines were considered as follows; ~ 18mm -
fusidic acid (Skov et ai. , 2001), ~ 16mm - neomycin, and ~ 14mm - streptomycin (Kim 
et ai. , 2004). Growth to the edge of the 200j.lg mupirocin disk indicated high-level 
resistance, whereas growth within a 14mm zone of inhibition with the 5j.lg mupirocin disk 
detected low-level resistance (Udo et ai. , 1999). In addition, susceptibility testing to a set of 
ten antibiotics was performed on isolates expressing resistance to oxacillin. The antibiotics 
included arnikacin (30j.lg), azithromycin (15j.lg), quinipristinldalfopristin (15j.lg), 
doxycycline (30j.lg), tobramycin (lOj.lg), methicillin (5j.lg), cefoxitin (30j.lg), oleandomycin 
(15j.lg), fosfomycin (50j.lg) and linezolid (30j.lg). Interpretative zone diameters for 
resistance (not stated in the NCCLS guidelines) to the following antibiotics were 
considered as follows : oleandomycin ~ 17mm and fosfomycin ~14mm (Members of the 
SFM Antibiogram Committee, 2003). 
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The D-test for determining inducible resistance of clindarnycin by erythromycin 
was performed. The erythromycin and clindarnycin disks were placed IS-18mm apart. A 
truncated or blunted clindarnycin zone of inhibition (D-shape) indicated inducible 
resistance. Constitutive resistance was recognized by a clindamycin zone diameter of :$ 
14mm (Fiebelkorn et al. , 2003). 
2.2.3.1 Determination of reduced susceptibility to vancomycin and teicoplanin and low 
and high-level resistance to mupirocin 
Isolates expressing phenotypic resistance to oxacillin were screened for intermediate 
resistance to vancomycin and teicoplanin. An inoculum equivalent to MacFarland 2 was 
swabbed onto Mueller Hinton agar (MHA) before placement of vancomycin and teicoplanin 
E-test strips (AB Biodisk, Solna, Sweden). The plates were incubated at 3SoC and MIC 
values were noted after 24 hours. Isolates with MIC ~ 2~glml (vancomycin and teicoplanin) 
were further screened on Brain Heart Infusion Agar (BHIA) using the E-test macrodilution 
method (Walsh et al. , 2001). The plates were incubated at 3SoC and MIC values were noted 
after 48 hours of incubation. Bacterial isolates with MIC values of :$4~glml and :$8~g/ml 
were considered as sensitive to vancomycin and teicoplanin respectively. MICs of 8-
16~g/ml (vancomycin) and 16~g/ml (teicoplanin) were regarded as intermediately 
resistance (NCCLS, 2000; Walsh et al., 2001). Isolates exhibiting low and high-level 
resistance to mupirocin were further assessed by the E-test method as stated above. 
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2.2.3.2 Susceptibility of MRSA isolates to heavy metals ions and nucleic-acid 
binding compounds 
Susceptibility to heavy metals (cadmiwn acetate, mercuric chloride) and nucleic-
acid binding compounds (ethidiwn bromide and propamidine isethionate) was performed on 
a nwnber of MRSA isolates. Disks were prepared in the laboratory with the indicated 
concentrations (10J-ll): cadmiwn acetate (50J-lg), propamidine isethionate (50J-lg), mercuric 
chloride, (109J-lg) and ethidiwn bromide (60J-lg). Interpretative zone diameters were 
considered according to Udo et al. (1999): ~ 9mm (resistance), 10-12mm (intermediate) 
for cadmiwn acetate; ~ 25mm - (resistance) for mercuric chloride; ~ 10mm (resistance), 
11-14mm (intermediate) for propamidine isethionate; and ~ 9mm (resistance), 10-14mm 
(intermediate) for ethidium bromide. 
2.2.4 DNA isolation on S. aureus isolates 
DNA isolation was carried out according to the method ofUdo et al. , (1999). 
Isolates were streaked on Brain Heart Infusion Agar (BHIA) and incubated at 37°C 
overnight. Using a sterile toothpick, six to seven colonies were added to an eppendorf 
tube containing 50J-lllysostaphin (150J-lglml) and 10111 RNase (10mglml). It was then 
incubated at 37°C for twenty minutes. Thereafter, S0J.11 of diluted Proteinase K (7.SJ.11 of 
20mglml Proteinase K and 1492J-ll of sterile distilled water) and 150J-l1 O.lM Tris were 
dispensed into the eppendorf tube. It was then incubated in a 60°C water bath for ten 
minutes and thereafter at 95°C for ten minutes. Centrifugation was carried out at 13000 
rpm for ten minutes and a volwne of 5 J-ll was used as template DNA for subsequent PCR 
reactions. 
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2.2.5 Molecular detection of the nue, mecA and mupA genes by peR 
Isolates resistant to oxacillin using the disk diffusion technique were confirmed as 
S. aureus by the detection of the nue gene using the polymerase chain reaction (PCR). In 
addition, the presence of the meeA gene was determined, which confirmed the isolates as 
MRS A. Primers (nuc-l) 5' - GCG ATT GAT GGT GAT ACG GTT - 3'; (nuc-2) 5' - AGC 
CAA GCC TTG ACG AAC TAA AGC - 3' and (mecA1) 5' - CTC AGG TAC TGC TAT 
CCA CC; (mec-A2) 5' - CAC TTG GTA TAT CTT CAC C - 3' which amplified a 280bp 
and 449bp segment of the nuc and mecA genes respectively were employed (Brakstad et 
al. , 1992; Bignardi et al. , 1996). The epidemic strain EMRSA-16 served as the positive 
control for the detection of both genes. In addition, low and high-level mupirocin 
resistant isolates detected by the disk diffusion method, were confirmed by their MIC 
values and the detection of the mupA gene using the primers (mupA-l) 5' - TGA CAA 
TAG AAA AGG ACA GG - 3' and (mupA-2) 5' - CTC TAA TTC AAC TGG TAA GCC 
- 3' which amplified a 190bp segment of the gene (Woodford et al. , 1998). 
Each PCR reaction was made up of the following : 251ll ofmastermix (Sigma), 
containing 1.5units of Taq DNA polymerase, 10mM Tris-HCl, 50mM KCl, 1.5mM 
MgCh, 0.001% gelatin and 0.2mM dNTPs, 1 III (20pmol) of the forward and reverse 
primers and 51ll of template DNA. Sterile distilled water was added to make a final 
volume of 50Ill. The thermocycler was programmed with the following parameters: 
predenaturation at 95°C for 5 minutes, 30 cycles of denaturation at 95°C for 30 seconds, 
annealing at 55°C for 30 seconds, extension at 72°C for 1 minute and final extension at 
72°C for 5 minutes. The PCR conditions were utilized for the detection of the nucA , 
mecA and mupA genes (Scottish MRSA Reference Laboratory Standard Operating 
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Procedure, 2004). peR products were detected by gel electrophoresis using 1.5% w/v 
agarose (Seakem, Whittaker USA). The agarose gel was run in IX TBE (0.OS9M Tris, 
0.OS9M Boric acid, 0.002M EDTA disodium) buffer (PH S.3) for 2 hours at SOY. 
Thereafter, the gels were stained with ethidium bromide and visualized under UV light. 
2.2.6 Data analysis 
The resistance rate to each antibiotic was calculated as the number of intermediate 
and resistant isolates observed divided by the total number of isolates. Thus, the 
prevalence ofMSSA and MRSA in Nigeria and South Africa was determined. 
Furthermore, resistance rates ofMSSA and MRSA in each country, to the antibacterial 
agents were ascertained. A comparative analysis of the resistance rates of S. aureus 
isolates, from both countries was also determined, and the student t-test (p<0.05) was 
employed in establishing significant differences. 
Antibiotyping ofMSSA isolates (in each country) was analysed based on their 
susceptibility to twenty antibiotics. Isolates with similar resistance profiles were grouped 
in the same anti biotype and the prevalence in both countries was ascertained. 
Antibiotyping of MRSA isolates was based on the susceptibility pattern of 
isolates to selected antibiotics, representing various classes of antimicrobial agents. They 
included penicillin (~-lactams), gentamicin (aminoglycosides), erythromycin (macrolide), 
chloramphenicol (phenicols), tetracycline (tetracyclines), trimethoprim (sulfonamides), 
rifampicin (ansamycins), ciprofloxacin (fluoroquinolones) and mupirocin. 
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Antibiotyping of MRS A isolates based on their susceptibility to aminoglycosides, 
tetracyclines, macrolide-lincosamide group of antibiotics, heavy metals and nucleic acid 
binding compounds was also determined. 
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2.3 RESULTS 
2.3.1 Recovery and distribution of S. aureus isolates from health institutions in 
Nigeria and South Africa 
The distribution of isolates obtained from the various health institutions in both 
countries, in relation to clinical samples is presented in Table 2.1. Of the 358 isolates 
identified as S. aureus in the various clinical laboratories in Southwestern Nigeria, 200 
isolates (56%) were confirmed as S. aureus based on growth and fermentation on mannitol 
salt agar, Gram stain, and positive results for catalase, coagulase and DNase tests. More 
than one-third of the total number of isolates (from Nigeria) was recovered from wound 
samples, 42 (21 %) from blood cultures, 17 (8.5%) from samples obtained from ocular-
related infections, 16 (8%) from urine cultures, and 11 (5.5%) from samples obtained 
from otitis media. Clinical information was unavailable for 30 S. aureus isolates. 
A total of233 isolates were obtained from a study on antibiotic resistance patterns 
of bacterial isolates from various health institutions in KwaZulu-Natal province, South 
Africa, in partnership with the Faculty of Pharmacy, University of KwaZulu-Natal. Only 
six isolates (2.6%) were misidentified. Wound samples were the main source of isolates 
recovered in KZN province, South Africa (83 .7%). Overall, a total of 427 S. aureus non-
duplicate isolates were obtained from various clinical samples in Nigeria and South 
Africa. 
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Table 2.1: Distribution of S. aureus isolates in relation to health institutions and 
clinical samples in Nigeria and South Africa 
Clinical samples 
Country Health Institutions (Location) I 2 3 4 5 6 7 8 Total 
Nigeria Hospital A, lIe-Ife 21 27 7 2 1 1 3 10 72 
Hospital B, lIe-Ife 5 0 0 0 0 0 0 0 5 
Hospital C, lIe-Ife 6 0 0 0 0 0 0 0 6 
Hospital D, lIesa 6 0 3 0 2 0 1 0 12 
Hospital E, Ipetumodu 3 0 0 0 0 0 0 0 3 
Hospital F, Ibadan 36 15 6 0 8 16 1 20 102 
Total 77 42 16 2 11 17 5 30 200 
South Africa Health Institutions (Location) 
Hospital A, Durban 6 3 I 1 0 0 0 0 II 
Hospital B, Durban 22 2 I 0 0 0 0 0 25 
Hospital C, Durban 2 0 0 0 1 0 2 1 6 
Hospital D, Durban 16 0 0 0 0 0 0 0 16 
Hospital E, Pietermaritzburg 6 0 0 0 0 0 0 0 6 
Hospital F, Pietermaritzburg 16 1 0 1 2 0 1 0 21 
Hospital G, Newcastle 0 0 0 3 0 0 0 0 3 
Hospital H, Greytown 7 0 0 0 1 0 1 0 9 
Hospital I, Kokstad 13 0 0 0 I I 0 0 15 
Hospital J, Eshowe 4 0 0 0 0 0 0 0 4 
Hospital K, Port Shepstone 8 0 0 I I 0 0 0 IO 
Hospital L, Scottburgh 0 0 I 2 I 0 0 2 6 
Hospital M, Ubombo 2 0 0 0 0 0 0 0 2 
Hospital N, Empangeni 88 0 0 1 0 0 1 3 93 
Total 190 6 3 9 7 1 5 6 227 
KEY 
Samples from 1- Wound culture; 2 - Blood; 3 - Urine; 4 - Sputum; 5 - otitis media; 
6 - eye-related infection; 7 - Other clinical samples (HYS, vaginal swab, endocervical swab, pericardial 
fluid, endotracheal aspirate); 8 - no clinical information. 
195 
2.3.2 Antibiotic susceptibility of S. aureus isolates from Nigeria 
The antibiotic susceptibility of 200 S. aureus isolates obtained from hospitals in 
Southwestern Nigeria is described in Table 2.2. All the isolates (MSSA and MRS A) were 
susceptible to teicoplanin, vancomycin, fusidic acid and rifampicin, while less than 3% 
were resistant to oxacillin, erythromycin, clindamycin, neomycin, minocycline and 
mupirocin. Most of the MSSA S. aureus isolates were resistant to penicillin and 
ampicillin (90%) followed by tetracycline (51.3%) and trimethoprim (47.2%), while less 
than 10% of MSSA isolates were resistant to gentamicin, kanamycin, chloramphenicol 
and ciprofloxacin. 
Only three isolates from SouthWestern Nigeria were confirmed as MRS A. The 
resistance rates are presented in Tables 2.2 and 2.4. Two isolates demonstrated 
intermediate resistance to oxacillin (zone sizes 12mm) but were confirmed as MRSA by 
the detection of the mecA gene. The MRSA isolates were resistant to tetracycline but 
susceptible to gentamicin, kanamycin, neomycin, chloramphenicol and mupirocin. Two 
of the three MRS A isolates were susceptible to streptomycin, trimethoprim, minocycline 
and ciprofloxacin while one isolate was susceptible to erythromycin and clindamycin. In 
addition, two MRSA were susceptible to amikacin, tobramycin, fosfomycin, 
quinipristinldalfopristin, linezolid, doxycycline, methicillin, cefotixin, ethidium bromide, 
and propamidine isethionate, but resistant to mercuric chloride and cadmium acetate 
(Table 2.4). 
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Table 2.2: Antibiotic susceptibility of S. aureus isolates (MSSA and MRSA) from 
Nigeria 
Nigeria Nigeria 
MSSA n=197 MRSA n=3 
Antibiotic Number of isolates Resistance Number of isolates 
that were: rate (%) that were: 
S R S I R 
Penicillin 19 178 90.4 0 0 3 
Ampicillin 19 178 90.4 0 0 3 
Oxacillin 197 0 0 0 2 I 
Erythromycin 194 3 1.5** 1 0 2 
Clindamycin 194 3 1.5** I 0 2 
Gentamicin 185 12 6.1 3 0 0 
Streptomycin 175 22 11.2** 2 0 1 
Kanamycin 183 14 7.1 3 0 0 
Neomycin 192 5 2.5** 3 0 0 
Trimethoprim 104 93 47.2** 2 0 1 
Trimethoprim/ 
Sulphamethoxazole 104 93 47.2** 2 0 1 
Tetracycline 96 101 51.3** 0 0 3 
Minocycline 194 3 1.5 2 0 1 
Teicoplanin 197 0 0 3 0 0 
Vancomycin 197 0 0 3 0 0 
Chloramphenicol 179 18 9.1 ** 3 0 0 
Ciprofloxacin 184 13 6.6** 2 0 1 
Fusidic acid 197 0 0 3 0 0 
Rifampicin 197 0 0 3 0 0 
Mupirocin (5I-lg) 196 I 0.5 3 0 0 
Mupirocin (2OOl-lg) 196 I 0.5 3 0 0 
KEY 
S - sensitive; I - Intermediate; R - Resistant 
* - Significant difference (p <0.05) (all s. aureus isolates from Nigeria) 




rate (%) rate (%) 
100 181 (90.5) 
100 181 (90.5) 
100 3 (1.5)* 
66.7 5 (2.5)* 
66.7 5 (2.5)* 
0 12 (6.0)* 
33.3 23 (11.5) 
0 14(7.0)* 
0 5 (2 .5)* 
33.3 94 (47)* 
33.3 94 (47)* 
100 104 (52)* 
33.3 4 (2.0)* 
0 0 
0 0 
0 18 (9.0) 
33.3 14 (7.0) 
0 0 
0 0* 
0 I (0.5)* 
0 I (0.5) 
2.3.3 Antibiotic susceptibility of S. aureus isolates from South Africa 
The susceptibility of227 S. aureus isolates from the KwaZulu-Natal province of 
South Africa to various antibiotics is illustrated in Table 2.3 . All the isolates (MSSA and 
MRSA) were susceptible to vancomycin, teicoplanin and fusidic acid and the proportion 
of isolates resistant to streptomycin, neomycin, chloramphenicol, ciprofloxacin and 
mupirocin was less than 10%. About 30% of isolates were resistant to erythromycin, 
clindamycin, trimethoprim and tetracycline. Resistance rates for rifampicin (20.3%), 
minocycline (24.2%), gentamicin and kanamycin (28.6%) were also noted. Penicillin and 
ampicillin were the least effective antibacterial agents. In addition to full susceptibility to 
vancomycin, teicoplanin and fusidic acid, MSSA isolates from South Africa were 
susceptible to oxacillin, streptomycin, neomycin and minocycline. Furthermore, less than 
1 % of MSSA were resistant to chloramphenicol, ciprofloxacin, rifampicin and mupirocin, 
while resistance to gentamicin, kanamycin and tetracycline was below 10%. Resistance 
rates for trimethoprim, clindamycin and erythromycin was 10.8% and 11.4%, 
respectively. 
The prevalence of MRS A (confirmed by the detection of the mecA gene) was 27% 
and the susceptibility of MRSA to various antibiotics, heavy metal ions and nucleic-acid 
binding compounds are presented in Tables 2.3 and 2.4. Among the aminoglycosides, more 
than 90% of MRSA were resistant to gentamicin, kanamycin and tobramycin. Amikacin 
was the most active aminoglycoside (16.4%), followed by streptomycin and neomycin 
(31.1 %). Only 9.8% of MRSA isolates were susceptible to tetracycline and minocycline. 
Resistance levels of MRSA to macrolide-lincosamide antibiotics were high -
azithromycin (80.3%), erythromycin (82%), clindamycin (82%) and oleandomycin 
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(82%). In addition, resistance to trimethoprim and trimethopimlsulfamethoxazole 
(sulphonamides) was above 80%. Other resistance rates include rifampicin (73.8%), 
doxycycline (36%), ciprofloxacin (18%) and chloramphenicol (16.4%). Resistance rates 
for heavy metal ions - mercuric chloride and cadmium acetate - was 46% and 82% 
respectively, while about 70% of MRS A were susceptible to propamidine isethionate and 
ethidium bromide. 
The ability of the disk diffusion method using oxacillin, methicillin and cefoxitin 
antibiotic discs to accurately identify MRSA was compared with peR detection of the 
mecA gene, which is considered the 'gold standard' . Of the 64 MRS A isolates studied, 
(confirmed by detection of the mecA gene), the oxacillin, methicillin and cefoxitin disk 
diffusion methods accurately detected 62 isolates as MRSA (Tables 2.2, 2.3 and 2.4). 
Only two MRSA from Nigeria were noted as intermediately resistant to oxacillin (12mm) 
but sensitive to cefoxitin (20mm; 28mm) and methicillin (1Smm; 24mm). 
As stated above, all the S. aureus isolates from both countries were susceptible to 
vancomycin and teicoplanin using the disk diffusion technique. All the MRSA studied 
were further screened for reduced susceptibility to glycopeptides using the E-test 
macrodilution method (Walsh et at., 2001) on Mueller Hinton Agar and Brain Heart 
Infusion Agar. The MRSA isolates were susceptible to vancomycin and teicoplanin based 
on the E-test method. In addition, MRS A from both countries were susceptible to 
quinipristinldalfopristin, fosfomycin and linezolid. 
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Table 2.3: Antibiotic susceptibility of S. aureus isolates (MSSA and MRSA) from 
South Africa 
South Africa South Africa 
MSSA n=1 66 MRSA n=61 
Antibiotic Number of isolates Resistance Number of isolates Resistance 
that were: rate (%) that were: rate (%) 
S R S R 
Penicillin 19 147 88.6 0 61 100 
Ampicillin 19 147 88.6 0 61 100 
Oxacillin 166 0 0 0 61 100 
Erythromycin 147 19 11.4** 11 50 82 
Clindamycin 148 18 10.8** II 50 82 
Gentamicin 160 6 3.6 2 59 96.7 
Streptomycin 166 0 0** 42 19 31.1 
Kanamycin 160 6 3.6 2 59 96.7 
Neomycin 166 0 0** 42 19 31.1 
Trimethoprim 148 18 10.8** 9 52 85.2 
Trimethopriml 
Sulphamethoxazole 148 18 10.8** 9 52 85 .2 
Tetracycline 153 13 7.8** 6 55 90.2 
Minocycline 166 0 0 6 55 90.2 
Teicoplanin 166 0 0 61 0 0 
Vancomycin 166 0 0 61 0 0 
Chloramphenicol 165 1 0.6** 51 10 1604 
Ciprofloxacin 165 1 0.6** 50 11 18.0 
Fusidic acid 166 0 0 61 0 0 
Rifampicin 165 1 0.6 16 45 73.8 
Mupirocin (5Ilg) 165 I 0.6 46 15 24.6 
Mupirocin (2OOllg) 165 1 0.6 60 1 1.6 
KEY 
S - sensitive; R - Resistant 
* - Significant difference (p <0.05) (all S. aureus isolates from South Africa) 





208 (91 .6) 




65 (28 .6)* 
19 (804) 














Table 2.4: Antibiotic susceptibility of MRSA from Nigeria and South Africa 
Nigeria South Africa 
MRSA (n=2*) MRSA (n=61) 
Antibiotic Number of isolates Resistance Number of isolates Resistance 
that were: rate (%) that were: rate (%) 
S R S I R 
Amikacin 2 0 0 51 0 10 16.4 
Tobramycin 2 0 0 3 10 48 95 .1 
Oleandomycin 1 1 50 11 5 45 82.0 
Azithromycin 1 I 50 12 0 49 80.3 
Fosfomycin 2 0 0 61 0 0 0 
Quinipristinl 
Dalfopristin 2 0 0 61 0 0 0 
Linezolid 2 0 0 61 0 0 0 
Doxycycline 2 0 0 39 12 10 36.1 
Methicillin 2 0 0 0 0 61 100 
Cefoxitin 2 1 33.3 0 0 61 100 
Ethidium bromide 2 0 0 42 3 16 31.1 
Mercuric chloride 0 2 100 33 0 28 45.9 
Cadmium acetate 0 2 100 11 10 40 82 
Propamidine 
lsethionate 2 0 0 43 1 17 29.5 
KEY 
* Apart from cefoxitin screening test, one MRSA isolate from Nigeria was not included in this analysis 
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2.3.4 Comparative analysis of resistance rates of S. aureus isolates from Nigeria and 
South Mrica 
Significant differences (student t-test: p < 0.05) were observed between the 
resistance rates of S. aureus isolates from Nigeria and South Africa (Tables 2.2 and 2.3). 
S. aureus resistance to erythromycin, clindamycin, rifampicin, minocycline, gentamicin, 
neomycin, kanamycin, mupirocin and oxacillin was significantly higher in South Africa 
compared with Nigeria. This could be ascribed to the marked difference in the prevalence 
of MRS A in both countries. However, resistance rates of S. aureus to trimethoprim, 
trimethoprim-sulfamethoxazole and tetracycline were significantly higher in Nigeria than 
in South Africa. 
2.3.5 Comparative analysis of resistance profiles of MSSA from Nigeria and South 
Africa 
The in-vitro activities of 20 antimicrobial agents against MSSA in Nigeria and 
South Africa were analysed (Tables 2.2 and 2.3). As expected, resistance to penicillin and 
ampicillin were high, exceeding more than 80%, in both countries. Statistical analysis 
indicated that MSSA resistance to streptomycin, neomycin, trimethoprim, trimethoprim-
sulfamethoxazole, tetracycline, chloramphenicol, and ciprofloxacin was significantly 
higher in Nigeria while erythromycin and clindamycin resistance was significantly higher 
in South Africa. 
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A total of 15 and 28 antibiotypes were identified among the MSSA isolates in South 
Africa and Nigeria respectively (Table 2.5). Overall, 4.6% (Nigeria) and 10.8% (South 
Africa) ofMSSA isolates were susceptible to all antibiotics tested. A total often MSSA 
from Nigeria were susceptible to penicillin but resistant to various antibiotics, while one 
MSSA with that profile was noted in South Africa. Resistance to penicillin was the 
dominant anti biotype in South Africa whereas in Nigeria, resistance to penicillin, resistance 
to penicillin, tetracycline and trimethoprim, resistance to penicillin and tetracycline, and 
resistance to penicillin and trimethoprim accounted for 25.4%, 20.8%, 14.2% and 10.7% of 
isolates, respectively. Notable differences in the prevalence ofMSSA with the following 
resistance profiles were observed: resistance to penicillin and tetracycline (Nigeria 14.2%; 
South Africa 1.2%), resistance to penicillin and trimethoprim (10.7%; 1.8%), and 
resistance to penicillin, tetracycline and trimethoprim (20.8%; 1.8%). Furthermore, the 
proportion of multi -drug resistant (defined as resistance to penicillin along with at least 
three classes of antibiotics) MSSA was 13.7% (27 of 197 isolates) and 3.6% (6 of 166 
isolates) in Nigeria and South Africa respectively. 
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Table 2.5: Antibiotypes ofMSSA from Nigeria and South Africa 
Nigeria South Africa 
MSSA MSSA 
(no=197) (no=166) 
Group Antibiogram No(%) Antibiogram No(%) 
I PeR 50 (25.4) PeR 114 (68.7) 
2 PeRTetRTmR 41 (20.8) Susceptible to all 18 (\0.8) 
antibiotics 
3 Pe~etK 28 (\4.2) PeREryR 9 (5.4) 
PeRTefMnR I (0.5) 
4 PeRTmR 21 (10.7) PeRTmRGnRKa
R 5 (3.0) 
5 Susceptible to all antibiotics 9 (4.6) PeRTefTmRE~ 4 (2.4) 
6 PeKTetKTmKCipTSt?' 4 (2.0) PeRTm
R 3 (1.8) 
PeRTetRTmRCipRGnRKanR 2 (1.0) 
PeRTetRTmRCipRStrRGnRKanR I (0.5) 
7 PeRTetRTmRChlR 6 (3.0) PeKTetKTm
K 3 (1.8) 
8 Tef 3 (1.5) PeKTef 2 (1.2) 
TefMnR 1 (0.5) 
9 PeRTmRChlR 3 (\.5) PeKTetKE~ 2 (1.2) 
10 PeRTmKStrK I (0.5) PeKTmREryK 1 (0.6) 
PeRTmRGnRKanR I (0.5) 
PeRTmRGnRStrRNeoRKanR I (0.5) 
II PeKTetKGnRTmTStf"RKanR 1 (0.5) PeKRf< 1 (0.6) 
PeRTetRGnRTmRStrRNeoRKanR 2 (1.0) 
12 TmR 2 (\.0) PeKTefEryKCipK I (0.6) 
13 PeKTetKChIKSt~ 2 (1.0) PeKChlREryR 1 (0.6) 
14 PeKTetKKanK 1 (0.5) TefTmRMuR 1 (0.6) 
PeRTetRGnRKanRMnR 1 (0.5) 
15 PeKTetKTmKS~ 2 (1.0) PeKTmREryRGnR 1(0.6) 
KaR 
16 ChlK I (0.5) 
17 TefMuK 1 (0.5) 
18 ChIKS~ 1 (0.5) 
19 GnRCipRKanRStrT 1 (0.5) 
20 PeRChlRStrR 1 (0.5) 
21 PeRTetREryR 1 (0.5) 
22 PeRTmRCipR 1 (0.5) 
23 PeRTetRTmRChIRSt~ I (0.5) 
24 PeRTmRChlRGnRStrRKanR I (0.5) 
25 PeRChlRCipRStrR I (0.5) 
26 PeKTmKCipKNeoKKanKStrK I (0.5) 
27 PeRTetRChIRC~Et=7 I (0.5) 
28 PeKTmKTefCipRGnREryRStrRNeoKKanK 1 (0.5) 
KEY 
Chl- Chloramphenicol; Cip - Ciprofloxacin; Ery - Erythromycin; Gn - Gentamicin; Ka - Kanamycin; Mu -
Mupirocin; Pe - Penicillin; Rf - Rifampicin; Str - Streptomycin; Tet - Tetracycline; 
Tm - Trimethoprim. 
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2.3.6 Macrolide-lincosamide resistance in S. aureus isolates from Nigeria and South 
Mrica 
The phenotypic resistance profile of 427 isolates for the macrolide-lincosamide 
group of antibiotics is illustrated in Table 2.6. A total of353 of the 427 isolates studied were 
susceptible to erythromycin. Resistance to erythromycin and inducible resistance to 
clindamycin were detected in 2.5% and 29.5% of S. aureus isolates from Nigeria and South 
Africa, respectively. Of the 19 erythromycin-resistant MSSA from South Africa, only one 
isolate exhibited the constitutive MLS resistance phenotype, which was absent in 
erythromycin-resistant MSSAI MRSA from Nigeria, and MRSA from South Africa. 
Table 2.6: Phenotypic resistance patterns of S. aureus isolates for erythromycin, and 
clindamycin in Nigeria and South Africa 
Nigeria n=200 South Africa n=227 
No. (%)of: 
Resistance pattern MSSA MRSA MSSA MRSA 
Erythromycin resistant, clindamycin susceptible 0 0 1(0.6) 0 
Erythromycin resistant, clindamycin resistant (constitutive) 0 0 1 (0.6) 0 
Erythromycin resistant, clindamycin resistant (inducible) 3 (1.5) 2 (66.7) 17 (10.2) 50 (82) 
Erythromycin susceptible clindamycin resistant 0 0 0 0 
Erythromycin susceptible clindamycin susceptible 194 (98.5) I (33.3) 147 (88.6) 11 (18) 
Total 197 3 166 61 
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2.3.7 Recovery and distribution of MRS A from various health institutions in 
Nigeria and South Africa 
The distribution of MRSA in relation to clinical samples and health institutions is 
described in Table 2.7. At least one MRSA was recovered from clinical samples in 13 of the 
14 health facilities in the KwaZulu-Natal province of South Africa. Only three MRSA 
isolates were obtained from hospitals in the Southwestern region in Nigeria. A total of 48 
MRSA isolates (78%) were recovered from wound samples, six (9.8%) from sputum, two 
from otitis media (3.3%), and one isolate each from blood, urine, eye-related infections and 
endotracheal aspirate' from hospitals in KZN province of South Africa. No clinical 







Distribution of MRSA in relation to health institutions and clinical 
samples from Nigeria and South Africa 
Clinical samples 
Health institutions and location 1 2 3 4 5 6 7 
(total number of S. aureus isolates) 
Hospital A, lIe-Ife (72) I 
Hospital C, lIe-Ife (6) I 
Hospital F, Ibadan (102) 1 
Total 3 
Health institutions and location 
(total number of S. aureus isolates) 
Hospital A, Durban (11) 4 1 1 1 
Hospital B, Durban (25) 8 
Hospital C, Durban (6) 2 I I 
Hospital D, Durban (16) I 
Hospital E, Pietermaritzburg (6) 2 
Hospital F, Pietermaritzburg (21) 4 
Hospital G, Madadeni (3) 2 
Hospital H, GreyTown (9) 1 
Hospital I, Kokstad (15) 2 1 
Hospital J, Eshowe (4) 4 
Hospital K, Port Shepstone (10) 3 ] 
Hospital L, Scottburgh (6) 1 1 
Hospital N, Empangeni (93) 17 1 
Total 48 ] ] 6 2 ] ] 
Samples from 1 - Wound culture; 2 - Blood; 3 - Urine; 4 - Sputum; 5 - otitis media; 6 - eye-related 

























2.3.8 Antibiotyping of MRSA from Nigeria and South Africa 
The antibiotypes of MRSA based on their resistance pattern to antibiotics 
representing various classes of antibacterial agents are illustrated in Table 2.8. Multi-drug 
resistance was defmed as resistance to at least four classes of antibiotics. MRSA from South 
Africa were categorized into 12 antibiotypes, and type VI accounted for about 40% of the 
total number of isolates. About 87% of MRSA were resistant to at least four classes of 
antibiotics. Resistance to six classes of antibiotics accounted for more than 40% and four 
isolates were resistant to eight classes of antibiotics. 
The MRSA from Nigeria were grouped into three antibiotypes and only two of the 
three isolates were multiresistant. 
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Table 2.8: Antibiotyping of MRSA isolates from Nigeria and South Africa 
South Africa (n=61) 
Type Antibiogram No(%) 
I PEN, GN, ERY, Cm.., TET, TS, CIP, MUP5 4 (6.6) 
II PEN, GN, ERY, TET, TS, CIP, MUP5 6 (9.8) 
III PEN,GN, ERY,Cm.., TET, TS,RF 4 (6.6) 
IV PEN,GN, ERY,TET, TS, RF, NnJP5 3 (4.9) 
V PEN, GN, ERY, TET, TS, RF, CIP 1 (1.6) 
VI PEN,GN, ERY, TET, TS, RF 25 (40.9) 
VII PEN, GN, Cm.., TET, TS, RF 2 (3.3) 
VIII PEN,GN, TET,TS,RF, MUP5 2 (3.3) 
IX PEN, GN, TET, TS, RF 5 (8.2) 
X PEN, GN, ERY,TET, RF 1 (1.6) 
XI PEN, GN, ERY 6 (9.8) 
XII PEN, TET, RF 2 (3.3) 
Subtotal 61 (100) 
Nigeria (n=3) 
XIII PEN, ERY, TET, CIP 1 (33 .3) 
XIV PEN, ERY, TET, TS 1 (33 .3) 
XV PEN, TET 1 (33.3) 
Subtotal 3 (100) 
Total 64 
KEY 
PEN - Penicillin (p-Iactams) 
GN - Gentamicin (aminoglycoside) 
ERY - Erythromycin (macrolide) 
cm.. - Chloramphenicol (phenicols) 
TET - Tetracycline (tetracyclines) 
TS - Trimethoprim (sulphonamides) 
RF - Rifamipicin (ansamycins) 
CIP - Ciprofloxacin (fluoroquinolones) 


















2.3.9 Distribution of MRSA antibiotypes among hospitals in South Africa 
The distribution of MRS A antibiotypes in health facilities in KwaZulu-Natal 
province, South Africa is described in Table 2.9. Multiresistant MRS A (resistance to at 
least four classes of antibiotics) was identified in 13 of the 14 health institutions in this 
province. The MRSA isolates with the predominant antibiotype VI was detected in 12 of 
the 14 hospitals studied. In addition, isolates grouped in antibiotype I which exhibited 
resistance to eight classes of antibiotics were identified in Hospitals A (Durban), C 
(Durban), E (Pietermaritzburg) and N (Empangeni), while MRSA in antibiotype II 
(resistance to seven classes of antibiotics) was noted in Hospitals A (Durban), B (Durban) 
and N (Empangeni). 
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Table 2.9: Distribution of MRS A antibiotypes in health institutions of the K waZulu-
Natal province in South Africa 
Hospitals (Location) Antibiotyping (number of isolates) 
Number of isolates Ant = antibiotype 
Durban 
Hospital A (7) ant I (I); ant II (I); ant VI (I); ant VIII (2); ant IX (1); ant XI (I); 
Hospital B (8) ant II (4); ant III (I); ant IV (I); ant VI (I); ant X (I) ; 
Hospital C (4) ant I (1); ant IV (I); ant VI (I); ant XI (I); 
Hospital D (I) ant VI (I) 
Pietermaritzburg 
Hospital E (2) ant I (1) ant XI (I); 
Hospital F (4) ant III (I); ant VI (2); ant XI (1) 
Newcastle 
Hospital G (2) ant VI (I); ant IX (I) 
GreyTown 
Hospital H (1) ant VI (I) 
Kokstad 
Hospital I (3) ant VI (2); ant VII (I) 
Eshowe 
Hospital J (4) ant IV (I); ant VI (I); ant XI (I); ant XII (1) 
Port Shepstone 
Hospital K (4) ant III (2); ant VI (2) 
Scottburgh 
Hospital L (3) ant VI (I); ant IX (1); ant XI (1) 
Empangeni 
Hospital N (18) ant I (I); ant II (1); ant V (I); ant VII (1); ant VI (11); ant IX (2); ant XII (I) 
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2.3.10 Susceptibility profdes of MRS A from Nigeria and South Africa with regards to 
the aminoglycoside, macrolide-lincosamide-streptogramin B, tetracycline 
group of antibiotics, heavy metals and nucleic acid binding compounds 
The resistance patterns of MRSA in relation to aminoglycosides, macrolide-
lincosamide-streptogramin B (MLSB), tetracycline group of antibiotics, heavy metal ions 
and nucleic-acid binding compounds is illustrated in Table 2.10. MRS A isolates resistant to 
gentamicin, kanamycin, and tobramycin but susceptible to amikacin, streptomycin and 
neomycin (aminoglycosides) was predominant (60%) in South Africa. This phenotype 
was followed by MRSA resistant to the six antibiotics in this group (16.4%). About 36% 
and 80% of MRS A were resistant to the tetracyclines and macrolide-lincosamide group 
of antibiotics respectively. In addition, 14 of MRS A isolates were resistant to heavy 
metal/nucleic-binding compounds. Overall, six MRSA isolates from Durban, 
Pietermartizburg and Empangeni were resistant to all the classes of antibacterial agents. 
Of the two MRSA isolates from Nigeria, one isolate was resistant to the macrolide-
lincosamide group of antibiotics. All the MRSA isolates from the two countries were 
susceptible to quinipristinldalfopristin. 
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Table 2.10: Antibiotyping of MRS A for the aminoglycoside, macrolide-lincosamide, 
tetracycline group of antibiotics, heavy metals and nucleic acid binding 
compounds 
Antibiogram South Africa Antibiogram 
MRSA 
Classes of antibiotics (N=61) Classes of antibiotics 
Aminoglycosides * * N(%) Aminoglycosides 
GnKKnK Am~StrSNeSTobK 37 (60.6) Susceptible to all 
GnKKnK AmKStrKNeKTobK 10 (16.4) Gn~Kn~ Am~StrKNe~Tob~ 
GnKKnK AmSStrKNeKTobK 7 (11.5) 
GnKKnK AmSStrSNeKTobK 2 (3.3) 
Susceptible to all 2 (3.3) 
GnKKnK AmSStrKNeSTobK 2 (3 .3) 
GnKKnK AmSStrSNeSTobs 1 (1.6) 
Macrolide-Lincosamide* * * Macrolide-Lincosamide** 
EryKOIK AzmKCcK1 49 (80.3) EryKOIKAzmKCcK1 
Susceptible to all 11 (18 .0) Susceptible to all 
Er~OIK AzmSCcK1 I (1.6) 
Tetracyclines Tetracyclines 
TetKMnKDos 33 (54.1) TetKMnKDo~ 
TetKMnKDoK 22 (36.1) TetKMn~Do~ 
Susceptible to all 6 (9.8) 
Heavy metals/ nucleic acid Heavy metals/nucleic acid 
binding agents binding agents 
EbSPi~Hg~CdK 21 (34.4) Eb~Pi~HgKCdK 
EbKpiKH,tCdK 14 (22.9) 
EbsPi~HltCdK 9 (14.8) 
Susceptible to all 6 (9.8) 
Eb~Pi~HgKCd~ 5 (8.2) 
EbKpiKHg~CdK 3 (4.9) 
EbKpiSHgSCdK 2 (3.3) 
EbSPiKHgSCdK I (1.6) 
KEY 
*One MRSA isolate from Nigeria was not included in this analysis 
** Aminoglycoside modifying enzyme analysis was not conducted 












AminogJycosides: Am - Amikacin; Gn - Gentamicin; Ka - Kanamycin; Ne - Neomycin; Tob - Tobramycin; 
Str - Streptomycin 
Macrolide-Lincosamide - Azm - Azithromycin; Cc - Clindamycin; Ery - Erythromycin; 01- Oleandomycin 
Tetracyclines - Do - Doxycycline; Mn - Minocycline; Tet - Tetracycline 
Heavy metals - Cd - Cadmium acetate; Hg - Mercuric chloride 
Nucleic-acid binding compounds - Eb - Ethidium bromide; Pi - Propamidine isethionate 
The superscript SIR represent susceptibility/resistance. 
CcRi - inducible resistance to clindamycin 
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2.3.12 Mupirocin resistance in S. aureus isolates from Nigeria and South Africa 
Susceptibility to mupirocin (51lg and 200llg) by the disk diffusion method was 
performed. A total of 17 isolates exhibited resistance to mupirocin, of which 14 MRSA 
isolates (from South Africa) exhibited low-level resistance. 1bis resistance phenotype was 
confirmed by E-test, with MICs values ranging from 8 to 241lg/ml. High-level resistance to 
mupirocin was confirmed by E-test (> 1 0241lg/ml) and detection of the mupA gene by PCR. 
High-level resistance was detected in two (MRSA and MSSA) isolates from South Africa, 




Staphylococcus aureus is one of the most common causes of both endemic and 
epidemic infections acquired in hospitals, which result in substantial morbidity and 
mortality. In Africa, it is one of the most frequently encountered microorganisms, obtained 
from various clinical samples, in the microbiology laboratory (Ako-Nai et aI. , 1995; Aseffa 
and Yohannes, 1996; Omari et al. , 1997; Mulholland et al. , 1999; Gebreselassie, 2002; 
Odusanya, 2002; Ben Jemaa et al. , 2004). In this study, 38.5% and 83.7% of S. aureus 
isolates from Nigeria and South Africa were obtained from wound samples (Table 2.1). 
Studies in African countries including Tanzania (Eriksen et al., 2003), Nigeria (Kolawole 
and Shittu, 1995; Oni et al., 1997; Emele et al. , 1999; Shittu et al., 2003a; Wariso and 
Nwachukwu, 2003), Kenya (Andhoga et al., 2002), Sudan (Mahdi et al. , 2000) and Ethiopia 
(Kotisso and Aseffa, 1998) have indicated that S. aureus is the most frequently isolated 
pathogen implicated in various wound infections. 
Bacterial infections of the skin and underlying soft tissues are one of the most 
common presentations in patients visiting emergency room clinics in hospitals and office-
based practices (Dykhuizen et al. , 1994; Tice, 1995; Nathwani et al. , 1998). Wound 
infection is a major concern among health care practitioners, not only in terms of 
increased trauma to the patient, but also in view of its burden on financial resources and 
the increasing requirements for cost-effective management within the healthcare system 
(Bowler, 2001). Nasal carriage of S. aureus has been identified as a key factor in the 
epidemiology and pathogenesis of S. aureus wound infection. Three sets of observations 
have indicated that carriers have higher rates of infection than non-carriers (Weinstein, 
1959; Kluytmans et al. , 1995; Kalmeijer et al., 2000); the strain causing infection is 
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usually the carriage strain in a given individual (Wenzel and Perl, 1995; Toshkova et al., 
2001); and eradication of carriage reduces nosocomial infection (Kluytmans, 1998; 
Wilcox et al. , 2003). The postulated sequence of events leading to infection is initiated 
with S. aureus nasal carriage, which is then disseminated via the hands to other body sites 
where infection can occur through breaks in the dermal surfaces. Another important mode 
of transmission is via transiently colonised hands of health care workers who acquire the 
organism after close contact with colonised patients or contaminated equipment (peacock, 
1980; Toshkova et al. , 2001). 
The resistance rates of S. aureus isolates from Nigeria and South Africa (Tables 2.2 
and 2.3) were compared with data from an international multi-centre study, in which 21 
laboratories in about 18 countries participated. The frequency of antibiotic resistance was 
ranked into four groups; low-level resistance (0-10%), concern (11-40%); major concern 
(41-80%) and antibiotic rarely useful (>80%) (Zinn et al. , 2004). As expected, S. aureus 
resistance to penicillin (88-90%) observed in the two countries studied was in agreement 
with data from Zinn et al. (2004), which reported high levels ranging from 73-97%. In 
addition, full susceptibility of isolates (MSSA and MRSA) from Nigeria and South Africa to 
fusidic acid was similar with data from Luthuania, the USA (Colorado, California, New 
Jersey), France and Poland. This study also confIrmed the report of Zinn et al. (2004) that 
fusidic acid showed excellent activity against S. aureus isolates in South Africa. All the 
isolates from Nigeria were susceptible to rifampicin (similar with data from Denmark, 
Norway, France, Sweden, Lithuania, USA-Colorado, Western Australia), and resistance to 
ciprofloxacin (7.0%) was comparable with data from Finland, Lithuania and the USA 
(Colorado). The proportion of S. aureus isolates resistant to ciprofloxacin from South Africa 
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(5.3%) was similar to the report from Sweden, while the resistance rate for rifampicin 
(20.3%) observed in this study was similar with the survey by Zinn et al. (2004) on S. 
aureus isolates from South Africa. The prevalence of S. aureus resistance to erythromycin 
and clindamycin in Nigeria was low (2.5%) but similar with data from Norway and Sweden 
(erythromycin), Malaysia and Sweden (clindamycin), while rates in South Africa (30%) 
were comparable with data from Kuwait (erythromycin) and Spain (clindamycin). 
Based on the grouping stated by Zinn et ai. , (2004), low-level resistance of S. aureus 
to fusidic acid, ciprofloxacin, chloramphenicol and mupirocin, was observed in both 
countries. S. aureus resistance to rifampicin, oxacillin, erythromyin, clindamycin, 
gentamicin, kanamycin, neomycin and minocycline in Nigeria could also be considered as 
low-level. Resistance to rifampicin, oxacillin, gentamicin, tetracycline, erythromycin, 
clindamycin, trimethoprim, kanamycin and minocycline of S. aureus isolates in South 
Africa could be of concern while resistance to tetracycline, trimethoprim and or 
trimethoprim-sulfamethoxazole is considered to be of major concern in Nigeria. Penicillin is 
considered as rarely useful in both countries. In this study, statistical analysis indicated a 
higher level of resistance to oxacillin, erythromycin, clindamycin, gentamicin, 
kanamycin, neomycin, rifampicin, minocycline and mupirocin in S. aureus isolates from 
South Africa compared with Nigeria. This trend was attributed to the higher prevalence 
of MRSA in South Africa. 
All the MSSA isolates from Nigeria and South Africa were susceptible to oxacillin, 
teicoplanin, vancomycin and fusidic acid. Moreover, MSSA from South Africa did not 
exhibit resistance to streptomycin, neomycin and minocycline. The resistance rates of 
MSSA from both countries (Tables 2.2 and 2.3) were compared with data from a SENTRY 
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survey (Diekema et al., 2001), and a study in Korea (Kim et al. , 2004). Notable similarities 
and differences in resistance trends were observed. Susceptibility of MSSA from Nigeria 
and South Africa to rifamipicin (>99%) was similar with data from the USA, Canada, Latin 
America, Europe, the Western Pacific, (SENTRY survey) and in Korea. However, the 
proportion ofMSSA resistant to trimethoprimltrimethoprim-sulfamethoxazole in Nigeria 
and South Africa were higher (47.2%; 10.8%) compared with the SENTRY «3%) and 
Korean (1.2%) surveys. Another comparative analysis of data from this study and that of 
Jones et al. (2003a), under the TSN database program, indicated that trimethoprim-
sulfamethoxazole was generally effective « 2% resistance) against most of the MSSA 
isolates (in-patients and ICU patients) from the United States, France, Germany, and Spain. 
Although data from the SENTRY and TSN surveys are greater in scale than this study, 
however, it appears that there is a high prevalence of MSSA resistant to trimethoprim and or 
trimethoprim-sulfamethoxazole in Nigeria. Trimethoprim is an antimicrobial agent used 
extensively in combination with sulfamethoxazole for the treatment of urinary, enteric, and 
respiratory infections in developing countries. Trimethoprim-sulfamethoxazole is listed 
among antibacterial agents that have been rendered ineffective or for which there are serious 
concerns regarding bacterial resistance, in many developing countries, including Nigeria 
(Okeke, 2003). It appears that misuse and overuse of these antibiotics in Nigeria could have 
contributed to this trend in Nigeria. A single amino acid substitution, Phe98 to Tyr98, in 
dihydrofolate reductase (DHFR) is the molecular origin of trimethoprim resistance in S. 
aureus (Dale et al. , 1997) and plasmid mediated high-level trimethoprim resistance is 
dominated by the ubiquitous Tn4003-mediated SI DHFR (Rouch et al. , 1989; Burdeska et 
al. , 1990). 
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A comparative analysis of the susceptibility patterns of MSSA isolates (in both 
countries) indicates that resistance of MSSA may have evolved under different antibiotic 
pressure. Most of the MSSA (98.5%) from Nigeria were susceptible to erythromycin, 
clindamycin and minocycline, whereas chloramphenicol and ciprofloxacin was effective 
against the majority (99.4%) ofMSSA from South Africa. Moreover, significant differences 
in the susceptibility ofMSSA in Nigeria and South Africa to some antibiotics were 
observed. MSSA resistance to erythromycin and clindamycin was significantly higher in 
South Africa, whereas, resistance to streptomycin, neomycin, trimethoprim, trimethoprim-
sulfamethoxazole, tetracycline, chloramphenicol, and ciprofloxacin was significantly 
higher in Nigeria (Tables 2.2 and 2.3). About 68% ofMSSA from South Africa were 
resistant only to penicillin, but 25% of MSSA isolates from Nigeria exhibited that resistance 
phenotype. Furthermore, multi-drug resistant MSSA was about four-fold higher in Nigeria 
compared with South Africa (13.7%; 3.6%). 
Epidemiological investigations of S. aureus at the moment have observed four 
major trends. In many countries, infections caused by multiresistant strains (especially 
methicillin-resistant S. aureus - MRSA) are of great concern, whereas in other countries, 
the frequency of MRSA is low. The third trend is the emergence of MRSA in the 
community and the fourth trend are the recent reports of vancomycin-intermediate and 
resistant S. aureus in hospitals. The emergence of MRSA has posed challenges in the 
treatment of infections especially their characteristic multidrug resistance, which restricts 
the options to treat infections caused by these pathogens (Van Belkum and Vertburgh, 
2001 ; NNIS, 2003; Subedi and Brahrnadathan, 2005). 
220 
One of the earliest reports on MRSA in Africa was that of Scragg et ai. , (1978). 
Thereafter, MRSA has been reported in South Africa (van den Ende and Rotter, 1986; 
Peddie et ai. , 1988; Gardie and Kirby, 1993), Ethiopia (Geyid and Lemeneh, 1991), 
Kenya (Omari et ai. , 1997), Senegal (Sow et ai., 1998), Sudan (Musa et ai. , 1999) and 
Nigeria (Rotimi et ai. , 1987; Okesola et ai., 1999). In this study, most of the MRSA were 
obtained from wound samples, and a marked variation in the prevalence of MRS A in both 
countries was observed (1.5% - Southwestern Nigeria; 27% - KZN province, South Africa) 
(Tables 2.2, 2.3 and 2.7). At least one MRSA isolate was recovered from clinical samples in 
13 out of the 14 health facilities in the KwaZulu-Natal province of South Africa (Table 2.7). 
The prevalence rates in this study were lower than reports from previous studies, in both 
countries. Investigations on the prevalence of MRSA in various health institutions in 
Southwestern Nigeria ranged from 9% to 50% (Rotimi et ai., 1987; Ako-Nai et ai. , 1991; 
Okesola et ai. , 1999; Kesah et ai. , 2003), while the prevalence of MRSA reported in other 
major cities such as Johannesburg and Cape Town in South Africa was between 34 and 42% 
(Diekema et ai. , 2001 ; Bell et ai., 2002; Christiansen et ai. , 2004; Zinn et ai., 2004). It 
should be noted, however, that most of these investigations were conducted in one health 
facility. However, analysis of the proportion of MRS A isolates obtained from hospitals 
within the city of Durban indicated that the prevalence increased to 34%, which is 
comparable with data from the major cities in South Africa. The low prevalence of MRSA 
observed in this study in Southwestern Nigeria is unexpected based on previous reports in 
this region. More studies are needed in understanding the current status on antibiotic 
resistance among S. aureus isolates in both countries. 
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Susceptibility results of MRS A from South Africa were compared with data from 
multicentre investigations conducted in the Czech Republic (Melter et al. , 2003), Belgium 
(Denis et al. , 2004) and South Korea (Kim et al. , 2004). The high proportion of MRS A from 
South Africa resistant to gentamicin, kanamycin, tetracycline, erythromycin and 
clindamycin (Table 2.3), was similar with data from the Czech Republic and South Korea. 
In addition, susceptibility to fusidic acid observed in this study was similar with data from 
the Czech Republic and Belgium. Apart from the glycopeptides (vancomycin and 
teicoplanin), all the MSRA in this study were susceptible to quinipristinJdalfopristin, 
fosfomycin and linezolid. There is evidence that differences in the prevalence of MRS A 
occur within countries as well as from hospital to hospital (Fluit et aI. , 2001). Multi-centre 
investigations have illustrated the geographical variation for the worldwide prevalence of 
MRSA, with low levels in the Northern European countries and high levels in the 
Southern European countries (Fluit et al., 2001; EARSS, 2002; Tiemersma et aI. , 2004) as 
well as parts of Australia, United States, Asia and South America (Diekema et al. , 2001; 
Zinn et al. , 2004). In this study, the geographic variation within the two countries could not 
be determined due to the varying and low numbers of MRSA obtained in the various health 
institutions. Analysis of the MRSA isolates from Southwestern Nigeria also could not be 
accomplished due to the number of isolates identified in this study. 
Multi-drug resistance in MRSA is frequently due to the successive acquisition of 
plasmids and transposons with resistance determinants (Witte, 1999) or to the spread of a 
few clonal resistant lineages. There was an obvious relationship between methicillin 
resistance and resistance to other antibiotics as previously noted in literature (Diekema et al. , 
2001; Fluit et al. , 2001 ; Kim et al. , 2004; Zinn et al. , 2004). More than 80% of MRS A 
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obtained from South Africa were resistant to erythromycin, clindamycin, trimethoprim, 
tetracycline, minocycline, gentamicin and kanamycin whereas the rates for MSSA was less 
than 12% (Table 2.3). About 87% of MRS A from South Africa were resistant to at least four 
classes of antibiotics and these multiresistant isolates were identified in 13 of the 14 health 
institutions in the KwaZulu-Natal province of South Africa (Table 2.8 and 2.9). MRSA 
belonging to antibiotype VI was identified in 12 of the 14 hospitals studied, indicating that 
isolates with this resistance phenotype are widespread in KZN. Furthermore, 
multiresistant MRSA exhibiting resistance to seven classes of antibiotics (antibiotype II) 
was detected in Hospitals A and B located in Durban and Hospital N in Empangeni, 
while MRSA with antibiotype I (resistance to eight classes of antibiotics) was identified 
in Hospitals A and C (Durban), E (Pietermaritzburg) and N (Empangeni) respectively 
(Table 2.9). These cities (especially Durban) are the most densely populated areas in KZN 
province of South Africa. Multi-resistant MRSA has been reported to be relatively high in 
African countries; including Morocco, Kenya, Nigeria and Cameroun (Kesah et al., 2003), 
but their antibiotypes were not determined. This study confirms previous investigations 
from various regions of the world on the multiresistant nature of MRS A (Schmitz et al. , 
1999a; Santos Sanches et al. , 2000; Fluit et al., 2001 ; Kim et al. , 2004). It also indicates that 
treatment of infections caused by MRS A may be difficult in South Africa, as there are 
reduced antimicrobial options, which could lead to substantial rates in morbidity and 
mortality in hospital patients and increased health cost. 
Accurate detection of MRS A is clinically important and errors in the detection of 
methicillin resistance could have adverse clinical consequences (Ribeiro et al., 1999). 
False-susceptibility results may result in treatment failure and the spread of MRS A if 
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appropriate infection control measures are not applied. Conversely, false-resistance 
results may increase health care costs following unnecessary isolation procedures, and 
may lead to overuse of glycopeptides (Gerberding et al. , 1991). Detection of methicillin 
resistance by phenotypic methods relies on the modification of culture conditions to 
improve expression, and thus detection, of resistance. Modifications have included 
lowering the incubation temperature, adding NaCI to agar or broth, and increasing the 
incubation time (Pottumarthy et al., 2005). The difficulty in detecting methicillin 
resistance by routine phenotypic susceptibility test methods is primarily due to the 
genetic and regulatory organization of the mecA gene apparatus that encodes the foreign 
PBP2A (Berger-Bachi and Rohrer, 2002). Transcription of mecA is regulated by two 
distinct but analogous sets of regulatory genes, mecRI-mec1 and a second homologous 
regulatory element blaR-blal of the staphylococcal penicillinase, blaZ. Mecl and Blal 
are repressors of transcription of mecA and blaZ genes. MecRI and BlaRl are 
transmembrane signal transducer molecules, which upon binding of the inducer molecule 
result in the activation of the molecule and cleavage of the repressors Mec1 and Blal , 
relieving mecA and blaZ repression (Berger-Bachi and Rohrer, 2002). 
A phenotypic test recently published by the National Committee for Clinical 
Laboratory Standards (NCCLS, 2004) for the confirmation of MRS A isolates is the 
cefoxitin disk diffusion method using standard susceptibility testing conditions for the 
prediction of mecA -mediated resistance in staphylococci. All S. aureus isolates showing a 
zone of inhibition of ::;19mm are considered mecA positive, while isolates showing zones 
of inhibition of~20mm are considered mecA negative. In this study, the oxacillin, 
methicillin and cefoxitin disk diffusion method accurately detected all the MRSA 
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(confirmed by detection of the mecA gene) from South Africa and one MRS A from 
Nigeria (Tables 2.3 and 2.4). However, based on the NCCLS guidelines (NCCLS, 2000, 
2004), two of the three MRSA from Nigeria were intermediately resistant to oxacillin 
(12mm) but sensitive to cefoxitin (20mm; 28mm) and methicillin (15mm; 24mm). This 
observation differs with recent reports on the superiority of cefoxitin over oxacillin in the 
detection of methicillin resistance (Boubaker et ai., 2004; Pottumarthy et ai. , 2005; Sharp 
et ai. , 2005; Velasco et ai., 2005). However, this study is in agreement with the 
observation of previous investigators that phenotypic methods are not completely reliable 
for the detection of MRSA (Cavassini et ai. , 1999; Louie et ai. , 2000; Brown and 
Walpole, 2001; Nicola et ai. , 2000; Sakoulas et ai., 2001; Boubaker et ai., 2004). The 
application of the disk diffusion method (oxacillin, methicillin, cefoxitin) is still 
considered useful but confirmation (detection of the mecA gene) is recommended, 
especially for detecting strains exhibiting heterogeneous resistance to methicillin. 
Two primary mechanisms are attributed to resistance to macrolides in staphylococci 
(Leclercq, 2002). The first involves macrolide efflux and is relatively common in S. aureus 
in some geographic areas. A specific efflux pump is encoded by the gene msr (AJ in 
staphylococci (Ross et ai. , 1990). Notably, this resistance does not create resistance to 
lincosamides (e.g. clindamycin and lincomycin), but only to macrolides, azalides 
(azithromycin), and group B streptogramins (e.g. quinipristin) (Ross et ai., 1990). The 
second mechanism of resistance to macrolides in staphylococci involves modification of the 
drug-binding site on the ribosome. This results in resistance to macrolides (and azalides), 
lincosamides and group B streptogramin and is commonly referred to as the MLSs 
resistance (Ross et ai., 1989; Roberts et ai., 1999). An erm gene, usually ermA or ermC, 
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encodes methylation of the 23S rRNA-binding site that is shared by these three drug classes. 
Phenotypically, expression ofMLS resistance in staphylococci is either constitutive or 
inducible. Strains with inducible MLSs resistance (MLSsi) demonstrate in-vitro resistance 
to 14- and 15 membered-ring macrolides (e.g. erythromycin), while appearing susceptible to 
16-membered-ring macrolides, lincosamides, and type B streptogramins. Strains with 
constitutive MLSs resistance (MLSsc strains) show in-vitro resistance to all of these agents 
(Roberts et at., 1999). This dissociated resistance arises from differences in the inducing 
capacities of MLS antibiotics, 14- and 15- membered-ring macrolides being better inducers 
than the other groups of drugs (Leclercq and Courvalin, 1991). Inducible resistance of 
clindamycin by erythromycin is demonstrated by the D-test. It involves the placement of an 
erythromycin disk in close proximity to a disk containing clindamycin, during antibiotic 
susceptibility testing, using the disk diffusion method. A truncated or blunted clindamycin 
zone of inhibition (D-shape) indicated inducible resistance. Constitutive resistance is 
recognized by a clindamycin zone diameter of ~ 14mm (Fiebelkorn et at., 2003). The D-
test has been shown to be a reliable indicator of MLSsi strains that harbour either the ermA 
or ermC genes (Fiebelkorn et at., 2003). The erm (A) genes are mostly spread in 
methicillin-resistant strains and are borne by transposons related to Tn554, whereas erm (C) 
genes are mostly responsible for erythromycin resistance in methicillin-susceptible strains 
and are borne by plasmids (Leclercq, 2002). 
Clindamycin represents a useful option for therapy for various MRSA infections, 
including musculoskeletal infections, skin and soft tissue infections and even pneumonia 
with empyema (Martinez-Aquilar et at. , 2003). It is also of particular importance as an 
alternative antibiotic in the penicillin-allergic patient (Fiebelkorn et at., 2003). However, 
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the use of clindamycin for the treatment of an infection due to an inducibly resistant strain of 
S. aureus has been somewhat hampered by concerns over possible inducible resistance to 
clindamycin and its impact on clinical outcome. These concerns have been raised especially 
for deep-seated infections or with large bacterial burden, such as endocarditis, abscesses, 
and osteomyelitis. The available clinical data are limited and somewhat conflicting, with 
some patients appearing to respond clinically to clindamycin therapy despite the presence of 
the MLSsi phenotype (Frank et ai. , 2002; Martines-Aquilar et ai., 2003). However, the risk 
of constitutive mutants selected in-vitro at frequencies of approximately 10-7 colony forming 
units in the presence of these antibiotics, leading to treatment failures has been reported in 
patients with inducibly resistant S. aureus infections (Watanakunakorn, 1976; Drinkovic et 
ai., 2001; Siberry et ai., 2003; Levin et ai., 2005). The use of clindamycin for uncomplicated 
cellulitis due to MLSsi community-acquired MRSA also remains an unanswered question, 
because this represents the most widespread presentation associated with this organism, and 
clindamycin represents an attractive therapeutic option. 
In this study, about 80% of S. aureus isolates susceptible to erythromycin and 
clindamycin were MSSA (Table 2.6), while the MLSsi phenotype was detected in 72 
isolates (20 MSSA and 52 MRSA). Furthermore, S. aureus isolates from South Africa 
accounted for about 93% with this resistance phenotype and 69% were MRSA from South 
Africa. The overall frequency of S. aureus resistance to MLSs in Nigeria was lower 
compared with South Africa and this difference was associated with the prevalence of 
MRSA in both countries. A recent survey in Pennsylvania (USA) reported that 68% of 
methicillin-susceptible and 12.3% of methicillin-resistant S. aureus were D-test positive 
(Levin et ai., 2005). The constitutive MLSs phenotype was detected in one MSSA from 
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South Africa, but absent in MRSA from Nigeria and South Africa. This observation is in 
contrast with that of Kim et al. (2004), in which 24% ofMSSA and 86% of the MRSA 
isolates in Korea, exhibited constitutive resistance. Furthermore, constitutive resistance is 
known to be a common occurrence among MRSA isolates in Belgian hospitals (Denis et al. , 
2004) and in a Greek hospital (Fokas et al., 2005). These findings indicate that the incidence 
of constitutive and inducible MLSB resistance in staphylococcal isolates varies by 
geographic region. 
Of the 61 MRSA from South Africa tested against MLSB antibiotics, resistance to 
erythromycin, oleandomycin, azithromycin and inducible resistance to clindamycin was the 
dominant phenotype (Table 2.10). The proportion of MRSA with the MLSBi phenotype 
(82%) indicates that clindamycin may not be a theraupeutic option for the treatment of an 
infection due to an inducibly resistant MRSA. If clindamycin is used for treatment of 
infections with MLSBi-producing isolates, close follow-up and monitoring offailure or 
relapse is needed. However, in more severe infections, the presence of the MLSBi phenotype 
should preclude the use of clindamycin. In patients with non-MLSBi S. aureus infection, 
clindamycin can be used safely and effectively. Clindamycin could also be considered for 
the treatment of infections caused by MSSA in Nigeria, based on the low resistance rate 
observed. 
In staphylococci, in-vitro susceptibility testing for clindamycin may indicate false 
susceptibility by the broth microdilution method and disk diffusion testing with 
erythromycin and clindamycin disks in nonadjacent positions (Fiebelkorn et al., 2003). In 
this study, the D-test demonstrated, like previous studies, to be a simple and reliable method 
to detect inducible resistance to clindamycin. The clinical microbiology laboratory should 
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consider routine testing and reporting of inducible clindamycin resistance in S. aureus. This 
is to ensure that clinicians rely on clindamycin test results and be informed about the 
possibility of clindamycin treatment failure in patients with infections caused by inducibly 
resistant isolates. Quinipristinldalfopristin showed excellent activity against all the MRSA 
isolates and might provide a valuable option for the treatment of MRS A infections in spite 
of the high prevalence of the MLSBi phenotype among these isolates. 
Tetracyclines are broad-spectrum antibiotics that have been used widely in human 
and veterinary medicine, as growth promoters in animal husbandry and even to treat 
bacterial infections in plants (Levy, 1992; Falkiner, 1998). It is therefore not surprising 
that tetracycline resistance is prevalent in a diverse range of bacteria and is encoded by a 
wide range of determinants. Tetracyclines are relatively inexpensive antibiotics, and in 
some countries, it is the second most frequently prescribed antimicrobial agents (after the 
penicillins) for the treatment of a number of bacterial infections, including those caused 
by staphylococci (Col and O'Connor, 1987; Levy, 1992). Two mechanisms of resistance 
to tetracyclines have been identified in Staphyiococcus spp: (i) active efflux resulting 
from acquisition of the plasmid-located genes, tetK (Khan and Novick, 1983; Guay et ai. , 
1993) and tetL, and (ii) ribosomal protection mediated by transposon-Iocated or 
chromosomal tetM or tetO determinants (Nesin et ai. , 1990; Schwarz et ai. , 1998). S. 
aureus carrying tetK only have been described as resistant to tetracycline, but susceptible 
to minocycline (Bismuth et ai. , 1990; Warsa et ai. , 1996). The tetM gene is believed to 
confer resistance to all available drugs of this group, including tetracycline and 
minocycline (Bismuth et ai. , 1990). Most tetM-positive isolates also carry the tetK gene 
and MRS A isolates are typically of tetM or tetKM genotype (Bismuth et ai., 1990). The 
229 
tetL gene has been found only in S. aureus isolates already carrying the tetM gene 
(Bismuth et al. , 1990). There are no reports of tetO-positive S. aureus strains. Both drug 
efflux and ribosomal protection are inducible in S. aureus in-vitro (Mojumdar and Khan, 
1988; Nesin et al. , 1990). 
Three antibiotypes were observed in the susceptibility testing of MRS A (from 
South Africa), with the tetracycline group of antibiotics (Table 2.10). More than half of 
the isolates (54%) were resistant to tetracycline, minocycline but susceptible to 
doxycycline, and about one-third were resistant to all the antibiotics in this group. 
Although induction of doxycyline and minocycline resistance and PCR of the respective 
resistance genes was not investigated, the resistance profile of the MRSA suggests that 
the tetM and tetKM genes may be the dominant genes present in these isolates. 
Arninoglycosides play an important role in the therapy of serious staphylococcal 
infections. They are potent bactericidal agents, inhibiting protein synthesis by binding to the 
30S ribosomal subunit. Gentamicin and tobramycin are often used with either a ~-lactam or 
a glycopeptide, especially in the treatment of staphylococcal endocarditis, as these drugs act 
synergistically (Schmitz and Jones, 1997). The main mechanism of amino glycoside 
resistance in staphylococci is drug inactivation by cellular aminoglycoside-modifying 
enzymes. Several gene loci encoding such modifying enzymes have been characterized in 
staphylococci. Clinically, the most important of these encode acetyltransferase (AAC), 
adenylyltransferase (ANT) or phosphotransferase (APR) activity. Resistance to gentamicin 
and concomitant resistance to tobramycin and kanamycin in staphylococci are mediated by a 
bifunctional enzyme displaying AAC (6') and APR (2") activity (Matsumara et ai. , 1984; 
Ubukata et ai. , 1984). The aae (6 }Ie-aph (2 ' ') genes encode this bifunctional enzyme 
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which is encoded on composite transposon Tn4001 . Resistance to neomycin, kanamycin, 
tobramycin and amikacin in staphylococci is mediated by an ANT (4' )-1 enzyme encoded 
by ant (4 ') -Ia. This gene is often carried on small plasmids, and then integrated into larger 
conjugative plasmids, and subsequently into the mec region of the chromosome of some S. 
aureus isolates, probably as a result ofIS257-mediated recombination events (Byrne et at., 
1991; Archer and Niemeyer, 1994; Stewart et at., 1994). Resistance to neomycin and 
kanamycin conferred by an APH (3 ')-III enzyme has also been described for staphylococci. 
The aph (3 ,)-Illa gene responsible for this phenotype is carried on the transposon of 
Tn5405, which may be located on both the chromosome and plasrnids (Derbsie et at. , 1996). 
The genetics of streptomycin resistance is somewhat more complex, being associated with 
an ant (6)-Ia gene, a resistance gene called str, chromosomal mutations (strA), an aph (3 ')-
III gene, and an ant (4 ')-Ia gene (Courvalin and Fiandt, 1980; Phillips and Shanson, 1984; 
Projan et at., 1988). 
The MRSA isolates from South Africa exhibited higher rates of resistance to 
arninoglycosides than MSSA (Table 2.3). It also supports the observation of a relationship 
between oxacillin and arninoglycoside resistance (Schmitz et at. , 1999b; Kim et at. , 2004). 
Amikacin was the most active of the aminoglycosides against MRSA in this study. 
However, a limitation of this study was that amino glycoside modifying enzyme analysis 
was not conducted on gentamicin-resistant, amikacin susceptible isolates. Considering the 
high rates of resistance to arninoglycosides, the inclusion of members of this group in 
conjunction with a ~-lactam or a glycopeptide may not be advisable for the treatment of 
MRSA infections in South Africa. Seven antibiotypes were observed among the isolates and 
resistance to gentamicin, kanamycin, tobramycin and susceptibility to amikacin, 
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streptomycin and neomycin was predominant (Table 2.10). This was followed by isolates 
resistant to all the aminoglycosides tested. The phenotypic resistance patterns of the MRSA 
indicate that most of them seemed likely to produce AAC (6') and APH (2"), with or 
without ANT (4' )-1, among the five-modifying enzymes. 
Parenteral glycopeptide (vancomycin and teicoplanin) are the mainstay of therapy 
for systemic infections. However, not all infections are life threatening, and oral antibiotics 
provide an alternative mode of therapy (Brumfitt and Hamilton-Miller, 1989), particularly 
when long-term therapy is required e.g. in the presence of prosthetic material. Rifampicin, 
fusidic acid, ciprofloxacin and trimethoprim-sulfamethoxazole are the widely used oral 
agents that have demonstrated consistent in-vitro activity and have been recommended in 
the therapy of MRS A infections (Gottlieb and Mitchell, 1998; Kim et ai. , 2004). In addition 
to the advantage of oral administration, these agents have also demonstrated better tissue 
penetration than the glycopeptide agents. Resistance may occur to one or more of the oral 
agents, hence susceptibility must be demonstrated by in-vitro testing before clinical use of 
these agents can be considered. Combination therapy with two oral agents is thought to be 
important to decrease the risk of selecting for mutants during therapy of MRSA infections 
(Brumfit and Hamilton-Miller, 1989; Maple et ai. , 1989; Shanson, 1990). Hence existing 
resistance to two or more of these agents practically excludes oral therapy from 
consideration. Rifampicin and fusidic acid is the usual combination used to treat MRSA 
infections in Australasia (Turnidge and Grayston, 1993). In view of the high rates of 
resistance of MRS A (South Africa) to rifampicin and trimethoprim-sulfamethoxazole (Table 
2.3), combination treatment with these antibacterial agents would be unreliable. Only fusidic 
acid showed excellent activity against the MRSA studied. 
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Treatment of S. aureus infections is becoming increasingly more complicated due to 
the emergence of vancomycin resistance in S. aureus. The first strain of S. aureus with 
reduced susceptibility to vancomycin (MIC, 81lg/ml) (strain Mu50) was reported in Japan in 
1997 (Hiramatsu et ai., 1997a). Since then, vancomycin-intennediate S. aureus (VISA) 
isolates have been reported in the United States, Europe and the Far East (Kim et ai. , 2000; 
Walsh and Howe, 2002). There are increasing reports of S. aureus strains showing 
heterointennediate resistance to vancomycin (h VISA) since the first report of the prototype 
strain (Mu3) by Hiramatsu et ai. , (1997b). In addition, three reports of isolates of 
vancomycin-resistant S. aureus (VRSA) (MIC, ~321lg/ml) in 2002 and 2004 from the 
United States have added more serious concern on this emerging trend (CDC 2002a, 2002b, 
2004). Different laboratory methods for the detection of vancomycin resistance have been 
proposed in order to understand the prevalence of S. aureus with reduced susceptibility to 
glycopeptides. These include the vancomycin agar-screening test, agar dilution, E-test, and 
population analysis (Hiramatsu et ai., 1997a; Walsh et ai., 2001; Howe et ai., 2000). The 
disk diffusion technique has been regarded as unreliable due to its low sensitivity (T enover 
et ai. , 1998), and the modified population analysis profile (P AP-AUC) is reported as the 
most reliable and reproducible method for defining population heterogenicity (Walsh and 
Howe, 2002). 
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All the MRSA isolates studied did not exhibit reduced susceptibility to vancomycin 
and teicoplanin using the E-test method on Mueller Hinton Agar and Brain Heart Infusion 
Agar (BHIA). Although isolates were sensitive to vancomycin and teicoplanin based on 
their MIC values, higher MIC (E-test) values (between 1-2Jlg/ml) for some MRSA isolates 
on Brain Heart Infusion Agar (BHIA) after incubation for 48 hours was observed. It appears 
that E-test on BHIA and prolonged incubation could be an appropriate and sensitive method 
for screening reduced susceptibility to glycopeptide in MRSA. lbis observation supports the 
report of Walsh et al. (2001) and Midolo et al. (2003). The detection of two MRSA isolates 
intermediately resistant to vancomycin in South Africa by Ferraz et al. (2000) indicate that 
continuous surveillance of reduced susceptibility to vancomycin is important and strategies 
for managing patients with infections caused by resistant strains should be established. 
Mupirocin is produced by Pseudomonasfluorescens (Fuller et al. , 1971) and has in-
vitro activity against a wide range of Gram-positive and some Gram-negative bacteria such 
as Haemophilus and Neisseria (Thomas et al., 1999). The 2% (20,000Jlg/ml) mupirocin 
ointment has been an effective antibacterial agent for the treatment of staphylococcal 
colonization and superficial wound infections such as impetigo, infected eczema and wound 
infections. This followed an increase in colonization and infections with MRSA (Kaufmann 
et al. , 1993; Poupard, 1995; Harbath et al., 1999). It has proved extremely effective in 
eradicating nasal carriage of MRS A from hospital patients and staff and is widely used as an 
infection control measure (Casewell, 1997; Eltringham, 1997). However, staphylococcal 
isolates resistant to mupirocin have been found worldwide (Schmitz et al. , 1998; Deshpande 
et al., 2002). 
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Staphylococci expressing mupirocin resistance can be divided into two groups: low-
level resistance (MuL) with MICs in the range 8-256~g/ml and high-level resistant (MuH) 
with MICs ~512~g/ml. Low-level resistance to mupirocin is thought to arise from point 
mutations within the usual chromosomal staphylococcal isoleucyl-tRNA synthetase gene 
(ileS) (Cookson, 1998). High-level resistance results from acquisition of a transferable 
plasmid carrying a new gene, ileS-2, encoding a second novel isoleucyl-tRNA synthetase, 
which has no affinity for mupirocin. It is also generally agreed that strains with high-level 
mupirocin resistance cannot be eradicated with mupirocin (Cookson, 1998). Low-level 
resistance is generally not transferable (Ramsey et ai., 1996), and until recently, 
chromosomal mupirocin resistance was considered clinically unimportant (Cookson, 1998; 
Henkel and Finlay, 1999). However, low-level mupirocin resistance appears to be more 
prevalent in clinical isolates than high-level resistance (Alarcon et ai., 1998; Schmitz et ai. , 
1998; Deshpande et ai. , 2002; Fujimura and Watanabe, 2003), and the emergence of low-
level mupirocin resistance is thOUght to increase failure rates for nasal decolonization of 
MRSA (Harbath et ai. , 2000; Watanabe et ai. , 2001; Decousser et ai. , 2003). Transmission 
between strains or species remains highly probable for the high-level resistance genes 
(Woodford et ai., 1998), which could evolve into a serious threat to hospital and community 
infection control (Cookson, 1998). 
The prevalence of mupirocin resistance in staphylococcal isolates varies from 
institution to institution regardless of geographic region monitored (Deshpande et ai. , 2002; 
Petinaki et ai., 2003). In this study, a total of 17 S. aureus isolates exhibited resistance to 
mupirocin and 94% of these isolates were obtained from South Africa (Table 2.2 and 2.3). 
The prevalence of mupirocin resistance (South Africa) in this study (7%) was higher than a 
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previous study (2%) by Zinn et ai. (2004). Morever, high-level mupirocin resistance in 
Nigeria (0.5%) and South Africa (0.9%) was lower than reports from Greece (1.6 and 2%) 
(Maniatis et ai., 2001 ; Petinaki et ai. , 2004), South Korea (5%) (Yun et ai., 2003) and 
Poland (11.3%) (Leski et ai. , 1999). Mupirocin resistance has been mainly observed in 
methicillin resistant staphylococci (Schmitz et ai. , 1998; Petinaki et ai. , 2004; Kresken et ai. , 
2004). However, the fIrst report of high-level resistance to mupirocin by Rahman et ai. 
(1987) was detected in methicillin-susceptible S. aureus. An important observation was that 
two MSSA from Nigeria and South Africa were mupA positive while all the isolates with 
low-level mupirocin resistance were MRSA from South Africa. It appears that mupirocin 
resistance in staphylococcal isolates appears to be an emerging trend especially in South 
Africa. Although few data exists on mupirocin resistance in MSSA isolates (Leski et ai. , 
1999; Jones et ai. , 2003b; Yun et ai. , 2003; Chaves et ai. , 2004; Kresken et ai. , 2004; 
Petinaki et ai. , 2004), it is suggested that MRSA along with MSSA should be routinely 
tested in both countries so that resistant isolates could be detected early, and to facililate the 
prompt institution of infection control measures. 
Biocides in the fonn of antiseptics and disinfectants have been useful adjuncts with 
antibiotics in infection control measures. Increasing apprehension of microbial 
contamination of everyday living environments have led to increased use of antiseptics 
and disinfectants both inside and outside health care settings (McDonnell and Russell, 
1999; Ug and Ceylan, 2003). Heavy metals such as AgN03, CUS04, HgCb, and ZnS04 
have antimicrobial properties and are used in disinfectant and antiseptic fonnulations. 
AgN03 was administered to prevent gonococcal eye infections, zinc as an antifungal 
antiseptic, while CUS04 is used as an algicide (Ronald, 1995). Research reports have 
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expressed concern that use of biocides may contribute to the development of antibiotic 
resistance (McDonnell and Russell, 1999; Levy 2000). Many antibiotic resistance genes 
are plasmid-borne and in some cases, resistance factors for metals are present on the 
same plasmids, such as mercury and cadmium (Christon et ai. , 1997). Resistance to 
acridines, ethidium bromide, quaternary ammonium compounds and propamidine 
isethionate is mediated by a common determinant on a group of structurally related 
plasmids. Many of these plasmids carry transposon Tn4001 , which encodes resistance to 
the aminoglycosides gentamicin, tobramycin and kanamycin, as well as to the 
dihydrofolate reductase inhibitor, trimethoprim (Russell, 1997). Cadmium resistance in S. 
aureus is mediated by the cadA and cadB genes, which have been studied extensively 
(Shalita et ai. , 1980; Nucifora et ai. , 1989; Silver and Phung, 1996). The cadA gene 
confers high-level resistance and is usually located on large plasmids such as pI258 
(Shalita et ai. , 1980; Nucifora et at. , 1989) that encode penicillinase production and 
resistance to other heavy metal ions (Shalita et ai. , 1980; Udo and Grubb, 1991), 
aminoglycosides (Udo and Grubb, 1991) and nucleic acid binding compounds 
(Townsend et at. , 1985). The cadB gene confers low-level cadmium resistance and has 
been demonstrated on a large plasmid, pII147 (Shalita et ai. , 1980) and on small 
multi copy plasmids (EI-SoW and Ehrlich, 1982). A chromosomal cadmium resistance 
determinant that is different from cadA and cadB has also been reported (Witte et at. , 
1986). 
In this study, heavy metal-resistance properties were associated with multi-drug 
resistance, which supports earlier reports (Schottel et ai. , 1974; Misra, 1992; AI-Haddad 
et ai. , 2001). The high level resistance (>80%) of MRS A in South Africa to cadmium 
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(Table 2.4) is not unexpected, as bacteria have evolved resistance mechanisms to toxic 
metals (Rosen, 1996). This trend is similar to an investigation on MRSA in Kuwait (AI-
Haddad et al. , 2001). However, resistance to mercuric chloride, propamidine isethionate 
and ethidium bromide, was lower in this study than the Kuwaiti survey. 
The identification of bacterial pathogens in human infection plays a key role in 
the management of patients in health care institutions. More than 40% of isolates obtained 
from the various clinical laboratories in South Western Nigeria and 2.6% of isolates from 
South Africa were misidentified as S. aureus. Although there is no reason to assume that 
serious rnisclassification bias may have affected the prevalence of MRSA in previous 
studies, the inaccurate reporting serves as an alert for laboratories in Nigeria, to review their 
procedures on the identification of S. aureus. 
Atypical isolates were recovered from both countries (Table 2.11). One isolate 
from Nigeria was catalase-negative while six from South Africa did not ferment mannitol 
(on mannitol salt agar). These isolates were identified as S. aureus based on their positive 
results with coagulase (slide and tube using rabbit plasma) and DNase tests. Catalase is 
an oxidoreductase that allows bacteria to inactivate toxic hydrogen peroxide and free 
radicals formed by the myeloperoxidase system within phagocytic cells (Friedberg et al. , 
2003). The production of catalase is a more or less a constant feature of Staphylococcus 
spp. It is universally used to distinguish, among Gram-positive cocci, Staphylococcus 
from Streptococcus. Most staphylococci are catalase positive with the exception of S. 
saccharolyticus and S. aureus subsp. anaerobius, which grow more rapidly under 
anaerobic conditions (Yilmaz et al., 2005). 
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Reports of catalase-negative S. aureus have been recognised as far back as 1955 
and from various parts of the world (Lucas and Seely, 1955; Everall and Stacey, 1956; Tu 
and Palutke, 1976; Carlson and Gorin, 1981 ; Millar et ai., 1986; Crawford et ai. , 1994; 
Nice, 1995; AI-Awagi et ai. , 1996; Klespies et ai. , 1996; Lee et ai. , 1996; Over et ai. , 
2000; Bertrand et ai., 2002; Friedberg et ai. , 2003; Yilmaz et ai. , 2005). Unlike the 
majority of previous reports of catalase negative S. aureus where resistance to only one 
or two antibiotics was observed (Carlson and Gorin, 1981; Millar et ai. , 1986; Nice, 
1995; AI-Awagi et ai. , 1996; Klespies et ai., 1996; Friedberg et ai. , 2003), the isolate 
from Nigeria (C20) was resistant to penicillin, ampicillin, streptomycin, neomycin, 
kanamycin and ciprofloxacin (Shittu et ai., 2003b). Two recent reports on catalase-
negative methicillin-resistant S. aureus have also been described (Bertrand et ai. , 2002; 
Yilmaz et ai. , 2005). There are still uncertainities regarding the pathogenic role ofthis 
organism. However, Bertrand et ai. (2002) indicated that a catalase-negative isolate 
belonged to a major epidemic clone in France. Moreover, a recent study has also 
indicated that septicaemia in an immunocompetent patient was caused by a methicillin-
resistant catalase-negative S. aureus strain (Yilmaz et ai., 2005). It is unclear whether 
these reports represent the true incidence of this phenotype or whether it is underreported 
because few laboratories use the catalase test to identify S. aureus. 
Data on mannitol-negative S. aureus are rare though it has been reported that due 
to genetic variation, some coagulase positive S. aureus isolates lack the ability to ferment 
mannitol, but are nevertheless regarded as S. aureus (Tu and Palutke, 1976). However, 
the fact that API STAPH misidentified two mannitol-negative isolates as S. iugdunensis 
(Table 2.10) suggests that incorrect or delayed identification is possible in the case of 
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atypical isolates. Interestingly, five of the six isolates, which did not ferment mannitol on 
MSA, were confirmed as MRSA by the detection of the species-specific nuc and mecA 
genes respectively. Laboratories are encouraged to investigate unusual isolates, which 
may be worth reporting and/or sending to regional or national reference centers. This 
appears to be the first report of catalase-negative and mannitol-negative S. aureus in 
Nigeria and South Africa respectively. 
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2.5 CONCLUSIONS AND RECOMMENDATIONS 
This study on antibiotic susceptibility of S. aureus isolates obtained from various 
clinical samples in Nigeria and South Africa has shed some light on the trends in the 
resistance patterns of S. aureus, in both countries. Baseline information in assisting 
physicians, clinical microbiologists and public health officials on critical issues regarding 
empirical and pathogen specific therapy, have also been highlighted. From this study, it is 
clear that continuous surveillance on resistance patterns of S. aureus in understanding 
new and emerging trends is of utmost importance. 
Inspite of the fact that the prevalence of MRS A in Nigeria was low compared 
with South Africa, it is clear that multi-resistant MSSA occurred frequently in Nigeria 
than in South Africa. The acquisition of the staphylococcal cassette chromosome mec 
(SCCmec) in its different forms by these MSSA isolates, in the hospital environment, 
could make them resistant to a number of antibiotics, thereby making it extremely 
difficult to control. This could have serious consequences on infection control measures 
in health institutions. Therefore strict antibiotic and infection control policies are 
important factors to be considered in order to forestall the emergence and dissemination 
of multi-resistant MRSA in Southwestern Nigeria. 
In view of the prevalence rates of MRS A in previous studies and this survey, it 
appears that this pathogen has become established in health institutions in KwaZulu Natal 
province of South Africa. The isolation of multiresistant MRSA in various hospital 
centres and the dissemination of isolates with antibiotype VI indicate that adequate steps 
in limiting spread are urgently needed. Reservoir identification of MRS A is key to 
controlling MRSA transmission. Culturing samples from hospitalized patients at high risk 
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of acquiring MRSA can facilitate detection and isolation of colonized patients. Contact 
precautions and the creation of isolation wards or temporary cohorts within a ward could 
also to be considered. Hand hygiene has also been credited as the single most effective 
measure to reduce the transmission of MRS A (Anonymous, 1996). Healthcare workers 
dealing with wound infections should wear a new pair of gloves, which are discarded 
after dealing with each patient. Gloves prevent contamination ofthe hands with 
microorganisms, and prevent bacteria on the hands of the health worker from inoculating 
the patient (Anonymous, 1996). Hand antisepsis before and after contact with wound 
patients could also decrease MRSA transmission. It should be noted that wearing of 
gloves does not replace the need for hand washing, as gloves can have small defects, and 
hands could be contaminated when the gloves are removed (Anonymous, 1996). The 
"search and destroy" policy has been effective in reducing the MRSA incidence rate in 
the Netherlands (Verhoef et al. , 1999). This involves strict antibiotic policy and 
quarantine of patients until MRSA cultures are negative and screening of all patients and 
health care workers once a patient is found to carry MRSA. Other precautions include the 
closure of the ward or ICU when two or more patients or health care worker are found 
positive with the same MRSA strain. Molecular typing could also be an integral part by 
helping to confirm epidemiologic associations and routes of spread. 
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The following observations and recommendations in this study are as follows: 
1. The D-test proved to be a simple, reliable method to detect inducible resistance to 
clindamycin, in S. aureus. It is recommended that routine screening on 
staphylococcal isolates should be standard practice in both countries. 
2. Clindamycin may not be a theraupeutic option for the treatment of an infection due 
to an inducibly resistant strain of S. aureus in both countries, especially in South 
Africa. 
3. Detection of methicillin resistance by PCR detection of the mecA gene is highly 
recommended for the confirmation of MRSA. 
4. Fusidic acid, rifampicin, minocycline and mupirocin are recommended for the 
treatment of MSSA infections in both countries. 
5. Apart from vancomycin and teicoplanin, fusidic acid, quinipristinldalfopristin, 
linezolid and fosfomycin are recommended for the treatment of MRS A infections 
in South Africa. 
6. In view of the high rates of resistance of MRS A isolates to rifampicin and 
trimethoprim-sulfamethoxazole, combination treatment with these antibacterial 
agents would be unreliable in the treatment of MRSA infections in South Africa, 
fusidic acid is recommended. 
7. In view of the clinical consequences of high-level mupirocin resistance and the 
serious threat to hospital and community infection control, MSSA and MRSA 
isolates should be screened in both countries. 
8. Laboratories are encouraged to investigate atypical S. aureus isolates, and confirm 
their identitiy by molecular techniques. 
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CHAPTER THREE 
MOLECULAR CHARACTERIZATION OF Staphylococcus aureus STRAINS 
FROM SOUTHWESTERN NIGERIA AND KW AZULU-NATAL 
PROVINCE OF SOUTH AFRICA 
3.1 INTRODUCTION 
The surveillance, investigation and control of health-care-associated infections 
have been one of the critical factors in hospital management worldwide. Each year, about 
two million people acquire nosocomial infections in hospitals in the United States and 
about 60% of these infections involve antibiotic resistant bacteria (Lowy, 1998). Among 
pathogens causing hospital infections, Gram-positive cocci such as staphylococci and 
enterococci have become predominant over the past two decades and the emergence of 
resistant organisms has added substantially to the burden and cost of health care-related 
infections (Stefani and Varaldo, 2003; Struelens et at. , 2004). 
The era of emerging resistant pathogens has necessitated a coordinated 
multidisciplinary approach to infection management and control in both the individual 
patient and hospital population, in order to understand the epidemiology of infectious 
diseases (Zaidi et at. , 2003). Infection control practitioners may often notice a cluster of 
cases with a common pathogen. Laboratory technologists may report a distinctive colony 
morphology, or biotype. Thus, a common dilemma with multiple isolates of similar 
organisms is assessing whether they represent the same strain. The analysis of the 
dynamics of nosocomial infections caused by pathogenic bacterial species depends 
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heavily on the accurate identification of these taxonomic entities, including the adequate 
definition of sub-specific strains and clones (van Belkum, 2003). Although a strain is 
usually defined as a pure microbiological culture obtained in the clinical microbiology 
laboratory (Dijkshoom et al., 2000), diagnosing a clone requires additional investigation 
(Lan and Reeves, 2001). The analysis of multiple bacterial isolates by various typing 
methods provides a means of characterizing different subgroups within a species. The 
division of strains into defined subgroups is called bacterial typing. 
Strain differentiation is the basis for the study of the epidemiology of infectious 
diseases (Frenay et al., 1996). Bacterial strain typing distinguishes epidemiologically 
related or clonal isolates from unrelated clones. A prerequisite for all existing typing 
schemes is the assumption that strains derived from one clone will share certain 
characteristics in contrast to strains derived from different clones (Busch and Nitschko, 
1999). Thus bacterial typing has several theoretical and practical implications: (i) to 
analyse the progress of outbreaks and to examine sequential isolates from patients, (ii) to 
associate unusual pathogenic mechanisms with certain strains and (iii) to increase our 
knowledge of epidemiology of infectious diseases (Power, 1996). 
Methods for typing organisms fall into 2 broad categories: (i) subtyping that is 
based on the analysis of the phenotype, itself an expression of the genome through 
translation into structural proteins and enzymes, and (ii) subtyping that is based on the 
analysis of the genome of an organism. Subtyping by phenotypic methods involves the 
characterization and differentiation of strains based on products of gene expression. 
Properties such as biochemical profiles, bacteriophage types, antigens present on a cell's 
surface, and antimicrobial susceptibility profiles are examples of phenotypic properties 
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that can be determined in the laboratory. Because they involve gene expression, these 
properties all have a tendency to vary based on changes in growth conditions, growth 
phase, and spontaneous mutation. 
Genotypic methods are those that are based on analysis of the genetic structure of 
an organism and include polymorphisms in DNA restriction patterns based on cleavage 
of the chromosome by enzymes that cleave the DNA into hundreds of fragments 
(frequent cutters), or into 10 to 30 fragment (infrequent cutters), and the presence or 
absence of extrachromosomal DNA. Genotypic variations are less subject to natural 
variation, although they can be affected by insertions or deletions of DNA into the 
chromosome, the gain or loss of extrachromosomal DNA, or random mutations that may 
create or eliminate restriction endonuclease sites (Tenover et al., 1997). The choice of a 
typing method depend's upon the needs, the skills level, resources of the laboratory and 
the type of question to be answered. An optimal typing method should show high 
typeability, adequate stability, high technical reproducibility and high discriminatory 
power. In addition, ease of use, ease of interpretation, rapidity, accessibility and low costs 
may be considered convenient criteria (Struelens, 1996). 
Historically, Staphylococcus aureus has been an example of a microorganism 
involved in cross-infection in which carriers among health workers or patients have been 
identified frequently as the source of outbreaks (Williams et al., 1966). Methicillin-resistant 
Staphylococcus aureus (MRS A) is one of the most important nosocomial pathogens that 
causes major outbreaks and represents a severe clinical threat to patients worldwide 
(Fluckiger and Widmer, 1999; Deplano et al. , 2000; Stranden et al. , 2003). For example, in 
the United States, MRSA has increased from 2% of all nosocomial infections in National 
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Nosocomial Infection Surveillance hospitals in 1980 to about 50% in 2004 (Farr, 2004). A 
recent study also reported that MRS A prevalence have increased significantly in 
Belgium, Germany, Ireland, the Netherlands and the United Kingdom (Tiemersma et al. , 
2004). The high mortality and morbidity rates of MRS A infections associated with the 
potential for intra- and inter-hospital dissemination are of great concern to medical staff 
and infection control specialists (Tambic et al. , 1997; Conterno et al., 1998). In view of 
this and the consequent implications on health-care costs, many hospitals have attempted 
to control the spread of MRS A. There is considerable epidemiological interest in the 
tracking of strains to gain a better picture of the distribution of strains in the population 
and the dynamics of clonal spread (Crisostomo et al. , 2001). Typing plays an important 
role in understanding the epidemiology of MRSA and evaluating the effectiveness of 
infection control and antimicrobial prescribing measures (Murchan et al. , 2003). 
A broad spectrum of technical instruments has been developed and varies from 
techniques that monitor phenotypic characteristics to those that involve genetic procedures 
that highlight DNA polymorphisms. The main genotypic techniques used for typing S. 
aureus include (i) plasmid analysis; (ii) Southern hybridization analysis of digested 
chromosomal DNA, such as ribotyping, ClaI-mecA ::Tn554 polymorphisms, and binary 
typing; (iii) polymerase chain reaction (PCR)-based techniques such as random amplified 
polymorphic DNA (RAPD), repetitive element sequence based-PCR (rep-PCR), 
amplified fragment length polymorphism, and SCCmec typing; (iv) pulsed-field gel 
electrophoresis (PFGE) and (v) sequence typing techniques such as staphylococcal 
protein A (spa) typing and multi locus sequence typing (MLST). These genotyping 
techniques minimize problems with typeability and reproducibility and, in some cases, 
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enable the establishment of large databases of characterized organisms (Aires de Sousa 
and de Lencastre, 2004). 
Molecular typing approaches have been used to a great advantage in identifying 
and monitoring the international spread of some unique S. aureus strains. Using a 
combination of genotyping such as DNA hybridization with the mecA and Tn554 probes, 
PFGE, RAPD, SCCmec typing, spa typing and MLST, seven internationally spread 
multi-resistant MRSA clones have been identified; the Iberian, Brazilian, Hungarian, 
New York/Tokyo, EMRSA-lS, EMRSA-16 and the paediatric clone (Aires de Sousa and 
de Lencastre, 2004; Perez-Roth et al. , 2004). Enright et al. (2002) also proposed a 
different nomenclature for these clones based on their sequence types (ST) (Enright et aI. , 
2000) and staphylococcal cassette chromosome mec (SCCmec) types (I through IV) 
(Hiramatsu et al. , 2001 ; Ito et al., 2001) i.e. the designation of the seven pandemic clones 
as ST247-IA, ST239-IIIA, ST 239-111, STS-II, ST 36-11, ST22-MRSA-IV and STS-IV 
respectively (Oliveira et al., 2001a; Enright et al. , 2002; Enright, 2003). 
Although studies have been carried out in many countries on MRSA, which has 
identified the appearance of multi-drug resistant MRSA clones replacing other MRSA 
lineages, there is paucity of data on the epidemiology of S. aureus (MSSA and MRS A) in 
Nigeria and South Africa using molecular epidemiological techniques. Recent information 
on clonal identities and diversity of S. aureus does not exist in both countries. 
Furthermore, data does not exist on the emergence and spread of worldwide multi-
resistant MRS A clones in the two countries. Monitoring the geographic expansion of S. 
aureus clones in the global surveillance network in different population is important and 
this study is expected to provide health personnel and policy makers in both countries, 
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with baseline information in establishing adequate infection control programmes and 
health intervention strategies and a better understanding on the global spread of this 
organIsm. 
Genetic relatedness of methicillin-resistant S. aureus obtained in this study was 
determined using three sets of epidemiological tools. They include antibiotyping, PCR-
RFLP of the coagulase gene and pulsed-field gel electrophoresis. Furthermore, selected 
methicillin-susceptible S. aureus (MSSA) from both countries were analysed by PCR-
RFLP of the coagulase gene. Carriage of plasmid DNA by MRSA strains was also 
investigated by plasmid analysis. 
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3.2 MATERIALS AND METHODS 
3.2.1 Plasmid DNA isolation 
Isolation of plasmid DNA was based on the cetyl trimethyl ammonium bromide 
method (CTAB) according to Udo and Grubb (1991). A pure culture of the test strain was 
inoculated onto an enriched medium (Brain Heart Infusion broth), and incubated in a 
shaker at 37°C overnight. A 10ml aliquot of the culture was dispensed into oakridge tubes 
and centrifuged at 4000rpm for IS minutes. The supernatant was discarded and the pellet 
was resuspended in 900,.!i ofNE buffer (2.SM NaCl, IOmM EDTA) (PH 8.0) and 100).!1 
lysostaphin (1S0).!g/ml). The cell suspension was incubated at 37°C for 30 minutes. This 
was followed by the addition of 2m I oflysing solution (O.S% cetrimide; O.S% sarkosyl), 
which was carefully dispensed through the sides of the tube. After incubation at 6SoC for 
20 minutes, the suspension was centrifuged at 12000rpm for IS minutes, the supernatant 
dispensed into oakridge tubes containing Sml of sterile distilled water and centrifuged at 
4000rpm for 10 minutes. The supernatant was discarded and the pellet was resuspended 
in 600).!1 E buffer (Tris 40mM, EDTA 2mM) (PH 8.0), 300).!1 NE buffer (2.SM NaCl, 
IOmM EDTA) (PH 8.0), 30).!1 RNase (10mg/ml), and incubated at 37°C for 30 minutes. 
Chloroform (1ml) was added after the incubation period, the tubes inverted gently for 5 
minutes, and centrifuged at 4000rpm for 30 minutes. The aqueous phase was removed 
and dispensed into a microfuge tube containing 7SO).!1 isopropanol, and centrifuged at 
13000rpm for S minutes. The supernatant was poured off and the tubes were allowed to 
dry at 37°C for 3 hours. The pellet was then resuspended in 40).!1 TE (I OmM Tris, O.1mM 
EDTA) buffer (PH 8.0) and stored at 4°C. Plasmids were analysed by agarose (0.6% w/v) 
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gel electrophoresis in IX TAB buffer (Tris 0.04M, Acetic acid 0.02M, EDTA disodium 
O.OOIM) (PH 7.2) at 25V for 16 hours. Plasmid profiles ofthe strains were based on the 
number and size of plasm ids. The WBG 4483 , Staphylococcus aureus strain, which has 4 
plasmids (40.3kb, 22.5kb, 4.4kb and 3.5kb) served as the plasmid molecular size 
standard. The approximate plasmid sizes (closed circular forms) were estimated by visual 
inspection and using the GeneTools program (SynGene Bioimaging System). 
3.2.2 DNA isolation of S. aureus strains 
DNA isolation was carried out according to the method ofUdo et al., (1999) and 
as described in Chapter Two (Section 2.2.4). 
3.2.3 PCR-RFLP of the coagulase gene 
Amplification of the 3' end region of the coagulase gene containing the 81-bp 
tandem repeats was performed as described by Goh et al., (1992). The gene primers are 
(COAG 2) 5'- CGA GAC CAA GAT TCA ACA AG3 ' and (COAG 3) 5' - AAA GAA 
AAC CAC TCA CAT CA3'. Each PCR reaction was made up of the following: 25 ~l of 
mastermix (Sigma), containing 1.5units of Taq DNA polymerase, lOmM Tris-HCI, 
50mM KCI, 1.5mM MgCh, 0.001% gelatin and 0.2mM dNTPs, 1~1 (20pmol) of the 
forward and reverse primers and 5 ~l of template DNA. Sterile distilled water was added 
to make a final volume of 50~1. The thermo cycler was programmed with the following 
parameters: 40 cycles of denaturation at 95°C for 30 seconds, annealing at 55°C for 2 
minutes and extension at 72°C for 4 minutes. The S. aureus ATCC 25923 strain served as 
the positive control in each PCR reaction. The PCR products were detected by gel 
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electrophoresis using 1.5% w/v agarose (Seakem, Whittaker USA) and run in IX TBE 
(0.OS9M Tris, 0.OS9M boric acid, EDTA disodium 0.002M) buffer (PH S.3) at SOV for 2 
hours. The gels were stained with ethidium bromide and visualized under UV light. 
Restriction fragment length polymorphisms (RFLPs) of the amplicons were 
determined by digestion with AZul (Fermentas, UK) by a modification of the protocol 
previously described by Lammler et aZ., (2001). The reaction mixture was made up of 
10J..lI of the PCR product, I .OJ..lI enzyme and 2J..lI of lOX restriction buffer. Sterile distilled 
water was added to make a final volume of20J..l1. It was then incubated at 37°C for 2 
hours. The restriction DNA digests was detected by electrophoresis in 2% w/v agarose 
(Seakem, Whittaker USA) in IX TBE buffer (0.OS9M Tris, 0.OS9M boric acid, EDTA 
disodium 0.002M) buffer (PH S.3) at SOV for 2 hours. The gels were stained with 
ethidium bromide and visualized under UV light. 
The sizes of the PCR products and of the restriction DNA digests (RFLPs with 
respect to the overall number of Sl-bp tandem repeats) was estimated by comparison 
with a IOObp molecular size standard marker, visual inspection and analysis using the 
GeneTools program (SynGene Bioimaging System). The strains were grouped on the 
basis of three characteristics of their PCR products, i.e. the presence of one or two PCR 
products, their size (s), and the AZul restriction digest patterns of the PCR products. 
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3.2.4 PFGE Typing 
PFGE typing of SmaI (Fermentas, UK) digested DNA was carried out by a 
modification of the protocol previously described by Bannerman et al. (1995). A colony 
was inoculated in a Brain Heart Infusion broth culture and incubated at 37°C overnight 
on a shaker. The pellet from 0.4 ml of this culture was washed in 0.8 ml NET buffer (10 
mM Tris, I mM EDTA, 10 mM NaCl), and re-suspended in 0.2ml of NET buffer. An 
aliquot of 50~llysostaphin (400~glml) and 150~1 of agarose (O.4g in 25ml of 0.5X TBE 
buffer) (Seakem, Whittaker USA) at 50°C was then added. The cell/agarose suspension 
was loaded into block molds (Bio-Rad) and allowed to solidify for 30 minutes. Cells 
were lysed by incubation at 37°C for 3 hours in lysis buffer (6 mM Trizma base, 100 mM 
EDTA, 1 M NaCl, 0.5% Brij 58, 0.2% sodium deoxycholate, 0.5% lauroyl sarcosine). 
This was followed by a second overnight incubation at 55°C in 25~1 of proteinase K 
(20mglml) and 475 ~l of proteolysis buffer (1 % lauroyl sarcosine, 7 5 ~g Proteinase K in 
0.5M EDTA). The blocks were washed three times (using a shaker) in 1 ml TE buffer (10 
mM Trizma base, 1 mM EDTA) at 37°C for 30 minutes. Thereafter, one quarter of each 
agarose block was prepared and washed four times (using a shaker) in Iml of sterile 
distilled water at 37°C for 30 minutes. It was then digested with 30 units of SmaI 
overnight according to the manufacturer' s instructions and loaded into the wells of 1 % 
PFGE certified agarose gel (Bio-Rad). 
Electrophoresis was performed in 0.5X TBE buffer (0.045M Tris, 0.045M boric 
acid, EDTA disodium O.OOIM) (PH 8) by the contour-clamped homogenous electric field 
method using a CHEF MAPPER system (Bio-Rad). The fragments were separated with a 
linear ramped pulse time of 6.8 s - 63.8 s over a period of 23 hours at 14°C. The gels 
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were stained with Illg/mi ethidium bromide (Sigma) solution for I hour, visualized under 
UV and photographed (SynGene Bioimaging System). 
The banding patterns were interpreted visually and the relatedness of the strains 
was determined according to the recommendation of Bannerman et al. (1995) and 
Jorgensen et al. (1996). In addition, the GelCompar II software version 4.0 (Applied 
Maths, Sint-Martens-Latem, Belgium) was used to calculate the Dice similarity indices 
and to construct a dendogram after cluster analysis by unweighted-pair-group-matching-
analysis (UPGMA). Band position tolerance was set at 1.5% and DNA fragments below 
80kb were not included in the analysis. By definition, two strains belong to the same 
cluster if their Dice similarity index is 85% or more. Strains showing the same PFGE 
pattern were grouped as a pulsotype and assigned using an alphabet (e.g. a, b, c etc). 
Numeric sub-codes were used to represent < 3 band difference (subtypes, e.g. ai , bl , c1 
etc). Strains with banding patterns that differed from the main pattern by at least 3 bands 
were grouped in a different type. 
293 
3.3 RESULTS 
3.3.1 Plasmid analysis 
A total of 16 plasmid profiles were observed among the 60 MRSA strains from 
South Africa (Table 3.1; Figures in Appendix 2). MRS A that carried at least one large 
plasmid (approximately 26-39kb), and one or more small plasmids (2.3-4.8kb) accounted 
for 40% of the total number of strains studied. A total of 47 MRSA (78.3%) strains 
harboured at least one small plasmid ranging from 1.2-4.8kb, while plasmid DNA could 
not be obtained from 13 strains (21 .7%). One of the MRSA from Nigeria possessed five 
plasmids ranging from 2.3 to 26.3kb. Analysis of the plasmid profiles and antibiogram of 
MRSA from South Africa indicated that strains in which plasmid DNA could not be 
isolated were resistant to three to six classes of antibiotics, while 45 of 47 MRS A strains 
that harboured at least one plasmid were resistant to six or more classes of antibiotics. 
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Table 3.1: Plasmid profiles of MRS A strains from South Africa and Nigeria 
Plasmid Approximate size Number 
Profile (kb) of strains 
South Africa 
1 26, 4.2, 3.3 2 
2 26, 23, 3.3 2 
3 28.5, 2.8 6 
4 No plasmid 13 
5 32, 4.2, 2.8 1 
6 37, 2.3 5 
7 34, 4.8, 2.3 1 
8 37, 3.7,2.3 3 
9 39.3, 3.7, 2.8 1 
10 1.2 1 
11 2.8 6 
12 38.3, 15.4, 2.3 3 
13 2.3 12 
14 3.7,2.8 2 
15 2.4, 2.3 I 
16 4.8,2.3 I 
Nigeria 
17 26, 19, 7.4, 4.2, 2.3 1 
18 5.2, 2.8 1 
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3.3.2 PCR-RFLP analysis of the coagulase gene (S. aureus strains from South 
Africa) 
Typing based on PCR-RFLP of the coagulase gene of strains from South Africa is 
illustrated in Table 3.2. PCR products of98 strains (37 MSSA and 61 MRS A) from 
South Africa were analyzed (Figures in Appendix 2). Due to the wide range of sizes of 
the PCR products, a cut-off value was determined with a limit of ± 20bp. Among the 
MRS A strains, a single amplicon of 750bp was detected in one strain (1.6%), of 850bp in 
two strains (3.3%), of 800bp in 14 (23%), and of 650bp in 43 strains (70.5%). No PCR 
product was detected in one MRSA strain (Figures in Appendix 2). 
Eleven differently sized PCR products were identified in MSSA strains. PCR 
amplification of the 3' end of the coagulase gene revealed a single amplicon in 34 of the 
37 strains, which ranged between 480bp and 950bp. Two PCR amplicons of 400bp, 
760bp were detected in one strain and of 400bp, 1000bp in two strains. A single amplicon 
of 480bp was detected in one strain and of 600bp, 650bp, 700bp and 950bp in two strains 
respectively. PCR products of 850bp (five strains), of 750bp and 900bp (six strains), and 
800bp (seven strains) were also identified. No PCR product was detected in one MSSA 
strain (Figures in Appendix 2). Overall, a single fragment of 650bp was detected in 45 S. 
aureus strains (MSSA and MRSA), followed by 800bp in 21 strains, of 750bp and 850bp 
in seven strains and 900bp in six strains. 
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A total of 11 distinct RFLP patterns (types 1-10 and 13) were observed among the 
98 strains examined after AZul digestion of the peR products (Table 3.2; Figures in 
Appendix 2). Two strains (one MRSA and one MSSA) failed to yield a product with the 
primers and were therefore classified as twelfth type (14a). The strains belonging to type 
7 were subdivided into seven subtypes; group 8 into five subtypes, types 3 and 5 into four 
subtypes and types 2 and 9 into two subtypes respectively. The 61 MRS A strains were 
classified into five main RFLP patterns (types 3,5, 7, 8 and 14) and most of the strains 
(67.2%) were grouped in subtype 3a. The 37 MSSA strains were categorized into 12 
genotypes, and two MSSA in subtype 5b shared similar RFLP patterns with one of the 
MRSA strains (Table 3.2). 
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Table 3.2: PCR-RFLP of the coagulase gene in MSSA and MRSA strains from South 
Africa 
Type Molecular Total mecA- mecA- 81 162 
weight number positive negative 
(±20bp) of 
strains 
la 480 1 0 1 + 
2a 600 1 
" 
0 1 + 
2b* 1 0 1 + 
3a 650 41 41 0 + 
3b 2 2 0 
3c 1 0 1 + 
3d 1 0 1 
4a* 700 1 0 1 + + 
4b 1 0 I + 
5a* 750 1 0 1 + + 
5b* 3 I 2 + 
5c I 0 I + 
5d 2 0 2 + 
6a 750,400 1 0 1 + 
7a** 800 5 5 0 + + 
7b*** 7 7 0 + 
7c 2 2 0 
7d 2 0 2 + + 
7e* 3 0 3 + 
7f I 0 1 
7g* I 0 I 
8a 850 I 1 0 + + 
8b* I 0 I + 
8c 2 0 2 + 
8d 2 0 2 
8e I I 0 
9a 900 5 0 5 + + 
9b I 0 1 + 
10a* 950 2 0 2 + 
13a* 1000,400 2 0 2 + 
14a No product 2 I I 
Total 98 61 37 
* . -SImIlar PCR RFLP patterns wIth MSSA straInS from Nlgena 
**Similar PCR-RFLP patterns with MRSA strains from Nigeria 
***Similar PCR-RFLP patterns with MSSA strains from Nigeria 
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3.3.2.1 Correlation between antibiotyping and PCR-RFLP of the coagulase gene 
among MRSA strains from South Africa 
The association between antibiotyping and PCR-RFLP of the coagulase gene in 
MRS A from South Africa is described in Table 3.3. Nine antibiotypes were noted for 
MRS A in type 3a (PCR-RFLP: 650bp; 81 , 567bp) and 88% of strains in the predominant 
antibiotype VI were grouped in PCR-RFLP subtype 3a. In addition, five of the six MRSA 
strains in antibiotype XI and four of the six MRS A assigned to antibiotype II belonged to 
PCR-RFLP subtypes 7a and 7b respectively. Furthermore, the four strains in antibiotype I 
was equally shared between subtypes 7b and 7c. 
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Table 3.3: Correlation between PCR-RFLP of the coagulase gene and antibiotyping of 
MRSA strains from South Africa 
Type (PCR-RFLP coagulase gene) Antibiogram (number of strains)/(antibiotype) 
± 20bp (number of strains) 
3a 650 (81 , 567) (41) PEN, GN, ERY, TET, TS, RF (22) - (antibiotype VI) 
PEN, GN, ERY, CHL, TET, TS, RF (4) - (III) 
PEN, GN, ERY, TET, TS, RF, MU5 (3) - (IV) 
PEN, TET, RF (2) - (XII) 
PEN, GN, TET, TS, RF, MU5 (2) - (VIII) 
PEN, GN, CHL, TET, TS, RF (2) - (VII) 
PEN, GN, TET, TS, RF (4) - (IX) 
PEN, GN, ERY, TET, RF (1) - (X) 
PEN, GN, ERY, TET, TS, RF, CIP (1) - (V) 
3b 650 (567) (2) PEN, GN, TET, TS, RF (1) - (IX) 
PEN, GN, ERY, TET, TS, RF (1) - (VI) 
5b 750 (81 , 243, 405) (1) PEN, GN, ERY, TET, TS, RF (1) - (VI) 
7a 800 (81, 162, 486) (5) PEN, GN, ERY (5) - (XI) 
7b 800 (81 , 324, 405) (6) PEN, GN, ERY, TET, TS, CIP, MU (4) - (II) 
PEN, GN, ERY, CHL, TET, TS, CIP, MU5 (2) - (I) 
7c 800 (324, 405) (2) PEN, GN, ERY, CHL, TET, TS, CIP, MU5 (2) - (I) 
8a 850 (81 , 162, 486) (1) PEN, GN, ERY (1) - (XI) 
8b 850 (81 , 324, 405) (1) PEN, GN, ERY, TET, TS, CIP, MU5 (1) - (II) 
8e 850 (324, 405) (1 ) PEN, GN, ERY, TET, TS, CIP, MU5 (1) - (II) 
14a No product (1) PEN, GN, ERY, TET, TS, RF (1) - (VI) 
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3.3.3 PCR-RFLP of the coagulase gene (S. aureus strains from Nigeria) 
A total of 54 strains (3 MRSA and 51 MSSA) from Nigeria were analyzed (Table 
3.4; Figures in Appendix 2). PCR amplification of the 3' end of the coagulase gene 
yielded a single amplicon in 47 of the 54 strains studied, which ranged between 600bp 
and 1000bp. Two PCR products of 750bp, 840bp were detected in two MSSA and of 
400bp, 1000bp in five MSSA strains. Furthermore, a PCR product of 650bp and 950bp 
was detected in one MSSA strain, of 600bp, 850bp and 900bp in two strains, and of 
1000bp in three strains. Single fragments of 700bp in six strains, of 800bp in nine strains, 
and of 750bp in 18 strains were also identified. A single amplicon of 750bp and 800bp 
was noted in one and two MRS A strains respectively. 
After the restriction analysis of PCR product using AluI, 11 different restriction 
fragment length polymorphism (RFLP) patterns were distinguished among the strains 
(Table 3.4; Figures in Appendix 2). The RFLP patterns are illustrated in Table 3.4. The 
strains belonging to type 7 were subdivided into five subtypes and types 4 and 5 into four 
subtypes respectively. Subtype 5b was predominant (13 strains) among the MSSA 
strains, followed by subtype 7b (6 strains), and type 13a (5 strains). MRSA and MSSA 
strains sharing the same RFLP pattern were observed in genotype 5b and 7h. One of the 
MRSA strains from Nigeria shared the same PCR-RFLP pattern (type 7a) with five 
MRSA strains from South Africa while six MSSA strains from Nigeria shared a similar 
pattern (type 7b) with seven MRSA strains from South Africa. MSSA and MRSA strains 
from the two countries were identified in subtype 5b (Tables 3.2 and 3.4). 
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Table 3.4: PCR-RFLP of the coagulase gene in MSSA and MRSA strains from Nigeria 
AluI restriction fragments 
Type Molecular Total mecA- mecA- 81 162 243 
weight number positive negative 
(±20bp) of 
strains 
2b* 600 1 0 1 + 
2c 1 0 1 + + 
3e 650 1 0 1 + 
4a* 700 2 0 2 + + 
4c 2 0 2 + + 
4d 1 0 1 + 
4e 1 0 1 + 
5a* 750 3 0 3 + + 
5b* 14 1 13 + + 
5e 1 0 1 + 
5f 1 0 1 
7a** 800 1 1 0 + + 
7b*** 6 0 6 + 
7e* 1 0 1 + + 
7g* 1 0 1 
7h 2 1 1 + + 
8b* 850 2 0 2 + 
9c 900 2 0 2 + 
lOa* 950 1 0 1 + 
lla 1000 3 0 3 + 
12a 840, 750 2 0 2 + + 
13a* 1000,400 5 0 5 + 
Total 54 3 51 
*Similar PCR-RFLP patterns with MSSA strains from South Africa 
**Similar PCR-RFLP patterns with MRSA strains from South Africa 
***Similar PCR-RFLP patterns with MRSA strains from South Africa 
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3.3.3.1 Comparative analysis of antibiogram of S. aureus strains from Nigeria and 
South Africa with similar PCR-RFLP patterns 
The antibiotic resistance profile of MSSA and MRSA strains from both countries 
with similar PCR-RFLP patterns of the coagulase gene is presented in Table 3.5. Of the 
37 and 51 MSSA strains from South Africa and Nigeria analyzed by PCR-RFLP of the 
coagulase gene, 14 and 29 strains with similar PCR-RFLP patterns were noted from 
South and Nigeria respectively, and seven groups were identified. Different resistance 
profiles of MSSA strains from Nigeria and South Africa with similar PCR-RFLP patterns 
were observed. Multi-resistant (defined as resistance to penicillin along with at least three 
classes of antibiotics) strains were noted among MSSA strains from South Africa in types 
2b and 4a (with identical resistance profiles) and 7e while multi-resistant MSSA from 
Nigeria was mainly identified in types 5b (10 strains) and 7e (one strain). MSSA from 
both countries with similar resistance profiles was noted only in type 5a. There was no 
correlation between antibiogram of the MRS A strain from Nigeria, which shared the 
same PCR-RFLP pattern (subtype 7a) with the five MRS A strains from South Africa. 
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Table 3.5: Antibiogram and PCR-RFLP of the coagulase gene in related MSSA and 
MRSA strains from Nigeria and South Africa 
South Africa (MSSNMRSA strains) Nigeria (MSSNMRSA strains) 
Type Size (±20bp) RFLP pattern Antibiogram (number of strains) Antibiogram (number of strains) 
2b 600 162, 405 PEN, ERY, TM, TET (I) PEN, TM (I) 
4a 700 81 , 162, 405 PEN, ERY, TM, TET (I) PEN, TM, TET (2) 
5a 750 81 , 162,405 PEN, TM, TET (I) PEN, TM, TET (3) 
5b 750 81,243, 405 PEN (2) PEN, TM, TET (2), 
PEN, CHL, CIP, STR (I), 
PEN, TM, CIP, TET, STR (4) 
PEN, TM, GN, TET, KAN, STR (I) 
PEN, TM, GN, NED, KAN, STR (I) 
PEN, TM, GN, CIP, TET, KAN, STR (I) 
PEN, TM, GN, TET, NED, KAN, STR (2) 
PEN, ERY, TM, GN, CIP, TET, NED, KAN, STR (I) 
7a* 800 81 , 162,486 PEN, GN, ERY (5) PEN, ERY, TET, CIP (I) (MRSA) 
(MRSA) 
7e 800 162, 243,405 PEN (I) PEN, TM, GN, CIP, TET (I) 
PEN, TM, GN, KAN (I) 
PEN, ERY, TM, GN, KAN (I) 
7g 800 810 PEN, ERY (I) PEN (I) 
8b 850 81 , 324,405 Susceptible to all antibiotics (I) PEN, TM, TET (2) 
lOa 950 162, 324, 486 PEN, ERY (2) PEN, TM, TET (I) 
13a 1000,400 162, 324,405,486 PEN, RF (I) PEN, TM, TET (5) 
PEN, ERY (I) 
·Slmllar PCR-RFLP patterns of MRS A strams from Nlgena and South Africa 
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3.3.4 PFGE typing 
The SmaI macrorestriction profiles of the MRSA strains from Nigeria and South 
Africa are presented in Figures 3.2 to 3.7. Visual interpretation and cluster analysis by 
Gel Compar grouped the 61 MRSA strains from South Africa into eight types, which 
comprised of pulsotypes a (21 of 61 strains; 34.4%), b (17 of 61; 27.8%), c (4 of 61 ; 
6.6%), d (10 of61; 16.4%), and g (6 of61; 9.8%). Types e, fand h were represented by 
single strains only. Four subtypes were identified in PFGE type a; five in type b and two 
in type d (Table 3.7). Discrepancies between visual and computer-aided interpretation 
was observed in one strain. However, it was assigned to type g (Figure 3.4; Lane 11). The 
PFGE patterns of MRSA strains in types a and b differed by two to four bands, indicating 
that the strains were related. In addition, comparison of the banding patterns of MRSA 
strains in the main type al with one of the strains from Ile-Ife, Nigeria (THCD) indicated 
a two to three band difference, suggesting that these strains are related (Figure 3.8; Lanes 
10 and 14). 
The distribution of MRS A PFGE types in health institutions within the KwaZulu-
Natal province of South Africa is described in Table 3.6 and Figure 3.1. Type a was 
noted in two hospitals in Durban, and one health institution in Pietermaritzburg, 
Newcastle, Greytown, Kokstad, Port Shepstone and Empangeni. Type b was identified in 
two health facilities in Durban and one in Pietermaritzburg, Kokstad, Eshowe, Scottburg 
and Empangeni. Type c was detected in hospitals located in Empangeni and Scottburgh, 
and type d in three of the four health facilities in Durban and one in Pietermaritzburg and 
Empangeni. Types e, f and h represented by single MRSA strains were noted in health 
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facilities in Newcastle, Durban and Pietermaritzburg respectively, while type g was 
observed in two hospitals in Durban and one in Pietermaritzburg, Eshowe and Scottburg. 
Table 3.6: Distribution of PFGE types of MRSA strains obtained from health 
institutions of the KwaZulu-Natal province in South Africa 
Hospitals (Location) Type Subtypes Number of strains 
Number of strains 
Durban 
Hospital A (7) a al I 
b b2, b4 3 
d dl 2 
g g I 
Hospital B (8) a aI , a2, a3 4 
d dl , d2 4 
Hospital C (4) b bl , b4 2 
d dl I 
g g I 
Hospital D (1) f f I 
Pietermaritzburg 
Hospital E (2) d dl I 
g g I 
Hospital F (4) a a4 I 
b b2 I 
g g I 
h h I 
Newcastle 
Hospital G (2) a al I 
e e I 
GreyTown 
Hospital H ()) a a3 I 
Kokstad 
Hospital I (3) a a3 I 
b b4 2 
Eshowe 
Hospital J (4) b bl , b2, b3 3 
g g I 
Port Shepstone 
Hospital K (4) a al 4 
Scottburgh 
Hospital L (3) b b2 I 
c c I 
g g I 
Empangeni 
Hospital N (18) a aI , a3 8 
b bl , b2, b5 5 
c c 3 
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Figure 3.1: Map of KwaZulu-Natal province in South Africa, location of the health institutions (A-N) 
and the PFGE types (illustrated in colours) 
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PFGE profiles ofMRSA from South Africa. Lanes 1, 8 and 15: S. aureus NcrC 8325; 
Lane 2: AC; Lane 3: AD; Lane 4: XQ; Lane 5: XW; Lane 6: 107 (2); Lane 7: ESA; Lane 
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PFGE profiles of MRS A from South Africa. Lanes 1, 8 and 15: S. aureus NCTC 8325; 
Lane 2: 513 ; Lane3 : 114XC; Lane 4: 131XB; Lane 5: MD24; Lane 6: MD43 ; Lane 7: 
GJC3; Lane 9: GJC7; Lane 10: GJC69; Lane 11: GT33 ; Lane 12: PM69; Lane 13 : 
E0052; Lane 14: E0070. 
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PFGE profiles of MRS A from South Africa. Lanes 1, 8 and 15: S. aureus NCTC 8325; 
Lane 2: E0084; Lane 3: E0099; Lane 4: KEHI2; Lane 5: KEH26; Lane 6: KEH77; 
Lane 7: KEH88; Lane 9: AD28; Lane 10: AD69; Lane II: AD77; Lane 12: AD79; Lane 
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PFGE profiles of MRSA from South Africa. Lanes 1, 8 and 15: S. aureus NCTC 8325; 
Lane 2: AD98; Lane 3: ESH20; Lane 4: ESH34; Lane 5: ESH37; Lane 6: ESH89; Lane 
7: EGU23; Lane 9: EGU28; Lane 10: EGU51; Lane 11: PS33; Lane 12: PS44; Lane 13 : 
PS50; Lane 14: PS94. 
2 3 4 5 6 7 8 9 10 11 12 13 14 15 
~ 











PFGE profiles of MRS A from South Africa. Lanes 1 and 15: S. aureus NCTC 8325; 
Lane 2: GPll ; Lane 3: GP74; Lane 4: RKK6; Lane 5: RKK8; Lane 6: RKKlO; Lane 7: 
RKK52; Lane 8: RKK53 Lane 9: RKK55 ; Lane 10: RKK56; Lane 11: RKK57; Lane 12: 











PFGE types as 
PFGE profiles of MRS A from Nigeria. Lane 1: S. aureus NCTC 8325; Lane 2: THCD; 
Lane 3: 15; Lane 4: 28IDA. 
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3.3.4.1 Clonal relationship between MRSA clones and EMRSA-15 and -16 
Analysis of the DNA banding patterns by PFGE of representative MRSA clones 
in South Africa, MRSA from Nigeria and two worldwide epidemic clones are illustrated 
in Figure 3.8 and Figures in Appendix 2. No clonal relationship between selected MRSA 
clones from South Africa and the pandemic clones EMRSA-15 and -16 was observed. 
However, visual inspection and comparison of the banding patterns of one MRS A 
obtained in Ibadan, Nigeria (28IDA) revealed that it differed from EMRSA-15 by two to 













2 3 4 5 6 7 8 9 10 II 12 13 14 15 
b4 a3 al al dl a3 a2 dl al E-15 E-16 j a5 
PFGE profiles of representative MRSA clones and worldwide clones. Lane I: S. aureus 
NCTC 8325; Lanes II and 12: EMRSA-I5 and EMRSA-I6; Lane 2: EGU23; Lane 3: 
EGUS1; Lane 4: PS33; Lane 5: PSSO; Lane 6: GPII; Lane 7: RKK6; Lane 8: RKKS3; 
Lane 9: RKK56; Lane 10: IKH; Lane 13: 28IDA (Nigeria); Lane 14: THCD (Nigeria); 
Lane 15: IS (Nigeria). 
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3.3.4.2 Relationships between PFGE and antibiotyping of MRSA strains from South 
Africa 
The PFGE profiles and antibiotyping of 61 MRSA from South Africa are 
presented in Table 3.7. As stated in Chapter two, antibiotyping of MRS A isolates was 
based on the susceptibility pattern of isolates to selected antibiotics, representing various 
classes of antimicrobial agents. 
Most of the MRSA strains (87%) were multiresistant (resistance to at least 4 
classes of antibiotics) and one MRSA each in subtypes b 1 and b3 and six MRSA in type 
g were non-multiresistant. A total of 14 of the 23 MRSA in the dominant antibiotype VI 
(Chapter Two) were grouped in type a, which comprised subtypes al (ten strains), a3 
(two strains), a2 and a4 (one strain) respectively. Other MRSA in antibiotype VI were 
noted in type b (five strains), made up of subtypes b5 (two strains), bl, b2, b4 (one 
strain); types c (three strains) e, fand h (one strain) respectively. All the strains assigned 
to type g (PFGE) belonged to anti biotype XI while MRSA in anti biotype I was grouped 
in subtype d 1. Furthermore, the six MRSA classified in antibiotype II were noted in 
subtypes dl and d2. Resistance to rifampicin was a distinct feature of MRS A in types a, 
b, c, e, f and h, while resistance to ciprofloxacin was a unique character for MRS A in 
type d, although one MRSA in subtype b 1 exhibited that resistance phenotype. In 
addition, strains in types d and g exhibited 100% susceptibility to rifampicin while 




PFGE patterns and antibiotyping of 3 and 61 MRSA strains from Nigeria 
and South Africa 
Subtypes Antibiotyping (number of strains) 
(number of strains) (number of strains) 
South Africa 
a (21) al (14) PEN, GN, ERY, TET, TS, RF (9) 
PEN, GN, ERY, CHL, TET, TS, RF (3) 
PEN, GN, TET, TS, RF (1) 
PEN, GN, ERY, TET, TS, RF (1) 
a2 (1) PEN, GN, ERY, TET, TS, RF (1) 
a3 (5) PEN, GN, ERY, TET, TS, RF (2) 
PEN, GN, ERY, TET, RF (1) 
PEN, GN, CHL, TET, TS, RF (1) 
PEN, GN, ERY, TET, TS, RF, MU5 (1) 
a4 (1) PEN, GN, ERY, TET, TS, RF (1) 
b (17) bi (4) PEN, TET, RF (1) 
PEN, GN, ERY, TET, TS, RF (1) 
PEN, GN, ERY, TET, TS, RF, CIP (1) 
PEN, GN, ERY, TET, TS, RF, MU5 (1) 
b2 (5) PEN, GN, TET, TS, RF (3) 
PEN, GN, ERY, TET, TS, RF (1) 
PEN, GN, ERY, CHL, TET, TS, RF (1) 
b3 (1) PEN, TET, RF (1) 
b4 (5) PEN, GN, TET, TS, RF, MU5 (2) 
PEN, GN, CHL, TET, TS, RF (1) 
PEN, GN, ERY, TET, TS, RF (1) 
PEN, GN, ERY, TET, TS, RF, MU5 (1) 
b5 (2) PEN, GN, ERY, TET, TS, RF (2) 
c (4) c (4) PEN, GN, ERY, TET, TS, RF (3) 
PEN, GN, TET, TS, RF (1) 
d (10) dl (9) PEN, GN, ERY, TET, TS, CIP, MU5 (5) 
PEN, GN, ERY, CHL, TET, TS, CIP, MU5 (4) 
d2 (1) PEN, GN, ERY, TET, TS, CIP, MU5 (1 ) 
e (1) e (1) PEN, GN, ERY, TET, TS, RF (1) 
f(1) f(l) PEN, GN, ERY, TET, TS, RF (1) 
g (6) g (6) PEN, GN, ERY (6) 
h (1) h (1) PEN, GN, ERY, TET, TS, RF (1) 
Nigeria 
a (1) a5 (1) PEN, ERY, TET, TS (1 ) 
i (1) i (1) PEN, TET(1) 
j (1) j (1) PEN, ERY, TET, CIP (1) 
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3.3.4.3 Correlation between various typing methods used in this study 
A comparative analysis of antibiotyping, PCR-RFLP of the coagulase gene and 
PFGE is illustrated in Table 3.8. The dominant genotype (3a) based on PCR-RFLP ofthe 
coagulase gene (with 38 strains) was further divided into six types (a, b, c, e, f and h) by 
PFGE. A total of 18 of the 21 MRSA belonging to type a and 16 of the 17 MRSA in type 
b were identified in the dominant group by PCR-RFLP ofthe coagulase gene (650bp; 
RFLP: 81, 567bp). All the MRS A strains in type d produced the PCR-RFLP pattern 
(800bp; 850bp, RFLP: 81, 324, 405bp; 324, 405bp) and were split between groups I and 
II (antibiotyping). MRSA in type g had a unique PCR-RFLP pattern (800bp; 850bp, 
RFLP: 81, 162, 486bp) and belonged to group XI by antibiotyping. 
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Table 3.8: Comparative analysis of antibiotyping, PCR-RFLP of the coagulase gene 
and PFGE in MRSA strains from South Africa 
(PCR-RFLP coagulase Number PFOE type Antibiotyping 
gene) ± 20bp of strains (number of 
strains) 
650 (81 , 567) 41 al (II ) PEN, ON, ERY, TET, TS, RF (6) 
PEN, ON, ERY, CHL, TET, TS, RF (3) 
PEN, ON, TET, TS, RF (I) 
PEN, ON, ERY, TET, TS, RF (I) 
a2 (I) PEN, ON, ERY, TET, TS, RF (I) 
a3 (5) PEN, ON, ERY, TET, TS, RF (2) 
PEN, ON, ERY, TET, RF (I) 
PEN, ON, CHL, TET, TS, RF (I) 
PEN, ON, ERY, TET, TS, RF, MU5 ( \) 
a4 (\) PEN, ON, ERY, TET, TS, RF (\) 
b\ (4) PEN, TET, RF (\) 
PEN, ON, ERY, TET, TS, RF (\) 
PEN, ON, ERY, TET, TS, RF, CIP (\) 
PEN, ON, ERY, TET, TS, RF, MU5 (\) 
b2 (4) PEN, ON, TET, TS, RF (2) 
PEN, ON, ERY, TET, TS, RF (I) 
PEN, ON, ERY, CHL, TET, TS, RF (\) 
b3 (\) PEN, TET, RF (I) 
b4 (5) PEN, ON, TET, TS, RF, MU5 (2) 
PEN, ON, CHL, TET, TS, RF (\) 
PEN, ON, ERY, TET, TS, RF (I) 
PEN, ON, ERY, TET, TS, RF, MU5 (\) 
b5 (2) PEN, ON, ERY, TET, TS, RF (2) 
c (4) PEN, ON, ERY, TET, TS, RF (3) 
PEN, ON, TET, TS, RF (\) 
e (\) PEN, ON, ERY, TET, TS, RF (I) 
f (I) PEN, ON, ERY, TET, TS, RF (I) 
h (I) PEN, ON, ERY, TET, TS, RF (I) 
650 (567) 2 al (I) PEN, ON, ERY, TET, TS, RF (\) 
b2 (I) PEN, ON, TET, TS, RFCI) 
750 (81, 243, 405) I al (I) PEN, ON, ERY, TET, TS, RF (I) 
800 (8\ , 324, 405) 6 d\ (6) PEN, ON, ERY, TET, TS, CIP, MU5 (4) 
PEN, ON, ERY, CHL, TET, TS, CIP, MU5 (2) 
800 (324, 405) 2 dl (2) PEN, ON, ERY, CHL, TET, TS, CIP, MUS (2) 
850 (81 , 324, 405) \ d2 (1) PEN, ON, ERY, TET, TS, CIP, MU5 (I) 
850 (324, 405) 1 d\ (1) PEN, ON, ERY, TET, TS, CIP, MU5 (I) 
800 (81 , \62, 486) 5 j!; (5) PEN, ON, ERY (5) 
850 (81 , \62, 486) \ j!; (I) PEN, ON, ERY (I) 
No product 1 al (1) PEN, ON, ERY, TET, TS, RF (I) 
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3.4 DISCUSSION 
Staphylococcus aureus has emerged over the past several decades as a leading 
cause of hospital- and community-acquired infections (Lowy, 1998). A significant 
component in the "success" of S. aureus has been its acquisition of antibiotic resistance 
factors (Chambers, 2001). As new antibiotics have come into use, S. aureus has 
responded soon after with resistant strains. This phenomenon has made therapy of 
staphylococcal diseases a global challenge. Resistance to methicillin was first described 
for S. aureus in 1960, shortly after the introduction of the drug in clinical practice 
(Jevons, 1961). Since then, methicillin-resistant S. aureus (MRS A) has become a widely 
recognized cause of morbidity and mortality throughout the world (Grubb, 1990). In view 
of this, considerable epidemiological interest in the tracking of strains has emerged in 
understanding the population and dynamics of clonal spread of MRS A in many health 
institutions (Crisostomo et al. , 2001). This study characterized MSSA and MRSA strains 
from Nigeria and South Africa using molecular epidemiological techniques in order to 
understand the clonal identities and diversity of S. aureus in both countries. Concordance 
between antimicrobial susceptibility patterns and the molecular typing methods was also 
investigated. 
The mechanisms by which S. aureus acquire resistance may be classified into two 
main categories: chromosomal gene mutation and acquisition of resistance genes as a 
result of conjugation, transduction and transformation. Arguably, the best understood 
mobile genetic elements are plasmids, which have been widely studied in S. aureus and 
MRS A since the 1970s (Meyers et al., 1976; McGowan et al. , 1979; Locksley et al. , 
1982; Coia et al. , 1988). Plasmid analysis, which is based on differentiating strains 
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according to the number and size of plasmids, was one of the first molecular techniques 
used for epidemiological investigations of MRS A (McGowan et at. , 1979). It is widely 
accepted that plasmid DNA may confer antibiotic resistance and therefore it might be 
assumed that multi-resistant MRSA strains would carry additional plasmids. Currently, it 
is suggested that more than 90% of MRS A strains carry plasmids while numerous studies 
have supported the important role plasmids play in staphylococcal multi-drug resistance 
(Lyon et at., 1983; Coia et at. , 1988; Morton et at., 1995; Paulsen et ai. , 1998; O'Brien et 
at. , 2002). 
Sixteen plasmid profiles were observed among the 60 MRSA strains studied from 
South Africa (Table 3.1). The presence of at least one large plasmid (approximately 26-
39kb), and one or more small plasmids (2.3-4.2kb) was noted in 40% of strains. In 
addition, 78.3% of strains carried at least one small plasmid ranging from 1.2-4.8kb. 
Although the demonstration of a high number of MRS A strains with plasmid DNA was 
not surprising, however, it differs from the report of Caddick et at. (2005) in which 
resistance determinants in multidrug-resistant MRSA isolates was not associated with 
plasmid carriage. In this study, all the strains in which plasmid DNA could not be 
obtained, were resistant to 3-6 classes of antibiotics, while 95.7% (45 of the 47) of 
MRSA strains that harboured at least a plasmid were resistant to six or more classes of 
antibiotics. 
Coagulase is produced by strains of S. aureus (Kloos and Scheifer, 1986). Its 
production is the principal criterion used in the clinical microbiology laboratory for the 
identification of S. aureus in human infections (Carter et at. , 2003). The coagulase gene 
has been a target for PCR genotyping in which size and DNA restriction endonuclease 
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site polymorphism within the eoa gene have been utilized for PCR restriction fragment 
length polymorphism (PCR-RFLP) analysis (Hookey et al. , 1998). The analysis of 
coagulase-encoding staphylococcal DNA genes have demonstrated variable sequences in 
the 3' -end coding region of allelic gene forms (Phonimdaeng et al. , 1990). DNA 
sequence analysis of the 3 ' -end of the coagulase gene revealed heterogeneity in the 
region containing the 81 bp tandem repeats coding repeated 27 -amino-acid-residue 
sequences of the coagulase C-terminal region. PCR amplification of this particular region 
produced DNA fragments of different sizes, which can be further discriminated by 
digestion with Alu1 (Goh et al. , 1992). Coagulase gene typing has been reported to be an 
attractive method for clinical laboratories because of its ease and speed, and has been 
widely used in genotyping of clinical S. aureus isolates (Goh et at. , 1992; Schwarzkopf 
and Karch, 1994; Tenover et at. , 1994; Kobayashi et at. , 1995; Lawrence et at. , 1996; 
Nada et at. , 1996; Hoefnagels-Schuermans et at., 1997; Hookey et at. , 1998; Wichelhaus 
et al. , 2001 ; Montesinos et at., 2002; Carter et al. , 2003). Furthermore, it is widely used 
for genotypic identification and differentiation of strains isolated from milk of bovine 
animals affected by mastitis (Aarestrup et at. , 1995; Fitzgerald et at. , 1997; Annemuller 
et at. , 1999; Raimundo et at., 1999; Schlegelova et at. , 2003; Scherrer et at., 2004; 
Katsuda et at., 2005). 
PCR of the coagulase gene yielded four and nine differently sized single PCR 
products ranging from 600 to 850bp to 480 to 950bp in MRSA and MSSA strains from 
South Africa respectively (Table 3.2). In addition, amplicons of 400, 750bp and 400, 
1000bp were identified in one and two MSSA strains respectively. Results of coagulase 
gene typing demonstrated that the MRSA and MSSA strains from South Africa were 
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classified into four and eleven RFLP patterns, respectively. However, two strains (one 
MSSA and MRSA) did not produce a coagulase gene-derived PCR product and was 
therefore considered as the twelfth group. The inability for a gene product to be obtained 
could be due to sequence variations at the sites targeted by the primers, as described by 
previous investigators (Hookey et al., 1998; Hookey et al., 1999; Montesinos et al., 
2002). A total of 67% of MRSA were classified into the subtype 3a, indicating that 
strains with this profile was predominant in health institutions in KwaZulu-Natal 
province of South Africa. In contrast, the MSSA strains were diverse and none of the 
RFLP patterns could be considered as a predominant group (Table 3.2). This finding is 
similar to previous studies by Goh et al. (1992) and Kobayashi et al. (1995). It also 
indicates that genomic variation was lower in MRS A than in MSSA strains. The ability 
of the PCR-RFLP of the coagulase gene to differentiate between MRSA and MSSA from 
South Africa was also observed (Table 3.2). The MSSA and MRSA strains did not share 
similar PCR-RFLP patterns in types 3, 7 and 8, while none of the MRSA strains were 
identified in types 1,2,4,6,9, 10 and 13. The RFLP patterns ofthe MRSA strains were 
unique and distinct from the MSSA strains, but two MSSA in subtype 5b shared similar 
PCR-RFLP patterns with one of the MRS A strains (Table 3.2). This trend (similar PCR-
RFLP patterns - subtype 5b) was also observed between MSSA and MRS A in Nigeria 
(Table 3.4). The ability of the PCR-RFLP to distinguish MSSA from MRSA strains has 
been reported by Lawrence et al. (1996), and offers an attractive option to be considered 
in the epidemiological analysis of S. aureus. 
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Of the 54 strains analyzed from Nigeria, eleven restriction fragment length 
polymorphism (RFLP) patterns were identified. A dominant RFLP pattern was noted 
among the MSSA strains (subtype 5b) and one of the MRSA shared the same pattern 
with MSSA in this group (Table 3.4). The level of concordance between antibiotyping 
and PCR-RFLP of the coagulase gene among strains with similar RFLP patterns, in both 
countries was low. Of the 37 and 51 strains from South Africa and Nigeria analyzed by 
PCR-RFLP of the coagulase gene, 14 and 29 strains exhibited similar PCR-RFLP 
patterns (Table 3.5). However, apart from strains in subtype 5a, which showed identical 
resistance profile, correlation between antibiogram and PCR-RFLP of the coagulase gene 
was low. Although one MRSA strain from Nigeria shared the same PCR-RFLP patterns 
with five MRSA strains from South Africa, they were assigned to different antibiotypes 
(XIII and XI) based on their susceptibility patterns. 
Schwarz and Cantor (1984) introduced the use of electric field pulsing techniques 
in conjuction with agarose gel electrophoresis for discrimination of large DNA 
molecules. PFGE, by far the most widespread molecular typing tool, is considered to be 
the method of choice for DNA fingerprinting of MRSA and other bacterial pathogens 
(Kaufmann, 1998). This study demonstrated that MRS A from South Africa belonged to 
eight types (a to h) as determined by PFGE (Tables 3.6 and 3.7). Moreover, the ability of 
clones to be transmitted over great distances was mainly observed in PFGE types a and b, 
which accounted for 62% of the total number of MRS A studied (Figure 3.1). Type a was 
identified in two hospitals in Durban, and one health institution in Pietermaritzburg, 
Newcastle, Greytown, Kokstad, Port Shepstone and Empangeni. Type b was noted in two 
health institutions in Durban and one in Pietermaritzburg, Kokstad, Eshowe, Scottburg 
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and Empangeni (Table 3.6; Figure 3.1). These findings indicate that inter-hospital spread 
ofPFGE types a and b occur frequently and regularly. Moreover, two to three band 
difference in the DNA patterns of the MRSA strains in the main PFGE types a and b was 
observed, indicating that these strains are closely related. These observations signify that 
there appears to be a major clone circulating in health institutions in KwaZulu-Natal 
province of South Africa. This is the first study, which has observed this trend, in this 
province. This development could be due to increased nosocomial transmission within 
and between hospitals and/or may be attributed to a virulence related property of these 
strains, which has not been determined. Previous studies in various parts of the world 
have shown that MRSA strains of identical or very similar clonal types have been 
recovered from hospitals separated by large geographic distances (Sanches et at. , 1995; 
Teixeira et at. , 1995; van Belkum et at. , 1997b; Aires de Sousa et at., 1998; Sa-Leao et 
at. , 1999; Coimbra et at. , 2000; Coimbra et at., 2003 ; Norazah et at., 2003; Preney et at. , 
2005). Epidemiological studies with different molecular typing techniques have also 
indicated that the massive geographical spread of MRS A results from the wide 
dissemination of a relatively small number of clones (Crisostomo et at., 2001 ; Enright et 
at., 2002; Oliveira et at., 2001 b; Stefani and Varaldo, 2003). 
Schmitz et at. (2000) suggested that the development of higher resistance rates to 
multiple antibiotics in MRSA is a consequence of the clonal spread of individual 
multiresistant strains. In this study, antibiotyping of MRS A from South Africa indicated 
that most of the strains (86.7%) were multiresistant (resistance to at least 4 classes of 
antibiotics) (Chapter Two). Apart from the non-multiresistant MRSA in subtypes bI , b3 
and g, multi-drug resistant MRS A were spread across the different pulsotypes and the 
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widely disseminated PFGE types a and b were resistant to at least five classes of 
antibiotics (Table 3.7). Although MRS A strains in type d were more resistant to a number 
of antibiotics (including low-level resistance to mupirocin) than other clones, 
dissemination of this clone was mainly observed in three of the four health facilities in 
Durban (Table 3.6 and 3.7; Figure 3.1). The multi-resistant nature of MRS A strains in the 
different pulsotypes identified and the dissemination of specific clones have clearly 
shown that adequate and effective infection control measures are urgently needed in 
health institutions in the KZN province, South Africa. 
Several authors have described the worldwide spread of MRSA clones. The 
Iberian clone was initially detected in an outbreak in the Bellvitge Hospital in Barcelona, 
Spain, in 1989 (Dominguez et al., 1994). Later, this clone was found to be widespread in 
at least eight Portuguese hospitals (Sanches et al., 1995; Aires de Sousa et al. , 1996; 
Sanches et al., 1996; Oliveira et al. , 1998), in addition to hospitals in Scotland, Italy, 
Belgium and Germany, and also in a hospital in New York City, USA (Mato et al. , 1998; 
Roberts et al. , 1998). Teixeira et al. (1995) first described the Brazilian epidemic clone to 
be widespread in Brazilian hospitals and also found to be disseminated in other countries 
in South America (Argentina, Paraguay and Chile) (Coimbra et al. , 2000) and in Europe 
(Portugal and the Czech Republic) (Aires de Sousa et al. , 1998; Oliveira et al. , 1998; 
Melter et al., 1999). Sa-Leao et al. (1999) described the intercontinental spread of 
another unique MRSA clone among pediatric patients in Portugal, Poland, Argentina, 
Colombia and New York. The Brazilian and Hungarian epidemic MRS A clones have 
been reported in Taiwan and China (Aires de Sousa et al. , 2003a), while the New 
Yorlc/Japanese clone initially verified in the USA (Coimbra et al. , 2003) has been 
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discovered in Brazil (Melo et ai. , 2004). The predominance of specific MRSA clones 
have also been described in Germany (Witte et ai. , 1997), Turkey (van Belkum et ai., 
1997a), Saudi Arabia (van Belkum et ai. , 1997b), Malaysia (Norazah et ai. , 2003), France 
(Preney et ai., 2005), Greece (Aires de Sousa et ai. , 2003b) and Poland (Leski et ai., 
1998). 
In this study, clonal relatedness between MRSA clones in South Africa and two 
worldwide epidemic clones EMRSA-15 and EMRSA-16 was investigated (Figure 3.34). 
There was no clonal relationship by PFGE analysis of selected MRSA strains from South 
Africa with the pandemic clones. However, comparison of banding patterns of one 
MRS A obtained in Hospital F, Ibadan, Nigeria (Chapter Two) revealed that it differed 
from EMRSA-15 by two to three bands, suggesting that they are closely related (Figure 
3.34; Lanes II and 13). EMRSA-15 is one of the most prevalent MRSA clones in 
hospitals in the United Kingdom and has been detected in northern Berlin, Germany, the 
Czech Republic and Spain (O'Neill et ai. , 2001; Witte et ai. , 2001 ; Moore and Lindsay, 
2002; Melter et ai. , 2003; Perez-Roth et ai. , 2004). Susceptibility patterns of the MRSA 
strain from Ibadan, Nigeria and EMRSA-15 were similar (resistance to erythromycin and 
ciprofloxacin). In addition, the strain was resistant to tetracycline. This appears to be the 
first report of the detection of an MRSA closely related to EMRSA -15 in Nigeria. In 
addition, MRSA in the main type al differed by two to three bands with one of the 
MRS A strains from Ile-Ife (THCD), indicating that these strains are related. This 
observation suggests that clonal dissemination of MRSA in type a is not restricted to 
South Africa. Epidemiological studies on the clonal relationship of MRS A in both 
countries would be useful and important in understanding this trend. 
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Assays for antibiotic sensitivity are routine standard procedures in all 
microbiology laboratories, and they represent a commonly used marker for MRS A 
phenotyping. Resistance markers have proved to be useful in identifying specific clones. 
The susceptibility of MRSA to trimethoprim-sulfamethoxazole and spectinomycin has 
proved to be useful in differentiating the Iberian and Brazilian clones (Aires de Sousa et 
ai., 1998). In addition, Norazah et ai. (2003) reported that resistance of MRS A to fusidic 
acid and rifampicin was unique in some strains in Malaysia. In this study, the dominant 
anti biotype was not helpful in discriminating between MRSA as it was detected in PFGE 
types a, b, c, f and h. However, resistance to ciprofloxacin and susceptibility to rifampicin 
was a unique character of the multi-resistant MRSA in type d (Table 3.7). Furthermore, 
all the strains assigned to type g (pFGE) had a unique antibiotype with 100% 
susceptibility to tetracycline and rifampicin (Table 3.7). These resistance markers could 
be useful in monitoring the spread of such clones and alert clinical microbiologists on the 
detection of new clones as and when they arise. 
DNA typing techniques have enabled molecular epidemiologists to discriminate 
bacterial strains belonging to the same species (Aires de Sousa et ai., 2001). The 
evaluation on the use of antibiotyping, PCR-RFLP of the coagulase gene and PFGE as 
typing tools in understanding the epidemiology of MRSA in South Africa was 
investigated. PFGE gave a wider spectrum of types and subtypes and the ability of this 
typing tool to define subclones allowed for greater discrimination among the MRSA 
strains. This was well demonstrated in the discrimination of MRSA in the dominant 
group 3a (PCR-RFLP of the coagulase gene) into six types (a, b, c, e, f and h) (Table 3.8). 
This observation agrees with previous reports that typing by PFGE provides higher 
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resolution, being able to distinguish subtypes not detected by any of the PCR-based 
procedures (Saulnier et al., 1993; Struelens et ai., 1993; Nada et al. , 1996; Hoefnagels-
Schuermans et al. , 1997; Kumari et al. , 1997; Vandenbergh et al. , 1999; Montesinos et 
al., 2002). 
Some degree of correlation between the two molecular typing methods was 
observed. A total of 18 of the 21 MRSA which belonged to PFGE type a and 16 of the 17 
MRS A in type b were identified in the dominant subtype 3a (PCR-RFLP of the coagulase 
gene), indicating that strains in these pulsotypes were genetically related. Furthermore, 
excellent correlation between antibiotyping, PCR-RFLP of the coagulase gene and PFGE 
was observed in identifying strains within type g. Only one strain in type g produced a 
differently sized amplicon by PCR detection of the coagulase gene, but the RFLP pattern 
was similar with the rest of the strains in the PFGE group. All the strains were grouped in 
antibiotype XI (Table 3.8; Chapter two). All the ten multi-drug resistant MRSA strains 
assigned in antibiotype groups I and II produced similar PCR-RFLP patterns indicating 
that they were closely related. PFGE typing revealed that these strains belonged to a 
unique type d. Although this study agrees with previous investigators that PFGE is a 
valuable tool for MRSA typing because of its high discrimatory power (Provost et al. , 
1992; Struelens et al., 1992; Schlichting et al. , 1993; Struelens et al. , 1993; Tenover et 
al., 1994; Nada et al., 1996; Na'was et al., 1998; Schmitz et al. , 1998; Olive and Bean, 
1999; Montesinos et al. , 2002), however, the combination ofPFGE, PCR-RFLP of the 
coagulase gene and antibiotyping provided useful and important information in 
understanding the epidemiology of MRSA in Nigeria and South Africa. 
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3.5 CONCLUSION 
The surveillance, investigation and control of health care-associated infections are 
hinged to a large extent on the clinical microbiology laboratory. The multiple roles that 
the microbiology laboratory play include accurate detection, species identification and 
susceptibility testing of microorganisms; epidemiologic analysis of clinical and screening 
test results; targeted microbiological surveys of the hospital environment; and 
epidemiologic typing of microbial isolates to support outbreak investigations (Struelens 
et ai. , 2004). The characterization of S. aureus strains from Nigeria and South Africa 
using epidemiological tools has provided useful data on the clonal identities and diversity 
of S. aureus in both countries. It also provided baseline information on the extent and 
geographic expansion of MRSA clones. The identification and establishment of some 
widely disseminated clones in health institutions in KwaZulu-Natal province of South 
Africa, the genetic relatedness of one MRSA from Nigeria and strains in the widely 
disseminated clone a in South Africa, and the clonal relatedness of one MRSA from 
Nigeria with EMRSA-15 indicate that urgent measures are needed in curtailing the spread 
and establishment of these clones in both countries. 
MRS A is usually transmitted by direct contact, therefore preventing contact 
between infected patients and potential carriers is a principal means of preventing its 
spread (Dent and Dent, 2005). It is also imperative to ensure that antibiotics are used 
prudently to minimize the emergence of resistance, and to discourage the spread of 
MRSA to patients unnecessarily treated with certain antibiotics. Compliance with 
infection control measures is even more important. These include screening policies, 
effective hand hygiene and appropriate isolation measures (Cookson, 2005). The "search 
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and destroy" policy has been effective in reducing the MRSA incidence rate in the 
Netherlands (Verhoef et at. , 1999). This involves strict antibiotic policy and quarantine of 
patients until MRS A cultures are negative and screening of all patients and health care 
workers once a patient is found to carry MRSA. In addition, a national registration 
system of MRSA patients and of hospitals experiencing an MRSA outbreak could be 
useful adjuncts. This would ensure that patients colonized with MRSA and those who are 
transferred from a hospital with an MRS A outbreak are tagged, traced and control 
measures initiated as appropriate. 
Although it has not been possible to elucidate why some clones spread rapidly 
than others, future studies would be important to investigate the genetic relationship of 
clones in both countries with other pandemic MRSA clones in order to ascertain if these 
clones were unique and specific to Nigeria and South Africa. There is also the need for 
more comparative studies on the molecular epidemiology of MRSA in both countries, 
and closer international collaboration to monitor the spread of current epidemic strains 
and the emergence of new ones. 
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CHAPTER FOUR 
CHARACTERIZATION OF MUPIROCIN RESISTANT Staphylococcus aureus 
STRAINS IN SOUTHWESTERN NIGERIA AND KW AZULU-NATAL 
PROVINCE OF SOUTH AFRICA 
4.1 INTRODUCTION 
In 1971, pseudomonic acid A was isolated as a metabolite of Pseudomonas 
fluorescens and shown to have antibacterial activity (Fuller et ai., 1971). The name was later 
changed by consensus to mupirocin to avoid any suggestion that it had anti-pseudomonal 
effect. The spectrum of antibacterial activity includes most Gram-positive and a few Gram-
negative bacteria such as Haemophilus and Neisseria (Thomas et ai., 1999). 
Enterobacteriaceae are intrinsically resistant due to a permeability barrier (Al-Masaudi et ai. , 
1988), and clinical application is, however, directed principally at Gram-positive cocci 
(Slocombe and Perry, 1991). It is an antibacterial agent with a unique action, binding 
competitively to bacterial isoleucyl-tRNA synthetase (IRS) and thus, by preventing the 
incorporation of isoleucine into growing polypeptide chains, arrests protein synthesis 
(Huges and Mellow, 1980; Morton et al. , 1995; Yao and Moellering, 1999). The antibiotic 
undergoes rapid breakdown in the tissues and can only be used topically. Mupirocin was 
first marketed for clinical use in the United Kingdom (UK) in 1985 and in the United States 
in 1988 (Mehtar, 1998) and is now available in more than 90 countries (Kresken et ai., 
2004). It has potent activity against staphylococci and is used for the treatment of skin and 
postoperative wound infections and the prevention of nasal carriage of methicillin-resistant 
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Staphylococcus aureus (MRSA) (Cookson, 1998). Reports of resistance in different parts of 
the world emerged with the widespread use ofmupirocin. Rahman et al. (1987) reported 
the first case of high-level resistance to mupirocin in methicillin-susceptible S. aureus. 
Subsequently, reports of mupirocin resistance have been described in Australia (Riley et al. , 
1994; Udo et al., 1994), Brazil (Bastos et al. , 1999; Ramos et aI. , 1999), Canada (Miller et 
aI. , 1996), Greece (Maniatis et al. , 2001 ; Petinaki et al. , 2004), Korea (Yun et al. , 2004), 
Kuwait (Udo et aI. , 1999; Udo et al. , 2001a; Udo et al. , 2001b; Udo et aI. , 2003), Malaysia 
(Norazah et al., 2001), New Zealand (Hefferman et al. , 1995; Skellen et al., 1998), Poland 
(Leski et al. , 1999), Saudi Arabia (Rich et al. , 1999), Spain (Alarcon et al., 1998; Perez-
Roth et al. , 2002; Chaves et al. , 2004), United Kingdom (Wise and Johnson, 1991; Connolly 
et al. , 1993), and the United States (Janssen et al. , 1993; Bradley et al., 1995; Ramsey et al. , 
1998; Jones et al. , 2003). 
Mupirocin resistance in staphylococci is divided into two groups: low- and high-
level resistance (MICs 8-256 and >256mgll) respectively (Cookson, 1998). In most cases, 
low-level resistance to mupirocin is related to alteration in the host IRS (Farmer et al., 1992; 
Antonio et al. , 2002). Until recently, chromosomal mupirocin resistance was considered 
clinically unimportant (Cookson, 1998; Henkel and Finlay, 1999). However, low-level 
mupirocin resistance appears to be more prevalent in clinical isolates than high-level 
resistance (Alarcon et al., 1998; Schmitz et al., 1998; Deshpande et al., 2002; Fujimura and 
Watanabe, 2003). Moreover, the emergence oflow-Ievel mupirocin resistance is thought to 
increase failure rates for nasal decolonization of MRS A (Harbath et al., 2000; Watanabe et 
ai. , 2001a; Decousser et ai., 2003). 
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The origin of high-level mupirocin resistance (mupH) is still a matter of speculation. 
Interestingly, it has been described in stored isolates, namely three high-level mupirocin 
resistant isolates of S. aureus and S. epidermidis from Nigeria in 1956 (Cookson, 1994), and 
a coagulase negative staphylococcal isolate from the UK in 1967 (Cookson, 1998), even 
before mupirocin was used clinically. High-level mupirocin resistant strains cannot be 
eradicated with mupirocin and constitute a serious clinical problem especially when they are 
resistant to methicillin (Perez-Roth et ai., 2002). The clinical isolates exhibiting high-level 
resistance to mupirocin contain two distinct IRS enzymes: the endogenous IRS and an 
additional IRS encoded by the ileS-2 gene (Morton et ai. , 1995). This additional enzyme is 
usually encoded by the mupA gene, which is carried on plasmids that vary in size, restriction 
patterns and their ability to be transferred in conjugation experiments (Rahman et ai. , 1990; 
Needlam et ai., 1994; Udo et ai., 1994; Morton et ai. , 1995; Udo et ai. , 1998). However, the 
mupA gene has also been reported in the genomic DNA of a few S. aureus isolates 
expressing low-level resistance, suggesting that the mupA gene may also be located in the 
chromosome (Ramsey et ai. , 1996; Fujimura et ai. , 2001). The first report on the 
chromosomal location of the mupA gene in S. aureus expressing high-level mupirocin 
resistance has also been described (Udo et ai. , 2003). The mupA gene, which has been 
cloned and sequenced, showed a low degree of homology with the staphylococcal ileS gene 
(Dyke et at. , 1991; Hodgson et at. , 1994). The deduced amino acid sequence indicated 
homology to the isoleucyl tRNA synthetase of Escherichia coli (Webster et ai. , 1984; Dyke 
et at., 1991), suggesting that mupirocin resistance might be the result of a modified isoleucyl 
tRNA synthetase. 
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Although several investigations have been conducted on mupirocin resistance 
among S. aureus strains in different parts of the world, there is no data on the 
characterization, genetic relatedness and clonal dissemination of mupirocin-resistant S. 
aureus in Nigeria and South Africa using phenotypic and molecular techniques. 
Characterization of strains in this study was determined by antibiotyping, resistotypng, 
PCR-RFLP of the coagulase gene and PFGE. Furthermore, the genetic location ofmupH 
resistance and the ability to transfer the resistance determinant was determined by 
plasmid analysis, curing and conjugation experiments. 
4.2 MATERIALS AND METHODS 
The S. aureus isolates resistant to mupirocin based on the disk diffusion technique, 
their MIC values (E-test) and detection of the mupA gene by PCR were investigated (See 
Chapter Two). The protocol for genetic characterization (Plasmid DNA isolation, PCR-
RFLP of the coagulase gene, PFGE typing) of strains was performed as described in 
Chapter three. 
The banding patterns were interpreted visually and the relatedness of the strains 
was determined according to the recommendation of Tenover et al. (1995). In addition, 
the GelCompar II software version 4.0 (Applied Maths, Sint-Martens-Latem, Belgium) 
was used to calculate the Dice similarity indices and to perform a dendogram after cluster 
analysis by unweighted-pair-group-matching-analysis (UPGMA). Band position 
tolerance and optimization were set at 2%. By definition, two isolates belonged to the 
same cluster if their Dice similarity index is 85% or more. DNA fragments below 80kb 
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were not included in the analysis. Strains showing the same PFGE pattern were grouped 
in a pulsotype as described in Chapter three. 
Two mupH strains (35IBA - Nigeria; RKK6 - South Africa) were selected for 
subsequent investigations involving curing and conjugation experiments. The resistance 
profiles of these strains are presented in Table 4.1. 
4.2.1 Curing of resistance determinants on plasmids 
The loss of resistance determinants (plasmids) was investigated according to the 
protocol ofUdo et al. (2001b). The two strains were checked for purity, streaked on 
Brain Heart Infusion Agar (BHIA), and incubated at 43°C for 24 hours. Sub-culturing 
onto a freshly prepared BHIA was repeated twice after 24 hours of incubation. Serial 
dilutions of the cured strain was plated on BHIA plates, and incubated at 37°C for 24 and 
48 hours. 
4.2.2 Preparation of selection plates and replica plating 
Selection plates containing BHIA with mupirocin (lOJlg/ml) was set up for strain 
35IBA, while BHIA plates with erythromycin (5Jlg/ml) and mupirocin (10 Jlg/ml) was 
prepared for RKK6. Single colonies were screened for loss of resistance by the replica 
plating method. Colonies, which grew on the primary plate but did not grow on the 
selection plates, were noted and susceptibility testing of these colonies was performed in 
order to confirm loss of resistance. Colonies that lost antimicrobial resistance were 
screened by plasmid analysis for the presence or absence of the resistance determinants. 
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4.2.3 Conjugation Experiments 
Plasmid transfer by conjugation was performed according to the protocol ofUdo 
et al. (2001b). Strains 35IBA (Nigeria) and RKK6 (South Africa) served as donor strains, 
while WBG 541 (Townsend et ai. , 1985) (resistant to fusidic acid and rifampicin), was 
the recipient strain. A 2ml volume of an overnight broth culture of the donor, recipient 
strains and mixture of the donor and recipient strains (2ml each) was dispensed into 
sterile universal bottles. The culture was then pelleted by centrifugation (2000rpm for 10 
minutes), the supernatant discarded and 4ml of 40% polyethylene glycol (PEG) was 
added to each bottle and incubated (with gentle shaking) at 37°C overnight in a water 
bath. This was followed by centrifugation at 2000rpm for 10 minutes; 1 ml of sterile Brain 
Heart Infusion Broth (BHIB) was added to each universal bottle, and vortexed gently to 
re-suspend the bacterial culture. Serial dilutions (undiluted, 10-1, 10-2, 10-3) of the mixture 
(donor and recipient strains) and undiluted culture of the donor and the recipient strains 
(control experiments) were plated onto BHIA containing appropriate antibacterial agents, 
and incubated at 37°C for 18-24 hours. Transfer was considered to have occurred when 
growth was observed on the selection plates from donor-recipient mixtures and not from 
the control experiments. Based on their resistance profiles, transcipients were screened on 
BHIA plates containing mupirocin (1 o Jlg/ml) , and fusidic acid (5Jlg/ml); erythromycin 
(5Jlg/ml) and fusidic acid (5Jlg/ml) for the experiment involving strain RKK6; mupirocin 
(lOJlg/ml) and fusidic acid (5Jlg/ml); tetracycline (5Jlg/ml) and fusidic acid (5Jlg/ml) for 
strain 35IBA. Single colonies of trans con jug ants were screened on BHIA containing 
appropriate antibiotics by the replica plating method. Sensitivity testing with selected 
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antibiotics was performed on transcipients and transfer frequency was expressed as the 
number of transconjugants per number of donor cells. 
4.2.4 Partial DNA sequencing and analysis of the i/eS-2 gene 
The PCR products obtained in the detection of the mupA gene (as described in 
Chapter Two) were purified using the High Pure PCR purification kit (Roche, USA) 
according to the manufacturer's instructions. Partial DNA sequencing was performed 
using the forward primer sequence: mupA-1: TGA CAA TAG AAA AGG ACA GG, 
which amplified a 190bp segment of the mupA gene. Automated sequencing was 
performed using the Spectrumedix SCE2410 genetic analysis system with the BigDye-
Deoxy Terminator Cycle Sequencing kit (Applied Biosystems). All reactions were 
performed according to the manufacturer's instructions. Chromatograms were analysed 
and edited using Chromas (version 2.3). An alignment of the DNA sequences was carried 
out by the ClustalX program (Thompson et af., 1997) based on the nucleotide sequence 
of the i/eS-2 gene in S. aureus J2870 (Hodgson et aI., 1994) submitted to the Gene Bank 
(Accession number X75439). 
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4.3 RESULTS 
4.3.1 Antibiogram of low and high-level mupirocin resistant S. aureus strains 
The results of the disk susceptibility testing with mupirocin disks (5 and 200 ~g/ml) 
revealed that 14 isolates from six health institutions in South Africa expressed low-level 
resistance to mupirocin. These included 11 strains from wound samples and one strain each 
from blood, urine specimens and endotracheal aspirate. Low-level mupirocin resistance was 
confirmed by E-test, with MICs values between 8 and 24~g/ml. Five strains had MICs of 
12~g/ml, four with MICs of 8 and 24~g/ml respectively and one strain had an MIC of 
16~g/ml (Table 4.1). 
The antibiotypes of the mupirocin-resistant strains based on their resistance pattern 
to antibiotics representing various groups of antibacterial agents are presented in Table 4.1. 
All the low-level mupirocin resistant strains were MRSA with 100% resistance to 
gentamicin, tetracycline and trimethoprim. A total of twelve strains were resistant to 
erythromycin, ten to ciprofloxacin and four to rifampicin and chloramphenicol respectively. 
Resistotyping revealed that six low-level mupirocinlmethicillin resistant strains exhibited 
resistance to cadmium acetate, propamidine isethionate, mercuric chloride and ethidium 
bromide, four to mercuric chloride, two to cadmium acetate and mercuric chloride, and one 
to cadmium acetate. One strain was susceptible to the heavy metals and nucleic-acid binding 
compounds. The mupA gene was not detected in the low-level strains. High-level mupirocin 
resistance was detected in two strains (one MSSA and one MRS A) from South Africa and 
one MSSA strain from Nigeria. This resistance phenotype was confirmed by E-test 
(> 1 024~g/ml), and detection of the mupA gene by PCR (Table 4.1 ; Figure in Appendix). 
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The methicillinlmupirocin resistant strain from South Africa was obtained from a wound 
culture while the mupirocin resistant strain from Nigeria was recovered from a blood 
culture. Information on the methicillin-susceptible mupirocin-resistant strain from South 
Africa was not available. 
4.3.2 Genotyping (PCR-RFLP of the coagulase gene, PFGE) of low and high-level 
mupirocin resistant S. aureus strains 
The PCR-RFLP analysis of the coagulase gene is presented in Tables 4.1 and 
Figures 4.1 and 4.2. PCR amplification of the coagulase gene revealed a single amplicon 
of 650bp, 800bp and 850bp among the low-level mupirocin-resistant strains. RFLP 
patterns of two fragments of 81 bp, 567bp were observed in four strains, of 325bp, 405bp 
in three strains, and of 81 bp, 324bp, 405bp in seven strains. The sizes ofthe PCR 
products for the high-level mupirocin-resistant strains were 650, 750 and 800bp 
respectively and three RFLP patterns (81 bp, 567bp; 243bp, 486bp and 81 bp, 162bp, 
567bp) were identified. 
The methicillinllow-Ievel mupirocin resistant strains were grouped based on the 
PFGE types as described in Chapter three. Two main PFGE patterns, designated types b 
and d were identified among the low-level mupirocin resistant strains (Figure 4.3). The 
PFGE types included subtype dl with nine strains; subtype b4 with three strains and one 
strain in subtypes bl and d2 (Table 4.1). The high level mupirocin-resistant strains were 
grouped into three PFGE patterns (a3 , k and il) (Table 4.1 ; Figure 4.4). DNA patterns of 
the methicillinlmupH resistant MRSA strain revealed that it differed by two to three 



















b4, indicating that these strains are closely related. A three-band difference was also 
observed between one of the MRSA (strain 15) and the high-level mupirocin MSSA 
strain (35IBA) from Nigeria (Figure 4.4; Lanes 3 and 8). 
Table 4.1: Characterization (antibiogram, PCR-RFLP ofthe coagulase gene and PFGE) 
of low and high-level mupirocin resistant S. aureus from Nigeria and South 
Africa 
Resistance pattern (Antibiogram and Resistotyping) mupA MIC Molecular RFLP (bp) 
gene E-test weight 
(J.1g/ml) (± 20bp) 
PEN, OX, ON, TET, TS, RF, MU (L), Cad, Hg - 24 650 81 , 567 
PEN, OX, ON, TET, TS, RF, MU (L) - 24 650 81 , 567 
PEN, OX, ON, ERY, TET, TS, RF, MU (L), Cad - 24 650 81 , 567 
PEN, OX, ON, ERY, TET, TS, RF, MU (L), Cad, Hg - 24 650 81 , 567 
PEN, OX, ON, ERY, TET, TS, CIP, MU (L), Cad, Pi, Hg, Eb - 8 800 81 , 324, 405 
PEN, OX, ON, ERY, TET, TS, CIP, MU (L), Cad, Pi, Hg, Eb - 8 800 81 , 324, 405 
PEN, OX, ON, ERY, TET, TS, CW, MU (L), Cad, Pi, Hg, Eb - 12 800 81 , 324, 405 
PEN, OX, ON, ERY, CHL, TET, TS, CW, MU (L), Cad, Pi, Hg, Eb - 8 800 81 , 324, 405 
PEN, OX, ON, ERY, CHL, TET, TS, CIP, MU (L), Hg - 12 800 81 , 324, 405 
PEN, OX, ON, ERY, TET, TS, CIP, MU (L), Hg - 12 850 81 , 324, 405 
PEN, OX, ON, ERY, CHL, TET, TS, CIP, MU (L), Hg - 12 800 324, 405 
PEN, OX, ON, ERY, TET, TS, CIP, MU (L), Cad, Pi, Hg, Eb - 16 850 324, 405 
PEN, OX, ON, ERY, CHL, TET, TS, CW, MU (L), Cad, Pi, Hg, Eb - 12 800 324, 405 
PEN, OX, ON, ERY, TET, TS, CIP, MU (L), Hg - 8 800 81 , 324, 405 
PEN, OX, ON, ERY, TET, TS, RF, MU (H), Cad + >1024 650 81 , 567 
TM, TET, MU (H) + >1024 750 243, 486 
35 IBA** TET, MU (H) + >1024 800 81 , 162, 567 
·Stram not screened for resIstance to heavy metals and nucleIc aCId bmdmg compounds 
··Strain from Nigeria 
PEN - Penicillin (p-Iactams) 
OX - Oxacillin (p-Iactams) 
GN - Gentamicin (aminoglycoside) 
ERY - Erythromycin (macrolide) 
CHL - Chloramphenicol (phenicols) 
MU (L) - Low-level mupirocin resistance 
TS - Trirnethoprirn (sulphonamides) 
RF - Rifamipicin (ansamycins) 
CIP - Ciprofloxacin (fluoroquinolones) 
TET - Tetracycline (tetracyclines) 
MU (H) - High-level mupirocin resistance 
Heavy metals - Cad: Cadmium acetate; Hg: Mercuric chloride 












































PCR detection of the coagulase gene in mupirocin-resistant strains. Lanes 2 and 3: 
negative and positive controls. Lanes 4-17: Low-level mupirocin (mupL) resistant MRSA 
strains: AD28, AD79, AD87, AD98, 510, 513, ESH34, GPII , KEHI2, KEH 26, RKK8, 
RKK55, RKK56, RKK57. Lanes 19-21: High-level mupirocin (mupH) resistant strains: 
RKK6, PI929 (South Africa), 35IBA (Nigeria). Lanes I and 22 are molecular weight 
markers. 









PCR-RFLP of the coagulase gene in mupirocin resistant strains. Lanes 2-15: mupL 
strains: AD28, AD79, AD87, AD98, 510, 513, ESH34, GPII, KEH12, KEH26, RKK8, 
RKK55, RKK56, RKK57. Lanes 17-19: mupH strains: RKK6, P1929 (South Africa), 















PFGE patterns oflow-Ievel mupirocin-resistant strains. Lanes 1-14: AD28, AD79, AD87, 
AD98, 510, 513, ESH 34, GPII, KEHl2, KEH26, R.KK8, R.KK55, R.KK56, RKK57. 
Lane 15: Molecular weight standard S. aureus NCTC 8325. 
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PFGE profiles of MRS AI High-level mupirocin resistant strains from Nigeria and South 
Africa. Lanes 1,6,9 and 10: S. aureus NCTC 8325; Lane 2: THCD; Lane 3: 15; Lane 4: 
28IDA; Lane 5: R.KK6 (high-level mupirocin resistant strain); Lane 7: PI929 (high-level 
mupirocin resistant strain); Lane 8: 35IBA (high-level mupirocin resistant strain). 
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4.3.3 Curing experiment 
To isolate the plasmids and determine the location of resistance determinants, two 
high-level mupirocin resistant strains - 35IBA (Nigeria) and RKK6 (South Africa) were 
selected and used in curing and conjugation experiments. In the curing experiment, six of 
the 293 colonies (2.0%) screened for strain 35IBA were found to have lost resistance to 
mupirocin but exhibited resistance to tetracycline. Plasmid analysis indicated that this 
was accompanied by the loss of approximately a 33-kb plasmid in the colonies screened 
by agarose gel electrophoresis (Figure 4.5). Of the 294 colonies screened on mupirocin 
and erythromycin selection plates for strain RKK6, loss of resistance to erythromycin and 
mupirocin was observed in three and six colonies respectively. Erythromycin and 
mupirocin resistance in the cured strains of RKK6 was lost together with a plasmid of 
approximately 2.3-kb and 37-kb respectively (Figure 4.5). Identical PFGE profiles were 
observed in the parent and cured strains, indicating that the mupA gene was not located 
on the chromosome of the two strains studied (Figure 4.6). 
4.3.4 Conjugation experiment 
No transconjugant was obtained on selection plates for strain 35IBA by the 
polyethylene glycol method. However, 120 colonies were identified from donor-recipient 
mixtures on BHIA plates containing mupirocin (lOJ.lg/ml), and fusidic acid (5J.lg/ml) for 
strain RKK6. In addition, two colonies were noted from donor-recipient mixtures on the 
selection plates containing erythromycin (5J.lg/ml) and fusidic acid (5J.lg/ml). Replica 
plating of98 colonies (transconjugants) on BHIA selection plates containing cadmium 
(5J.lg/ml), erythromycin (5J.lg/ml) and mupirocin (lOJ.lg/ml) yielded one, three and 98 
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colonies respectively. Susceptibility pattern of the parent and cured strains along with the 
transconjugants are presented in Table 4.2. The transfer frequency was calculated as 1.2 x 
10-5 and 2 x 10-8 for mupirocin and erythromycin resistance determinants respectively. 
Susceptibility testing oftranscipients and plasmid analysis indicated that 
transconjugants resistant only to mupirocin carried a plasmid of approximately 37kb 
(Figure 4.7). However, seven fragments (12.6, 10.9,6.3,4.8,2.5,2.3 and 1.7kb) were 
obtained in the transconjugant (transMup) with the mupirocin plasmid by EeaRl 
restriction analysis, indicating that the size of the mupirocin plasmid was 41.1kb (Figure 
4.8). A total of nine fragments (17.3, 12.6, 10.9,6.3,4.8,2.7,2.5,2.3, 1.7 kb) were 
obtained from restriction analysis of the transconjugant with the plasmids associated with 
resistance to mupirocin and cadmium (transCad). Apart from the seven fragments that 
were common to the two transconjugants, two fragments of 17.3 and 2.7kb were 
identified in transCad, indicating that the size of the cadmium plasmid is about 20-kb 
(Figure 4.8). Furthermore, transcipients exhibiting resistance to erythromycin carried a 
2.3-kb plasmid (Figure 4.5). 
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Table 4.2: Susceptibility profile of parent, cured, recipient strains and 
transconjugants derived from strain RKK6. 
Isolate Resistance pattern MIC mupA 
E-test gene 
(llglm1) 
35 IBA (parent) TetK MUpK >1024 + 
35 IBA (yellow) - cured strain Te~ ND -
RKK 6 (parent) OxK, EtY, CdKJ, RpK, Te~, MUpK >1024 + 
RKK 6c A (cured strain ofRKK6) OxK, RpK, TetK, MUpK >1024 + 
RKK 6 c D (cured strain of RKK6) OxK, EryK, CdKJ, RpK ND -
Trans Mup (transconjugant ofRKK6) Rp", Fc'" Mup" >1024 + 
Trans Ery (transconjugant of RKK6) Ery", CdKJ , Rp", FcK ND -
Trans Cad (transconjugant of RKK6) Rp", Fc", CadK, MUpK >1024 + 
WBG 541 (recipient strain) Rp", FcK ND -
Tet ~ Tetracycline; Mup - Mupirocin; Ox - Oxacillin; Ery - Erythromycin; 
CdRi - Clindamycin (inducible resistance); Rp - Rifampicin; Fc - Fusidic acid; Cad - Cadmium 
The superscript R represents resistance. 














Plasmid profile of parent, cured strains and transconjugants: Only closed circular (CCC) 
DNA are labelled. Lanes 1 and 5: WBG 4483; Lanes 2-4: High level mupirocin strains 
Lane 2 - RKK6 (South Africa), Lane 3 - 35IBA (Nigeria), Lane 4 - PI929 (South Africa); 
Lane 6: RKK6 parent strain; Lane 7 - RKK6cA (cured strain ofRKK6 - resistant to 
mupirocin, susceptible to erythromycin); Lane 8 - RKK6cD (cured strain ofRKK6-
susceptible to mupirocin, resistant to erythromycin); Lane 9 - 35IBA parent; Lane 10 -
35IBA yellow - cured strain of 35IBA (susceptible to mupirocin, resistant to 
tetracycline); Lane 11 - Trans (Mup) - transconjugant ofRKK6 (resistant to mupirocin 
only); Lane 12 - Trans (Cad) transconjugant ofRKK6 (resistant to mupirocin and 











3 4 5 6 
PFGE patterns of high-level mupirocin resistant strains - parent and cured strains. Lane I: 
S. aureus NCTC 8325; Lane 2: RKK6 (parent strain); Lane 3 - RKK6cA (cured strain of 
RKK6 - resistant to mupirocin, susceptible to erythromycin); Lane 4 - RKK6cD (cured 
strain ofRKK6 - susceptible to mupirocin, resistant to erythromycin); Lane 5 - 35IBA 
parent strain; Lane 6 - 35IBA yellow - cured strain of35IBA (susceptible to mupirocin, 











Plasmid profile of trans con jug ants derived from the methicillinlmupirocin resistant S. 
aureus (strain RKK6) from South Africa. Lane 1 - WBG 4483 (only the closed circular 
forms of the plasmids are labelled); Lane 2 - Trans (Mup) - transconjugant ofRKK6 
(resistant to mupirocin only); Lane 3 - Trans (Cad) transconjugant ofRKK6 (resistant to 






















EcoRI restriction analysis of trans con jug ants derived from the methicillinimupirocin 
resistant S. aureus strain from South Africa. Lane 1 - Molecular weight standard, phage 
lambda DNA digested with HindIII; Lane 2 - Trans (Mup) - transconjugant ofRKK6 
(resistant to mupirocin only); Lane 3 - Trans (Cad) transconjugant ofRKK6 (resistant to 
mupirocin and cadmium). 
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4.3.5 Partial DNA sequence analysis of the ileS-2 gene 
The alignment of partial DNA sequences of the i/eS-2 gene in S. aureus J2870, 
the high-level mupirocin-resistant S. aureus strains and one of the transconjugants 
(transMup) obtained in this study is presented in Figure 4.9. The analysis indicated that 
the i/eS-2 gene of S. aureus strains from South Africa and the transconjugant was 
identical to that of S. aureus J2890. However, two base substitutions (nucleotide 
positions 641 Ato c; 671 AtoT) were observed in the MSSA strain 35IBA from Nigeria. The 
first base substitution (nucleotide positions 641 Atoc; AAG to CAG) did not lead to a 
change in the amino acid arginine. However, the second base substitution (671 AtoT; ATT 
to TTT) indicated a change in the amino acid sequence of the i/eS-2 gene in S. aureus 
































* Partial DNA sequence of the i/eS-2 gene of S. aureus J2890 
Figure 4.9: Alignment of DNA sequences of the ileS-2 gene in S. aureus J2870 (nucleotide positions 
590 t0735) and the high-level mupirocin-resistant S. aureus strains and transconjugant 
obtained in this study. The nucleotide sequence coloured black indicate regions of base 
substitutions in strain 35IBA from Nigeria. 
Mup gene 
G P P T A N G L P H A G H V L G R V I K D L V A R K T Met Q G F 
Y V E R K A G W D T H G L P 
RKK 6 
G P P T A N G L P H A G H V L G R V I K D L V A R K T Met Q G F 
Y V E R K A G W D T H G L P 
35IBA 
G P P T 
Y V E R 
Figure 4.10: 
A N G L P H A G H V L G R V I K D L V A R K T Met Q G F 
K A G W D T H G L P 
Amino acid sequences of the gene products (nucleotide positions 595 to 730). The amino 
acid sequence coloured black indicate change in amino acid from leucine (ileS-2 gene in 
S. aureus J2870 and RKK6) to phenylalanine in strain 35IBA (Nigeria). 
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4.4 DISCUSSION 
This study investigated the emergence and characterization of low and high-level 
mupirocin resistant S. aureus strains in Nigeria and South Africa, using phenotypic and 
molecular methods. Clinical isolates of mupirocin-resistant S. aureus was reported in 1987 
(Rahman et ai. , 1987), and resistance has frequently been attributed to the clinical use of 
mupirocin over extended periods (Udo et al. , 1998) or in areas of highly concentrated 
application, such as dermatology or burns units (Eltringham, 1997; Poupard, 1995). In this 
study, a total of 17 strains were resistant to mupirocin and 16 (94%) of these strains were 
obtained from South Africa (Table 4.1). The low-level resistant strains were MRSA and 
recovered from six health institutions in the KwaZulu-Natal (KZN) province of South 
Africa. Mupirocin is prescribed and administered in the treatment of MRSA infections and 
S. aureus nasal colonization among hospital patients in KZN in South Africa, and it appears 
that selective pressure of mupirocin use could have contributed to what appears to be an 
emerging trend. The reports on the increase in failure rates for nasal decolonization of 
MRSA due to the emergence of low-level mupirocin resistance (Harbath et al. , 2000; 
Watanabe et al. , 2001a; Decousser et ai. , 2003) should be of serious concern as no low-level 
mupirocin resistance MRSA had previously been reported in the KZN province in South 
Africa. However, the low-level mupirocin resistant MRSA were susceptible to teicoplanin, 
vancomycin, fusidic acid, linezolid, fosfomycin, and quinipristin-dalfopristin (Chapter 
Two). 
S. aureus strains exhibiting high-level mupirocin resistance were detected in both 
countries. They consisted of a MSSA and one MRSA in Hospitals B and C in Durban, 
South Africa, and one MSSA from Hospital F, Ibadan, Nigeria (Chapter Two: Table 2.1; 
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Table 4.1). An important finding is that mupirocin is not prescribed or administered in the 
hospital in Ibadan, Nigeria, where the high-level strain was obtained. Data exists that high-
level mupirocin resistant isolates of S. aureus and S. epidermidis have been isolated in 
Nigeria as early as 1956 (Cookson, 1994), before the introduction ofmupirocin in clinical 
practice. Other workers have also reported mupirocin resistant S. aureus without any 
apparent exposure to the agent (Cookson et al. , 1990; Hefferman et al., 1995). This could be 
due to the fact that mupirocin is a natural product to which microorganisms have 
presumably been exposed in nature (Chatfield et aI., 1994). Although the high-level 
mupirocin-resistant strains were present in low numbers, they were not detected prior to this 
study because susceptibility testing for mupirocin resistance was not performed in hospitals 
in both countries. Few data are available on mupirocin resistance in MSSA isolates (Leski et 
al., 1999; Jones et ai., 2003; Yun et ai., 2004; Chaves et ai., 2004; Kresken et aI., 2004; 
Petinaki et ai., 2004). However, the isolation ofMSSA resistant to mupirocin indicates that 
MSSA should also be routinely tested for mupirocin resistance in both countries. This is to 
allow for early detection of resistant isolates and to facilitate the early institution of infection 
control measures. 
Characterization of the mupirocin-resistant strains was determined using 
antibiogram, PCR-RFLP of the coagulase gene and PFGE. PCR of the coagulase gene in 
low-level mupirocin resistant strains revealed that the dominant type (10 of 14 low-level 
mupirocin resistant strains) produced a single amplicon of 800 or 850bp with similar RFLP 
patterns (Table 4.1; Figures 4.1 and 4.2). Two main PFGE types (b and d) were identified 
in the low-level mupirocin resistant strains studied and type d was identified as the 
dominant clone (Table 4.1; Figure 4.3). Some degree of correlation was observed in the 
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analysis of the three typing methods (antibiogram, PCR-RFLP and PFGE). The low-level 
mupirocin resistant MRSA strains with a PCR product of 6S0bp (RFLP pattern: 81, 
S67bp) belonged to the main clone b by PFGE typing. There was good correlation 
between antibiogram and the two genotyping methods, although an additional resistance 
character (resistance to erythromycin) was noted in two strains in PFGE type b (Table 
4.1). MRSA strains with PCR-RFLP pattern (81,324, 40Sbp; 324, 40Sbp) had similar 
resistance pattern, except for four strains, in which resistance to chloramphenicol was 
also observed. PFGE typing indicated that these strains belonged to the main dominant 
clone d. The low-level mupirocin resistant strains with the PFGE type b were observed in 
two health institutions in Durban and one in Eshowe while strains with type d were noted 
in three health facilities located in Durban, one in Pietermaritzburg, Greytown and 
Empangeni (Chapter two; Table 2.1 and Table 4.1). MRSA strains in clone d were 
resistant to at least eight classes of antibiotics. The emergence and spread of low-level 
mupirocin resistance in MRSA has been reported in a community hospital in Japan 
(Watanabe et al., 2001b). This study has demonstrated that clonal dissemination of 
multiresistant MRS A strains exhibiting low-level resistance to mupirocin exists in health 
institutions in KwaZulu-Natal province of South Africa. 
Analysis using the three typing methods indicated that the high-level mupirocin-
resistant strains did not arise from the same clone (Figure 4.4). However, DNA patterns 
of the methicillinlmupH resistant MRSA strain showed that it differed by two to three 
bands from the low-level mupirocin resistant strains assigned to PFGE subtype b 1 and 
b4, indicating that these strains are related (Chapter Three). Moreover, a three-band 
difference was also detected between one MRS A (strain IS) and the high-level mupirocin 
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MSSA strain (35IBA) from Nigeria indicating that they are genetically related (Figure 
4.4). The ability of MRS A strains in main clone a (in which the mupirocinimethicillin 
resistant S. aureus strain belonged) to be transmitted over great distances (Chapter 
Three), the establishment of clone d in hospitals in Durban, clearly indicate that urgent 
measures need to be taken to prevent clonal dissemination of the mupirocinimethicillin 
resistant S. aureus in KZN, South Africa. Furthermore, the discovery of the mupirocin 
resistant strain from a health facility in Nigeria in which the antibiotic is not administered 
or prescribed, and the relatedness of one MRSA with the mupH MSSA indicate that more 
studies are needed in understanding the genetics and evolution of mupirocin resistance of 
S. aureus, in Nigeria. 
Plasmid-mediated resistance to antimicrobial agents among pathogenic bacteria 
constitutes a major clinical and economic problem worldwide, which has been the subject of 
extensive genetic and biochemical studies. Plasmid transfer in vitro is used to characterize 
plasmids and establish the genetics and spread of plasmid-linked resistance genes. 
Multiresistant S. aureus isolates commonly harbour two or more plasmids that often vary in 
size and resistance phenotypes. In such circumstances, an effective study of plasmid-linked 
resistance determinants depends upon the successful transfer of plasmids from resistant 
isolates to suitably marked sensitive, and plasmid free recipients (Udo et ai. , 1991). In S. 
aureus, mixed-culture transfer, phage mediated conjugation and conjugation can transfer 
resistance determinants in vitro (Lacey 1980; Archer and Johnston, 1983; Forbes and 
Schaberg, 1983; McDonnell et ai. , 1983; Townsend et ai., 1985). 
In the late 1970s and early 1980s, studies on the transfer of plasmids mediating 
gentamicin resistance between strains and between species of staphylococci firmly 
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established conjugative transfer as a mechanism whereby resistance genes borne on 
plasmids could be disseminated in staphylococci (Naidoo and Noble, 1978; Naidoo and 
Noble, 1981; Forbes and Schaberg, 1983; McDonnell et al. , 1983). In this study, the 
genetic location of the high-level mupirocin resistance was determined by plasmid 
analysis, involving curing and conjugation experiments. Three features were identified in 
the transfer experiments and plasmid analysis of strain RKK6 that harboured the 
mupirocin plasmid. The first feature was the transfer of the plasmid mediating mupirocin 
resistance (Table 4.2; Figure 4.7). A total of seven fragments were detected by EcoRI 
restriction analysis in the transconjugant harbouring the mupirocin plasmid, indicating 
that the size of the mupirocin plasmid was 41.1kb (Figures 4.8). This was higher than the 
estimated size of 37kb calculated from the undigested plasmid DNA (Figure 4.5). As the 
41.1-kb high-level mupirocin plasmid mediated its own transfer in conjugation experiments, 
it fits the description of a conjugative plasmid. No transconjugants were obtained on 
selection plates for strain 35IBA (Nigeria) by the polyethylene glycol method, suggesting 
that the mupirocin plasmid is not non-self-transmissible or that other conditions are 
needed. Phage-mediated conjugation was however, not performed on the mupirocin-
resistant strain. Some authors have suggested that high-level mupirocin resistance genes 
reside on transposons (Rahman et al. , 1989; Cookson, 1990; Slocombe and Perry, 1991) 
and the first report of the chromosomal location of the mupA gene in S. aureus expressing 
high-level mupirocin resistance have been described (Udo et al. , 2003). In this study, PFGE 
analysis of the parent and cured strains indicated that the mupA was plasmid-mediated 
(Figure 4.6). High-level mupirocin resistance has been found in self-transmissible and 
non-self transmissible plasmids in different countries (Rahman et al., 1989; Udo et al. , 
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1994; Connolly et ai. , 1993; Udo et ai., 1997), and this study has demonstrated what 
appears to be the first report of a conjugative mupi,rocin plasmid in South Africa and a 
non-conjugative mupirocin plasmid in Nigeria. 
Although staphylococcal gentamicin resistance (Townsend et ai. , 1985; Projan and 
Archer, 1989) and the cryptic (Udo et ai., 1991 ; Udo et ai., 1992) conjugative plasmids have 
been known to mobilize non-conjugative plasmids, conjugative transfer of plasmids 
mediating mupirocin resistance have been found to encompass the co-transfer of small non-
conjugative plasmids encoding resistance to tetracycline, gentamicin and chloramphenicol 
(Needham et ai. , 1994; Udo et ai., 1997; Udo et ai. , 1998; Udo et ai. , 2001a; Udo et ai. , 
2001b) and large plasmids encoding resistance to penicillin (Pawa et ai. , 2000). The transfer 
of resistance determinants mediating mupirocin and triclosan resistance in MRSA has 
also been reported (Cookson et ai. , 1991). The second feature observed in this study was 
the transfer of the 41.1-kb plasmid, which accompanied transfer of the high-level 
mupirocin resistance and the co-transfer of what appears to be a 20-kb plasmid encoding 
cadmium resistance. It is proposed that the 41.1-kb plasmid belongs to a class of mupirocin 
resistance conjugative plasmids that are capable of mobilizing certain staphylococcal non-
conjugative and conjugative plasmids (projan and Archer, 1989; Udo et ai., 1991; Udo et 
ai. , 1992). The third feature was the transfer of the plasmid mediating erythromycin 
resistance, indicated by the carriage of a 2.3-kb plasmid. The demonstration of conjugative 
transfer of the mupirocin plasmid and co-transfer of additional resistance markers clearly 
support the judicious use of this topical antibiotic in health institutions in South Africa. This 
should be considered prior to incorporating mupirocin into an infection control program. In 
hospital settings in which mupirocin might be used on a broad basis, such as in the control 
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of certain postoperative wound infections, it would be essential to monitor the emergence of 
mupirocin-resistant strains. 
Preliminary investigations using partial sequence analysis revealed that the ileS-
gene of strains RKK6, P1929, TransMup (transconjugant ofRKK6) and S. aureus J2870 
was identical (Figure 4.9). However, alignment of the ileS-gene in 35IBA and S. aureus 
12870 revealed a base substitution (nucleotide position 671 A to T; ATT to TTT) in the 
DNA sequence of the mupH strain from Nigeria, leading to a change in the amino acid 
sequence from leucine to phenylalanine (Figure 4.9). Future studies involving full 
sequence analysis of ileS-2 gene in strain 35IBA will probably provide new insights on 
the evolution of the ileS-2 gene in S. aureus. 
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4.5 CONCLUSION 
The emergence of mupirocin resistance in both countries and the potential loss of 
one of the major weapons in MRSA infection control emphasize the need that prolonged 
and widespread use of mupirocin in healthcare facilities should be discouraged. MRSA 
eradication strategies should be designed carefully with reliable laboratory screening for 
resistance and periodic antibiotic prescribing and infection control audits. In this way, if 
resistance does emerge, it is more likely to be detected rapidly, and action taken early and 
effectively to minimize spread. Any agent should not be used as a substitute for poor 
infeCtion control and antibiotic prescribing practices, but as part of an overall policy 
developed, audited and reviewed by the local relevant health care workers. It is also 
recommended that routine testing of MSSA and MRSA for mupirocin resistance be 
conducted even in facilities where mupirocin is not being used, because mupirocin-resistant 
strains can be introduced into such facilities, where it can spread among patients. This will 
facilitate the early detection of resistance and can help control the spread of mupirocin-
resistant MRSA. 
Although the possibility of horizontal transfer of this conjugative plasmid among 
Staphylococcus spp was not established, there is evidence that a larger pool of mupirocin 
resistance exists in coagulase-negative staphylococci than in S. aureus in many countries 
(Deshpande et al. , 2002; Yun et al. , 2004; Kresken et al. , 2004; Petinaki et al. , 2004). The 
former may act as a reservoir for high-level resistance in patients treated with mupirocin. 
Management of MRSA infections may also require screening for mupirocin resistance 
among coagulase negative staphylococci. 
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CONCLUDING REMARKS AND FUTURE RESEARCH STUDIES 
This study on the susceptibility patterns and epidemiology of S. aureus strains 
from Nigeria and South Africa has provided baseline information for physicians, clinical 
microbiologists and public health officials in the establishment of adequate infection 
control programmes, and national drug policies in the treatment of staphylococcal 
infections. The multi-resistant nature of some MSSA isolates from Nigeria, multi drug-
nature of MRSA strains from South Africa, the emergence of mupirocin-resistant S. 
aureus and isolation of atypical S. aureus strains from both countries clearly indicate the 
need for continuous surveillance in understanding new and emerging trends in the 
susceptibility patterns of S. aureus. Future studies include the characterization of multi-
drug resistant S. aureus isolates, which involves the detection of genes conferring 
resistance to macrolides, lincosamides, aminoglycosides and tetracycline. 
Bacterial strain typing, or subspeciation, has become an important clinical tool to 
investigate nosocomial transmission. The characterization of S. aureus strains from both 
countries using various epidemiological tools has identified some widely disseminated 
MRS A clones, establishment of multi-drug resistant clones in health institutions in 
K waZulu-Natal province of South Africa and the genetic relatedness of one MRSA strain 
from Nigeria with the pandemic EMRSA-15. An epidemic clone is known for its ease of 
transmission, long-term persistence, rapid intra- and inter-hospital spread and ability to 
cross geographical and continental boundaries. Future studies would be important in 
investigating the genetic relationship of clones from the two countries with other 
393 
pandemic MRSA clones in order to ascertain if these clones were unique and specific to 
Nigeria and South Africa. More studies on the comparative analysis of the molecular 
epidemiology of MRSA in both countries are of great importance. There is also the need 
for closer international collaboration to monitor the spread of current epidemic strains 
and the emergence of new ones. Further characterization of MRSA strains using SCCmec 
typing and MLST would clearly assist in understanding the evolution of MRS A clones, 
and the behaviour and fitness of this successful pathogen under hospital conditions. 
Although it was not been possible to elucidate why some MRSA clones spread rapidly 
than others, urgent measures are needed in curtailing the spread and establishment of 
these clones. In this regard, future studies in understanding virulence related property 
such as increased adherence resulting in colonization and infection could be of major 
importance with respect to control of MRSA dissemination. In addition, future studies 
involving full sequence analysis of the ileS-2 gene in the mupirocin-resistant strain from 
Nigeria would probably provide new insights on the evolution of the ileS-2 gene in S. 
aureus. 
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Antibiotic susceptibility patterns of S . aureus isolates from Nigeria 
No PG AM E TM GM C CIP RP CO T NE FC TC VA MU MN K 5 TS OX KF CX Type of specimen 
026 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
054 1 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 Blood 
045 1 1 0 1 1 0 0 0 0 1 1 0 0 0 0 0 1 1 1 0 0 0 Wound swab 
021 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Urine 
036 1 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 Wound swab 
09 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0 0 Wound swab 
019 1 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 Urine 
024 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 Urine 
01 2 1 1 0 1 1 0 0 0 0 1 1 0 0 0 0 0 1 1 1 0 0 0 NA 
0 32 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Sputum 
037 1 1 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 Ear swab 
02B 1 1 0 1 1 0 0 0 0 0 1 0 0 0 0 0 1 1 1 0 0 0 Sputum 
053 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
023 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Semen 
015 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Blood 
01B 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Blood 
014 1 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 Blood 
029 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Blood 
016 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Urine 
04 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 NA 
035 1 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
020 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
040 1 1 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 Wound swab 
07 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 HVS 
051 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
06 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
052 1 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
J6 1 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 NA 
E 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Blood 
K 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
A27 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 NA 
A1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
THK 1 1 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 Wound swab 
THW 1 1 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 Wound swab 
THE 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
THF 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
21B 1 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
C1 1 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 NA 
C34 1 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 NA 
C20 1 1 0 1 0 0 1 0 0 0 1 0 0 0 0 0 1 1 1 0 0 0 NA 
C35 1 1 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 NA 
C4 1 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 NA 
C5 1 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 NA 
C22 1 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 NA 
C25 1 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 NA 
C49 1 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 NA 
C40 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 NA 
C4B 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 NA 
41B 1 1 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 Wound swab 
SIB 1 1 0 1 0 1 0 0 0 1 0 0 0 0 0 0 0 1 1 0 0 0 Wound biopsy 
C32 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 NA 
31B 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Ear swab 
B6 1 1 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 Ear swab 
B35 1 1 0 1 0 1 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 HVS 
B1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound aspirate 
BB 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 Ear swab 
B21 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 Breast aspirate 
B10 1 1 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 Urine 
B3 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 Wound aspirate 
B5 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 Wound aspirate 
B19 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Urine 
B9 1 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 Aspirate 
B26 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Aspirate 
B31 1 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 Urine 
F 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Blood 
10 1 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 Blood 
13 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 Blood 
0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 Blood 
19 (1) 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Blood 
5 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Blood 
G 1 0 1 0 0 1 0 0 1 0 0 0 0 0 0 0 1 1 0 0 0 Blood 
R 1 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 Blood 
H 1 0 1 1 0 0 0 0 1 0 0 0 0 0 0 1 1 1 0 0 0 Blood 
C 1 0 1 0 0 1 0 0 1 0 0 0 0 0 0 0 1 1 0 0 0 Blood 
P 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 Blood 
E1 1 0 0 1 0 0 0 0 1 0 0 0 0 0 1 1 0 0 0 0 0 Blood 
20 1 1 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 Blood y 1 1 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 Blood 
V 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 Blood 
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1 0 0 
o 0 0 
o 0 0 
o 0 0 
o 0 0 
1 0 0 
o 0 0 
o 0 0 
1 0 0 
o 0 0 
o 0 0 
o 0 0 
o 1 0 
o 0 0 
o 0 0 
o 0 0 
o 0 0 
o 0 0 
o 0 0 
o 0 0 
o 1 0 
o 0 0 
o 0 0 
o 0 0 
o 0 0 
1 0 0 
o 0 0 
o 0 0 
o 0 0 
o 0 0 
o 0 0 
18 13 0 

































































































































































































































































































































































































































































































o 0 0 0 0 
o 0 0 1 0 
o 0 0 0 0 
o 0 1 1 0 
o 0 0 0 0 
o 0 0 0 0 
o 1 0 0 
o 0 0 0 
o 0 0 0 
o 0 0 0 
o 0 0 1 0 
o 0 0 0 0 
o 0 0 0 0 
o 0 1 1 0 
o 0 0 0 0 
o 0 0 1 0 
o 0 0 0 0 
o 0 0 0 0 
o 0 0 1 0 
o 0 0 0 0 
o 0 0 1 0 
o 0 0 0 0 
o 0 0 1 0 
o 0 0 0 0 
o 0 0 1 0 
o 0 0 0 0 
o 0 0 0 0 
o 0 0 1 0 
o 0 0 0 
o 0 0 0 
o 0 0 0 
o 0 0 0 
o 0 0 0 0 
o 0 0 0 0 
o 0 0 0 
o 1 1 0 
o 0 0 0 
o 0 0 0 
o 0 0 0 0 
o 0 0 1 0 
o 0 0 0 0 
o 0 0 0 0 
o 0 0 1 0 
o 0 0 0 0 
o 0 0 0 0 
o 0 0 0 0 
o 0 0 1 0 
o 1 0 1 0 
o 0 0 0 0 
o 0 0 1 0 
o 0 0 1 0 
o 1 1 0 
o 0 0 1 0 
o 0 1 0 0 
o 0 0 1 0 
1 0 0 0 0 
o 0 0 1 0 
o 0 0 1 0 
o 0 0 0 0 
o 0 0 0 
o 0 0 0 
o 0 0 0 
o 0 0 0 
o 0 0 0 
o 0 0 0 
o 0 0 0 
o 0 0 0 
o 0 0 0 
o 0 0 0 
o 0 0 1 0 
o 0 0 0 0 
o 0 0 1 0 
o 0 0 1 0 
o 0 0 1 0 
o 0 0 0 0 
o 0 0 1 0 
o 0 0 0 0 
o 0 0 1 0 
o 0 0 1 0 
o 0 0 0 0 
o 0 0 0 0 
o 0 a a 
o 0 0 0 
o 1 0 1 0 
o 0 0 a a 
o 0 0 0 
o 0 0 0 
o 0 0 0 
o 1 1 1 0 
o 0 0 0 0 
o 0 0 0 0 
o 0 a 0 0 
o 0 0 1 0 
o 0 0 0 0 
3 14 22 93 0 

































































































































































































No PG AM E TM GM C CIP RP CD T NE FC TE VA MU MN K S TS OX KF CX 
MSSA - Nigeria - 1! 2 isolates Intermediately resistant to oxacillin 
Susceptibility patterns of MRSA Isolates from Nigeria 
No PG AM E TM GM C CIP RP CD T 
28 IDA 1 0 0 0 1 0 1 
THCD 1 1 0 0 0 0 1 
15 0 0 0 0 0 0 0 









TS OX KF ex 
o 1 0 1 
1 1 0 0 






























































































Type of specimen 




Antibiotic susceptibility patterns of MSSA Isolates from South Africa 
No PG AM E TM GM C CIP RP CD T NE FC TC VA MU MN K S TS OX KF CX Type of specimen 
GJC 391 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Urine 
GJC 741 1 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 Sputum 
GJC 931 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 NA 
EDD 11 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
EDD 15 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
EDD 201 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
EDD 301 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Earawab 
EDD 331 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 HVS 
EDD 381 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
EDD 41 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
EDD451 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
EDD491 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
EDD 541 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 Wound.wab 
EDD 55 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
EDD 581 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
EDD 64 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
EDD750 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
EDD791 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Ear.wab 
EDD 870 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Blood 
EDD 961 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Sputum 
GT6 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
GT7 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound.wab 
GT30 1 1 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 Wound swab 
GT34 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
GT41 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Vaginal swab 
GT67 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Ear.wab 
GT68 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
GT85 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
BS 35 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
BS66 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound.wab 
RKK4 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
RKK34 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
RKK391 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Blood 
RKK49 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
RKK 500 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Urine 
RKK54 1 1 1 1 0 0 0 0 1 1 0 0 0 0 0 0 0 0 1 0 0 0 Wound swab 
RKK63 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
RKK65 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Blood 
RKK66 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
RKK68 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
RKK821 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
RKK831 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
RKK841 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
RKK851 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
RKK 860 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
RKK881 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
RKK991 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
EGU 131 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
EGU 17 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
EGU 421 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
EGU 471 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
EGU 591 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound.wab 
EGU 601 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Ear.wab 
EGU 631 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound.wab 
EGU 70 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
EGU 72 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound.wab 
EGU 751 1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 Wound swab 
EGU 81 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
EGU 83 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
KEH 591 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 Endotracheal aspire1 
GP85 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
GP86 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
GP99 1 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
GP98 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
PS27 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
PS 28 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
PS 46 CIt 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound .wab 
PS47 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound .wab 
PS61 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Ear.wab 
PS 90 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
AD59 1 1 1 0 0 0 1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 Blood 
AD68 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
AD 80 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Blood AD93 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 










319 1 1 








































XM 1 1 
XN 1 1 














NG 24 1 1 
NG 36 0 0 
P1929 0 0 
TOTAL 147 147 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































No PG AMPE TM GM C CIP RP CD T NE FC TEC VAN MUP MN K S TS OX KF CXM Type of specimen 
GJC 3 1 1 1 1 1 0 0 1 1 1 0 0 0 0 0 1 1 0 1 1 0 0 Sputum 
GJC 7 1 1 0 1 0 0 0 1 0 1 0 0 0 0 0 1 1 0 1 1 Ear swab 
GJC 69 1 0 1 1 0 0 1 0 1 0 0 0 0 0 1 1 0 1 0 0 
EDD 52 1 1 1 0 0 1 1 0 0 0 0 0 1 0 1 0 0 Wound swab 
EDD 70 1 1 1 1 0 1 1 0 0 0 0 0 1 1 0 0 Wound swab 
EDD 84 1 1 1 0 0 1 1 1 0 0 0 0 0 1 0 1 0 0 Wound swab 
EDD99 0 1 0 0 0 1 0 1 0 0 0 0 0 1 0 1 1 Wound swab 
GT33 0 0 1 1 0 0 0 0 0 0 0 0 Wound swab 
RKK6 0 0 1 1 1 1 0 0 0 1 0 0 0 Wound swab 
RKK8 1 0 1 0 1 1 0 0 0 1 1 1 1 1 Wound swab 
RKK10 0 0 0 1 1 1 0 0 0 0 0 0 0 0 Wound swab 
RKK52 1 0 1 1 0 0 0 0 0 0 1 0 0 Wound swab 
RKK53 0 0 1 1 0 0 0 0 0 0 1 0 0 Wound swab 
RKK55 0 1 0 1 1 0 0 0 1 1 1 Wound swab 
RKK56 1 0 1 0 1 1 1 0 0 0 1 1 1 Wound swab 
RKK57 1 0 1 0 1 1 1 0 0 0 1 1 1 1 Wound swab 
EGU23 0 1 0 1 0 1 0 0 0 0 0 1 0 0 Wound swab 
EGU28 1 0 0 1 1 0 0 0 0 0 0 0 0 Wound swab 
EGU51 1 0 0 1 1 0 0 0 0 0 1 0 0 0 Eye swab 
KEH 12 1 0 0 1 1 0 0 0 0 1 1 0 0 0 Wound swab 
KEH 26 1 1 1 0 1 1 0 0 0 1 1 1 1 1 Endotracheal aspirate 
KEH 77 0 0 0 0 0 1 0 0 0 0 0 1 0 1 1 Wound swab 
KEH 88 1 0 0 1 1 0 0 0 0 0 1 0 1 0 0 Ear swab 
GP 11 1 1 1 0 1 1 0 0 0 1 1 1 1 1 Wound swab 
GP74 0 0 0 0 0 1 0 0 0 0 0 1 0 1 1 Wound swab 
PS33 0 0 1 0 0 0 0 0 1 0 1 0 0 Sputum 
PS44 0 0 1 0 0 0 0 0 0 1 0 0 Wound swab 
PS 50 0 1 0 0 0 0 0 0 0 0 Wound swab 
PS 94 0 1 1 0 0 0 0 0 0 0 0 Wound swab 
AD 28 1 1 1 1 0 1 1 0 0 0 1 1 1 1 Wound swab 
AD 69 0 1 0 0 1 0 1 0 0 0 0 0 1 0 1 0 0 Wound swab 
AD 77 1 0 0 0 0 1 0 1 0 0 0 0 0 1 0 1 1 Wound swab 
AD 79 0 1 0 0 1 0 1 0 0 0 0 1 1 0 0 0 Blood 
AD 84 1 1 0 0 1 1 1 0 0 0 0 0 1 0 0 1 Sputum 
AD 87 1 1 0 1 0 1 1 0 0 0 1 1 1 1 1 Wound swab 
AD 98 0 1 0 0 1 0 0 0 0 0 1 1 0 0 0 Catheter tip 
MD24 0 1 0 0 1 0 1 0 0 0 0 0 1 0 0 0 Sputum 
MD43 1 1 0 0 1 1 1 0 0 0 0 0 1 0 1 1 1 Sputum 
PM69 1 1 0 0 1 1 0 0 0 0 0 1 0 1 0 0 Wound swab 
ESH 20 1 1 0 0 1 1 0 0 0 0 0 1 0 1 0 0 Wound swab 
ESH 34 1 1 1 0 0 1 1 1 0 0 0 0 1 1 1 0 1 0 0 Wound swab 
ESH 37 0 0 0 0 0 1 0 1 0 0 0 0 0 1 0 0 0 0 0 Wound swab 
ESH 89 1 0 0 0 0 0 1 0 0 0 0 0 1 1 0 1 1 Wound swab 
107-2 0 0 1 0 0 0 0 0 0 1 0 0 Wound swab 
203 0 0 1 0 0 0 0 0 0 1 0 0 Wound swab 
503 .. 0 0 1 0 0 0 0 0 0 0 0 Wound swab 
510 1 1 0 1 0 0 0 1 1 1 1 Wound swab 
511 0 0 1 0 0 0 0 0 0 0 0 Wound swab 
513 0 0 1 0 0 0 1 1 1 1 Wound swab 
ESA 0 1 0 0 0 0 0 0 0 0 Wound swab (bums) 
HAS 0 0 0 0 0 0 0 0 0 0 Wound swab 
SSA 1 0 0 0 0 0 0 0 0 0 0 Wound swab 
lKH 1 1 0 0 1 0 0 0 0 0 0 0 0 Wound swab 
2KH 1 1 1 1 0 0 1 0 0 0 0 0 0 0 0 Wound swab 
4KH 1 1 1 1 0 0 1 0 0 0 0 0 0 1 0 0 Wound swab 
AC 1 1 1 1 0 0 1 1 0 0 0 0 1 1 1 0 0 Wound swab 
AD 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Wound swab 
XB 1 1 1 1 0 0 1 0 0 0 0 0 0 1 0 0 Wound swab 
XC 1 0 1 0 0 0 0 0 0 0 0 0 1 0 0 Wound swab 
XQ 1 1 0 1 1 0 1 0 1 0 0 0 0 0 1 1 0 1 0 0 Wound swab 
XW 1 1 0 1 0 0 1 0 1 0 0 0 0 0 1 1 0 1 0 0 Sputum 
NO 61 61 50 52 59 10 11 45 50 55 19 0 0 0 15 55 59 19 52 61 17 18 
% 100 100 82 85.2 97 16.4 18 74 82 90 31 0 0 0 24.6 90 97 31 85 100 28 29.51 % 
399 
Amlnoglycosides MLS antibiotics Tetracyclines Heavy Metals 
No GM KM AM SM NE TOB EM OL AZMCC aD TE MH DO No EB Pi Hg Cd 
GJC3 1 1 0 0 0 In! 1 1 1 1 0 1 1 0 GJCO 0 0 In! 
GJC7 0 1 1 int 1 1 0 1 0 0 0 0 GJCint 1 1 1 
GJC69 0 0 0 1 0 0 0 0 0 1 1 0 GJCO 0 0 0 
EDD52 0 0 0 1 1 1 1 1 0 1 0 EDEO 0 0 1 
EDD70 0 1 0 1 1 1 0 1 1 int EDEO 0 0 1 
EDD84 0 0 0 0 1 1 0 1 1 In! EDEO 0 0 
EDD99 0 1 1 In! 1 0 0 0 0 EO(1 1 1 
GT 33 0 0 0 1 1 0 1 1 0 GT :O 0 0 int 
RKK6 0 0 1 1 1 0 1 int RK.O 0 0 1 
RKK8 1 1 1 1 int 1 0 1 1 RK. 1 1 1 1 
RKK10 0 0 1 1 1 1 0 1 0 RK.O 0 0 1 
RKK52 0 0 0 1 1 0 1 0 RK.O 0 0 1 
RKK53 0 0 0 1 1 0 1 0 RK.1 1 0 In! 
RKK55 1 1 1 1 1 0 1 1 RK.O 0 1 0 
RKK56 1 1 1 1 int 1 0 1 1 RK.O 0 1 0 
RKK57 1 1 1 1 1 1 1 1 0 1 1 RK.1 1 1 1 
EGU 23 0 1 0 1 0 0 0 0 0 0 EGlint 0 0 In! 
EGU28 0 0 0 1 1 1 1 1 0 0 EGlint 0 0 int 
EGU51 0 0 0 1 1 1 1 1 0 0 EGlO 0 1 
KEH 12 0 0 0 1 1 1 1 1 0 int KE~O 0 1 
KEH26 1 1 1 1 1 int 1 1 0 1 KE~O 0 0 
KEHn 0 1 1 int 1 0 0 0 0 KE~1 1 
KEH 88 0 0 0 1 1 0 1 1 int KE~O 0 
GP11 1 1 1 1 int 1 0 1 1 1 GP 1 1 
GP74 0 1 1 1 1 1 0 0 0 0 GP 1 1 1 
PS 33 0 0 0 1 1 1 0 1 1 0 PS:O 0 1 
PS44 0 0 0 1 1 0 1 int PS·O 0 1 0 
PS 50 0 0 0 1 1 0 1 int PS'O 0 1 1 
PS 94 0 0 0 1 1 1 0 1 1 0 P$!O 0 0 1 
AD28 1 1 1 1 In! 1 1 0 1 1 1 AD:O 0 1 1 
AD69 0 0 0 0 0 0 0 0 1 1 0 AD'O 0 1 1 
AD 77 0 1 1 int 1 1 1 1 0 0 0 0 AD ' 1 1 1 1 
AD 79 0 0 0 1 0 0 0 0 0 1 1 0 AD ' O 0 0 0 
AD 84 0 0 0 1 1 1 1 1 0 1 1 0 AD'O 0 0 1 
AD 87 1 1 1 1 1 1 1 1 1 0 1 1 1 ADI1 1 1 1 
AD 98 1 0 0 0 1 0 0 0 0 0 1 1 0 AD!O 0 1 1 
MD24 1 0 0 0 In! 0 0 0 0 0 1 1 0 MD 0 0 0 0 
MD43 1 0 0 0 int 1 1 1 1 0 1 1 0 MD 0 0 0 int 
PM 69 1 0 0 0 1 1 1 1 1 0 1 1 0 PM ' O 0 0 0 
ESH20 1 1 0 0 0 1 1 1 1 1 0 1 1 0 ES~O 0 0 1 
ESH 34 1 1 0 0 0 1 1 1 1 1 0 1 1 0 ES~O 0 0 1 
ESH37 0 0 0 0 0 0 0 0 0 0 0 1 1 0 ES~O 0 1 0 
ESH89 1 1 0 1 1 int 1 1 1 1 0 0 0 0 ES~1 1 1 1 
SSA1 1 1 0 0 0 1 1 1 1 1 0 1 1 int SSP 0 0 0 1 
1KH 1 1 0 0 0 1 1 1 0 1 1 int 1KH1 1 1 1 
2KH 1 0 0 0 1 0 1 1 0 2KH1 1 0 1 
4KH 1 0 0 0 1 0 1 int 4KH1 1 1 1 
ESA 1 0 0 0 0 1 int ESP 1 1 0 1 
HAS 0 0 0 0 1 int HA~O 0 1 1 
Aminoglycoaides MLS antibiotics Tetracyclines Heavy Metals 
No GM KM AM SM NE TOB EM OL AZMCC aD TE MH DO No EB Pi Hg Cd 
AC 1 1 0 1 1 int 1 1 1 1 0 1 0 AC 0 0 0 0 
xa 1 1 0 0 0 int 0 0 0 0 0 1 0 xa 0 0 0 In! 
AD 0 0 0 0 0 0 0 0 0 0 0 1 0 AD 0 0 0 0 
107-2 1 1 0 0 0 1 1 1 1 1 0 1 0 107, 0 0 0 In! 
XW 1 1 0 0 0 1 0 0 0 0 0 1 0 XWO 0 0 In! 
203 1 1 0 0 0 1 1 1 0 1 0 2030 0 0 1 
503 Red 1 1 0 0 0 1 1 1 1 0 1 0 503 0 int 0 1 
511 1 1 0 0 0 1 1 1 1 0 1 0 5110 0 0 In! 
513 1 1 1 1 1 1 1 1 1 0 1 1 5131 1 1 1 
510 1 1 1 1 1 1 1 1 1 0 1 1 5101 1 1 1 
114XB Re< 1 1 0 0 0 1 1 1 1 1 0 1 1 0 114: 0 0 0 1 
131 XC R.1 1 0 0 0 1 0 0 0 0 0 1 1 0 1310 0 0 1 
TOTAL 59 59 10 19 19 48 50 45 49 50 0 55 55 10 T0l16 17 28 40 
% 
GM KM AM SM NE TOB EM OL AZMCC aD TE MH DO EB Pi Hg Cd 
10 5 12 3 1 10 
INT INT INT INT INT INT 
Susceptibility pattem of two MRSA from Nigeria 
Amlnoglycosk:les M LS antibiotics T etracycJines Heavy Metals 
No GM KM AM SM NE TOB EM OL AZMCC aD TE MH DO No EB Pi Hg Cd 
THCD 0 0 0 1 0 0 1 1 1 1 0 1 1 0 THeO 0 1 1 
15 0 0 0 0 0 0 0 0 0 0 0 1 0 0 15 0 0 1 1 
400 
SusceJiibliy pottems 01 MRSA ioofate. from SoLih Africa 
No MET PEN GM KMAMSM EM CC CM TE W MH RF SH FD AZM ClP NV DO Ol QD FOX TOB EB Pi H9 Cd MUP200 FOS llD MUPS VAN TEIC MUP VAN TElCO TypeolSjlOcimen 
GJC3 I I I I 0 0 I I 0 I I I I 0 0 I 0 0 0 I 0 I irl 0 0 0 i1t 0 0 0 0 1.5 1.5 0 0 SplAum 
GJC7 I I 0 I I 0 0 0 0 0 I 0 0 0 0 0 I 0 I in! ill I I I 0 0 0 0 2 2 0 0 EJr swab 
GJC69 0 0 0 I 0 0 0 0 0 0 0 I 0 0 0 0 0 1.5 1.5 0 0 NA 
EDD52 I I 0 0 0 I 0 1.5 1.5 0 WO ....... b 
EDD70 0 irl 0 0 0 0 2 1.5 0 WO ....... b 
EDDfI.I 0 irl 0 0 0 2 1.5 0 WO ....... b 
EDD99 0 0 0 i1t 0 2 2 WO ....... b 
GT33 0 0 0 I i1t 0 2 1.5 WO ....... b 
RKK6 0 irl 0 I I 0 1.5 I >102. 0 WO ....... b 
RKK8 0 I ill 0 0 1.5 1.5 8 0 WO ....... b 
RKKIO 0 0 I 0 0 1.5 1.5 0 WO ....... b 
RKK52 0 0 I 0 0 1.5 2 WO ....... b 
RKK53 0 0 I 0 i1t 0 I WO ....... b 
RKK55 0 I 0 0 0 I I 12 WO ....... b 
RKK56 0 I ill 0 0 2 2 8 WO ....... b 
RKK57 0 I I 0 0 1.5 I 12 WO ....... b 
EGU23 0 0 0 0 .1 i1t 0 2 2 WO ....... b 
EGU28 0 0 0 ill i1t 0 2 1.5 WO ....... b 
EGU51 0 0 0 0 0 1.5 1.5 Eye swab 
KEH 12 0 i1t 0 0 0 2 1.5 24 WO ....... b 
KEH26 0 I ill 0 0 0 2 3 12 EndoInclleal.spiraI. 
KEH77 0 0 i1t I 0 1.5 1.5 WO ....... b 
KEH88 0 i1t I 0 0 1.5 1.5 Ear swab 
GPII 0 ill I I 0 1.5 1.5 WO ....... b 
GP74 I I 0 2 2 WO ....... b 
PS 33 I I 0 1.5 1.5 SplAum 
PS 44 i1t I I 0 1.5 2 WO ....... b 
PS 50 in! 0 1.5 1.5 WO ....... b 
PS94 0 0 1.5 I WO ....... b 
AD 28 I ill 0 2 1.5 12 WO ....... b 
AD 69 0 0 0 1.5 I WO ....... b 
AD 77 0 I i1t 0 3 2 WO ....... b 
AD 79 0 0 I 0 2 1.5 24 Blood 
ADfI.I 0 I 0 2 1.5 $pIAum 
AD 87 I I 0 2 2 16 WO ....... b 
AD 98 0 0 2 I 24 Collletertip 
MD24 0 i1t 0 1.5 1.5 SplAum 
MDC 0 irl i1t 0.75 0.75 SplAum 
PM 69 0 I 0 1.5 1.5 WO ....... b 
ESH20 0 2 1.5 WO ....... b 
ESH34 0 1.5 1.5 24 WO ....... b 
ESH37 0 2 I WO ....... b 
ESH89 0 irl 2 2 WO ....... b 
SSAI i1t I I I WO ....... b 
IKH i1t I 1.5 1.5 WOIlld ... b 
2KH 0 I 1.5 1.5 WO ....... b 
4KH irl I I 2 WOIlld ... b 
ESA irl 1.5 1.5 WO ....... b(bLms) 
HAS irl 1.5 1.5 WO ....... b 
AC 0 i1t I I WOIlld ... b 
XQ 0 irl i1t 1.5 I WO ....... b 
AD 0 0 1.5 1.5 WO ....... b 
107·2 i1t 1.5 I WO ....... b 
XW i1t 1.5 1.5 SplAum 
203 I 2 I WO ....... b 
503 Rod i1t I 1.5 1.5 WO ....... b 
511 0 0 i1t 2 2 WO ....... b 
513 0 I I 2 2 8 WO ....... b 
510 I I I I I I I 2 2 12 WO ....... b 
114XBR~1 I I I 0 I I I 0 I I 0 0 3 2 WO ....... b 
131 XCR,I I 0 0 0 I I I I I 0 0 I I I I 0 0 3 2 WO ....... b 
TOTAL 61 61 59 59 10 19 50 50 10 55 52 55 45 58 49 II 10 46 61 48 16 17 28 40 I 0 15 TOTAL 
% 100 100 96.7 96.7 16 31 .1 82 82 16 90 85 90 73.8 95.1 80 18 16 75 100 78.69 26.23 27.9 45.9 65.6 1.63934 0 24.59 % 
SusceJiibliy pottemollwoMRSA from Nigeria 
No MET PEN GM KM AM SM EM CC CM TE W MH RF SH FD AZM CIP NV DO Ol QD FOX TOB EB Pi H9 Cd MUP200 FOS llD MUPS VAN TEIC MUP VAN TaCO Type 01 SjIOcimen 
THCD 0 I 0 0 0 I I I 0 I 0 0 0 I 0 0 0 1 0 0 0 0 0 I I 0 0 0 0 1.5 1.5 0 0 WO ....... b 15 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 I 0 0 0 2 1.5 0 0 WO ....... b 
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APPENDIX 2 
6 7 8 9 10 1J 12 13 14 15 16 17 
peR detection of the mecA gene (449bp). Lane 10: molecular weight marker; Lanes 2-9; 11-17: MRSA 
strains. 
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
peR detection of the nuc gene (280bp). Lanes 1 and 20: molecular weight markers; Lane 2: negative 
control; Lane 3-19: positive S. aureus strains 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
peR detection of the mupA gene (l90bp) in low and high-level mupirocin resistant strains. Lanes 3-16: 
low-level mupirocin resistant strains; Lane: 17-19: high-level mupirocin resistant strains RKK6, Pl929 
(South Africa), 35IBA (Nigeria). 
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Plasmid profiles of MRS A strains from South Africa and Nigeria 
Plasmid Approximate size Strain Numbers 
Profiles (kb) 
I 26, 4.2,3.3 SIO, AD28 
2 23, 3.3 AD87, SI3 
3 28.S, 2.8 S03, AD84, 114XC, 131XB, ESH34, RKKS7 
4 No plasmid AD69, AD77, AD98, ESH37, GP74, AD, ESH89, XW, MD24, 
GlC7, GlC69, KEH77, AD79 
S 32,4.2,2.8 EGU23 
6 37, 2.3 EGU28, EGUSI , PS33, RKK6, RKKIO 
7 34,4.8,2.3 PS44 
8 37,3.7, 2.3 PSSO, PS94, RKKS2 
9 39.3, 3.7, 2.8 GPII 
10 1.2 RKKS3 
II 2.8 RKKS6,203 , SII , ESH20, RKK8, RKKSS 
12 38.3, IS .4, 2.3 lIili, 2KH, 4KH 
13 2.3 AC, GJC3, KEH88, EDD84, KEHI2, 
GT33, PM69, EDDS2, ESA, HSA, SSA, 107(2) 
14 3.7,2.8 XQ,KEH26 
IS 2.4, 2.3 MD43 
16 4.8,2.3 EDD70 
17 26, 19, 7.4, 4.2, THCD* 
2.3 
18 S.2,2 .8 IS* 
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I 2 3 4 5 6 7 8 9 10 II 12 1314 15 16 17 18 19 20 
Plasmid profiles I 4 4 4 3 2 4 II 3 I II 2 3 3 II 3 4 4 5 
4.4 
3.3 
Plasmid profiles of MRS A strains from South Africa. Lane 1: AD28; Lane 2: AD69; Lane 3: AD77; Lane 
4: AD79; Lane S: AD84; Lane 6: AD87; Lane 7: AD98; Lane 8: 203; Lane 9: S03; Lane 10: S10; Lane 11: 
SII; Lane 12: S13; Lane 13: 114XC; Lane 14: 131XB; Lane IS: ESH20; Lane 16: ESH34; Lane 17: 
ESH37; Lane 18: ESH89; Lane 19: EGU23; Lane 20: WBG 4483 . Only closed circular (CCC) DNA of 
WBG 4483 are labelled. 
I 2 3 4 5 6 7 8 9 10 II 12 13 14 15 16 17 18 19 20 





Plasmid profiles of MRS A strains from South Africa. Lane 1: EGU 28; Lane 2: EGUSl; Lane 3: PS 33; 
Lane 4: PS44; Lane S: PSSO; Lane 6: PS94; Lane 7: GPll; Lane 8: GP74; Lane 9: RKK6; Lane 10: RKK8; 
Lane 11: RKKI0; Lane 12: RKKS2; Lane 13: RKKS3; Lane 14: RKKSS; Lane IS: RKKS6; Lane 16: 
RKKS7; Lane 17: lKH; Lane 18: 2KH; Lane 19: 4KH; Lane 20: WBG 4483 . Only closed circular (CCC) 
DNA of WBG 4483 are labelled. 
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I 2 3 4 5 6 7 8 9 10 II 12 13 14 15 16 17 18 19 20 





Plasmid profiles of MRS A strains from South Africa. Lane 1: AC; Lane 2: AD; Lane 3: XQ; Lane 4: XW; 
Lane 5: 107(2); Lane 6: ESA; Lane 7: HSA; Lane 8: SSA; Lane 9: MD24; Lane 10: MD43; Lane 11: 
GJC3; Lane 12: GJC7; Lane 13: EDD70; Lane 14: EDD84; Lane 15: KEHI2; Lane 16: GJC69; Lane 17: 
GT33; Lane 18: PM 69; Lane 19: EDD 52; Lane 20: WBG 4483. Only closed circular (CCC) DNA of 
WBG 4483 are labelled. 
23456789 





Plasmid profiles of MRS A strains (South Africa) and MRSA and MSSA strains from Nigeria. Lane I : 
KEH26; Lane 2: KEH77; Lane 3: KEH88 (MRSA strains from South Africa); Lane 4: THCD (MRS A _ 
Nigeria); Lane 5: 35IBA; Lane 6: lIBA (MSSA strains - Nigeria); Lane 7: 15 (MRSA - Nigeria); Lane 8: 
WBG 4483, Lane 9: WBG 4483. Only closed circular (CCC) DNA ofWBG 4483 are labelled. 
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PCR-RFLP of the coagulase gene (MSSA and MRSA strains from South Africa) 
Strain Molecular RFLP (bp) Strain Molecular RFLP (bp) 
Number weight (bp) Number weight (bp) 
*GT6 480 81 , 405 *GSA 690 81 , 162, 405 
*RKK 54 580 162, 405 *AD68 720 162, 243, 405 
*EDD79 600 81 , 486 
*EGU 60 740 81 , 243,405 
XW 640 81 , 567 *KEH 59 740 81 , 324, 405 
AD 69 630 81,567 *GJC 39 750 81 , 324, 405 
EDD84 640 81 , 567 *EDD 30 730 81 , 243, 486 
AD 650 81 , 567 *GT 30 730 81 , 162, 405 
XQ 640 81,567 *RKK65 730 81 , 243, 405 
107 (2) 650 81 , 567 AC 730 81 , 243, 405 
ESA 640 81 , 567 
HAS 650 81 , 567 *AD59 760, 380 81 , 324, 405 
SSA 640 81 , 567 
503 650 81 , 567 510 810 324, 405 
511 650 81 , 567 513 810 81 , 324, 405 
114XC 650 81 , 567 GJC7 820 81 , 162, 486 
131XB 650 81 , 567 EDD99 780 81 , 162,486 
MD24 650 81,567 KEH26 790 81 , 324,405 
MD43 650 81,567 KEH77 780 81 , 162, 486 
GJC3 650 81 , 567 AD 28 810 324, 405 
GT33 630 81,567 AD 77 780 81 , 162, 486 
PM 69 650 81 , 567 GP 11 790 81 , 324, 405 
EDD52 650 81 , 567 GP74 790 81 , 162, 486 
EDD70 650 81 , 567 RKK8 820 81,324, 405 
KEH 12 640 81 , 567 RKK56 820 81 , 324, 405 
KEH88 630 81 , 567 RKK55 820 81 , 324, 405 
AD 79 640 81 , 567 RKK57 790 81 , 324, 405 
AD 84 640 81 , 567 *AD80 810 81 , 162, 648 
PS 33 650 81 , 567 *EDD 38 820 81 , 162, 648 
PS44 650 81,567 *GT67 820 162, 243, 405 
PS 50 640 81 , 567 *EGU 75 800 162, 243,405 
PS 94 650 81 , 567 *EDD49 810 810 
RKK6 640 81 , 567 *XF 810 324, 486 
RKK 10 640 81 , 567 *MSA 810 162, 243, 405 
RKK52 640 81 , 567 
RKK53 650 81 , 567 ESH89 840 81 , 162, 486 
1 KH 630 81 , 567 AD 87 830 324, 405 
2KH 640 81,567 *RKK 50 830 81 , 324, 405 
4KH 650 567 *RKK39 830 162, 243, 405 
GJC69 660 567 *RKK 82 850 243, 486 
AD 98 660 81 , 567 *PS 61 840 243, 486 
ESH20 660 81 , 567 *GJC 74 840 162, 243, 405 
ESH34 660 81 , 567 
ESH 37 660 81 , 567 *EDD 11 900 162, 324, 486 
EGU23 660 81 , 567 *AB 910 81,162, 648 
EGU28 660 81,567 *AE 910 81 , 162, 648 
EGU 51 670 81 , 567 *XN 900 81 , 162, 648 
406 
*EDD 33 660 324,405 *PM 13 880 81 , 162, 648 
*GT41 660 81,486 *EDD 87 890 81 , 162, 648 
*GP 99 950 162,324,486 
*XSA 930 162,324,486 
*XZ 980,400 162, 324, 405, 
486 
*WSA 1000,420 162, 324, 405, 
486 
*EDD 96 No product 
203 No product 
*MSSA strains 
407 






PCR detection of the coagulase gene in MRSA strains from South Africa. Lane 1: AC; Lane 2: AD; Lane 
3: XQ; Lane 4: XW; Lane 5: 107(2); Lane 6: ESA; Lane 7: HSA; Lane 8: SSA; Lane 9: 203; Lane 10: 503 ; 
Lane 11 : 510; Lane 12: 511; Lane 13 : 513; Lane 14: 114XC; Lane 15: 131XB; Lane 16: MD24; Lane 17: 







PCR detection of the coagulase gene in MRSA strains from South Africa. Lanes 1 and 19 are molecular 







EDD70; Lane 8: EDD84; Lane 9: EDD99; Lane 10: KEHI2; Lane 11: KEH26; Lane 12: KEH77; Lane 13 : 









PCR detection of the coagulase gene in MRSA strains from South Africa. Lanes I and 20 are molecular 
weight markers. Lane 2: AD87; Lane 3: AD98; Lane 4: ESH20; Lane 5: ESH34; Lane 6: ESH37; Lane 7: 
ESH89; Lane 8: EGU23; Lane 8: EGU28; Lane 9: EGU51 ; Lane 10: PS33 ; Lane II: PS44; Lane 12: PS50; 









2 3 4 5 6 7 8 9 
PCR detection ofthe coagulase gene in MRSA strains from South Africa. Lane 1 is the 
molecular weight marker. Lane 2: RKK52; Lane 3: RKK53 ; Lane 4: RKK55; Lane 5: 

























6 7 8 9 10 11 12 \3 14 15 16 17 18 19 20 
PCR detection of the coagulase gene in MSSA strains from South Africa. Lanes I and 20 are molecular 
weight markers. Lanes 2 and 3 are negative and positive controls. Lane 4: AB; Lane 5: AE; Lane 6: XN; 
Lane 7: XZ; Lane S: GSA; Lane 9: XSA; Lane 10: AD 59; Lane II : AD6S; Lane 12: ADSO; Lane 13: EDD 
II; Lane 14: EDD30; Lane 15: EDD33; Lane 16: EDD3S; Lane 17: EDD79; Lane IS: EDDS7; Lane 19: 
EDD96. 
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 
PCR detection of the coagulase gene in MSSA strains from South Africa. Lanes I and 19 are molecular 
weight markers. Lane 2: GT6; Lane 3: GT30; Lane 4: GT4I ; Lane 5: GT67; Lane 6: PS 61 ; Lane 7: 
RKK39; Lane S: RKK50; Lane 9: RKK54; Lane 10: RKK65; Lane 11 : RKKS2; Lane 12: EGU60; Lane 13 : 























2 3 4 5 
peR detection of the coagulase gene in MSSA strains from South Africa. Lane I: 
























RFLPs of the coagulase gene in MRSA strains from South Africa. Lanes 1 and 20 are molecular weight 
markers. Lane 2: AC; Lane 3: AD; Lane 4: XQ; Lane 5: XW; Lane 6: 107(2); Lane 7: ESA; Lane 8: HSA; 
Lane 9: SSA; Lane 10: 203 ; Lane 11: 503; Lane 12: 510; Lane 13: 511 ; Lane 14: 513 ; Lane 15: 114XC; 
Lane 16: 131XB; Lane 17: MD24; Lane 18: MD43; Lane 19: GJC3 . 
2 3 4 5 6 7 8 9 10 II 12 13 14 15 16 17 18 19 
RFLPs of the coagulase gene in MRSA strains from South Africa. Lanes 1 and 19 are molecular weight 
markers. Lane 2: GJC7; Lane 3: GJC69; Lane 4: GT33 ; Lane 5: PM 69; Lane 6: EDD52; Lane 7: EDD70; 
Lane 8: EDD84; Lane 9: EDD99; Lane 10: KEHI2; Lane 11: KEH26; Lane 12: KEH77; Lane 13: KEH88; 




















8 9 10 II 12 13 14 15 16 17 18 19 20 
RFLPs of the coagulase gene in MRSA strains from South Africa. Lanes 1 and 20 are molecular weight 
markers. Lane 2: AD87; Lane 3: AD98; Lane 4: ESH20; Lane 5: ESH34; Lane 6: ESH37; Lane 7: ESH89; 
Lane 8: EGU23; Lane 9: EGU28; Lane 10: EGU51; Lane 11: PS 33; Lane 12: PS44; Lane 13: PS50; Lane 










2 3 4 5 6 7 8 9 
RFLPs of the coagulase gene in MRSA strains from South Africa. Lane 1 is the 
molecular weight marker. Lane 2: RKK52; Lane 3: RKK53; Lane 4: RKK55; Lane 5: 



























RFLPs of the coagulase gene in MSSA strains from South Africa. Lanes 1 and 20 are molecular weight 
markers. Lane 2: AB; Lane 3: AE; Lane 4: XN; Lane 5: XZ; Lane 6: GSA; Lane 7: XSA; Lane 8: AD59; 
Lane 9: AD68; Lane 10: AD80; Lane 11 : EDDll ; Lane 12: EDD30; Lane 13 : EDD33; Lane 14: EDD38; 
Lane 15: EDD79; Lane 16: EDD87; Lane 17: EDD96; Lane 18: GT 6; Lane 19: GT30. 










RFLPs of the coagulase gene in MSSA strains from South Africa: Lanes 1 and 17 are molecular weight 
markers. Lane 2: GT41 , Lane 3: GT67; Lane 4: PS61 ; Lane 5: RKK39; Lane 6: RKK50; Lane 7: RKK54; 
Lane 8: RKK65; Lane 9: RKK82; Lane 10: EGU60; Lane 11 : EGU75; Lane 12: KEH59; Lane 13: GJC39; 












RFLPs of the coagulase gene in MSSA strains from South Africa. Lane I: Molecular 
weight marker. Lane 2: EDD49; Lane 3: XF; Lane 4: MSA; Lane 5: WSA. 
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PCR-RFLP of the coagulase gene (MSSA and MRSA strains from Nigeria) 
Strain No Molecular RFLP (bp) Strain No Molecular weight RFLP (bp) 
weight (bp) (bp) 
P 570 162, 405 4 IDA 820 162,243, 405 
B31 570 81 , 243, 405 35 IBA 810 81 , 162, 567 
28* Ife 810 81,324, 405 
2IBA 660 243, 405 El 810 81 , 324, 405 
5IB 820 81 , 324, 405 
23* IBA 720 81,243, 405 llIBA 820 81 , 324,405 
C20 720 243, 405 12IBA 820 81 , 324, 405 
C35 720 81 , 162, 405 13(1) IBA 810 81 , 324, 405 
B6 720 81 , 162, 405 40*IBA 810 810 
BlO 720 81,243, 405 *THCD 810 81 , 162, 567 
B35 720 162,405 *28 IDA 820 81 , 162, 486 
32 IDA 730 81 , 243, 405 19 830 81 , 324, 405 
1 IBA 730 81 , 243, 405 4IB 830 81 , 324, 405 
22 IDA 730 81 , 243, 405 
D12 760 81,243, 405 16* IBA 900 81,324,486 
D28 760 81 , 243,405 19* IBA 880 81 , 324, 486 
D37 760 81,162,405 
D45 750 81 , 243 , 405 71BA 970 162, 324,486 
10 750 81,243, 405 
29 750 81 , 162, 405 I*IBA 1000 162,324, 486 
H 750 81 , 243, 405 D40 1000 162, 324, 486 
R 740 81 , 162, 405 11 1010 162, 324, 486 
G 730 81 , 243, 405 
C 740 81 , 243, 405 32 840, 750 81 , 162, 324, 405 
Y 740 729 20 840, 750 81 , 162, 324, 405 
15Ife 730 81 , 243, 405 
40Ife 740 243,405 18*IBA 980, 400 162,324, 405, 486 
4 IBA 740 81 , 243, 405 50IBA 990, 400 162, 324, 405, 486 
9IBA 730 81 , 243, 405 THK 1000, 410 162,324, 405, 486 
*15 730 81 , 243,405 THW 980, 410 162, 324, 405,486 
B9 980, 400 162, 324, 405, 486 

















PCR detection of the coagulase gene. MRSA and MSSA strains from Nigeria. MRSA 
strains from Nigeria. Lane 1: strain No. 15 - (Hospital C); Lane 2: THCD (Hospital A) 
and Lane 5: 28 IDA (Hospital F). MSSA strains: Lane 3: 4IDA; Lane 4: 22IDA; Lane 6: 
32IDA; Lane 7: 1 IBA; Lane 8: 35IBA. Lane 9 is the molecular weight marker. 
2 3 4 5 6 7 8 9 10 II 12 13 14 15 16 17 18 19 20 
PCR detection of the coagulase gene in MSSA strains from Nigeria. Lanes 1 and 20 are molecular weight 
markers. Lanes 2 and 3 are negative and positive controls. Lane 4: Dl2; Lane 5: D28; Lane 6: D37; Lane 7: 
D45; Lane 8: 10; Lane 9: 29; Lane 10: H; Lane 11: R; Lane 12: G; Lane 13 : C; Lane 14: P; Lane 15: Y; 
























PCR detection of the coagulase gene in MSSA strains from Nigeria. Lanes 1 and 12 are molecular weight 
markers. Lane 2: 9IBA; Lane 3:I6*IBA; Lane 4: I9*IBA; Lane 5: 23*IBA; Lane 6: C20; Lane 7: C35; 















PCR detection of the coagulase gene in MSSA strains from Nigeria. Lanes 1 and 20 are 
molecular weight markers. Lanes 2 and 3 are negative and positive controls; Lane 4: 
D40; Lane 5: 11 ; Lane 6: 32; Lane 7: 19; Lane 8: 20; Lane 9: EI ; Lane 10: THK; Lane 
11: THW; Lane 12: 20*Ife; Lane 13 : 89; Lane 14: 4IB; Lane IS : SIB; Lane 16: I *IBA, 
Lane 17: 7IBA; Lane 18: 11IBA; Lane 19: 12IBA. 
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peR detection of the coagulase gene in MSSA strains from Nigeria. Lanes I and 6 are molecular weight 
















RFLPs of the coagulase gene in MRSA and MSSA strains from Nigeria. MRSA strains Lane 1: strain No. 
15 - (Hospital C); Lane 2: THCD (Hospital A) and Lane 5: 28 IDA (Hospital F). MSSA strains Lane 3: 
4IDA; Lane 4: 22IBA; Lane 6: 32IDA; Lane 7: lIBA; Lane 8: 35IBA. Lane 9 is the molecular weight 
marker. 
2 3 4 5 6 7 8 9 \0 11 12 13 14 15 16 17 18 19 20 
RFLPs of the coagulase gene in MSSA strains from Nigeria. Lanes 1 and 20 are molecular weight markers. 
Lane 2: D12; Lane 3: D28; Lane 4: D37; Lane 5: D45 ; Lane 6: 10; Lane 7: 29; Lane 8: H; Lane 9: R; Lane 
10: G; Lane 11: C; Lane 12: P; Lane 13: Y; Lane 14: 15Ife; Lane 15: 40Ife; Lane 16: 2IBA; Lane 17: 































RFLPs of the coagulase gene in MSSA strains from Nigeria. Lanes 1 and 10 are molecular weight markers. 
Lane 2: 19*IBA; Lane 3: 23*IBA; Lane 4: C20; Lane 5: C35; Lane 6: B6; Lane 7: BI0; Lane 8: B31 ; Lane 
9: B35. 
RFLPs of the coagulase gene in MSSA strains from Nigeria. Lane 1 is molecular weight marker. Lane 2: 
D40; Lane 3: 11; Lane 4: 32; Lane 5: 19; Lane 6: 20; Lane 7: El ; Lane 8: THK; Lane 9: THW; Lane 10: 
20*Ife; Lane 11 : B9; Lane 12: 4IB: Lane 13 : 5IB; Lane 14: I*IBA; Lane 15: 7IBA; Lane 16: lUBA; Lane 











al bl bl b5 c dl c EI5 EI6 al e c g b2 
PFGE profiles of representative MRSA clones and worldwide clones. Lane 1: S. aureus NCTC 832S; Lanes 
9 and 10: EMRSA-lS and EMRSA-16; Lane 2: AC; Lane 3: AD; Lane 4: ESA; Lane S: HSA; Lane 6: 
S03Red; Lane 7: Sl3 ; Lane 8: 114XC; Lane 11: MD24; Lane 12: MD43; Lane 13: GJC3 ; Lane 14: GJC7; 










a3 f a4 g b4 g EI5 EI6 dl g b4 al bl g 
PFGE profiles of representative MRSA clones and worldwide clones. Lane 1: S. aureus NCTC 832S; Lanes 
8 and 9: EMRSA-lS and EMRSA-16; Lane 2: GT33; Lane 3: PM69; Lane 4: EDDS2; Lane S: EDD99; 
Lane 6: KEHI2; Lane 7: KEH77; Lane 10: AD28; Lane II AD77; Lane 12: AD79; Lane 13 : AD84; Lane 
14: ESH34; Lane IS: ESH89. 
422 
Antibiotyping and PFGE of MRS A strains from Nigeria and South Africa 
Strain no PFGE Antibiograrn Strain no PFGE Antibiogram 
type type 
AC al PEN, GN,ERY, TET,TS, RF 510 dl PEN, GN, ERY, CHL, TET, TS, CIP, MU5 
107-2 al PEN, GN, ERY, TET, TS, RF 513 dl PEN, GN, ERY, TET, TS, CIP, MU5 
203 al PEN, GN, ERY, TET, TS, RF KEH26 dl PEN, GN, ERY, CHL, TET, TS, CIP, MU5 
511 al PEN, GN, ERY, TET, TS, RF AD28 dl PEN, GN, ERY, CHL, TET, TS, CIP, MU5 
MD24 al PEN, GN, TET, TS, RF AD87 dl PEN, GN, ERY, TET, TS, CIP, MU5 
AD84 al PEN, GN, ERY, TET, TS, RF GPII dl PEN, GN, ERY, CHL, TET, TS, CIP, MUS 
PS33 al PEN,GN, ERY, TET, TS, RF RKK8 dl PEN, GN, ERY, TET, TS, CIP, MU5 
PS44 al PEN, GN,ERY, TET, TS, RF RKK56 dl PEN, GN, ERY, TET, TS, CIP, MU5 
PS50 al PEN, GN, ERY, Cllt, 'fET, TS, RF RKK57 dl PEN, GN, ERY, TET, TS, CIP, MU5 
PS94 al PEN, GN, ERY, CHL, TET, TS, RF RKK55 d2 PEN, GN, ERY, TET, TS, CIP, MU5 
RKK52 al PEN, GN, ERY, CHL, TET,TS, RF 
IKH al PEN, GN, ERY, TET, TS, RF MD43 e PEN, GN, ERY, TET, TS, RF 
2KH al PEN, GN, ERY, TET, TS, RF 
4KH al PEN,GN, ERY, TET, TS, RF PM69 f PEN, GN, ERY, TET, TS, RF 
RKK53 a2 PEN,GN, ERY, TET, TS, RF 
XQ a3 PEN, GN, CHL,TET, TS, RF GJC7 g PEN, GN, ERY 
EGU51 a3 PEN, GN, ERY, TET, TS, RF EOD99 g PEN, GN, ERY 
GT33 a3 PEN, GN, ERY, TET, TS, RF KEH77 g PEN, GN, ERY 
RKK6 a3 PEN, GN, ERY, TET, TS, RF, MU5 AD77 g PEN, GN, ERY 
RKKIO a3 PEN, GN, ERY,TET, RF ESH89 g PEN, GN, ERY 
EOO52 a4 PEN, GN, ERY, TET, TS, RF GP74 g PEN, GN, ERY 
EOO84 h PEN, GN, ERY, TET, TS, RF 
AD bl PEN, TET, RF 
ESA bl PEN, GN, ERY, TET, TS, RF, CIP THCO* a5 PEN, ERY, TET, TS 
KEH88 bl PEN, GN, ERY, TET, TS, RF 
ESH34 bl PEN, GN, ERY, TET, TS, RF, MU5 15 i PEN, TET 
XW b2 PEN, GN, TET TS RF 
GJC69 b2 PEN, GN, TET, TS, RF 28IDA j PEN, ERY, TET, CIP 
EOD70 b2 PEN, GN, ERY, CHL, TET, TS, RF 
AD69 b2 PEN, GN, TET, TS, RF 
ESH20 b2 PEN, GN, ERY, TET, TS, RF 
ESH37 b3 PEN,TET, RF 
KEHI2 b4 PEN, GN, ERY, TET, TS, RF, MU5 
AD79 b4 PEN, GN, TET, TS, RF, MU5 
AD98 b4 PEN, GN, TET, TS, RF, MU5 
EGU23 b4 PEN, GN,CHL, TET, TS, RF 
EGU28 b4 PEN, GN, ERY, TET, TS, RF 
HSA b5 PEN, GN, ERY, TET, TS, RF 
SSA b5 PEN, GN, ERY, TET, TS, RF 
503 c PEN, GN, ERY, TET, TS, RF 
114XC c PEN, GN, ERY, TET, TS, RF 
131XB c PEN, GN, TET, TS, RF 
GJC3 c PEN, GN, ERY, TET, TS, RF 
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PCR-RFLP of the coagulase gene and PFGE patterns of MRS A strains from 
South Africa 
Strain Molecular RFLP PFGE Strain Molecular RFLP (bp) PFGE 
Number weight (± (bp) type Number weight (bp) type 
20bp) 
AC 730 81 , 243, 405 al 
XW 640 81 , 567 b2 
AD 69 630 81 , 567 b2 GJC7 820 81,162, 486 g 
EDD84 640 81 , 567 h EDD99 780 81 , 162, 486 g 
AD 650 81,567 bl KEH77 780 81 , 162, 486 g 
XQ 640 81 , 567 a3 AD 77 780 81 , 162,486 g 
107 (2) 650 81 , 567 al GP74 790 81 , 162, 486 g 
ESA 640 81 , 567 bl 
HSA 650 81 , 567 b5 RKK8 820 81 , 324, 405 dl 
SSA 640 81 , 567 b5 RKK56 820 81 , 324, 405 dl 
503 650 81 , 567 c RKK57 790 81 , 324, 405 dl 
511 650 81 , 567 al GP 11 790 81 , 324, 405 dl 
114XC 650 81 , 567 c KEH26 790 81 , 324,405 dl 
131XB 650 81 , 567 c 513 810 81 , 324, 405 dl 
MD24 650 81,567 al AD 28 810 324, 405 dl 
MD43 650 81,567 e 510 810 324, 405 dl 
GJC3 650 81,567 c 
GT33 630 81 , 567 a3 ESH89 840 81 , 162,486 g 
PM 69 650 81 , 567 f AD 87 830 324, 405 dl 
EDD52 650 81 , 567 a4 RKK55 830 81 , 324, 405 d2 
EDD70 650 81 , 567 b2 
KEH 12 640 81 , 567 b4 
KEH88 630 81 , 567 bl 203 No product al 
AD 79 640 81 , 567 b4 
AD 84 640 81 , 567 al 
PS 33 650 81 , 567 al 
PS 44 650 81,567 al 
PS 50 640 81 , 567 al 
PS 94 650 81 , 567 al 
RKK6 640 81 , 567 a3 
RKK 10 640 81 , 567 a3 
RKK52 640 81 , 567 al 
RKK53 650 81 , 567 a2 
lKH 630 81 , 567 al 
2KH 640 81 , 567 al 
AD 98 660 81 , 567 b4 
ESH20 660 81 , 567 b2 
ESH34 660 81 , 567 bl 
ESH37 660 81,567 b3 
EGU23 660 81 , 567 b4 
EGU28 660 81,567 b4 
EGU 51 670 81 , 567 a3 
4KH 650 567 al 
GJC69 660 567 b2 
424 
PFGE of MRS A strains (South Africa) - Dendogram 
PFGE groups 
a c a b d 
"' "' "' N N N 
'" '" '" ., ., ., () () () 
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PFGE types 
c b e f 
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Figure 3.31: PFGE of MRS A strains (South Africa) - Dendogram 
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Dendogram of representative MRS A clones (South Africa) 
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